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5-Fluorouracil (5-FU) and capecitabine belong to the group of fluoropyrimidines, which 
represent the backbone of anti-cancer treatment for various types of cancer, such as 
colorectal, breast and gastric cancer. Fluoropyrimidines are used by millions of patients 
worldwide each year1-3 and are often combined with other chemotherapeutic drugs (e.g. 
irinotecan or oxaliplatin), immunotherapeutic drugs or act as a radio-sensitizer in chemo-
radiotherapy.4,5 
 5-FU was developed by Heidelberger et al. in the 1950’s.6 The anti-cancer effect of 5-FU is 
caused by three active metabolites, as shown in Figure 1. The first is 5-fluoro-2′-deoxyuridine-
5′-monophosphate (5-FdUMP), which inhibits the enzyme thymidylate synthase (TS). The 
inhibition of TS leads to a reduced production of deoxythymidine monophosphate (dTMP), 
resulting in the inhibition of DNA synthesis and repair. Two other metabolites, fluorouridine 
triphosphate (FUTP) and fluorodeoxyuridine triphosphate (FdUTP), are incorporated into 
RNA and DNA, respectively. This results in RNA and DNA damage and ultimately cell death.7 
 In February 2001, European approval and market authorization for Xeloda® (capecitabine) 
was given, the first oral pro-drug of 5-FU used in the treatment of metastatic colorectal 
cancer. Besides the advantage of oral administration, capecitabine is also a tumour-specific 
therapy for colorectal and breast cancer. Thymidine phosphorylase (TP), the third enzyme 
converting capecitabine into 5-FU, was found to be more expressed in breast and colorectal 
tumour cells compared to normal tissue. This leads to higher 5-FU levels in tumour cells 
compared to plasma, and thus a higher anti-cancer effect of capecitabine with less toxicity.8-10
 5-FU has a relatively narrow therapeutic index and, depending on the type of treatment 
regimen, up to 30% of patients suffer from severe toxicity such as diarrhoea, nausea, (oral) 
mucositis, myelosuppression and hand-foot syndrome (HFS). These side-effects can lead 
to mortality in approximately 1% of patients.11,12 Toxicity is classified using the common 
terminology criteria for adverse events (CTC-AE) and grades 3 and higher are considered 
severe toxicity (range 0–5).
Dihydropyrimidine dehydrogenase
The enzyme dihydropyrimidine dehydrogenase (DPD) plays a key role in the metabolism 
of 5-FU. It is the rate limiting enzyme degrading over 80% of the drug into the inactive 
metabolite 5-fluoro-5,6-dihydrouracil (DHFU). Because of this, DPD plays an important 
role in the development of toxicity.13-16 DPD is mainly expressed in the liver, but also in 
other tissues.17,18 DPD shows great interpatient and intrapatient variability, is influenced 
by circadian rhythm19,20 and possibly gender.21-24 Some patients are partially DPD deficient 
(incidence 3–8%) or completely DPD deficient (incidence 0.2%).23-25 DPD deficient patients 
have higher levels of active 5-FU metabolites and therefore an increased risk to develop 
severe or even fatal fluoropyrimidine-induced toxicity.26-28 In addition, the onset of toxicity 
occurs faster in DPD deficient patients compared to patients with a normal DPD enzyme 
activity.28 Up to 60% of the patients who experienced severe fluoropyrimidine-induced 






























































































































































































































































































































































































































In order to prevent severe fluoropyrimidine-induced toxicity, interpatient differences must 
be overcome and treatments must be individualized (personalised medicine). As DPD is an 
important factor for the onset of severe fluoropyrimidine-induced toxicity, DPD deficient 
patients are an interesting target for personalised medicine. Yet, DPD deficient patients 
generally do not show specific phenotypic features and must be identified otherwise. One 
way to use personalised medicine, is through pharmacogenetics or pharmacogenomics 
(PGx). In PGx, the influence of human genetic variation in drug metabolic pathways or 
molecular drug targets on drug therapy response (both efficacy as toxicity) is studied. 
 DPD is encoded by the DPYD gene, which consists of 26 exons and is located on 
chromosome 1p21.3.29,30 Over 1,000 variants or single nucleotide polymorphisms (SNPs) are 
known in DPYD, some leading to altered DPD enzyme activity.31-33 A well-known example 
is the variant DPYD*2A, which is located at the intron downstream of exon 14. This point 
mutation at a splice donor site leads to skipping of exon 14 and results in a catalytically 
inactive enzyme.34 
 Heterozygous carriers of DPYD*2A are partially DPD deficient. Of four variants (DPYD*2A, 
rs3918290, c.1905+1G>A, IVS14+1G>A; DPYD*13, rs55886062, c.1679T>G, I560S; c.2846A>T, 
rs67376798, D949V; c.1236G>A/HapB3, rs56038477, E412E) sufficient evidence has been 
provided showing the association with severe fluoropyrimidine-induced toxicity.13,35-41 Other 
DPYD variants have been described, however evidence on the association with toxicity is 
limited or missing.
 Previously, Deenen et al. have shown that prospective genotyping of DPYD*2A, followed 
by initial dose reductions in heterozygous carriers, resulted in a reduction of severe 
fluoropyrimidine-induced toxicity in these patients.42 In this study, 28% of the DPYD*2A 
variant allele carriers treated with reduced dosages experienced severe fluoropyrimidine-
induced toxicity compared to 73% of DPYD*2A variant allele carriers treated with regular 
dosages in a historic cohort. The risk of toxicity for DPYD*2A variant allele carriers was 
reduced to the wild-type level of 23%. Efficacy of the treatment was not expected to be 
reduced, as exposure to active metabolites of 5-FU were similar in DPYD*2A variant allele 
carriers treated with a reduced dose and wild-types. In addition, the study showed that 
prospective screening was feasible and did not increase costs.
 Over time, genotyping in general has become very attractive for routine diagnostics, with 
decreasing costs of the assays and better interpretation of the data. Yet, implementation of 
prospective DPYD genotyping remained limited for a substantial period, as evidence of its 
effectivity from a randomized clinical trial (RCT) was lacking. 
Aim and outline of this thesis
The general aim of this thesis is to study how to further reduce severe fluoropyrimidine-
induced toxicity, in addition to genotyping of DPYD*2A, while keeping aspects of 
implementation of any method in clinical practice in mind. 
 The first part of the thesis is entitled “DPYD genotyping: proof of principle and 
implementation in clinical practice”. In chapter 2 we present a review, in which we summarize 
the evidence on the association with severe fluoropyrimidine-induced toxicity for four DPYD 
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1variants. In addition, we discuss the advantages and disadvantages of DPYD genotyping.43 In 
chapter 3, literature is extensively checked to discuss the effect of four DPYD variants on DPD 
enzyme activity. This is converted into a gene activity score for each DPYD variant, which will 
be used in PGx guidelines to translate the DPYD genotype into a DPD phenotype.44 Chapter 
4 contains the Dutch Pharmacogenetics Working Group (DPWG) PGx guideline for DPYD 
and fluoropyrimidines. The guideline provides a dose reduction advice for heterozygous 
DPYD variant allele carriers of DPYD*2A, DPYD*13, c.2846A>T and c.1236G>A. In addition, 
a statement is made that DPYD genotyping should be performed for all patients prior to 
treatment with fluoropyrimidines, as the clinical implication score for DPYD is essential. 
Then, in chapter 5, DPYD genotyping is applied prospectively in a nationwide clinical trial.45 
Patients with an intention to treatment with fluoropyrimidines are genotyped for DPYD*2A, 
DPYD*13, c.2846A>T and c.1236G>A. Heterozygous carriers are treated with an initially 
reduced dose of fluoropyrimidines according to the DPWG PGx guidelines at the start of 
the study. The goal of the study is to show that DPYD genotyping improves patient safety. In 
chapter 6 we show a cost analysis of prospective DPYD genotyping of four DPYD variants.46 
In chapter 7, we look into severe toxicity in patients who receive fluoropyrimidines as part 
of chemoradiation therapy.47 Fluoropyrimidine dosages in chemoradiation therapy are 
substantially lower compared to fluoropyrimidine dosages in other treatment regimens. 
Current PGx guidelines do not distinguish fluoropyrimidine dosing recommendations 
between treatment regimens. Therefore, in this chapter we compare severe toxicity 
between wild-type patients and DPYD variant allele carriers, either treated with standard 
or reduced fluoropyrimidine dosages, who receive chemoradiation therapy. In chapter 8, 
the first 21 months of implementation of DPYD genotyping at Leiden University Medical 
Center is evaluated, to study the feasibility of DPYD genotyping in daily clinical care.48 
Clinical acceptance of DPYD genotyping as well as adherence to the genotyping results are 
the main objectives of this study. In chapter 9 we look into the aspect of quality control of 
genotyping in the laboratory, in specific confirmation practice.49 We use DPYD genotyping as 
an example. We discuss if it should be required to have two independent genotyping assays 
to correctly determine a genotype. Implementation of DPYD genotyping in clinical practice 
can improve if there is consensus on laboratory requirements. 
In the first part of this thesis we describe how to reduce severe fluoropyrimidine-induced 
toxicity by DPYD genotyping of DPYD*2A, DPYD*13, c.2846A>T and c.1236G>A. Yet, is 
it known that not all severe fluoropyrimidine-induced toxicity can be predicted using 
DPYD genotyping of these four variants. Therefore, we investigate other options, beyond 
genotyping of the current four DPYD variants, to reduce severe fluoropyrimidine-induced 
toxicity. This is shown in the second part of this thesis, entitled “beyond current DPYD 
pharmacogenetics”. 
 In chapter 10 we investigate four DPD phenotyping assays. The goal of the study is to 
determine the clinical value of each DPD phenotyping assay, by assessing clinical validity 
parameters (e.g. sensitivity and specificity) for DPD deficiency and the onset of severe 
fluoropyrimidine-induced toxicity. In the following chapters, we focus on future application 
of genetics. In chapter 11 we investigate a special group of DPYD variant allele carriers, i.e. 
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the compound heterozygous patients.50 These patients carry multiple DPYD variants and the 
effect of the DPYD variants on the DPD enzyme activity cannot be predicted using the gene 
activity score. We determine the prevalence of these patients using several publicly available 
databases. In addition, we describe a few patient cases and apply additional genotyping 
assays to determine the location of the DPYD variants on the alleles (phasing), in order to 
determine a gene activity score and predict the DPD phenotype. In chapter 12 we describe 
a genome-wide association study. It is expected that other enzymes besides DPD, and thus 
other genes besides DPYD, are involved in the onset of severe fluoropyrimidine-induced 
toxicity. With the genome-wide approach we aim to discover other variants, outside the 
DPYD gene, which are associated to the onset of severe fluoropyrimidine-induced toxicity. 
 This thesis ends with a general discussion, including future perspectives (chapter 13), 
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DPYD GENOTYPING:  PROOF OF PRINCIPLE
AND IMPLEMENTATION IN CLINICAL PRACTICE

CHAPTER 2
Prospective DPYD genotyping to reduce the risk of 
fluoropyrimidine-induced severe toxicity: 
ready for prime time
Eur J Cancer. 2016;54:40-8
Carin A.T.C. Lunenburg, Linda M. Henricks, Henk-Jan Guchelaar, Jesse J. Swen, 




5-Fluorouracil (5-FU) and capecitabine are among the most frequently prescribed anticancer 
drugs. They are inactivated in the liver by the enzyme dihydropyrimidine dehydrogenase 
(DPD). Up to 5% of the population is DPD deficient and these patients have a significantly 
increased risk of severe and potentially lethal toxicity when treated with regular doses of 
5-FU or capecitabine. DPD is encoded by the gene DPYD and variants in DPYD can lead 
to a decreased DPD activity. Although prospective DPYD genotyping is a valuable tool to 
identify patients with DPD deficiency, and thus those at risk for severe and potential life-
threatening toxicity, prospective genotyping has not yet been implemented in daily clinical 
care. Our goal was to present the available evidence in favour of prospective genotyping, 
including discussion of unjustified worries on cost-effectiveness, and potential underdosing. 
We conclude that there is convincing evidence to implement prospective DPYD genotyping 
with an upfront dose adjustment in DPD deficient patients. Immediate benefit in patient 
care can be expected through decreasing toxicity, while maintaining efficacy. 
Prospective DPYD genotyping: ready for prime time
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Case: fatal toxicity following treatment with capecitabine
A 52-year-old woman with human epidermal growth factor receptor 2 (HER2)-positive 
metastasised breast cancer was treated with capecitabine 1,250 mg/m2 twice daily, for 14 
days every three weeks, plus intravenous trastuzumab on day 1. The first cycle was fully 
completed; at day 18 of treatment mild diarrhoea and a herpes zoster infection located 
at her mouth were noticed during routine outpatient visit. Due to low haematological 
laboratory values (leucocytes, neutrophils CTC-AE grade 2, and thrombocytes CTC-AE grade 
3), the second cycle was planned to be deferred by one week. However, three days later she 
returned to the hospital with now severe diarrhoea (CTC-AE grade 4), sepsis, neutropenic 
fever, severe leucopenia and life-threatening thrombocytopenia and mucositis, for which she 
was admitted to the intensive care unit. A long and intensive hospitalisation period followed, 
but despite optimal treatment and supportive care, the patient did not recover from severe 
toxicity and deteriorated even further. At day 34 of admission the patient deceased as a 
result of this severe toxicity. Genetic testing revealed that the patient was heterozygous for 
DPYD*2A, a variant allele known to result in dihydropyrimidine dehydrogenase deficiency.1 
In case screening would have been performed prior to start of therapy, capecitabine dosage 
could have been reduced by 50%, thereby possibly preventing fatal capecitabine-induced 
toxicity.2
Introduction
5-Fluorouracil (5-FU) and its oral pro-drug capecitabine belong to the group of the 
fluoropyrimidine drugs, and are among the most frequently used anticancer drugs in the 
treatment of common cancer types such as colorectal, stomach, breast, head and neck 
and skin cancer.3-7 5-FU has a relatively narrow therapeutic index and, depending on type 
of treatment regimen, around 15–30% of patients suffer from severe toxicity such as 
diarrhoea, nausea, mucositis, stomatitis, myelosuppression, neurotoxicity and hand-foot 
syndrome.4,8-12 These side-effects lead to mortality in approximately 0.5–1% of patients 
using 5-FU and capecitabine.4,13 
  The enzyme dihydropyrimidine dehydrogenase (DPD) plays a key role in the catabolism of 
5-FU. It is the rate limiting enzyme degrading over 80% of the drug to its inactive metabolite 
5-fluoro-5,6-dihydrouracil.9,14,15 Because of this, DPD is an important factor for efficacy,16,17 as 
well as the development of toxicity.10 DPD is encoded by the gene DPYD, which consists of 23 
exons on chromosome 1p22.18 More than 160 single nucleotide polymorphisms (SNPs) are 
known within this gene, some resulting in altered enzyme activity.19 Eighty DPYD variants 
were experimentally tested for their enzyme activity20 and DPYD variants may result in an 
absolute or a partial DPD-deficiency (0.5% versus 3–5% of the population, respectively).21,22 
About 30–50% of the patients treated with a fluoropyrimidine drug who suffer from severe 
or life-threatening toxicity (grade 3–5) have no or decreased DPD enzyme activity, and 50–
88% of patients carrying a variant in DPYD suffer from grade ≥3 fluoropyrimidine-related 
toxicity.6,10,11,21,23-25
 Although pharmacogenomic tests in general have the potential to improve clinical 
outcome by increasing efficacy and decreasing toxicity, and the potential to decrease the 
cost of healthcare, their use in routine clinical practice is still limited.26 This also holds true 
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for the use of DPYD genotyping prior to start of treatment with fluoropyrimidines.27,28 
Other DPD deficiency screening methods (e.g. phenotyping) have been described,29 and 
are currently being investigated (NCT02324452), but we feel are not ready yet for clinical 
application. In the current paper, we present an overview on the evidence for prospective 
DPYD genotyping and discuss critical questions related to its implementation. Associations 
of DPYD variants with fluoropyrimidine-induced toxicity, prevention of severe toxicity upon 
DPYD testing, cost consequences and existing guidelines will be discussed. 
Available evidence for the association of DPYD variants and 5-FU-induced severe toxicity
The relationship between DPYD variants and 5-FU-induced severe toxicity is widely 
acknowledged. Recently, data have been summarised in three separate meta-analyses.8,9,30 
Terrazzino et al. evaluated 4,094 patients (15 studies) for DPYD*2A (IVS14+1G>A; rs3918290) 
and 2,308 patients for c.2846A>T (D949V, rs67376798). They confirmed the clinical validity 
of these SNPs as risk factors for the development of fluoropyrimidine-associated severe 
toxicities (details in Table 1).9 The second meta-analysis, performed by Rosmarin et al., 
included data of 4,855 patients (17 studies). They describe eight DPYD variants of which 
DPYD*2A and c.2846A>T also showed convincing evidence of an association with toxicity 
(Table 1).8 The third meta-analysis of Meulendijks et al., included data of 7,365 patients (eight 
studies) and confirmed the association between severe toxicity and the variants DPYD*2A 
and c.2846A>T, but also for DPYD*13 (I560S; c.1679T>G; rs55886062) and c.1236G>A/
HapB3 (E412E; rs56038477) (Table 1). Very recently, three additional papers, not part of the 
three meta-analyses, have confirmed significant associations between DPYD variants and 
toxicity (Table 1).4,31,32 Although multiple variants of DPYD have been described, DPYD*2A, 
DPYD*13, c.2846A>T and c.1236G>A/HapB3 are the variants that are most extensively 
studied and convincingly associated with fluoropyrimidine-related severe toxicity.8,9,30
 The HuGE risk translator33 is an online tool to calculate test characteristics for the 
evaluation of the predictive ability of genetic markers. Data (e.g. odds ratio) from two 
of three meta-analyses described above could be entered as a ‘two-risk genotype’ for 
DPYD*2A and c.2846A>T, resulted in low (~10 to ~25%) sensitivity and positive predictive 
values and high (>96%) specificity and negative predictive values (NPV). The number needed 
to screen (i.e. genotype) appears to be 210–250 patients and the number needed to treat 
(i.e. apply dose adjustments) is five or six patients (Table 2). Important to note is that values 
for diagnostic test criteria of a pharmacogenomic test based on SNPs in DPYD can never 
reach 100%, because not all DPD deficiencies and toxicity can be explained by variants in 
DPYD.34 It must also be said that the high specificity (±98%) and high NPV (±96.5%) in this 
setting are most important, when the goal is to treat all patients with a variant (including 
false-positives). The consequence of a (false) positive result is a relatively low-risk dose-
reduction for the first of many cycles, which can be adjusted in safe conditions in the second 
cycle and onwards if no toxicity occurs. The consequence of a false negative result may be 
much larger since it could result in a too high systemic drug exposure that subsequently 
leads to severe, potentially lethal toxicity, which is associated with long-lasting hospital and/
or intensive care unit (ICU) admissions. 
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In a previous study approximately 10% of the DPYD*2A variant allele carriers treated with 
the standard fluoropyrimidine dose deceased as a result of drug-induced severe toxicity.35 
The approach of pre-treatment genotyping followed by a reduced starting dose plus 
tolerance-guided dose titration could prevent the occurrence of severe toxicities in DPYD 
variant allele carriers, resulting in a direct safer use with minimum risk of underdosing. The 
above mentioned test characteristics are reached using the two most investigated SNPs and 
these values will probably improve when a larger panel of DPYD SNPs is probed. Costs are 
not likely to increase substantially when adding SNPs because genotyping costs continue to 
decrease.36,37 Although more DPYD variants that alter DPD enzyme activity are continuously 
discovered and studied, the perfect set of SNPs has not been defined yet. Currently we 
feel there is substantial evidence to support dose recommendations for at least four 
variants (DPYD*2A, c.2846A>T, DPYD*13 and c.1236G>A/HapB3).38 Another possibility for 
prospective screening could be the more informative, but hugely more expensive genotyping 
of the entire coding region of DPYD. However we have focused on genotyping SNPs. To 
date, SNP genotyping has been most extensively studied, is technically feasible in a general 
hospital setting and multiple guidelines providing SNP-based dose recommendations are 
available. 
What is needed for implementation of DPYD genotyping in daily routine clinical care?
Clinical implementation of a biomarker test such as DPYD pharmacogenomics is hampered 
due to the on-going discussion on whether a randomised clinical trial (RCT) is considered 
necessary to provide the required evidence before clinical implementation.26,29,37,39-45 Despite 
the fact that RCTs are considered the gold standard study design to prove effectiveness, 
adequate evidence can also be provided by small-scale, innovative, prospective interventional 
studies.40 However, with the available evidence favouring upfront genotyping, it may not be 
ethically feasible to randomise patients, and patients may not be willing to be included in 
the control arm with an increased risk for severe toxicity. Indeed, the only attempt at a 
prospective randomised study was performed in France. Boisdron-Celle et al. presented a 
multicentre prospective cohort study of upfront DPD deficiency screening executed from 
2008 until 2012.46 The purpose of the study was to confirm the medical and economic 
aspect of upfront DPD deficiency screening in a prospective way as was done retrospectively 
by Traoré et al.47 Patients using 5-FU based chemotherapy were included in one of two 
parallel patient cohorts (arm A and arm B). Patients in arm A were prospectively screened 
for DPD-deficiency (a combined genotyping and phenotyping approach), and patients in 
arm B were retrospectively tested. A total of 1,130 patients were included (arm A: 720 
patients, arm B: 410 patients). One patient died due to 5-FU early-onset toxicity and it was 
retrospectively confirmed that this patient was DPD deficient (arm B). The enrolment of 
patients was prematurely closed for ethical reasons, because of the proven 5-FU-induced 
toxic death of this patient.46,48 Against this background, we conclude that evidence from a 
randomised prospective clinical trial on DPYD genotyping will never be acquired for ethical 
reasons. In addition, some predictive biomarkers were previously implemented without 
evidence from an RCT. Clinical use of (K)RAS selection for EGFR therapy was influenced 
by updated registration texts for epidermal growth factor receptor (EGFR) inhibitors from 
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the Food and Drug Administration (FDA)49 and European Medicines Agency (EMA) after 
retrospective analyses of three studies (CRYSTAL trial, OPUS trial and CA225025).50-52 Also 
hormone receptor status for hormone therapy in breast cancer has never been proven in a 
prospective randomised study.
Table 1. Toxicity associations of DPYD variants
Group DPYD variant Association with 5-FU and/or capecitabine grade ≥3 
toxicity




DPYD*2A (rs3918290) Overall toxicity (5.42 [2.79–10.52], p<0.001)
Diarrhoea (5.54 [2.31–13.29], p<0.001)
Haematological toxicity (15.77 [6.36–39.06], p<0.001)
Mucositis (7.48 [3.03–18.47], p<0.001)
c.2846A>T (rs67376798) Overall toxicity (8.18 [2.65–25.25], p<0.001)




DPYD*2A (rs3918290) Overall toxicity (6.71 [1.66-27.1], p=0.0075) (5-FU in.)
Diarrhoea (7.71 [1.61–36.9], p=0.011) (5-FU in.)
Mucositis/stomatitis (7.15 [1.75–29.1], p=0.0061) 
(5-FU bo.)
Neutropenia (12.90 [3.13–53.3], p=0.00040) (5-FU bo.)
c.2846A>T (rs67376798) Overall toxicity (9.35 [2.01–43.4], p=0.0043) (cap)
Diarrhoea (3.14 [0.82–11.9], p=0.093) (cap)
Hand-foot syndrome (1.31 [0.35–4.96], p=0.69) (cap)
DPYD*2A (rs3918290)
c.2846A>T (rs67376798)




DPYD*2A (rs3918290) Overall toxicity (*2.85 [1.75–4.62], p<0.0001)
c.2846A>T (rs67376798) Overall toxicity (*3.02 [2.22–4.10], p<0.0001)
DPYD*13 (rs55886062) Overall toxicity (*4.40 [2.08–9.30], p<0.0001)
Gastrointestinal toxicity (*5.72 [1.40–23.33], p=0.015)
Haematological toxicity (*9.76 [3.03–31.48], p=0.00014)
c.1236G>A/HapB3 
(rs56038477)
Overall toxicity (*1.59 [1.29–1.97], p<0.0001)
Gastrointestinal toxicity (*2.04 [1.49–2.78], p<0.0001)




rs12132152 (AF: 0.03) Overall toxicity (3.83 [3.26–4.40], p=4.31*10–6) (cap)
Hand-foot syndrome (6.12 [5.48–6.76], p=3.29*10–8) (cap)
Diarrhoea (0.44 [0–1.32], p=0.065) (cap)
rs12022243 (AF: 0.22) Overall toxicity (1.69 [1.45–1.94], p=2.55*10–5) (cap)
Hand-foot syndrome (1.43 [1.16–1.7], p=0.0096) (cap)




rs76387818 Overall toxicity (4.05 [3.47–4.62], p=2.11*10–6) (cap)
Hand-foot syndrome (6.44 [5.79–7.09], p=1.75*10–8) (cap)
Diarrhoea (0.44 [0–1.33], p=0.071) (cap)
rs7548189 Overall toxicity (1.67 [1.43–1.91], p=3.79*10–5) (cap)
Hand-foot syndrome (1.42 [1.15–1.69], p=0.011) (cap)
Diarrhoea (1.21 [0.84–1.58], p=0.0015) (cap)
table continues
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Group DPYD variant Association with 5-FU and/or capecitabine grade ≥3 
toxicity




c.496A>G (rs2297595) Overall toxicity (5.94 [1.29–27.22], p=0.022) (cap)








Hand-foot syndrome (p<0.02) (cap)
Brief summary of a few selected studies showing the results of DPYD variants and their associations 
with 5-FU and/or capecitabine induced severe toxicity. Included are three meta-analyses and three 
more recent papers. Results originating with only 5-FU or only capecitabine are explicitly marked. 
Rosmarin et al. have also tested 5-FU infusion and 5-FU bolus separately. Meulendijks et al. have 
described RR values, not OR values, as shown by *.  
Abbreviations: 5-FU: 5-fluorouracil; in: infusion; bo: bolus; cap: capecitabine; CI: confidence interval; 
OR: odds ratio; RR: relative risk; AF: allele frequency.
Table 2. Test characteristics of genotyping for DPYD*2A and c.2846A>T
Test characteristics Terrazzino et al.9 Rosmarin et al.8
Sensitivity 14.5% 11.8%
Specificity 97.6% 98.4%
Positive predictive value 19.8% 23.6%
Negative predictive value 96.5% 96.4%
Number needed to screen (i.e. genotype) 210 patients 251 patients
Number needed to treat (i.e. apply dose adjustments) 6 patients 5 patients
Clinical utility test characteristics of genotyping for DPYD*2A and c.2846A>T, calculated using “The 
HuGE Risk translator”33 for Terrazzino et al. and Rosmarin et al.
Clinical implementation of DPD deficiency testing
Advantages and disadvantages of phenotyping and genotyping as possible DPD deficiency 
screening methods were described previously29 and several institutes53-59 have executed 
(prospective) screening of DPYD variants or DPD deficiency in a study context. Unfortunately, 
available literature of clinical implementation remains limited to only a few centres in 
France, Germany, the Netherlands, Ireland and the United States of America (USA).44,53,60,61 
An established and well-recognised DPYD clinical implementation program is that of the 
‘Institut de Cancerologie de l’Ouest’ in Angers (France) where screening for DPD deficiency 
has been a regular procedure for over 10 years. Besides this institute, over 100 centres 
in France use the ‘Onco Drug Personalized Medicine’ or ODPM Tox™ and 2,000 patients 
are being screened with this approach every year.62,63 Boisdron-Celle et al. describe a 
large trial in which 11,104 patients were prospectively screened (combining genotyping 
and phenotyping) and patients with a DPYD variant or decreased DPD activity received 
an individual dose adjustment. Genotyping in the trial consisted of 24 mutations in DPYD 
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and phenotyping included the DHU/U ratio. Two hundred forty seven patients with grade 
3–5 toxicity were retrospectively tested. In total, 3% of all patients carried one or more 
mutations. Twenty seven out of 247 retrospectively tested patients died of whom 16 (59%) 
and 24 (89%) were identified with genotyping or phenotyping, respectively. The combined 
approach would have identified 98% of grade 3–5 toxicity patients and 100% of mortalities.63 
(Cost) Effectiveness of DPD deficiency testing
A prospective, multicentre study was conducted by Deenen et al., in which 2,038 patients 
were screened for DPYD*2A prior to start with 5-FU or capecitabine.64 Twenty-two patients 
(1.1%) were heterozygous carriers of DPYD*2A and patients received an initial dose reduction 
of 50% when starting therapy, followed by dose titration based on clinical tolerance. Toxicity 
results showed that the risk of grade ≥3 toxicity was significantly reduced to 28% compared 
to 73% in historical controls (p<0.001). Drug-induced death reduced from 10% to 0%. This 
study convincingly shows that pre-treatment genotyping of DPYD*2A followed by dose 
adjustment in carrier patients improves patient safety. A cost analysis was executed using a 
decision analytic model from a health care payer perspective, including only direct medical 
costs. Genotyping costs were €75 per test. The average total treatment cost per patient was 
slightly lower for screening (€2,772) than for non-screening (€2,817). The approach was 
shown to be feasible in routine clinical practice.64 Ahmed et al. presented a cost analysis of 
a retrospective screening for four DPYD variants in 31 patients who experienced grade 3–5 
toxicity. Five patients carried a variant and were admitted to the ICU due to toxicity. The costs 
of hospital admission (€155,083) were much higher than the screening costs of all patients 
starting with fluoropyrimidine therapy for CRC during the study period (€26,800).53 Another 
retrospective study of 48 patients shows cost effectiveness with DPYD screening costs 
for four variants being almost nine times lower than hospital admissions of four patients 
(£1,776 versus £15,525; approximately €2,500 versus €21,500).58 We must bear in mind 
that genotyping technology is developing fast and prices continue to decline.37 Phenotyping 
tests have been recently reviewed by van Staveren et al., and to our knowledge, to date no 
additional cost-effectiveness analysis for a phenotyping test has been published.29
Recommendations and guidelines of DPYD pharmacogenomics 
Warnings or contraindications for using 5-FU/capecitabine in DPD deficient patients are stated 
by the FDA and EMA.65,66 This is meaningless without knowing, and thus testing a patient 
for DPD deficiency. No formal recommendations on pre-therapeutic (upfront) screening for 
DPD deficiency are given by health authorities, regulatory agencies or guideline committees 
from the National Comprehensive Cancer Network or American Society of Clinical Oncology. 
The European Society for Medical Oncology explicitly states that they do not recommend 
upfront routine testing for DPD deficiency despite the risk of severe and potential lethal 
toxicity.67 It is unknown to us what arguments underlie this recommendation. Only in cases 
of severe toxicity due to 5-FU treatment DPD deficiency screening is strongly recommended, 
and exposure to standard dose of 5-FU is contraindicated in proven DPD deficiency patients, 
according to guidelines published in 2012.67 The lack of official recommendations on pre-
therapeutic genotyping is limiting the process of implementation. One of the reasons may 
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be that such a recommendation is drug-specific and not tumour-type specific while oncology 
guidelines are traditionally tumour-type specific (e.g. KRAS mutation, human epidermal 
growth factor receptor 2 (HER2) expression).
 The Clinical Pharmacogenetics Implementation Consortium and the Dutch 
Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association provide 
evidence-based guidelines and recommendations what dose adjustments to apply in 
DPYD variant allele carriers.37,68,69 Recommendations depend on the DPYD allele and carrier 
status (heterozygous, homozygous), and are guided by the gene activity score. After initial 
reduction dosages can be further titrated based on clinical tolerance. Dose reductions are 
75, 50 or 25% for gene activity scores of 0.5, 1 and 1.5, respectively. The gene activity score 
varies from 0 (no DPD activity) to 2 (normal DPD activity).38,69 
Barriers for clinical implementation
Potential barriers hampering the clinical implementation of prospective DPYD testing are:
 ‘Perceived lack of scientific evidence’;
The evidence for the association of DPYD variants and severe fluoropyrimidine-induced 
toxicity has been discussed and is considered convincing. Furthermore, an RCT is considered 
unethical and unnecessary.
 ‘There is a lack of laboratory facilities and there is no reimbursement’;
The number of laboratories that offer genetic testing for DPYD is continuously increasing, 
techniques are easier to operate and prices for genetic testing will continue to decrease.37 
The cost of a DPYD genetic test is currently in the range of €50 to €100. These amounts are 
negligible compared to the costs of treatment that could easily reach €10,000 or more.70 
This genetic test (which is a once-in-a-lifetime test when no additional SNPs are added) 
should be as normal as testing for other contraindications for drugs such as liver enzymes, 
renal function or physical condition. Laboratories usually offer the test with a turnaround 
time of 2–3 days which is acceptable and does not result in treatment delay, which is a 
serious concern of clinicians and patients. 
 ‘There is not enough guidance on how to use the test’;
Peer reviewed guidance on how to use the outcomes of the genetic test is well covered.37,38,68,69
 ‘There is a risk of underdosing patients’;
Guidelines advise to reduce the dose of fluoropyrimidines in the first cycle in patients 
carrying DPYD variants associated with decreased DPD activity to create similar systemic 
drug levels compared to wild-type patients. In the following cycles tolerance-guided dose 
titration is used to create the most optimal treatment. This strategy minimises the risk for 
underdosing. In addition, 5-FU and capecitabine are often used in combination with other 
anti-cancer drugs, so only a fraction of the total therapy is reduced. 
 ‘Phenotyping tests are more specific’;
Phenotyping tests measuring DPD enzyme activity directly are more closely predicting DPD 
deficiency as compared to DPYD genotyping. However, DPD enzyme measurements are also 
more expensive, more time consuming, have dreadful logistics (can be time-dependent), 
high turnaround-times (>1 week) and only a very limited number of laboratories provide 
the tests. For these reasons DPD enzyme activity measurements are less likely to be 
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implemented as a routine clinical test compared to the genotyping test. 
 ‘Genetic screening does not predict DPD deficiency perfectly’;
Patients who do not carry a DPYD variant can still develop severe side-effects and patients 
carrying a DPYD variant do not necessarily develop toxicity. Clearly, as with other drugs, 
other patient and treatment characteristics also influence the risk of severe toxicity. The 
sensitivity and specificity shall for this reason never reach 100% as discussed above. In 
the USA, with a population of 300 million, there are 1,300 deaths each year due to 5-FU 
induced toxicity.71 More than half of the deceased patients could have been identified using 
genotyping according to Boisdron-Celle et al.63
Summary
Although pharmacogenomics in general has the potential to result in safer use of drugs 
by supporting individualised therapy, this unfortunately has not resulted in clinical 
implementation of DPYD screening in the oncology field. Based on the available evidence, 
we argue that upfront DPYD screening using a pharmacogenomic test in patients planned 
to be treated with a fluoropyrimidine should become the standard of care. Treatment with 
fluoropyrimidines has been the cornerstone chemotherapy for several oncological indications 
for more than 50 years, and will probably continue to stay so. With the increasing incidence 
of cancer the number of patients who are likely to be treated with a fluoropyrimidine 
drug will increase, as well as the number of patients that would be saved from 5-FU or 
capecitabine induced severe toxicity when using pre-treatment genetic screening. In 2010, 
Ciccolini et al. already pointed out that it was time to mandate the integration of systematic 
prospective testing for DPYD as part of routine clinical practice in oncology.10 Based on the 
arguments given above we truly believe it is time to add upfront DPYD genotyping to the 
current guidelines and to start implementation of DPYD screening without further delay. 
When upfront testing followed by dose adjustments is fully functional as part of routine 
clinical practice we can expect that grade ≥3 fluoropyrimidine-related toxicity substantially 
decreases without the risk of underdosing. 
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The dihydropyrimidine dehydrogenase enzyme (DPD, encoded by the gene DPYD) plays 
a key role in the metabolism of fluoropyrimidines. DPD deficiency occurs in 4─5% of the 
population and is associated with severe fluoropyrimidine-related toxicity. Several SNPs 
in DPYD have been described that lead to absent or reduced enzyme activity, including 
DPYD*2A, DPYD*13, c.2846A>T and c.1236G>A/haplotype B3. Since these SNPs differ in 
their effect on DPD enzyme activity, a differentiated dose adaption is recommended. We 
propose the gene activity score for translating DPYD genotype into phenotype, accounting 
for differences in functionality of SNPs. This method can be used to standardize individualized 
fluoropyrimidine dose adjustments, resulting in optimal safety and effectiveness.
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The fluoropyrimidine anticancer drug 5-fluorouracil (5-FU) and its oral prodrug capecitabine 
are frequently used in the treatment of a variety of cancers, including breast, colorectal, head 
and neck and gastric cancer. The dihydropyrimidine dehydrogenase enzyme (DPD), encoded 
by the gene DPYD, plays a key role in the metabolism of fluoropyrimidines. Over 80% of the 
administered dose of 5-FU is metabolized by DPD in the liver into the inactive metabolite 
5,6-dihydro-5-fluorouracil, which makes DPD the rate-controlling enzyme for inactivation of 
5-FU.1 DPD deficiency occurs in 4─5% of the population and results in decreased inactivation 
of 5-FU. This can lead to an increase in active metabolites of 5-FU which is associated with an 
increased risk of severe and even fatal toxicity.2-4 Toxicity could be limited by exposing DPD-
deficient patients to a decreased dose of fluoropyrimidines, to keep plasma levels of 5-FU and 
its metabolites at a therapeutic level for these patients. Over 30 genetic polymorphisms in 
DPYD have been described among which several lead to reduced function or a nonfunctional 
DPD enzyme.4-6 Polymorphisms can appear in heterozygous form (one SNP on one allele), 
homozygous form (two identical SNPs on two alleles) or double heterozygous form (two 
different SNPs on either one or two alleles, the latter is also called compound heterozygous). 
Two SNPs on two alleles lead to a larger decrease in DPD enzyme activity, compared with 
the heterozygous form. An example of a DPYD polymorphism is the splice-site variant 
DPYD*2A (IVS14+1G>A; c.1905+1G>A; rs3918290), which leads to deletion of exon 14 
and hence a nonfunctional DPD enzyme and is the most studied polymorphism in DPYD. 
 In recent years, genotyping costs have dropped significantly and pre-emptive testing for 
single or multiple SNPs to guide treatment with fluoropyrimidines has become accessible. 
Upfront genotype-directed dose adaptation of fluoropyrimidines is feasible and has been 
shown to increase safety for patients and to be cost-effective for DPYD*2A.7,8 However, only 
a minority of institutions have implemented screening programs as standard of care.9-11 
Some physicians are reluctant to implement upfront genotype-guided dosing due to a lack 
of results from prospective randomized studies comparing genotype-guided and traditional 
dosing. The only prospective randomized study was terminated prematurely for ethical 
reasons as one patient in the control arm died due to 5-FU-related toxicity.12
 In addition to DPYD*2A, other SNPs in DPYD have been described to result in decreased 
DPD enzyme activity, including DPYD*13 (c.1679T>G; I560S; rs55886062), c.2846A>T 
(D949V; rs67376798) and c.1236G>A (E412E; rs56038477, in haplotype B3).13-15 However, 
not all of these SNPs result in a similar decrease in DPD enzyme activity as DPYD*2A.3,14,16 
As a result of the growing number of alleles and their range of activity, deriving DPD 
phenotype from genotype is increasingly challenging. In the near future the number of 
alleles will increase even further, since genetic testing is developing fast and single SNP 
testing might be replaced by testing SNP panels, whole exome sequencing or even whole 
genome sequencing. Consequently, there is a need for an individualized recommendation 
of dose adjustment of fluoropyrimidines, taking into account the specific genetic variants 
and their resulting reductions in DPD enzyme activity. In this paper we describe a method 
for translation of DPYD genotype into DPD phenotype making use of the gene activity score. 
This method accounts for the differences in functionality of the SNPs in DPYD, which results 
in a more differentiated dose adjustment and thus in optimal safety and effectiveness. 
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Previous guidelines and recommendations 
According to the US FDA and EMA capecitabine and 5-FU are contraindicated in patients with 
a known DPD deficiency.17,18 However, no recommendations are given for upfront screening 
for DPD deficiency and no distinction is made between heterozygous or homozygous DPD-
deficient patients. Also the American Society of Clinical Oncology, European Society for 
Medical Oncology and National Comprehensive Cancer Network do not state any genotyping 
guidelines or recommendations prior to fluoropyrimidine treatment. In the guideline of 
the Clinical Pharmacogenetics Implementation Consortium (CPIC, a network that provides 
guidelines on the translation of genetic laboratory tests into actionable prescribing 
decisions) patients heterozygous for DPYD*2A, DPYD*13 or c.2846A>T are considered to 
have intermediate or partial DPD enzyme activity and recommended for these patients is 
an initial dose reduction of at least 50% (no dosing recommendations are given for other 
SNPs, including c.1236G>A, because evidence on these variants was considered weak or 
conflicting).19 Also the Pharmacogenetics Working Group of the Royal Dutch Society for the 
Advancement of Pharmacy (KNMP) has provided guidelines. They recently updated their 
online guidelines for dose adjustments for fluoropyrimidines from a 50% dose reduction 
for heterozygous carriers to more specified dose reductions of 25 or 50% in heterozygous 
carriers of a SNP in DPYD (depending on the specific SNP), and 50, 75 or 100% in patients 
carrying more than one SNP in DPYD.20,21 We consider the dosing guidance of the CPIC and 
KNMP very useful and would like to add the gene activity score to these guidelines. With the 
gene activity score we can facilitate in a more specific dose adjustment in fluoropyrimidine 
treatment using current knowledge on differences in DPD enzyme activity due to DPYD 
variants. 
Known DPYD alleles and their effect on DPD enzyme activity
DPYD*2A (rs3918290)
DPYD*2A is the most widely studied polymorphism in DPYD. The SNP was first described 
by Vreken et al. in a case series of two unrelated patients.22 and McLeod et al. named it 
DPYD*2A in an article in which the nomenclature for a series of DPYD SNPs was defined.23 
Allele frequencies of DPYD*2A have been reported to vary between ∼0.1 and 1.0% in 
African-American and Caucasian populations, respectively.13,19,24,25 DPYD*2A leads to 
skipping of the entire exon 14 and deletion of 165 base pairs which results in a truncated 
protein that is catalytically inactive.22,26 This was recently confirmed in a study by Offer et 
al. where in an in vitro model of DPD activity several DPYD variants were homozygously 
expressed in mammalian cells and the enzymatic activity of expressed protein was 
completely absent.27 This indicates that in heterozygous carriers of this variant, who have 
one dysfunctional allele and one functional allele, ∼50% of the normal DPD enzyme activity 
will remain. Furthermore, a correlation between the DPYD*2A variant and reduced enzyme 
activity in peripheral blood mononuclear cells (PBMCs) was found in several ex vivo studies 
that confirmed decreased function of DPYD*2A26,28-30 and consequently an association was 
also found between DPYD*2A and reduction in fluoropyrimidine clearance in patients.31,32 
In numerous studies an association between DPYD*2A allele carriership and the increased 
risk of toxicity related to fluoropyrimidine treatment was confirmed.4,24,31,33-45 For example, 
DPYD gene activity score
43
3
in a meta-analysis by Terrazzino et al. a strong correlation between the DPYD*2A allele and 
overall grade >3 toxicity was found (odds ratio [OR] 5.42, p<0.001).33 Deenen et al. described 
a mean capecitabine dose reduction of 50%, guided by toxicity, in patients carrying DPYD*2A, 
compared with a mean dose reduction of 10% in wild-type patients.42 Also, an initial dose 
reduction of capecitabine or 5-FU of 50% of standard dose has proven to decrease the risk 
of severe toxicity in DPYD*2A carriers.7,8 The above mentioned in vitro, ex vivo and in vivo 
studies provide solid evidence for the nonfunctionality of DPYD*2A and a 50% reduced 
function in patients heterozygous for DPYD*2A.
c.2846A>T (rs67376798)
The c.2846A>T variant allele was first described by van Kuilenburg et al. in 2000.28 The 
c.2846A>T polymorphism leads to a structural change in the DPD enzyme that interferes 
with cofactor binding or electron transport.16 Reported allele frequencies of c.2846A>T vary 
from 0.1 to 1.1% in African-Americans and Caucasians, respectively.13,19,24,46 In vitro data show 
that homozygous expression of the c.2846A>T variant results in an activity of 59% compared 
with wild-type (p=0.0031).13 Although the enzyme activity of c.2846A>T is significantly 
impaired, it is not comparable to the extent observed for DPYD*2A, where homozygous 
expression resulted in a completely nonfunctional enzyme.27 This finding that homozygous 
expression of c.2846A>T results in ∼50% reduction, suggests that a heterozygous carrier 
would have around 25% reduction in DPD activity. Furthermore, also in clinical practice 
a difference between the effect of the DPYD*2A variant and the c.2846A>T variant has 
been observed. Deenen et al. described an average 25% dose reduction for c.2846A>T 
heterozygous patients in response to fluoropyrimidine-related toxicity, compared with 50% 
for DPYD*2A heterozygous patients.42 Although there are less publications for c.2846A>T 
than for DPYD*2A, several studies and two meta-analyses found an association between the 
c.2846A>T variant and increased risk of severe fluoropyrimidine-associated toxicity, which 
indicates that a dose reduction is warranted.4,24,33,36,41,42,44,45,47 In the study by Rosmarin et al. 
an OR of 9.35 (p=0.0043) was found between c.2846A>T and capecitabine-related severe 
(grade >3) toxicity.47 The evidence described above shows that c.2846A>T has rest-activity 
left, but that a dose reduction would still be required to prevent toxicities that would occur 
using a full dose of fluoropyrimidines. Therefore, based upon the available evidence we can 
assume that a dose reduction of 25% is most rational.
DPYD*13 (rs55886062)
DPYD*13 was first described by Collie-Duguid et al. as “T1679G”.48 The allele frequency was 
found to vary from 0.07 to 0.1% in Caucasians.19,24 The precise functional consequences 
of the DPYD*13 variant have not yet been unraveled, but are thought to be related to 
destabilization of a sensitive region of the protein.16 DPYD*13 has been found in patients 
with decreased enzyme activity, not in patients showing normal DPD enzyme activity.29 
Homozygous expression of this variant resulted in a 75% reduction of DPD enzyme activity 
compared with wild-type, as reported in an in  vitro  study by Offer et al.27 This suggests 
that this variant almost completely inactivates the protein. Decreased DPD enzyme activity 
in patients with the DPYD*13 variant was determined only in a limited number of ex vivo 
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studies using PBMCs.16,29,30,48 A major variation of enzyme activity was found, ranging from 
1.7 times to 500 times decreased as compared with the normal enzyme activity and once the 
enzyme activity was undetectable,30 although it must be mentioned that these results could 
be influenced by other copresent DPYD variants. Patients with DPYD*13 showed severe 
toxic side effects in several studies.4,24,29,44,48,49 Also dose adjustments were described by two 
groups.4,24 Morel et al. described a heterozygous patient that experienced severe grade 4 
toxicity. After a 6-week treatment interruption, 5-FU was safely reintroduced with individual 
pharmacokinetic adjustment, based on 5-FU plasma levels.4 The above mentioned studies 
show that DPYD*13 results in an almost nonfunctional enzyme and consequently low 
enzyme activity levels. Without a dose reduction toxicities are likely to develop, however 
safe use of 5-FU is still possible with a dose adjustment. We suggest a starting dose of 50% 
for patients carrying DPYD*13 to ensure safe and effective use of fluoropyrimidines. 
c.1236G>A/HapB3 (rs56038477)
The c.1236G>A variant was first described by Seck et al., as a silent mutation that displays 
normal DPD enzyme activity.46 The c.1236G>A polymorphism occurs in exon 11 and is a 
synonymous variant that is in complete linkage with c.483+18G>A, c.680+139G>A, c.959-
51T>G and c.1129-5923C>G;14 these variants in linkage have been termed haplotype B3.14,15 
The c.1129-5923C>G intronic polymorphism (rs75017182) results in aberrant splicing and is 
likely to be the responsible variant for the effect on DPD enzyme activity.3,14 The frequency 
of heterozygous patients in Caucasian populations was reported to vary between 2.6 and 
6.3%.14,15,42,49,50 DPD enzyme activity for c.1236G>A carriers was measured in PBMCs in two 
studies.14,46 Enzyme activities were reported to be 2.9, 4.2, 6.2 and 1.6 nmol/(mg*h) (normal 
value=9.6±2.6 nmol/[mg*h]) for one homozygous and three heterozygous carriers of 
c.1236G>A, respectively.14 In addition, a heterozygous patient in another study was found to 
have an enzyme activity of 10.2 nmol/(mg*h), which was reported as ‘normal activity’, since 
the enzyme activity of the population ranged from 4.8─15 nmol/(mg*h).46 Unfortunately 
data on c.1236G>A and enzyme activity are limited and not consistent. The homozygous 
patient still had 30% DPD activity remaining.18 Furthermore we observed two homozygous 
patients with this variant in our own institute with a relevant DPD enzyme activity left of 
around 50%, showing that this variant does not result in a completely nonfunctional enzyme 
(author’s unpublished data). In the study of Sistonen et al. the ratio between endogenous 
dihydrouracil (DHU) and uracil (U) was measured in patients carrying the c.1129-5923C>G 
variant.50 This ratio can be used as a phenotyping marker for DPD enzyme activity, as 
described in several studies.51-55 Sistonen et al. found a statistically significant decrease in 
DHU/U-ratio compared with wild-type patients (p=0.044). However, no significant effect 
for the other DPYD risk variants (DPYD*2A, DPYD*13 and c.2846A>T) was observed, which 
might be caused by the small sample size of patients with those variants. The c.1236G>A/
HapB3 variant has been associated with severe and lethal toxicity.14,15,42,49,56 For example, 
Froehlich et al. found a relative risk of 3.74 (p=2x10-5) in c.1236G>A/HapB3 carriers for 
severe toxicity (grade 3─5).49 In contrast, no significant effect of the c.1236G>A/HapB3 
variant was found in two other studies.44,47 A dose reduction to prevent toxicity may be 
advantageous since multiple studies found a correlation with severe toxicity; however the 
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degree of dose reduction cannot easily be determined with the enzyme activity from only 
two published studies and conflicting results in clinical studies. In heterozygous patients, 
a dose reduction of 50% would be too large since c.1236G>A/HapB3 does not result in a 
completely nonfunctional enzyme. No dose reduction at all would be in contradiction to 
the correlation found between this variant and toxicity. Therefore a more cautious dose 
reduction of 25% seems appropriate, to avoid both increased risk of toxicity and prevent 
underdosing. 
 Also our own experimental data support the differentiation between various SNPs in 
DPYD. We determined the endogenous pretreatment ratio between DHU and U in a large 
cohort of patients (N=539) treated with capecitabine or 5-FU.57 This cohort is a subset 
of patients participating in a prospective multicenter trial of DPYD*2A-guided dosing of 
fluoropyrimidines (clinicaltrials.gov identifier: NCT00838370).7,8 The DHU and U levels 
were measured in pretreatment serum samples using a validated LC-MS/MS method,58 
chromatographic separation was performed on an Acquity UPLC® HSS T3 column (150 x 
2.1 mm ID, particle size 1.8 μm), and a triple quadruple mass spectrometer (API5500, AB 
Sciex, USA) was used for quantification of U and DHU. The method was validated over a 
concentration range of 1 to 100 ng/ml for U and 10 to 1000 ng/ml for DHU. Genotyping 
of DPYD variants was performed using standard PCR methods. A distinction was made 
between patients heterozygous for DPYD*2A, c.2846A>T, DPYD*13 or c.1236G>A and wild-
type patients (Figure 1). For patients heterozygous for DPYD*2A, c.2846A>T, DPYD*13 and 
c.1236G>A the median relative DHU/U ratio compared with wild-type is 52, 68, 50 and 
101% respectively. These results confirm that DPD enzyme activity differs between carriers 
of certain DPYD polymorphisms and points toward a differentiated dose reduction for each 
individual SNP.
Gene activity score
The gene activity score method is based on the principle that variant alleles can differ in 
the extent to which they influence enzyme activity. Such a method was first described by 
Steimer et al. where a ‘quantitative functional gene dose’ is assigned to alleles of the gene 
CYP2D6, a highly polymorphic gene that is involved in the metabolism of various clinically 
used drugs, including antidepressants, antipsychotics and opioids.59 Thereafter Gaedigk et 
al. introduced the ‘activity score’ and divided CYP2D6 alleles in three categories, consisting 
of fully functional alleles (value of 1), reduced activity alleles (value of 0.5) and nonfunctional 
alleles (value of 0).60 The values for both alleles of a patient are summed, leading to an 
individual gene activity score that represents the enzymatic phenotype of the patient. This 
method results in a uniform way of describing phenotypes and can be used for adjusting the 
dose of a drug. For CYP2D6 it has been demonstrated that the gene activity score is valid 
and easy-to-use for translating genotype and predicted phenotype.60 The gene activity score 
may also be useful to properly interpret different DPD enzyme activities, translate these into 
a phenotype and thus personalize fluoropyrimidine treatment according to DPYD genotype. 
With this tool a more precise distinction between nonactive and reduced activity alleles can 
be made and it also provides the possibility to include novel SNPs which may be identified 
in the near future using whole exome and whole genome sequencing. The activity score as 
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proposed by Gaedigk et al. has proven beneficial for CYP2D6, for which a large number of 
polymorphisms are known. 
 
Figure 1. DHU/U ratio according to DPYD genotype 
Shown are individual values and a box plot with the median of the DHU/U ratio for patients with a 
DPYD polymorphism or DPYD wild-type patients. 
Abbreviations: DHU: Dihydrouracil, U: Uracil
We have fully investigated and described four SNPs in DPYD (DPYD*2A, c.2846A>T, DPYD*13, 
c.1236G>A/HapB3). This literature review describes what DPD enzyme activities are to be 
expected in patients with a certain SNP in DPYD. In addition to that, we have shown additional 
data of pretreatment DHU/U ratio in correlation to DPYD*2A, c.2846A>T, DPYD*13 and 
c.1236G>A. We focus on these four SNPs because, based on the available literature data, we 
believe they are the most relevant. Additional SNPs can be easily added to the gene activity 
score in the future when sufficient data are available. An outline for the suggested assigned 
values to various alleles of DPYD is given in Table 1. So far only the four SNPs described above 
are included, because sufficient evidence is available that they result in low DPD enzyme 
activity and severe fluoropyrimidine-related toxicity. Consequently, following the calculated 
gene activity scores for DPYD an individualized dose recommendation for fluoropyrimidines 
can be given, as is shown in Table 2. This is a recommendation for a starting dose; after the 
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first or second cycle the dose can be titrated according to tolerance. Wild-type patients 
have two fully functional alleles, are allocated the maximal gene activity score of 2 and will 
receive the standard starting dose. Patients heterozygous for DPYD*2A or DPYD*13 have 
one nonfunctional allele and one fully functional allele, will therefore have an expected 
DPD enzyme activity of 50% and receive a gene activity score of 1. The recommended dose 
reduction of capecitabine or 5-FU for those patients is 50%. Patients carrying one allele with 
the c.2846A>T or c.1236G>A/HapB3 variant will have one decreased activity allele and one 
fully functional allele, which results in DPD enzyme activity of ∼75% of normal. They are 
allocated a gene activity score of 1.5, for which a recommended starting dose of 75% of the 
standard dose applies. 
Table 1. Values for activity assigned to alleles of DPYD
Activity Value Alleles Ref.
0 DPYD*2A (rs3918290) 4,8,10,11,19,27,29-46
DPYD*13 (rs55886062) 4,19,30,32,33,46,49,50
0.5 c.2846A>T (rs67376798) 4,13,24,33,36,41,42,44,47
c.1236G>A/HapB3 (rs556038477) 14,15,42,44,46,47,49,50,56
1 DPYD *1 (wild-type)
These values for both alleles of a patient are summed, leading to an individual gene activity score.
Table 2. Initial dose recommendation for DPYD gene activity score







There is ample evidence that shows that DPD-deficient patients develop severe toxicities 
when treated with a normal dose of fluoropyrimidines. Even though this relation is widely 
known, there is no global systematic approach to prevent severe toxic side effects using DPYD 
polymorphisms as predictive markers. Upfront DPYD*2A screening has been implemented 
in a limited number of institutions and other SNPs are increasingly added to the standard 
genetic screening. Testing for an increasing number of SNPs that result in different DPD 
enzyme activities makes it harder to derive a dosing advice. The gene activity score is a new 
method for translating DPYD genotype into DPD phenotype. It can be used to standardize 
the process of describing DPD enzyme activity, which stimulates uniformity. In the CPIC 
guideline a dose recommendation of 50% is advised for DPYD*2A, DPYD*13 and c.2846A>T.19 
In the gene activity score as proposed in this manuscript we adopt these recommendations 
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for DPYD*2A and DPYD*13, but deviate in the dose advice for c.2846A>T and include a 
dose advice for c.1236G>A/HapB3. We have summarized in vitro, ex vivo and in vivo studies 
to determine the appropriate dose recommendation for these SNPs. In addition, we have 
shown our own experimental data. Our data are in agreement with previous data and show 
a 50% reduced DPD enzyme activity in patients heterozygous for DPYD*2A and DPYD*13 
and an ∼25% decreased activity for heterozygous patients with c.2846A>T. Unfortunately, 
our data on c.1236G>A do not correspond and additional data containing DPD enzyme 
activity measurements in patients with c.1236G>A/HapB3 are scarce and not in agreement. 
Including our study, three out of four studies suggest that c.1236G>A results in an enzyme 
activity close to normal levels. However, Sistonen et al. showed a significant reduction in 
DHU/U ratio in patients carrying this variant50 and associations with the development of 
severe toxic side effects have also been described. The toxicity data point out that a dose 
reduction for c.1236G>A/HapB3 is required, but a dose reduction of 50% would be too 
large considering the measured enzyme activities. Therefore a dose reduction to 75% of 
the normal dose for heterozygous patients seems appropriate in order to prevent toxicity as 
well as to prevent underdosing. After the initial dose reduction the patient should be closely 
monitored and the dose can be adjusted according to occurring toxicity.
 Currently only four SNPs in DPYD are allocated a gene activity score, since we consider 
these variants are the most relevant polymorphisms. It has been described before that 13 to 
19 variants are expected to result in DPD deficiency61,62. However, more research is necessary 
on the effect of these other SNPs on DPD enzyme activity before they can be included in the 
gene activity score. With the gene activity score approach it is possible to continuously keep 
adding variant alleles or updating the values of the gene activity score that are assigned to 
variant alleles. When new information on effects on enzyme activity is published, this can 
be included, while the currently proposed gene activity score can already be used in clinical 
practice. In addition, more research is needed with regard to compound heterozygous 
patients (patients who carry two different SNPs) and homozygous patients. These patients 
would benefit from an additional phenotyping test to measure the DPD enzyme activity as 
to determine the optimal dose adjustment or decide to treat with an alternative drug. 
 Both genotyping and phenotypic biomarkers have been proposed in order to predict and 
reduce toxicity in patients. However, the gold standard of phenotyping (measuring DPD 
enzyme activity in PBMCs) is not easy to implement as a routine test and other phenotyping 
methods, such as uracil test dose, endogenous DHU/U ratio and 2-13C-uracil breath test, 
have not yet been fully validated or standardized.63 Compared with phenotyping methods, 
genotyping methods are faster, easier and less expensive, so it is expected that it will be 
implemented more often as standard of care for patients undergoing fluoropyrimidine 
treatment. 
 The dose recommendations described in this article will be implemented in an upcoming 
large prospective clinical trial (NCT02324452) in the Netherlands where upfront genotypic 
assessment of DPYD will be performed for around 1250 patients treated with capecitabine or 
5-FU. Simultaneously, our work was recently implemented by the Dutch Pharmacogenetics 
Working Group by using the gene activity score for translating DPYD genotype into DPD 
phenotype.21 
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 To conclude, we propose using the gene activity score for the translation of DPYD genotype 
into a numeric value that can be easily used to describe DPD phenotype and to advise an 
individualized dose adjustment for the use of fluoropyrimidines. 
Future perspective
We expect that in the future more knowledge will be gained regarding relevant SNPs in DPYD 
other than the ones described in this article. Currently there are 13 to 19 SNPs expected 
to result in DPD deficiency. In addition, SNPs in other genes involved in fluoropyrimidine 
metabolism or mRNA could influence the DPD enzyme activity and could thus in the future 
be added to the activity score. The design of the gene activity score makes it possible to add 
other DYPD SNPs while maintaining a uniform method for describing DPD activity using a 




1. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. 
Nat Rev Cancer. 2003;3(5):330-338.
2. Johnson MR, Diasio RB. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency 
in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv  Enzyme  Regul. 
2001;41:151-157.
3. Amstutz U, Froehlich TK, Largiader CR. Dihydropyrimidine dehydrogenase gene as a major 
predictor of severe 5-fluorouracil toxicity. Pharmacogenomics. 2011;12(9):1321-1336.
4. Morel A, Boisdron-Celle M, Fey L, et al. Clinical relevance of different dihydropyrimidine 
dehydrogenase gene single nucleotide polymorphisms on 5-fluorouracil tolerance. Mol Cancer 
Ther. 2006;5(11):2895-2904.
5. Del Re M, Di Paolo AD, van Schaik RH, et al. Dihydropyrimidine dehydrogenase polymorphisms 
and fluoropyrimidine toxicity: Ready for routine clinical application within personalized medicine? 
EPMA Journal. 2010;1(3):495-502.
6. Hsiao H-H, Lin S-F. Pharmacogenetic syndrome of dihydropyrimidine dehydrogenase deficiency. 
Current Pharmacogenomics. 2007;5(1):31-38.
7. Deenen MJ, Cats A, Mandigers CM, et al. [Prevention of severe toxicity from capecitabine, 
5-fluorouracil and tegafur by screening for DPD-deficiency]. Ned  Tijdschr  Geneeskd. 
2012;156(48):A4934.
8. Deenen MJ, Cats A, Sechterberger MK, et al. Safety, pharmacokinetics (PK), and cost-effectiveness 
of upfront genotyping of DPYD in fluoropyrimidine therapy. J Clin Oncol. 2011;Conference: 
Annual Meeting of the American Society of Clinical Oncology (ASCO) Chicago:20 May 2011.
(suppl: abstract 3606).
9. Boisdron-Celle M, Capitain O, Metges JP, Lecomte T, Matysiak-Budnik T, Morela A. Severe 
fluoropyrimidines toxicities: Screen effectively for DPD deficiencies. Fundamental  and Clinical 
Pharmacology. 2013;Conference: 17th Annual Meeting of French Society of Pharmacology and 
Therapeutics:June 2013.
10. Siffert W. Pharmacogenetics in daily routine clinical practice. Drug Metabol Drug Interact. 
2012;Conference: 6th Santorini Conference Biologie Prospective 2012 Santorini Island Greece.
(var.pagings):A11-A12.
11. Dunnenberger HM, KR C, JM H, et al. Preemptive Clinical Pharmacogenetics Implementation: 
Current Programs in Five US Medical Centers. Annu Rev Pharmacol Toxicol. 2015;55:89-106.
12. Boisdron-Celle M, Capitain O, Metges J-P, et al. Prevention of 5-FU-induced health-threatening 
toxicity by pretherapeutic DPD deficiency screening: Medical and economic assessment of 
a multiparametric approach. J Clin Oncol. 2013;Conference: Annual Meeting of the American 
Society of Clinical Oncology (ASCO) Chicago:20 May 2013.
13. Offer SM, Fossum CC, Wegner NJ, Stuflesser AJ, Butterfield GL, Diasio RB. Comparative functional 
analysis of DPYD variants of potential clinical relevance to dihydropyrimidine dehydrogenase 
activity. Cancer Res. 2014;74(9):2545-2554.
14. Van Kuilenburg ABP, Meijer J, Mul ANPM, et al. Intragenic deletions and a deep intronic mutation 
affecting pre-mRNA splicing in the dihydropyrimidine dehydrogenase gene as novel mechanisms 
causing 5-fluorouracil toxicity. Hum Genet. 2010;128(5):529-538.
15. Amstutz U, Farese S, Aebi S, Largiader CR. Dihydropyrimidine dehydrogenase gene variation and 
DPYD gene activity score
51
3
severe 5-fluorouracil toxicity: a haplotype assessment. Pharmacogenomics. 2009;10(6):931-944.
16. Van Kuilenburg ABP, Dobritzsch D, Meinsma R, et al. Novel disease-causing mutations in the 
dihydropyrimidine dehydrogenase gene interpreted by analysis of the three-dimensional protein 
structure. Biochem J. 2002;364(1):157-163.
17. EMA. European Medicines Agency. Xeloda (capecitabine): EPAR, product information. 2015; 
http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000316/
human_med_001157.jsp&mid=WC0b01ac058001d124. Accessed 29 July 2015.
18. FDA. U.S. Food and Drug Administration. Pharmacogenomic information capecitabine/
fluorouracil 2015; www.fda.gov. Accessed 29 July 2015.
19. Caudle KE, Thorn CF, Klein TE, et al. Clinical Pharmacogenetics Implementation Consortium 
guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin 
Pharmacol Ther. 2013;94(6):640-645.
20. Swen JJ, Nijenhuis M, De BA, et al. Pharmacogenetics: from bench to byte--an update of 
guidelines. Clin Pharmacol Ther. 2011;89(5):662-673.
21. KNMP. Pharmacogenetics Working Group of the Royal Dutch Society for the Advancement of 
Pharmacy. [Background information on DPD pharmacogenetics]. 2014; http://www.knmp.nl/
downloads/g-standaard/farmacogenetica/Algemene-achtergrondtekst-Farmacogenetica-2013-
Dihydropyrimidine-Dehydrogenase.pdf. Accessed 29 July 2015.
22. Vreken P, VanKuilenburg ABP, Meinsma R, et al. A point mutation in an invariant splice donor site 
leads to exon skipping in two unrelated Dutch patients with dihydropyrimidine dehydrogenase 
deficiency. J Inherit Metab Dis. 1996;19(5):645-654.
23. McLeod HL, Collie-Duguid ESR, Vreken P, et al. Nomenclature for human DPYD alleles. 
Pharmacogenetics. 1998;8(6):455-459.
24. Lee AM, Shi Q, Pavey E, et al. DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant 
colon cancer treatment (NCCTG N0147). J Natl Cancer Inst. 2014;106(12).
25. van Kuilenburg AB, Muller EW, Haasjes J, et al. Lethal outcome of a patient with a complete 
dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: 
frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res. 
2001;7(5):1149-1153.
26. van Kuilenburg AB, Vreken P, Beex LV, et al. Heterozygosity for a point mutation in an invariant 
splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. 
Eur J Cancer. 1997;33(13):2258-2264.
27. Offer SM, Wegner NJ, Fossum C, Wang K, Diasio RB. Phenotypic profiling of DPYD variations 
relevant to 5-fluorouracil sensitivity using real-time cellular analysis and in vitro measurement of 
enzyme activity. Cancer Res. 2013;73(6):1958-1968.
28. van Kuilenburg AB, Haasjes J, Richel DJ, et al. Clinical implications of dihydropyrimidine 
dehydrogenase (DPD) deficiency in patients with severe 5-fluorouracil-associated toxicity: 
identification of new mutations in the DPD gene. Clin Cancer Res. 2000;6(12):4705-4712.
29. Ezzeldin HH, Lee AM, Mattison LK, Diasio RB. Methylation of the DPYD promoter: an alternative 
mechanism for dihydropyrimidine dehydrogenase deficiency in cancer patients. Clin Cancer Res. 
2005;11(24 Pt 1):8699-8705.
30. Johnson MR, Wang K, Diasio RB. Profound dihydropyrimidine dehydrogenase deficiency resulting 
from a novel compound heterozygote genotype. Clin Cancer Res. 2002;8(3):768-774.
Chapter 3
52
31. van Kuilenburg AB, Hausler P, Schalhorn A, et al. Evaluation of 5-fluorouracil pharmacokinetics in 
cancer patients with a c.1905+1G>A mutation in DPYD by means of a Bayesian limited sampling 
strategy. Clin Pharmacokinet. 2012;51(3):163-174.
32. van Kuilenburg AB, Maring JG, Schalhorn A, et al. Pharmacokinetics of 5-fluorouracil in patients 
heterozygous for the IVS14+1G > A mutation in the dihydropyrimidine dehydrogenase gene. 
Nucleosides Nucleotides Nucleic Acids. 2008;27(6):692-698.
33. Terrazzino S, Cargnin S, Del RM, Danesi R, Canonico PL, Genazzani AA. DPYD IVS14+1G>A and 
2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-
analysis. Pharmacogenomics. 2013;14(11):1255-1272.
34. Magnani E, Farnetti E, Nicoli D, et al. Fluoropyrimidine toxicity in patients with dihydropyrimidine 
dehydrogenase splice site variant: the need for further revision of dose and schedule. Intern 
Emerg Med. 2013;8(5):417-423.
35. Kristensen MH, Pedersen PL, Melsen GV, Ellehauge J, Mejer J. Variants in the dihydropyrimidine 
dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict 
early toxicity of 5-fluorouracil in colorectal cancer patients. J Int Med Res. 2010;38(3):870-883.
36. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil 
treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study 
Group. J Clin Oncol. 2008;26(13):2131-2138.
37. Salgado J, Zabalegui N, Gil C, Monreal I, Rodriguez J, Garcia-Foncillas J. Polymorphisms in the 
thymidylate synthase and dihydropyrimidine dehydrogenase genes predict response and toxicity 
to capecitabine-raltitrexed in colorectal cancer. Oncol Rep. 2007;17(2):325-328.
38. Largillier R, Etienne-Grimaldi MC, Formento JL, et al. Pharmacogenetics of capecitabine in 
advanced breast cancer patients. Clin Cancer Res. 2006;12(18):5496-5502.
39. Salgueiro N, Veiga I, Fragoso M, et al. Mutations in exon 14 of dihydropyrimidine dehydrogenase 
and 5-Fluorouracil toxicity in Portuguese colorectal cancer patients. Genet Med. 2004;6(2):102-
107.
40. van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. High prevalence of the IVS14 + 1G>A 
mutation in the dihydropyrimidine dehydrogenase gene of patients with severe 5-fluorouracil-
associated toxicity. Pharmacogenetics. 2002;12(7):555-558.
41. Boisdron-Celle M, Remaud G, Traore S, et al. 5-Fluorouracil-related severe toxicity: a comparison 
of different methods for the pretherapeutic detection of dihydropyrimidine dehydrogenase 
deficiency. Cancer letters. 2007;249(2):271-282.
42. Deenen MJ, Tol J, Burylo AM, et al. Relationship between single nucleotide polymorphisms and 
haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin 
Cancer Res. 2011;17(10):3455-3468.
43. Raida M, Schwabe W, Hausler P, et al. Prevalence of a common point mutation in the 
Dihydropyrimidine dehydrogenase (DPD) gene within the 5 ‘-splice donor site of intron 14 in 
patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls. Clinical Cancer 
Research. 2001;7(9):2832-2839.
44. Loganayagam A, Arenas HM, Corrigan A, et al. Pharmacogenetic variants in the DPYD, TYMS, CDA 
and MTHFR genes are clinically significant predictors of fluoropyrimidine toxicity. Br  J Cancer. 
2013;108(12):2505-2515.
45. Joerger M, Huitema AD, Boot H, et al. Germline TYMS genotype is highly predictive in patients 
DPYD gene activity score
53
3
with metastatic gastrointestinal malignancies receiving capecitabine-based chemotherapy. 
Cancer Chemother Pharmacol. 2015;75(4):763-772.
46. Seck K, Riemer S, Kates R, et al. Analysis of the DPYD gene implicated in 5-fluorouracil catabolism 
in a cohort of Caucasian individuals. Clin Cancer Res. 2005;11(16):5886-5892.
47. Rosmarin D, Palles C, Church D, et al. Genetic markers of toxicity from capecitabine and other 
fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-
analysis. J Clin Oncol. 2014;32(10):1031-1039.
48. Collie-Duguid ES, Etienne MC, Milano G, McLeod HL. Known variant DPYD alleles do not explain 
DPD deficiency in cancer patients. Pharmacogenetics. 2000;10(3):217-223.
49. Froehlich TK, Amstutz U, Aebi S, Joerger M, Largiader CR. Clinical importance of risk variants in 
the dihydropyrimidine dehydrogenase gene for the prediction of early-onset fluoropyrimidine 
toxicity. International Journal of Cancer. 2015;136(3):730-739.
50. Sistonen J, Buchel B, Froehlich TK, et al. Predicting 5-fluorouracil toxicity: DPD genotype and 
5,6-dihydrouracil:uracil ratio. Pharmacogenomics. 2014;15(13):1653-1666.
51. Gamelin E, Boissdron-Celle M, Guerin-Meyer V, et al. Correlation between uracil and dihydrouracil 
plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with 
advanced colorectal cancer: A potential interest for predicting 5-FU toxicity and determining 
optimal 5-FU dosage. J Clin Oncol. 1999;17(4):1105-1110.
52. Jiang H, Lu J, Jiang J, Hu P. Important role of the dihydrouracil/uracil ratio in marked interpatient 
variations of fluoropyrimidine pharmacokinetics and pharmacodynamics. J Clin Pharmacol. 
2004;44(11):1260-1272.
53. Wettergren Y, Carlsson G, Odin E, Gustavsson B. Pretherapeutic uracil and dihydrouracil levels 
of colorectal cancer patients are associated with sex and toxic side effects during adjuvant 
5-fluorouracil-based chemotherapy. Cancer. 2012;118(11):2935-2943.
54. Kristensen MH, Pedersen P, Mejer J. The value of dihydrouracil/uracil plasma ratios in predicting 
5-fluorouracilrelated toxicity in colorectal cancer patients. J Int Med Res. 2010;38(4):1313-1323.
55. Ben FR, Gross E, Ben AS, Hassine H, Saguem S. The dihydrouracil/uracil ratio in plasma, clinical 
and genetic analysis for screening of dihydropyrimidine dehydrogenase deficiency in colorectal 
cancer patients treated with 5-fluorouracil. Pathol Biol (Paris). 2009;57(6):470-476.
56. Largiader CR, Amstutz U, Froehlich TK, et al. The dihydropyrimidine dehydrogenase gene as a 
major predictor of severe 5-fluorouracil toxicity: a classic reborn? . Paper presented at: Cold 
Spring Harbor, New York, USA, 17 November-21 November 2010Presented at: 2010 meeting on 
Pharmacogenomics and Personalized Medicine. .
57. Meulendijks D, Henricks LM, Jacobs BAW, et al. Pretreatment serum uracil concentration as a 
predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer. 2017;116(11):1415-
1424.
58. Jacobs BAW, Rosing H, de Vries N, et al. Development and validation of a rapid and sensitive 
UPLC-MS/MS method for determination of uracil and dihydrouracil in human plasma. J Pharm 
Biomed Anal. 2016;126:75-82.
59. Steimer W, Zopf K, von Amelunxen S, et al. Allele-specific change of concentration and 
functional gene dose for the prediction of steady-state serum concentrations of amitriptyline 




60. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ, Leeder JS. The CYP2D6 activity score: 
translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther. 
2008;83(2):234-242.
61. Zhang X, Diasio RB. Regulation of human dihydropyrimidine dehydrogenase: implications in the 
pharmacogenetics of 5-FU-based chemotherapy. Pharmacogenomics. 2007;8(3):257-265.
62. Mattison LK, Soong R, Diasio RB. Implications of dihydropyrimidine dehydrogenase on 
5-fluorouracil pharmacogenetics and pharmacogenomics. Pharmacogenomics. 2002;3(4):485-
492.
63. van Staveren MC, Guchelaar HJ, van Kuilenburg ABP, Gelderblom H, Maring JG. Evaluation 





Dutch Pharmacogenetics Working Group (DPWG) guideline for 
the gene-drug interaction of DPYD and fluoropyrimidines
Submitted (under review)
Carin A.T.C. Lunenburg*, Cathelijne H. van der Wouden*, Marga Nijenhuis, 
Mandy H. Crommentuijn-van Rhenen , Nienke J. de Boer-Veger, 
Anne Marie Buunk, Elisa J.F. Houwink, Hans Mulder, Gerard A. Rongen, 
Ron H.N. van Schaik, Jan van der Weide, Bob Wilffert, Vera H.M. Deneer, 






Despite advances in the field of pharmacogenetics (PGx), clinical acceptance has remained 
limited. The Dutch Pharmacogenetics Working Group (DPWG) aims to facilitate PGx 
implementation by developing evidence-based pharmacogenetics guidelines to optimize 
pharmacotherapy. This guideline describes the starting dose optimization of three anti-
cancer drugs (fluoropyrimidines: 5-fluorouracil, capecitabine and tegafur) to decrease the 
risk of severe, potentially fatal, toxicity; such as diarrhoea, hand-foot syndrome, mucositis 
or myelosuppression. Dihydropyrimidine dehydrogenase enzyme (DPD) deficiency (encoded 
by the DPYD gene) increases risk of fluoropyrimidine-induced toxicity. The DPYD-gene 
activity score, determined by four DPYD variants, predicts DPD activity and can be used to 
optimize an individual’s starting dose. The gene activity score ranges from 0 (no DPD activity) 
to 2 (normal DPD activity). Subjects with a gene activity score of 0 are recommended not 
to initiate fluoropyrimidines. Alternatively, DPD activity may be determined to adjust the 
dose accordingly. Subjects with a gene activity score of 0.5, 1 or 1.5 are recommended to 
initiate therapy with 25%, 50% or 75% of the normal dose of 5-fluorouracil or capecitabine, 
respectively. When initiating tegafur, an alternative chemotherapeutic agent, or a low dose 
is recommended. Dose may be increased in subsequent cycles in patients experiencing no 
or clinically tolerable toxicity. Subjects with a gene activity score of 2 (reference) should 
receive a normal dose. In case it is not possible to calculate the gene activity score based 
on DPYD genotype, we recommend to determine the DPD activity. Based on the DPWG 
clinical implication score, DPYD genotyping is considered “essential”, therefore directing 
DPYD testing prior to initiating treatment with fluoropyrimidines.
Disclaimer
The Pharmacogenetics Working Group of the KNMP (DPWG) formulates the optimal 
recommendations for each phenotype group based on the available evidence. If this 
optimal recommendation cannot be followed due to practical restrictions, e.g. therapeutic 
drug monitoring or a lower dose is not available, then the health care professional should 
consider the next best option. 




The role of heritable genetic variation on drug response is referred to as pharmacogenetics 
(PGx). Germline mutations in pharmacogenetic loci can predict phenotypic differences in 
drug response and can be used to guide dose and drug selection to achieve safer and more 
(cost)effective pharmacotherapy. PGx guided pharmacotherapy is one of the first clinical 
applications of genomics in medicine. Despite scientific and clinical advances in the field of 
PGx, clinical adoption has remained limited. Barriers preventing implementation have been 
previously reported.1 Some of these barriers have been overcome in the past years. One of 
these barriers was the lack of clear guidelines on how to interpret and apply PGx test results. 
 The Royal Dutch Pharmacists Association (KNMP) established the Dutch Pharmacogenetics 
Working Group (DPWG) in 2005 to overcome this barrier.2 The main objectives of the DPWG 
are 1) to develop PGx informed therapeutic recommendations based on systematic literature 
review, and 2) to assist physicians and pharmacists by integrating the recommendations 
into computerized systems for drug prescription, dispensing, and automated medication 
surveillance. This manuscript thus provides both the content required for enabling local 
translation of assay results into the predicted phenotype (in this case the gene activity 
score) and for programming therapeutic recommendations into local clinical decision 
support systems. With the objective of implementing PGx into routine care, the DPWG 
has additionally developed the clinical implication score, which is given to every gene-
drug interaction. The aim of this score is to direct clinicians on whether or not to order 
relevant PGx genotyping tests before initiating therapy. Recently, the DPWG guidelines were 
endorsed by the European Association of Clinical Pharmacology and Therapeutics (EACPT) 
and the European Association of Hospital Pharmacists (EAHP).3,4Other initiatives such as 
the Clinical Pharmacogenetics Implementation Consortium (CPIC) were also established to 
support clinical implementation.5,6 
 The DPWG is a multidisciplinary group in which (clinical) pharmacists, physicians, clinical 
pharmacologists, clinical chemists and epidemiologists are represented. From 2005 onwards, 
the DPWG has systematically executed 90 risk analyses for potential gene-drug interactions 
resulting in 49 guidelines providing therapeutic recommendations for one or more aberrant 
phenotypes.7 Available DPWG guidelines and future updates will be published in an effort 
to provide transparency of their development and to fulfil the public demand for their 
publication. 
 This guideline describes the starting dose optimization of three anti-cancer drugs 
(fluoropyrimidines: 5-fluorouracil, capecitabine and tegafur) to decrease the risk of 
severe, potentially fatal, toxicity; such as diarrhoea, hand-foot syndrome, mucositis or 
myelosuppression. Dihydropyrimidine dehydrogenase enzyme (DPD) deficiency (which is 
encoded by the DPYD gene) increases the risk of fluoropyrimidine-induced toxicity. The gene 
activity score is currently based on the results of four DPYD variants, predicts DPD enzyme 
activity and is used to optimize an individual’s starting dose. The gene activity score ranges 
from 0 (no DPD activity) to 2 (normal DPD activity). This manuscript provides an overview of 
the guideline development and summarizes the pharmacotherapeutic recommendations. 
Additionally, a comparison to alternative guidelines is presented. The gene-drug interaction 
section includes background on the pharmacological mechanism of the interaction. In 
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addition it also includes a list of the DPYD variants associated with toxicity and the method 
developed by DPWG for local translation of assay results into the gene activity score. This 
information may be useful for laboratories to select and design a DPYD genotyping assay and 
subsequently determine the patients’ predicted phenotype based on the genotype results. 
Consequently, the literature review supporting the DPYD-fluoropyrimidine interaction is 
described and the DPWG guideline is presented. A summary of all references identified 
by the systematic review which were subsequently used to develop this guideline, can be 
found in Supplementary Tables 1 and 2. The recommendations provided in this manuscript 
can be used in combination with a patients’ predicted phenotype to optimize starting dose 
of fluoropyrimidines, thereby decreasing the risk of severe and potentially fatal toxicity.
Drugs: fluoropyrimidines (5-fluorouracil, capecitabine and tegafur with DPD-inhibitors)
Fluoropyrimidines are antimetabolite drugs widely used in the treatment of colorectal, 
breast, stomach and skin cancer. Each year, over two million patients worldwide receive 
treatment with fluoropyrimidines. This includes 5-FU and its oral pro-drugs capecitabine 
and tegafur. Up to 30% of patients experience severe toxicity (common terminology criteria 
for adverse events, CTC-AE, grade ≥3), including diarrhoea, hand-foot syndrome, mucositis 
and myelosuppression. For ~1% of patients toxicity is fatal.8,9 Toxicity may occur within the 
first treatment cycle (early onset), supporting the importance of optimizing the starting dose 
of fluoropyrimidine pharmacotherapy on a personalized basis, before initiating therapy.10 
 Capecitabine is metabolised into 5-FU in three consecutive steps. Capecitabine is firstly 
metabolised to 5’-deoxy-5-fluorocytidine (5’-DFCR) by carboxylesterase, subsequently, 5’-
DFCR is converted into 5’-deoxy-5-fluorouridine (5’-DFUR) by cytidine deaminase, and to 
5-FU by thymidine phosphorylase. 5-FU is metabolised in tissues to 5-fluoro-2’-deoxyuridine 
and then to 5-fluoro-2’-deoxyuridine-5’-monophosphate, the active metabolite of the drug. 
The active metabolite inhibits the enzyme thymidylate synthase, resulting in inhibition of 
DNA synthesis and repair, inducing cell apoptosis and thus, its effect. Additionally, toxic 
effects resulting from partial incorporation of 5-FU and its metabolites in DNA and RNA 
contribute to the drug’s mechanism of action.11
 Tegafur is metabolised into 5-FU and into the less cytotoxic metabolites 3-hydroxytegafur, 
4-hydroxytegafur and dihydrotegafur by CYP2A6. The less toxic metabolites are renally 
cleared. Tegafur was combined with the DPD inhibitor uracil and is now combined with 
the DPD inhibitor gimeracil and the orotate phoshoribosyltransferase (OPRT) inhibitor 
oteracil. Oteracil diminishes the activity of 5-FU in normal gastrointestinal mucosa. The 
DPD inhibitors diminish the formation of functionally inactive metabolites of 5-FU that 
contribute to adverse events like stomatitis and mucositis. Both uracil and gimeracil inhibit 
DPD activity reversibly and have a shorter elimination half-life and thus shorter period of 
action than tegafur. For this reason, genetic variants influencing DPD enzyme activity are 
clinically relevant for tegafur in combination with DPD inhibitors. 
Gene: dihydropyrimidine dehydrogenase (DPYD)
The DPYD gene encodes the enzyme DPD. DPYD is located on chromosome 1p21.3, and 
transcription variant 1 (NM_000110.3) has 26 exons, spanning approximately 900 kb.12 
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Over 160 different allele variants in DPYD have been identified and described in literature.13 
According to the gnomAD browser,14 which contains whole exome data of almost 140,000 
individuals, DPYD contains 2,190 known variants. The prevalence of individual variants is 
low. The effect of genetic variation on DPD enzyme activity is not fully established for the 
majority of variants and the size of the effect can differ between variants. 
 The frequency of the various DPYD variants and the associated phenotypes appears 
to vary significantly between nations and ethnic groups. For example, in the Caucasian 
population, approximately 3─5% has a partial DPD enzyme deficiency and 0.1─0.2% has 
a complete DPD enzyme deficiency. On the other hand, approximately 8% of the African 
American population has a partial DPD enzyme deficiency.15,16
Gene-drug interaction
Pharmacological mechanism
A schematic overview of fluoropyrimidine metabolism is shown in Figure 1. The DPD enzyme 
is mainly found in liver, but also intestinal mucosa, leucocytes, tumour cells and other 
tissues. Over 80% of 5-FU is inactivated to 5-fluoro-5,6-dihydrouracil (DHFU) by DPD. The 
decreased metabolic activity of DPD leads to increased intracellular concentrations of active 
metabolites of 5-FU.17 The increased intracellular concentration of 5-fluoro-2’-deoxyuridine-
5’-monophosphate (FdUMP) increases the risk of toxicity such as diarrhoea, hand-foot 
syndrome, mucositis and myelosuppression. Variants in the DPYD gene can result in reduced 
or even absent DPD enzyme activity, increasing the risk of severe toxicity. For example, 73% 
of the patients with DPYD*2A experienced severe toxicity when treated with a full dose, 
compared to 23% of *1 allele carriers (wild-type patients) who experienced toxicity.18 Many 
enzymes are involved in fluoropyrimidine metabolism, however, this guideline is limited to 
the role of the DPD enzyme in causing toxicity.
 Since the genetic variation in DPYD only partially determines DPD enzyme activity, these 
guidelines for dose adjustment based on the predicted phenotype are no more than a tool 
that can be used to achieve the desired intracellular concentration of the active metabolite, 
to minimize risk of toxicity. The absence of tested variants does not eliminate the risk of 
toxicity. Pharmacokinetic dose adjustment (guided by steady-state plasma concentrations 
or AUC) may also be useful to optimize the dose of 5-FU. This is, however, currently not 
routinely used for capecitabine and tegafur, as they are mainly converted into 5-FU within 
tissue. 
DPYD variants associated with toxicity
The variants known or suspected to have an effect on DPD enzyme activity, are listed in Table 
1. These variants are mapped by the level of evidence for which association with toxicity has 
been established (columns) and the variant’s effect on DPD enzyme activity (rows). Novel 
variants in DPYD will continue to be identified with the introduction of next generation 
sequencing techniques to clinical practice. However, in order for these variants to be 
included in Table 1, sufficient evidence regarding the effect on enzyme function or the onset 
of toxicity must be investigated, possibly by using the DPYD-Varifier19 or by phenotyping 
patients who carry a novel variant. An update of this guideline will be published when a 
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renewed recommendation is given following newly published articles.
Translation of genotype to predicted phenotype
The DPWG has concluded that four variants have sufficient evidence to be implemented 
into clinical care: DPYD*2A (IVS14+1G>A), DPYD*13 (c.1679T>G), c.2846A>T and c.1236G>A 
(in linkage disequillibrium with c.1129-5923C>G). The current guideline only reports 
recommendations for these four variants; no recommendations are provided for other 
variants in DPYD or other genes. The results of this genotyping panel can be used to predict 
a patient’s phenotype, i.e. the DPD enzyme activity. This predicted DPD activity can be 
expressed as the DPYD-gene activity score, which ranges from 0 (no or virtually no DPD 
enzyme activity) to 2 (normal DPD enzyme activity due to homozygosity for fully functional 
alleles, both assigned an activity score 1). The gene activity score is a sum of the two activities 
of protein isoforms expressed from both alleles. The development of the gene activity score 
is published elsewhere.20
 The included variants are those for which substantial and sufficient evidence on the 
relation to severe toxicity has been established. It is a limitation to restrict to these four 
variants, as other variants may influence DPD activity as well. However, not all variants 
having a possible effect on DPD enzyme activity may have been identified yet or evidence 
for identified variants is insufficient. Therefore, this may result in the incorrect prediction of 
the DPD enzyme activity. Another limitation is that currently used genotyping methods are 
unable to determine the allelic location of the variants, but only the dichotomous presence 
or absence of the variant. This becomes a limitation when two or more different genetic 
variants are identified in a patient. In this case, either both genetic variants may be on 
the same allele, resulting in a genotype with one fully functional allele and one reduced 
functionality allele, or alternatively, both genetic variants may reside on different alleles, 
resulting in two alleles with inactive or reduced functionality. The latter is more likely to 
occur. The total gene activity score, however, differs between these cases. When the DPD 
enzyme activity cannot be predicted correctly, an additional phenotyping test is required to 
determine the DPD enzyme activity. The relationship between genotype result and predicted 
phenotype in patients carrying no variants or one or more variants leading to decreased DPD 
enzyme activity are shown in Supplementary Table 3. The frequency of individuals carrying 
two or more of four variants considered in the current guideline is rare, but can be assigned 
a gene activity score. A complete genotype to predicted phenotype translation table can be 
found in Supplementary Table 4, which can be used to program the translation of genotype 
results into predicted phenotypes in laboratory information systems. 
 
















































































































































































































































































































































































































































































































































































































































































































































Table 1. Known DPYD variants stratified by level of evidence on the association with toxicity and 
predicted DPD enzyme activity 
The variants in this table were selected based on literature in Supplementary Table 1 and 2. 
However, high allele frequency variants reported only in case reports with fluoropyrimidine toxicity 
were excluded. For these variants the association with DPD enzyme activity, and resulting severe 
fluoropyrimidine-induced toxicity, cannot be determined. 
                        Level of evidence
DPD enzyme activity
Sufficient evidencea Insufficient evidenceb
Fully functionalc DPYD *4 = c.1601G>A 
DPYD *5 = c.1627A>G 
DPYD *9A = c.85T>C
Reduced functionalityd c.2846A>T 
c.[1236G>A;1129-
5923C>G] (hapB3)e  
c.496A>G
c.1129-15T>C (IVS10-15T>C) 





DPYD *9B = c.85T>C(;)c.2657G>A
DPYD *10 = c.2983G>T
DPYD *11 = c.1003G>T













a DPWG has concluded an association between fully functional variants and no resulting toxicity, and 
an association between reduced functionality variants or fully dysfunctional variants and association 
with the onset of severe fluoropyrimidine-induced toxicity;
b DPWG has concluded there is insufficient evidence to associate a predicted DPD enzyme activity for 
these variants and the onset of severe fluoropyrimidine-induced toxicity;  
c These variants are not included in the prospective DPYD genotyping panel, as there is no effect 
on predicted DPD enzyme activity, and therefore there is no association with the onset of severe 
fluoropyrimidine-induced toxicity;
d The effect of the variant on the protein sequence suggests that the protein may still be partially 
functional. Therefore residual metabolic DPD capacity may be present;
e Variant c.1236G>A, which does not lead to an alternative amino acid, is in complete linkage 
disequilibrium with variant c.1129-5923C>G, which leads to aberrant splicing in mRNA, which leads to 
a premature stop codon as a result. The resulting DPD enzyme activity is 50% of the normal activity. 
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Both variants are part of haplotype B3;
f The effect of the variant on the protein sequence suggests that the protein may be fully dysfunctional; 
g These variants have decreased in vitro enzyme activity.
Variants from the table according to multiple nomenclatures (HGVS: NM_000110.3, NP_000101.2 and 
NC_000001.10): 
(rs67376798, c.2846A>T, p.(Asp949Val), g.97547947T>A), (rs56038477, c.1236G>A, p.(Glu412=), 
g.98039419C>T, in haplotype B3), (rs75017182, c.1129-5923C>G, g.98045449G>C, in haplotype 
B3), (rs3918290, *2A, c.1905+1G>A, IVS14+1G>A, g.97915614C>G), (rs55886062, *13, c.1679T>G, 
p.(Ile560Ser), g.97981343A>C), (rs2297595, c.496A>G, p.(Met166Val), g.98165091T>C), 
(rs56293913, c.1129-15T>C,  IVS10-15T>C, g:98039541A>G), (rs1801160, *6, c.2194G>A, 
p.(Val732Ile), g.97770920C>T), (rs17376848, c.1896T>C, p.(Phe632=), g.97915624A>G), 
(rs72549303, *3, c.1897delC/c.1898delC, p.(Pro633Glnfs), g.97915622delG), (rs72549309, *7, 
c.299_298delTCAT, p.(Phe100Serfs), g.98205971_98205974delATGA), (rs1801266, *8, c.703C>T, 
p.(Arg235Trp), g.98157332G>A), (rs1801265 + rs1801267, *9B, c.85T>C + c.2657G>A, p.(Cys29Arg) 
+ p.(Arg886His), g.98348885G>A+ g.97564154C>T), (rs1801268, *10, c.2983G>T, p.(Val995Phe), 
g.97544627C>A), (rs72549306, *11, c.1003G>T, p.(Val335Leu), g.98058899C>A), (rs80081766, *12, 
c.62G>A, p.(Arg21Gln), g.98348908C>T), (rs78060119, c.1156G>T, p.(Glu386Ter), g.98039499C>A), 
(rs777425216, c.1651G>A, p.(Ala551Ser), g.97981371C>A), (c.1845G>T, p.(Glu615Asp)), (98205969, 
c.300C>A, (p.Phe100Leu)), (rs183385770, c.1024G>A, p.Asp342Asn, g.98058878C>T), (rs183385770, 
c.1025A>G, p.Asp342Asn, g.98058878C>T), (rs72549304, c.1475C>T, p.Ser492Leu, g.98015165G>A), 
(rs59086055, c.1774C>T, p.(Arg592Trp), g.97915746G>A), (g.(619762_619763)_(620801_620802)
dup), (rs1801158, *4, c.1601G>A, p.(Ser534Asn), g.97981421C>T), (rs1801159, *5, c.1627A>G, 
p.(Ile543Val), g.97981395T>C), (rs1801265, *9A, c.85T>C, p.(Cys29Arg), g.98348885G>A).
Additional phenotyping test when genotype is unable to predict phenotype
In contrast to the DPYD genotyping test, which aims to predict DPD enzyme activity, a DPD 
phenotyping test can be performed to measure the actual DPD enzyme activity. Possible 
methods to perform phenotyping are to measure the DPD enzyme activity in peripheral 
blood mononuclear cells (PBMCs) or to measure the uracil concentrations in plasma or 
urine.21 The average Caucasian DPD enzyme activity is 9.9±0.95 nmol/hour per mg protein.22 
Less commonly performed methods include: 1) the 2-13C-uracil breath test,23 where 13C02 is 
measured, which is a product of 2-C13-uracil degradation by DPD and other enzymes involved 
in the katabolic route of pyrimidines; 2) the quantification of the uracil/dihydrouracil ratio in 
plasma, where endogenous substrates uracil and dihydrouracil are measured,24,25 although 
recently it was shown that uracil levels were superior to the dihydrouracil/uracil ratio as a 
predictor of severe toxicity;26 3) measurement the metabolism of a single dose of uracil.27 
However, all DPD phenotyping tests have their limitations. Currently, the DPD enzyme 
activity measurements from PBMCs are considered the best developed DPD phenotyping 
test in The Netherlands.27,28
Supporting body of evidence
A detailed description of the methods used for literature collection, assessment and 
preparation of the gene-drug monograph has previously been published elsewhere.2,7 In brief, 
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a systematic review of literature was performed and relevant articles were summarized by 
a scientist of the Royal Dutch Pharmacists Association (MN). The performed search strategy 
can be found in Supplementary Material 1. Each article was provided with two scores: 1) 
quality of evidence and 2) clinical impact. The quality of evidence was scored on a 5-point 
scale ranging from 0 (lowest; data on file) to 4 (highest; well performed controlled studies or 
meta-analysis) and the clinical impact of clinical effect was scored on a 7-point scale ranging 
from AA# (positive effect) to F (highest negative effect). The criteria used to develop these 
scores have been published in detail previously.2,7 This clinical impact scale (AA#─F) runs 
parallel to the common terminology criteria for adverse events (CTC-AE); where CTC-AE 
grade 5 severity is equal to clinical relevance score F (death) and CTC-AE grade 1 severity 
is equal to clinical relevance score B. The clinical relevance score additionally includes the 
scores AA#, AA and A, since these do not exist in the CTC-AE. These regard “Positive clinical 
effect”, “No clinical or kinetic effect”, and “Significant kinetic effect or not clinically relevant 
effect”, respectively. The summaries of articles, and their respective scores, reviewed to 
devise this guideline can be found in the Supplementary Table 1 and 2. The summaries of 
each article and their respective scores were checked by two independent DPWG members. 
 For 5-FU/capecitabine, the initial literature search was performed on March 24th 2009, 
followed by a second search on July 9th 2014. To update this guideline to the current date, 
an additional literature search was performed on October 19th 2017, resulting in eleven 
additional papers. Case reports concerning systemic 5-FU or capecitabine therapy were 
excluded in this literature review, due to a large number of case reports and other available 
publications of greater evidentiary quality. Kinetic studies from 2009 onwards were only 
included if the kinetic parameters were given per genotype. Clinical studies were only 
included if the patient numbers exceeded 500 (from 2009 onwards) or 1,000 (from May 
2014 onwards) and the patient numbers with partially functional activity were at least 
ten or if the study investigated a variant for which no studies were as yet included or if 
the study investigated the effect of dose adjustment. From 2009, articles investigating the 
effect of a group containing both polymorphisms known to increase the risk of toxicity and 
polymorphisms not known to increase the risk of toxicity were not included. If more than 
one article described data of the same patient group and the same polymorphisms, only the 
article with data from the largest amount of patients was included.
 For tegafur, the initial literature search was performed on August 20th 2009, followed by a 
second and third search on October 2nd 2012 and July 27th 2015. To update this guideline to 
current date, an additional literature search was performed on October 19th 2017, resulting 
in no additional papers. 
General conclusion of evidence
In the systematic review performed for 5-FU/capecitabine, 16 of 18 studies and all three 
meta-analyses found an increased risk of grade ≥3 toxicity (either overall toxicity or at 
least one specified type of toxicity) for patients carrying variants resulting in reduced DPD 
enzyme activity (ranging from gene activity score 0 to 1.5). This increased risk was shown 
separately for patients assigned DPYD-gene activity scores 1 and 1.5, but gene activity scores 
0 and 0.5 were only investigated when grouped with patients assigned other gene activity 
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scores. However, the increased risk of toxicity for patients assigned gene activity scores 0 
and 0.5 can be concluded based on the confirmed association for gene activity scores 1 
and 1.5, where deficiency is less, and is further supported by cases of patients assigned 
gene activity scores 0 and 0.5 who developed severe toxicity. Only one study investigating 
clinical outcome concluded there was no effect of variants on risk of toxicity. Based on the 
systematic review, the DPWG concludes that a gene-drug interaction is present and that 
DPD enzyme deficiency increases risk of severe toxicity in patients using capecitabine/5-FU. 
The highest quality of evidence concluding a gene-drug interaction was scored 4.
 In the systematic review performed for tegafur with the DPD inhibitor uracil, one case 
report described four patients who used standard doses and developed severe toxicity. 
These patients were assigned DPYD-gene activity scores 1 and 1.5. Toxicity (CTC-AE grade 
4) was similar to that reported in patients treated with 5-FU or capecitabine, both of which 
are given without a DPD inhibitor. There were no data available for patients assigned DPYD-
gene activity score 0 or 0.5, however the increased risk of toxicity among these patients can 
be concluded based on the confirmed association with toxicity for gene activity scores 1 
and 1.5, where deficiency is less. Based on the systematic review, the DPWG concludes that 
there is a clinically relevant gene-drug interaction present and that DPD enzyme deficiency 
increases risk of severe toxicity in patients using tegafur with DPD inhibitors. The highest 
quality of evidence concluding a gene-drug interaction was scored 2.
Pharmacotherapeutic recommendations
The DPWG therapeutic recommendation using a patient’s pre-therapeutic PGx test result to 
optimize starting dose of 5-FU/capecitabine and tegafur with DPD inhibitors is summarized 
in Supplementary Table 5 and 6, respectively. 
 In brief, when initiating 5-FU, capecitabine or tegafur pharmacotherapy, a gene activity 
score of 0 recommends choosing an alternative chemotherapy or determining the residual 
DPD enzyme activity and adjusting the fluoropyrimidine starting dose accordingly. When 
initiating 5-FU or capecitabine, a gene activity score of 0.5, 1 or 1.5 recommends a starting 
dose of 25%, 50% or 75%, respectively. Further titration of the dose is possible, guided by 
toxicity. When initiating tegafur, a gene activity score of 0.5, 1 or 1.5 recommends choosing 
an alternative chemotherapy or starting with a lower dose and titrating dose based upon 
toxicity. A gene activity score of 2 (reference value) does not result in a recommendation 
for dose adaptation for 5-FU, capecitabine or tegafur. If genotype results cannot predict the 
gene activity score correctly, for example due to multiple identified variants, it is advised to 
determine the DPD enzyme activity to define an initial starting dose.
 Where possible, dose adjustments have been calculated based on 5-FU clearance or 
AUC after administration of 5-FU or capecitabine. Data were also extrapolated to tegafur 
with DPD inhibitor, as this compound also follows the same catabolic and anabolic routes 
after conversion to 5-FU after clearance of the DPD inhibitor from the body. Data on 5-FU 
clearance are only available for patients carrying DPYD*1/DPYD*2A, DPYD*1/c.2846A>T 
and DPYD*2A/c.2846A>T. There are data from one patient with DPYD*1/DPYD*13 who 
developed severe toxicity after 5-FU use, from one patient with c.2846A>T/c.2846A>T and 
from one patient with c.1236G>A/c.2846A>T. 
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See Supplementary Table 7 and 8 for an overview of suggested pop-up texts for electronic 
prescribing systems for pharmacists and physicians. These can be used to program alerts 
into the clinical decision support system (CDSS). Spanish, Greek, Italian, German, Slovenian 
and Dutch translations of both the guidelines and background information are available on 
PharmGKB.org. 
Implications for clinical practice
There is currently an ongoing debate regarding whether and which single-drug gene pairs 
should be implemented into routine care. Points of debate include the amount of evidence 
that is necessary supporting effectiveness of pre-emptive genotyping, the cost-effectiveness 
of the intervention and reimbursement of PGx testing.29,30 This inconclusive debate seems to 
have hampered implementation of drug-gene pairs which seem ready for implementation.1,31 
In an effort to overcome this inconclusiveness and to direct clinicians on whether or not to 
order relevant PGx genotyping tests before initiating therapy, the DPWG has developed the 
clinical implication score. The pre-emptive PGx results for a certain drug-gene pair can be 
scored as: essential, beneficial, potentially beneficial or not required. The development of 
these categories and the systematic scoring criteria are discussed elsewhere.32 In brief, the 
implications for clinical practice are based on a list of four criteria regarding the following: 
the clinical effect associated with the gene-drug interaction, the level of evidence supporting 
the clinical effect, the effectiveness of the intervention in preventing the clinical effect 
(which includes the number needed to genotype) and the PGx information included in the 
drug-label. The scores provided for each of these criteria by the DPWG can be found in 
Supplementary Table 9. 
 As a result, the DPWG has concluded the clinical implication score of DPYD-
fluoropyrimidines to be “essential”. This score dictates that DPYD genotyping prior to 
treatment must be performed for all patients initially being prescribed therapy with 5-FU, 
capecitabine or tegafur with DPD inhibitors, to optimize the initial dose and to prevent 
potentially fatal toxicity. 
Differences between available guidelines
Other guidelines regarding the gene-drug interaction of DPYD and fluoropyrimidines have 
been developed. To the best of our knowledge, guidelines are available from CPIC,11,33 
French (French Network of Pharmacogenetics, RNPGx)34 and Italian (Associazione Italiana 
di Oncologia Medica, AIOM-SIF) [unpublished guidelines, edited by the AIOM-SIF Working 
Group] initiatives. We have compared the DPWG guidelines to other available guidelines 
published in English. This regards only the CPIC guideline, since the French and Italian 
guidelines are unpublished or not in English.
CPIC
Differences between CPIC and DPWG methodology, genotype to phenotype conversion 
and recommendations have previously been described in detail.6 However, both guidelines 
have been updated.33,35 The current DPWG and CPIC guidelines5 for DPYD/fluoropyrimidines 
differ regarding the therapeutic recommendations. In contrast to CPIC, DPWG distinguishes 
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between 5-FU/capecitabine and tegafur within the therapeutic recommendations for 
fluoropyrimidines, where the CPIC guideline does not provide any dosing recommendations 
for tegafur due to the limited available evidence. DPWG also further distinguishes 
between systemic and cutaneous routes of administration within the 5-FU/capecitabine 
recommendations. The therapeutic recommendations for 5-FU/capecitabine also differ 
regarding the following: 1) For patients with gene activity score 0: DPWG recommends 
phenotyping while CPIC does not when no alternative is available. 2) For patients with 
gene activity score 0.5: DPWG recommends initiating therapy with 25% of standard dose 
or an alternative whereas CPIC recommends an alternative or a strongly reduced dose with 
therapeutic drug monitoring, but does not provide an absolute percentage. 3) For patients 
with gene activity score 1.5 the DPWG recommends a 75% standard dose whereas CPIC 
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Search terms used to perform the literature review of DPYD-[5-FU/capecitabine/tegafur] 
interactions.
Search strategy
Pubmed was used to search English, Dutch, German articles were accepted. Keywords 
were the drugs of interest (fluorouracil, capecitabine and tegafur/S1), the gene and 
variations (DPYD, DPD, dihydropyrimidine dehydrogenase), and others (e.g. metabolizer, 
pharmacogenetics, polymorphism). The complete search string was; 
Fluorouracil and capecitabine
Search performed in 2009: (“Fluorouracil”[Mesh] OR fluorouracil) AND (“Dihydropyrimidine 
Dehydrogenase Deficiency”[Mesh] OR metabolizer OR metaboliser OR polymorph* OR 
“Polymorphism, Genetic”[MeSH] OR “Pharmacogenetics”[MeSH]) AND (English[lang] OR 
German[lang] OR Dutch[lang]) 
 (“capecitabine “[Substance Name] OR capecitabine) AND (“Dihydropyrimidine 
Dehydrogenase Deficiency”[Mesh] OR metabolizer OR metaboliser OR polymorph* OR 
“Polymorphism, Genetic”[MeSH] OR “Pharmacogenetics”[MeSH]) AND (English[lang] OR 
German[lang] OR Dutch[lang]) 
 (“Fluorouracil”[Mesh] OR fluorouracil OR “capecitabine “[Substance Name] OR 
capecitabine) AND ((“Dihydrouracil Dehydrogenase (NADP)”[Mesh] OR (dihydropyrimidine 
dehydrogenase)) AND mutation) AND (English[lang] OR German[lang] OR Dutch[lang])
 Search performed in 2014: (“Fluorouracil”[Mesh] OR fluorouracil OR “capecitabine” 
[Supplementary Concept] OR capecitabine) AND (“Dihydropyrimidine Dehydrogenase 
Deficiency”[Mesh] OR “Dihydropyrimidine Dehydrogenase Deficiency” OR 
metabolizer OR metaboliser OR polymorph* OR “Polymorphism, Genetic”[MeSH] OR 
“Pharmacogenetics”[MeSH]) AND (English[lang] OR German[lang] OR Dutch[lang])
 Search performed in 2017: (“Fluorouracil”[Mesh] OR fluorouracil OR “Capecitabine”[Mesh] 
OR capecitabine OR fluoropyrimidines) AND (“Dihydrouracil Dehydrogenase (NADP)”[Mesh] 
OR  “Dihydropyrimidine Dehydrogenase Deficiency”[Mesh] OR “Dihydropyrimidine 
Dehydrogenase Deficiency” OR “Dihydropyrimidine Dehydrogenase” OR DPYD OR DPD) 
AND (English[lang] OR German[lang] OR Dutch[lang])
Tegafur
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(“Dihydropyrimidine Dehydrogenase Deficiency”[Mesh] OR metabolizer OR metaboliser 
OR polymorph* OR “Polymorphism, Genetic”[MeSH] OR “Pharmacogenetics”[MeSH]) AND 
(English[lang] OR German[lang] OR Dutch[lang])
 Search performed in 2015: (“Tegafur”[Mesh] OR “S 1 (combination)” [Supplementary 
Concept] OR  “tegafur-gimeracil-oteracil” [Supplementary Concept] OR tegafur[Text Word] 
OR S1 OR S-1 OR Teysuno) AND (“Dihydropyrimidine Dehydrogenase Deficiency”[Mesh] OR 
Dihydropyrimidine Dehydrogenase OR DPD OR DPYD) AND (English[lang] OR German[lang] 
OR Dutch[lang])
OR Teysuno) AND ("Dihydropyrimidine Dehydrogenase Deficiency"[Mesh] OR  
 
Search performed in 2017: ("Tegafur"[Mesh] OR "S 1 (combination)" 
[Supplementary Concept] OR  "tegafur-gimeracil-oteracil" [Supplementary 
Concept] OR tegafur OR S1 OR S-1 OR “S 1” OR Teysuno) AND ("Dihydrouracil 
Dehydrogenase (NADP)"[Mesh] OR  "Dihydropyrimidine Dehydrogenase  
 
Reference Code Effect Comments 





















































e Score A  
 
 
5 patients, being either homozygous for a gene 
variant or having two different gene variants, 
received capecitabine or 5-FU treatment with doses 
based on the pre-treatment DPD activity in peripheral 
blood mononuclear cells. Pre-treatment DPD activity 
was also determined in a patient with genotype 
c.2846A>T/c.2846A>T, who did not receive 
treatment, because she was disease free after 
surgery. For 3 patients, the AUC of 5-FU after the first 
dose of capecitabine was determined, normalised to 
a dose of 850 mg/m2 and compared to 22 patients 
from another study receiving combined 
chemotherapy with capecitabine 850 mg/m2.      
 
Genotyping: 
- 2x c.1236A>G/c.1236A>G 
- 2x c.2846A>T/c.2846A>T 
- 1x *2A/*2A  
- 1 carrier of both c.1236A>G and c.2846A>T (either 
c.1236A>G/c.2846A>T (on separate alleles) or 




- Of the four patients with gene activity score 1, 
the two patients with genotype 
c.1236A>G/c.1236A>G had respectively 79% and 
42% of the normal DPD activity. The first was 
treated with 75% of the normal capecitabine dose 
in cycle 1 and with 100% in cycle 2. The second 
was treated with 50% of the normal 5-FU dose. 
The patients did not have severe toxicity on the 
reduced doses.  
The two patients with genotype 
c.2846A>T/c.2846A>T had respectively 29% and 
10% of the normal DPD activity. The first was 
treated with 17% of the normal capecitabine dose 
(278 mg/m2 once daily in combination with 
radiotherapy as neoadjuvant treatment) and the 
second was the patient who did not need 
treatment. The first patient tolerated treatment 
Authors’ conclusion: 






variant allele carriers 
is feasible and that 
therapy does not 
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and the dose should 
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in cycle 1 and with 100% in cycle 2. The second 
was treated with 50% of the normal 5-FU dose. 
The patients did not have severe toxicity on the 
reduced doses.  
The two patients with genotype 
c.2846A>T/c.2846A>T had respectively 29% and 
10% of the normal DPD activity. The first was 
treated with 17% of the normal capecitabine dose 
(278 mg/m2 once daily in combination with 
radiotherapy as neoadjuvant treatment) and the 
second was the patient who did not need 
treatment. The first patient tolerated treatment 
Authors’ conclusion: 
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well without occurrence of severe toxicity and 
surgery was performed after treatment. The dose-
corrected AUC of 5-FU in this patient was 866% of 
that of control patients.        
The mean DPD activity in these patients was 40%. 
There was a large variance in DPD activity 
between these patients (10-79%).    
- The patient with genotype *2A/*2A had 
undetectable DPD activity and tolerated 
monotherapy with 0.65% of the normal 
capecitabine dose (65 mg/m2 every 5 days) for 1 
month after which grade 2 diarrhoea developed. 
After a rest period of 3 weeks, treatment was 
restarted with the same dose, but every third gift 
was skipped (0.43% of the normal dose). The 
patient tolerated this dose also after addition of 
oxaliplatin and bevacizumab as originally planned 
and had stable metastatic colorectal carcinoma as 
best treatment response. 
The dose-corrected AUC of 5-FU in this patient 
was 13.812% of that of control patients.       
- The carrier of both c.1236A>G and c.2846A>T 
had 45% of the normal DPD activity, 
corresponding to gene activity score 1 (variants on 
different alleles). He was treated with 51% of the 
normal capecitabine dose in cycle 1 (daily dose of 
900 mg/m2 in combination with oxaliplatin), which 
was tolerated without toxicity. Increase to 71% of 
the planned dose (daily dose of 1250 mg/m2) in 
cycle 2 resulted in grade 3 thrombocytopenia. The 
dose was reduced to 57% of the normal dose 
(1000 mg/m2 daily), which was continued during 
cycle 3. However, because grade 2 
thrombocytopenia developed after 8 days, the 
dose was reduced to 29% of the normal dose (500 
mg/m2 daily) for the rest of the cycle, resulting in 
platelets to increase to normal values. Progression 
of metastatic colorectal cancer was established 
after 3 cycles and capecitabine treatment was 
discontinued. 
The dose corrected AUC of 5-FU in this patient was 
227% of that of control patients.        
 
NOTE: Patients were genotyped for *2A, *13, 
c.2846A>T and c.1236G>A. 
 
DPD activity 
compared to gene 
activity 2: 
gene act. 1: 41%  
gene act. 0: 0% 







a patient with 








e Score A  
 
A 59-year-old women with 0.5% of the normal DPD 
activity tolerated adjuvant chemotherapy with 0.8% 
of the normal capecitabine dose (77 mg/m2 on days 1 
and 6 of the first cycle and on days 1, 6 and 11 of the 
following cycles) in combination with oxaliplatin for 
eight cycles. Capecitabine-related toxicity like 
diarrhoea, hand-foot syndrome or leukopenia did not 
occur. However, sensory neuropathy developed 
during the first cycle, and became more severe (grade 
Authors’ conclusion: 
‘This case report 











e deficiency.  
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3) during the second cycle. Because this was most 
likely caused by oxaliplatin, the oxaliplatin dose was 
decreased to 75% from the third cycle onwards and 
discontinued after the sixth cycle.  
The dose-corrected AUC of 5-FU in this patient was 
11.271% of that of control patients. 
Her genotype was *2A/(duplication of exon 17 and 
18).  
 
NOTE: The patient was initially genotyped for *2A, 
*13, c.2846A>T and c.1236G>A. Additional gene 
variants were not found by sequencing of all 23 
coding exons and flanking intronic regions, after 
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1606 *2A-negative patients from Deenen 2016 were 
genotyped for other gene variants. 
Toxicity was defined as toxicity grade ≥ 3, global 
toxicity as any toxicity, hospitalisation as toxicity 
related hospitalisation. Only outcomes during the first 
cycle of chemotherapy were included.  




- 19 carriers of c.2846A>T  
- 3 carriers of *13  
- 58 carriers of c.1236A>G  
  
Results: 












gastrointestinal toxicity NS 





*13 global toxicity NS 




haematological toxicity 24.9 (1.74-
354) (S) 
hospitalisation NS, trend 
for an 
Authors’ conclusion: 
‘None of the 
individual DPYD 
variants were found 





combined, there was 
evidence for an 
association with 
global severe 
toxicity. In addition, 
DPYD c.1679T>G 
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3) during the second cycle. Because this was most 
likely caused by oxaliplatin, the oxaliplatin dose was 
decreased to 75% from he ird cycle onwards and 
is ontinued after the sixth cycle.  
The dose-corrected AUC of 5-FU in this patient was 
11.271% of that of control patients. 
Her genotype was *2A/(du lication of exon 17 and 
18).  
 
NOTE: The patient was initially genotyped for *2A, 
*13, c.2846A>T and c.1236G>A. Additional gene 
variants were not found by sequencing of all 23 
coding exons and lanking intronic regions, after 
which copy numbers of sequences were an lysed. 
pharmacokinetically-
guided d se 
administration, 
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surgery was performed after treatment. The dose-
corrected AUC of 5-FU in this patient was 866% of 
that of control patients.        
The mean DPD activity in these patients was 40%. 
There was a large variance in DPD activity 
between these patients (10-79%).    
- The patient with genotype *2A/*2A had 
undetectable DPD activity and tolerated 
monotherapy with 0.65% of the normal 
capecitabine dose (65 mg/m2 every 5 days) for 1 
month after which grade 2 diarrhoea developed. 
After a rest period of 3 weeks, treatment was 
restarted with the same dose, but every third gift 
was skipped (0.43% of the normal dose). The 
patient tolerated this dose also after addition of 
oxaliplatin and bevacizumab as originally planned 
and had stable metastatic colorectal carcinoma as 
best treatment response. 
The dose-corrected AUC of 5-FU in this patient 
was 13.812% of that of control patients.       
- The carrier of both c.1236A>G and c.2846A>T 
had 45% of the normal DPD activity, 
corresponding to gene activity score 1 (variants on 
different alleles). He was treated with 51% of the 
normal capecitabine dose in cycle 1 (daily dose of 
900 mg/m2 in combination with oxaliplatin), which 
was tolerated without toxicity. Increase to 71% of 
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platelets to increase to normal values. Progression 
of metastatic colorectal cancer was established 
after 3 cycles and capecitabine treatment was 
discontinued. 
The dose corrected AUC of 5-FU in this patient was 
227% of that of control patients.        
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For the 3 gene variants combined, sensitivity was 
6%, specificity 95%, positive predictive value 13% 
and negative predictive value 88% for prediction 
of global toxicity grade ≥ 3 in the first cycle. 
 
NOTE: No association was found for the gene variants 
*4 (84 carriers), except for a trend for gastrointestinal 
toxicity. However, most studies including a meta-
analysis (Meulendijks 2015) do not show an 
association of this gene variant with toxicity. In 
addition, results regarding the effect on DPD activity 
are inconsistent. 
ref. 4 – 
FU/CAP, 
mono/comb  


























A 51-year old male developed severe colitis with 
mucous stools (grade 4 toxicity) and neutropenic 
fever (neutrophils 0.18x109/L) on day 21 of 
neoadjuvant treatment with standard dose 
capecitabine (825 mg/m2 twice daily) and 
radiotherapy. His genotype was *1/*2A. 
The patient tolerated adjuvant therapy with 5-FU 300 
mg/m2 per day as a continuous intravenous infusion 
(25% of the standard dose) and without bolus 
injections of 5-fluorouracil very well. Higher doses 
were not attempted, because they were judged not 
to influence recurrence or survival. 
 
Authors’ conclusion: 






even with 50% dose 





that dosing of 5-FU 
should be 
customized in 
patients with DPD 
deficiency based on 
clinical judgment 
taking into account 
the severity of 
toxicity from initial 
exposure.’ 
ref. 5 – CAP, 
mono/comb  
Meulendijks 











Three patients treated with capecitabine containing 
chemotherapy were retrospectively determined to 
have genotype c.1236A>G/c.1236A>G. Gene variants 
*2A, *13 and c.2846A>T were not present in these 
patients. More than 4 weeks after the last treatment 




clinical data indicate 
that the c.1129-5923 
























































peripheral blood mononuclear cells was determined 
and cDNA was analysed.   
 
Results: 
- A 47-year old female developed leukocytopenia 
grade 2 (2.3x109/L), neutropenia grade 2 (1.3x109/L), 
hand-foot syndrome grade 1, diarrhoea grade 1 and 
fatigue grade 1 on day 9 of neoadjuvant treatment 
with standard dose capecitabine (825 mg/m2 twice 
daily) and radiotherapy. Because the symptoms 
intensified, the capecitabine dose was reduced by 
40% on day 15. After dose reduction, treatment was 
well tolerated. Five days after a dose increase by 10%, 
she again developed leukopenia grade 2 (2.5x109/L) 
and neutropenia grade 1 (1.5x109/L). Despite this, 
treatment could be finished at reduced dose. The 
patient received surgery and was disease-free four 
years after treatment.  
The DPD activity of the patient was 41% of the normal 
DPD activity. 
- A 67-year old male developed fatigue grade 2 on day 
7 of treatment with capecitabine 850 mg/m2 on day 
1-14 of the three-week cycle, docetaxel, oxaliplatin 
and bevacizumab.  On day 11, the patient was 
hospitalised with neutropenia grade 2 (1.3x109/L) and 
fever grade 1 (38.7oC, without apparent focus). After 
release from hospital, he refused further treatment. 
Because of disease progression, capecitabine 800 
mg/m2 twice daily (64% of the standard dose) was 
started four months later as monotherapy. The 
patient again developed fatigue grade 2 and refused 
further treatment after cycle 1. 
The DPD activity of the patient was 55% of the normal 
DPD activity. 
- A 69-year old male tolerated 4 weeks of 
neoadjuvant treatment with standard dose 
capecitabine (825 mg/m2 twice daily) and 
radiotherapy well. Treatment was completed without 
dose reductions or delays, and without adverse 
events and haematological changes. The patient had 
a relapse one year after surgery and died as a result 
of progressive disease before determination of DPD 
activity could be performed.  
 
cDNA analysis of the first two patients showed that 
they produced roughly equal amounts of wild type 
mRNA and aberrantly spliced mRNA with a premature 
stop codon. 
 
The authors indicate that the starting dose of 
capecitabine was relatively low in these patients 
(compared to the monotherapy dose of 1250 mg/m2 
twice daily). So, higher doses might have resulted in 
more pronounced toxicity. Amstutz 2009 describes a 
clinically relevant, 
and support an 
upfront dose 
reduction of the 
fluoropyrimidine 






versus gene activity 
2: 
gene activity 1: 60% 
 
DPD activity versus 
gene activity 2: 
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patient with genotype c.1236A>G/c.1236A>G, who 
developed fatal toxicity during the first cycle with full 
dose 5-FU plus cisplatin.  
 
NOTE: Patients were genotyped for c.1129-5923C>G 
and checked for the presence of c.1236G>A and 
c.959-51T>G, which are in complete linkage 
disequilibrium with c.1129-5923C>G in haplotype B3. 































































The results of routine prospective genotyping and 
genotype-guided dosing were retrospectively 
evaluated in patients receiving capecitabine or 5-
fluorouracil, either as combined chemotherapy 
(different combinations) or as monotherapy (with or 
without radiotherapy). Genotyping was originally only 
for *2A (275 patients), but from approximately 30% 
of the total study time genotyping for *13 and 
2846A>T was added (214 patients) and from 65% of 
the total study time genotyping for c.1236G>A was 
added (n = 109). Recommended dosing reductions 
were 50% of the normal dose per *2A- and *13-
variant and 25% per c.1236A>G-variant. 
Recommended dosing reduction per c.2846A>T-
variant was 50% (change to a recommendation of 
25% reduction was only after the study), but was not 
applied. 14 patients with gene variants were 
identified. 
Due to the low number of patients with DPD variants 
the study was not powered to formally test the effect 
of genotype-guided dosing on fluoropyrimidine-




- 8x *1/c.1236A>G 
- 5x *1/*2A  
- 1 carrier of both *2A and c.2846A>T (either 
*2A/c.2846A>T (on separate alleles) or 
*1/(*2A+c.2846A>T) (variants on the same allele)) 
 
Results: 
- 8 patients (5x *1/c.1236A>G and 3x *1/*2A) 
received the recommended initial dose reduction 
and did not develop toxicity grade 3-4 in cycle 1.  
The dose of 4 patients was subsequently 
increased. Two patients (1x *1/c.1236A>G with a 
dose increase to 100% of the normal dose and 1x 
*1/*2A with a dose increase to 60% of the normal 
dose) did not develop toxicity grade 3-4. A patient 
with genotype *1/*2A developed diarrhoea grade 
3 and enteritis after dose increase to 80% of the 
normal dose. Another patient with this genotype 
developed hand-foot-syndrome grade 2-3 after 
multiple cycles with the normal dose.        
Authors’ conclusion: 
‘Prospective DPYD 
screening can be 
implemented 
successfully in a real 
world clinical setting, 
is well accepted by 
physicians and 



























- 3 patients (1x *1/c.1236A>G and 2x *1/*2A) did 
not receive an initial dose reduction and 
developed toxicity grade 3-4 in cycle 1. For two of 
these patients, therapy was started before the 
genotype was known. For the third patient, the 
oncologist did not reduce the dose, because the 
dose in the chemotherapy regimen was already 
relatively low (capecitabine plus radiotherapy). 
For 1 patient with genotype *1/*2A, the dose was 
subsequently reduced to 50% of the normal dose 
and the patient did not develop toxicity grade 3-4 
anymore. The other 2 patients quitted 
fluoropyrimidine therapy.     
- For the carrier of both *2A and c.2846A>T, there 
was no dose recommendation, because it was not 
known whether the variants were on different 
alleles or on the same allele. Because therapy had 
to be started before the DPD-activity would have 
been determined, the physician decided to use a 
50% dose reduction, taking into account the 
results of genotyping and that this patient had 
tolerated 5-FU containing regimens before. 
Fluoropyrimidine therapy was stopped in this 
patient after the first cycle due to toxicity (≤ grade 
3).    
- 2 patients (both with genotype *1/c.1236A>G) 
did not start fluoropyrimidine therapy. 
 
ref. 7 – FU, 
comb  
































A subset of patients from Lee 2014 was reanalysed: 
1953 patients, negative for *2A, *13 and c.2846A>T, 
and treated with 12 cycles of adjuvant FOLFOX 
therapy (5-FU, folinic acid and oxaliplatin) with or 
without cetuximab. 62.9% of patients had any grade ≥ 
3 adverse event, with 32.7% having any grade ≥ 3 
adverse event common to 5-FU treatment. 
Adverse events classified as common to 5-FU 
treatment were fatigue, anorexia, dehydration, 
diarrhoea, stomatitis/mucositis, nausea/vomiting, 
leukopenia, neutropenia, febrile neutropenia, 
thrombocytopenia, and pain. Most frequent 5-FU 
adverse events included diarrhoea (12.5%), 
neutropenia (10.3%), pain (5.4%), fatigue (5.2%), 
nausea/vomiting (4.7%), and mucositis (4.1%).  
Results were adjusted for clinicopathological factors 
like age, sex, treatment, total number of treatment 
cycles and dose modifications. The latter two 
outcomes (higher percentage of patients with 
premature continuation and with dose modification) 
might be results of 5-FU adverse events instead of 
causes.  
Cetuximab increased the risk of 5-FU adverse events. 
Results were adjusted for this, but this indicates that 
adverse events common to 5-FU are not the same as 









adverse event rate. 





















patient with genotype c.1236A>G/c.1236A>G, who 
developed fatal toxicity during the first cycle with full 
dose 5-FU plus cisplatin.  
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adverse event rate. 









































- 1875x *1/*1 
- 77x *1/c.1236A>G  
- 1x c.1236A>G/c.1236A>G  
  
Results: 
Risk of grade ≥ 3 adverse event for 
c.1236A>G/c.1236A>G versus *1/c.1236A>G 
versus *1/*1: 
any adverse event NS, trend for an increase 
(p=0.082) 
ORadj for (*1/c.1236A>G + 
c.1236A>G/c.1236A>G) 
compared to *1/*1 also 
showed a trend for an 
increase (NS, p=0.127). 
diarrhoea NS 







NOTE: Results were reported for 1129-5923C>G, 
which was in complete linkage disequilibrium with 
the also genotyped c.1236G>A. 
ref. 8 – 
FU/CAP, 
mono/comb  






ne therapy: a 
safety and 
cost analysis. 























e Score A 
1631 patients received genotype-guided therapy with 
capecitabine (90% of patients) or 5-FU (10% of 
patients), either as combined chemotherapy 
(different combinations) or as monotherapy (with or 
without radiotherapy). Genotyping was for *2A. For 
*1/*2A, dose reduction in the first two cycles was ≥ 
50% and was followed by dose titration based on 
tolerance. Initial dose was not reduced for *1/*1. 
Patients with the *1/*2A genotype were compared 
with 48 patients with this genotype, treated with the 
full initial dose in published cohorts studies without 
genotype-guided dosing. Of these 48 patients, 79% 
was treated with 5-fluorouracil, 19% with 
capecitabine and 2% with tegafur combined with 
uracil. In addition, patients with the *1/*2A genotype 
were compared to patients with the *1/*1 genotype. 
For 16 *1/*2A-patients, 5-fluorouracil AUC in blood 
plasma after the first capecitabine dose was 
compared with that of 25 unselected patients from 
two studies (n = 11 and n = 14 per study). 
For 15 *1/*2A-patients, DPD enzyme activity in 
peripheral mononuclear blood cells was determined 
and compared with the mean Caucasian DPD enzyme 
activity (mainly *1/*1-patients). 
The study had 100% power to detect a reduction of 
the incidence of grade ≥ 3 toxicity in *2A-carriers 
from 85% to 20%. 
Authors’ conclusion: 
‘DPYD*2A genotype-
guided dosing results 
in adequate systemic 
drug exposure and 
significantly 
improves safety of 
fluoropyrimidine 
therapy for the 
individual patient. On 
a population level, 
upfront genotyping 
seemed cost saving.’ 
 
AUC versus gene 
activity 2: 























































The risk of grade ≥ 3 toxicity was higher in 
combination therapy than in monotherapy and 
chemo-radiotherapy regimens. 
Genotyping: 
- 1613x *1/*1 
- 18x *1/*2A  
 
Results: 
Treatment characteristics of *1/*2A-patients: 
- The initial dose varied from 29% to 60% of the 
full dose (median 46%). The final dose varied from 
17% to 91% of the full dose. The median dose per 
treatment cycle was 48% (range 17% to 91%). All 
patients were treated with capecitabine.         
- 5 patients developed toxicity grade ≥ 3 (first 
cycle 29% to 60% of the normal dose, final cycle 
17% to 60% and maximum 29% to 67%) 
- 2 patients developed toxicity grade 0 (first of the 
two cycles with 29% and second cycle with 59% of 
the nor-mal dose and all five cycles 48% of the 
normal dose, respectively) 
- 11 patients developed toxicity grade 1 to 2 (first 
cycle 30% to 50% of the normal dose, final cycle 
24% to 91% and maximum 46% to 91%) 
- Toxicity was short in duration and well controlled 
using standard supportive care.  
- For 6 patients, the dose was increased during 
treatment (dose in first cycle 29% to 47% of the 
normal dose; maxi-mum dose 46% to 91%).  
In two of these patients (dose increase from 47% 
to 53% and from 44% to 67%, respectively), the 
dose was later reduced to the initial dose again 
because of toxicity.    
- For 3 patients, the initial dose was still too high 
and had to be reduced further (initial dose 29% to 
44% of the normal dose, final dose 17% to 24%).  
- Of 4 evaluable patients, 2 achieved a partial 
response and 2 had stable disease. 
In 4 of 5 patients with rectal cancer treated with 
chemo-radiotherapy, down staging of the tumour 
from pT3-4 to ypT0-2 was reached. 
 
Percentage of *1/*2A patients with toxicity for 
reduced dosing compared to full dosing: 
  value for 
full dosing 
any grade ≥ 3 
toxicity 
x 0.38 (S) 73%  
In addition, the observed 
toxicity was short in 
duration with reduced 
dosing and usually long-
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grade ≥ 3 
haematological 
toxicity 
x 0.26 (S) 66%  
grade ≥ 3 
gastrointestinal 
toxicity 





Percentage of patients with toxicity for *1/*2A on 
reduced dosing compared to *1/*1 on full dosing: 
   value for 
*1/*1 
any toxicity grade ≥ 
3 
NS 23% 
grade 1-2 NS 54% 
haematolog
ical toxicity 
grade ≥ 3 NS 10% 
grade 1-2 NS 35% 
diarrhoea grade ≥ 3 NS 8% 
grade 1-2 NS 29% 
hand-foot 
syndrome 
grade ≥ 3 NS 5% 
grade 1-2 NS 28% 
The authors indicate that the comparable toxicity 
burden suggests that *1/*2A is not underexposed 
when treated with a median dose of 48%. 
 
Dose-normalised pharmacokinetics and DPD 
enzyme activity for *1/*2A compared to *1/*1: 
  value 
for 
*1/*1 
5-FU AUC normalised to a 
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Meta-analysis of 8 cohort studies with in total 7365 
patients treated with 5-FU or capecitabine, either as 
combined chemotherapy (different combinations) or 
as monotherapy (with or without radiotherapy). 
Data on *13 were derived from 5 studies including a 
total of 5,616 patients and 11 carriers of *13. Data on 
c.1236G>A were derived from 6 studies including a 
total of 4,261 patients and 174 heterozygous carriers 
and 3 homozygous carriers of c.1236A>G. Data on 
*2A were derived from 7 studies including a total of 
5.737 patients and 60 carriers of *2A. Data on 
c.2846A>T were derived from all 8 studies including a 
total of 7,318 patients and 85 carriers of c.2846A>T.  
1 of the 8 studies in this meta-analysis is also included 
in the meta-analysis of Rosmarin 2014 (Rosmarin 
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Meta-analysis of 8 cohort studies with in total 7365 
patients treated with 5-FU or capecitabine, either as 
combined chemotherapy (different combinations) or 
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included in the meta-analysis of Terrazzino 2013 
(Morel 2006 and Deenen 2011). 
5 of the 8 studies in this meta-analysis are also 
included separately in this risk analysis: Morel 2006, 
Deenen 2011, Lee 2014, Rosmarin 2014 and 
Meulendijks 2017.  
If possible, a RR was calculated for each study based 
on individual patient data and adjusted for age, sex, 
and treatment regimen. For 2 of the 5 studies for *13, 
it was not possible to use individual patient data. A 
random-effects model was used for the meta-
analysis.  
Haematological toxicity included thrombocytopenia, 
neutropenia, leukocytopenia, and anaemia. Gastro-
intestinal toxicity included diarrhoea, 
mucositis/stomatitis, and nausea/vomiting.  
Short timeframe was defined as shorter than the 
complete treatment duration, long timeframe as the 
whole treatment duration. 
In addition, a meta-analysis of 3 case-control studies 
with in total 799 patients was performed for 
c.1236G>A. One of these case-control studies is also 
included in the meta-analysis of Rosmarin 2014 
(Schwab 2008) and two in the meta-analysis of 
Terrazzino 2013 (Schwab 2008 and Kleibl 2009). One 
of these case-control studies is also included 
separately in this risk analysis (Schwab 2008). 
 
Results:  









any toxicity 4.40 (2.08-9.30) (S) 22%  












- (RR could not be 
calculated due to 
an incidence of 0% 
in *1/*13) 
 
The heterogeneity between the studies was 
significant and substantial, possibly because of the 
small number of *1/*13. 
There was no indication of publication bias. 
The results for any toxicity were similar when 
patients carrying *2A and/or c.2846A>T were 
excluded from the meta-analysis. The association 
remained significant with p< 0.0167 after 
exclusion of any study from the meta-analysis, 
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(Morel 2006 and Deenen 2011). 
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If possible, a RR was calculated for each study based 
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it was not possible to use individual patient data. A 
random-effects model was used for the meta-
analysis.  
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In addition, a meta-analysis of 3 case-control studies 
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Percentage of patients with toxicity for *1/*2A on 
reduced dosing compared to *1/*1 on full dosing: 
   value for 
*1/*1 
any toxicity grade ≥ 
3 
NS 23% 
grade 1-2 NS 54% 
haematolog
ical toxicity 
grade ≥ 3 NS 10% 
grade 1-2 NS 35% 
diarrhoea grade ≥ 3 NS 8% 
grade 1-2 NS 29% 
hand-foot 
syndrome 
grade ≥ 3 NS 5% 
grade 1-2 NS 28% 
The authors indicate that the comparable toxicity 
burden suggests that *1/*2A is not underexposed 
when treated with a median dose of 48%. 
 
Dose-normalised pharmacokinetics and DPD 
enzyme activity for *1/*2A compared to *1/*1: 
  value 
for 
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5-FU AUC normalised to a 
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Meta-analysis of 8 cohort studies with in total 7365 
patients treated with 5-FU or capecitabine, either as 
combined chemotherapy (different combinations) or 
as monotherapy (with or without radiotherapy). 
Data on *13 were derived from 5 studies including a 
total of 5,616 patients and 11 carriers of *13. Data on 
c.1236G>A were derived from 6 studies including a 
total of 4,261 patients and 174 heterozygous carriers 
and 3 homozygous carriers of c.1236A>G. Data on 
*2A were derived from 7 studies including a total of 
5.737 patients and 60 carriers of *2A. Data on 
c.2846A>T were derived from all 8 studies including a 
total of 7,318 patients and 85 carriers of c.2846A>T.  
1 of the 8 studies in this meta-analysis is also included 
in the meta-analysis of Rosmarin 2014 (Rosmarin 
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c.2846A>T were d rived from all 8 studies including a 
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included in the meta-analysis of Terrazzino 2013 
(Morel 2006 and Deenen 2011). 
5 of the 8 studies in this meta-analysis are also 
included separately in this risk analysis: Morel 2006, 
Deenen 2011, Lee 2014, Rosmarin 2014 and 
Meulendijks 2017.  
If possible, a RR was calculated for each study based 
on individual patient data and adjusted for age, sex, 
and treatment regimen. For 2 of the 5 studies for *13, 
it was not possible to use individual patient data. A 
random-effects model was used for the meta-
analysis.  
Haematological toxicity included thrombocytopenia, 
neutropenia, leukocytopenia, and anaemia. Gastro-
intestinal toxicity included diarrhoea, 
mucositis/stomatitis, and nausea/vomiting.  
Short timeframe was defined as shorter than the 
complete treatment duration, long timeframe as the 
whole treatment duration. 
In addition, a meta-analysis of 3 case-control studies 
with in total 799 patients was performed for 
c.1236G>A. One of these case-control studies is also 
included in the meta-analysis of Rosmarin 2014 
(Schwab 2008) and two in the meta-analysis of 
Terrazzino 2013 (Schwab 2008 and Kleibl 2009). One 
of these case-control studies is also included 
separately in this risk analysis (Schwab 2008). 
 
Results:  









any toxicity 4.40 (2.08-9.30) (S) 22%  












- (RR could not be 
calculated due to 
an incidence of 0% 
in *1/*13) 
 
The heterogeneity between the studies was 
significant and substantial, possibly because of the 
small number of *1/*13. 
There was no indication of publication bias. 
The results for any toxicity were similar when 
patients carrying *2A and/or c.2846A>T were 
excluded from the meta-analysis. The association 
remained significant with p< 0.0167 after 
exclusion of any study from the meta-analysis, 

































































































included in the meta-analysis of Terrazzino 2013 
(Morel 2006 and Deenen 2011). 
5 of the 8 studies in this meta-analysis are also 
included separately in this risk analysis: Morel 2006, 
Deenen 2011, Lee 2014, Rosmarin 2014 and 
Meulendijks 2017.  
If possible, a RR was calculated for each study based 
on individual patient data and adjusted for age, sex, 
and treatment regimen. For 2 of the 5 studies for *13, 
it was not possible to use individual patient data. A 
random-effects model was used for the meta-
analysis.  
Haematological toxicity included thrombocytopenia, 
neutropenia, leukocytopenia, and anaemia. Gastro-
intestinal toxicity included diarrhoea, 
mucositis/stomatitis, and nausea/vomiting.  
Short timeframe was defined as shorter than the 
complete treatment duration, long timeframe as the 
whole treatment duration. 
In addition, a meta-analysis of 3 case-control studies 
with in total 799 patients was performed for 
c.1236G>A. One of these case-control studies is also 
included in the meta-analysis of Rosmarin 2014 
(Schwab 2008) and two in the meta-analysis of 
Terrazzino 2013 (Schwab 2008 and Kleibl 2009). One 
of these case-control studies is also included 
separately in this risk analysis (Schwab 2008). 
 
Results:  
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- (RR could not be 
calculated due to 
an incidence of 0% 
in *1/*13) 
 
The heterogeneity between the studies was 
significant and substantial, possibly because of the 
small number of *1/*13. 
There was no indication of publication bias. 
The results for any toxicity were similar when 
patients carrying *2A and/or c.2846A>T were 
excluded from the meta-analysis. The association 
remained significant with p< 0.0167 after 
exclusion of any study from the meta-analysis, 






























































































except for Loganayagam 2013. After exclusion of 
Loganayagam 2013, the p-value was 0.0433. 
The effect of *13 on risk of severe toxicity seemed 
similar in studies with long and short timeframes. 
The sensitivity of *13 in prediction of grade ≥ 3 
toxicity was 0.3% and the positive predictive value 
46%.  
 
Risk of grade ≥ 3 toxicity for (*1/c.1236A>G + 
c.1236A>G/c.1236A>G) compared to *1/*1: 
  
 






any toxicity 1.59 (1.29-1.97) (S) 22%  
   haematological 
toxicity 
2.07 (1.17-3.68) (S)  
gastrointestinal 
toxicity 
2.04 (1.49-2.78) (S)  
hand-foot 
syndrome  
NS (also for the sub-
group treated with 
capecitabine)    
 
There was no significant heterogeneity between 
the studies. 
There was no indication of publication bias. 
The results for any toxicity were similar when 
patients carrying *2A and/or c.2846A>T were 
excluded from the meta-analysis. The association 
remained significant after exclusion of any study 
from the meta-analysis. 
The effect of c.1236A>G on risk of severe toxicity 
seemed similar in studies with long and short 
timeframes. 
The sensitivity of c.1236A>G in prediction of grade 
≥ 3 toxicity was 6.4% and the positive predictive 
value 41%.  
The meta-analysis of the case-control studies did 
not show a significant result, probably due to the 
smaller number of patients. 
The authors reported to have treated 3 patients 
with genotype c.1236A>G/c.1236A>G safely with 
low dose capecitabine (825 mg/m2 twice a day). 
 
Risk of grade ≥ 3 toxicity for *2A-carriers compared 
to *1/*1: 





any toxicity 2.85 (1.75-4.62) (S) 29%  
The heterogeneity between the studies was 
significant and strong. 
There was no indication of publication bias. 
 
Risk of grade ≥ 3 toxicity for c.2846A>T-carriers 
compared to *1/*1: 




any toxicity 3.02 (2.22-
4.10) (S) 
25%  
The heterogeneity between the studies was 
significant and strong. 
There was no indication of publication bias. 
 
NOTE: c.1236G>A is in complete linkage 
disequilibrium with c.1129-5923C>G in haplotype B3. 
Studies analysing both gene variants were pooled.  
 
NOTE: Meta-analysis of 5 studies with in total 3900 
patients, 182x *1/*4 and 2x *4/*4, showed no 
significant association between *4 and grade ≥ 3 
toxicity. The only study that found a significant effect 
(Loganayagam 2013) was the cause of strong 
heterogeneity between the studies. In addition, 
results regarding the effect of *4 on DPD activity are 
inconsistent. 
ref. 10 – FU, 
comb  











































2594 patients were treated with 12 cycles of adjuvant 
FOLFOX therapy (5-fluorouracil, folinic acid and 
oxaliplatin; 91.9% of patients) or FOLFIRI therapy (5-
fluorouracil, folinic acid and irinotecan; 8.1% of 
patients) with or without cetuximab. Part of the 
patients received 6 cycles of FOLFOX followed by six 
cycles of FOLFIRI with or without cetuximab. 62.0% of 
patients had any grade ≥ 3 adverse event, with 33.1% 
having any grade ≥ 3 adverse event common to 5-
fluorouracil treatment. 
Adverse events classified as common to 5-fluorouracil 
treatment were fatigue, anorexia, dehydration, 
diarrhoea, stomatitis/mucositis, nausea/vomiting, 
leukopenia, neutropenia, febrile neutropenia, 
thrombocytopenia, and pain. Most frequent 5-
fluorouracil adverse events included diarrhoea 
(12.0%), neutropenia (11.7 %), nausea/vomiting 
(5.0%), fatigue (4.9%), and mucositis (4.2%).  
Follow-up for disease free survival was for 5 years. 
Results were adjusted for clinicopathological factors 
like age, sex, treatment, total number of treatment 
cycles and dose modifications. The latter two 
outcomes (higher percentage of patients with 
premature continuation and with dose modification) 
might be results of 5-fluorouracil adverse events 
instead of causes.  
Cetuximab increased the risk of 5-fluorouracil adverse 
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variants (DPYD*2A 
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Loganayagam 2013, the p-value was 0.0433. 
The effect of *13 on risk of severe toxicity seemed 
similar in studies with long and short timeframes. 
The sensitivity of *13 in prediction of grade ≥ 3 
toxicity was 0.3% and the positive predictive value 
46%.  
 
Risk of grade ≥ 3 toxicity for (*1/c.1236A>G + 
c.1236A>G/c.1236A>G) compared to *1/*1: 
  
 






any toxicity 1.59 (1.29-1.97) (S) 22%  
   haematological 
toxicity 
2.07 (1.17-3.68) (S)  
gastrointestinal 
toxicity 
2.04 (1.49-2.78) (S)  
hand-foot 
syndrome  
NS (also for the sub-
group treated with 
capecitabine)    
 
There was no significant heterogeneity between 
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There was no indication of publication bias. 
The results for any toxicity were similar when 
patients carrying *2A and/or c.2846A>T were 
excluded from the meta-analysis. The association 
remained significant after exclusion of any study 
from the meta-analysis. 
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not show a significant result, probably due to the 
smaller number of patients. 
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low dose capecitabine (825 mg/m2 twice a day). 
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2594 patients were treated with 12 cycles of adjuvant 
FOLFOX therapy (5-fluorouracil, folinic acid and 
oxaliplatin; 91.9% of patients) or FOLFIRI therapy (5-
fluorouracil, folinic acid and irinotecan; 8.1% of 
patients) with or without cetuximab. Part of the 
patients received 6 cycles of FOLFOX followed by six 
cycles of FOLFIRI with or without cetuximab. 62.0% of 
patients had any grade ≥ 3 adverse event, with 33.1% 
having any grade ≥ 3 adverse event common to 5-
fluorouracil treatment. 
Adverse events classified as common to 5-fluorouracil 
treatment were fatigue, anorexia, dehydration, 
diarrhoea, stomatitis/mucositis, nausea/vomiting, 
leukopenia, neutropenia, febrile neutropenia, 
thrombocytopenia, and pain. Most frequent 5-
fluorouracil adverse events included diarrhoea 
(12.0%), neutropenia (11.7 %), nausea/vomiting 
(5.0%), fatigue (4.9%), and mucositis (4.2%).  
Follow-up for disease free survival was for 5 years. 
Results were adjusted for clinicopathological factors 
like age, sex, treatment, total number of treatment 
cycles and dose modifications. The latter two 
outcomes (higher percentage of patients with 
premature continuation and with dose modification) 
might be results of 5-fluorouracil adverse events 
instead of causes.  
Cetuximab increased the risk of 5-fluorouracil adverse 
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outcomes were not. In addition, this indicates that 
adverse events common to 5-fluorouracil are not the 
same as 5-FU-induced adverse events. 
 
Genotyping: 
- 2532x *1/*1 
- 24x *1/*2A  
- 26x *1/c.2846A>T 
- 1x *2A/c.2846A>T 
- 1x *1/274C  
- 5x *2A-genotyping failed 
- 5x c.2846A>T-genotyping failed 
  
Results: 
Risk of grade ≥ 3 toxicity, premature treatment 
termination and disease free survival for *2A-










any toxicity ORadj = 3.58 (95% 
CI: 1.01-12.64) (S) 
62%  
any 5-FU toxicity ORadj = 14.91 (95% 
CI: 4.26-52.18) (S) 
33% 
   diarrhoea NS 12% 
neutropenia x 5.7 (S) 11% 
nausea/vomiting x 4.2 (S) 4.8% 
fatigue NS 4.8% 
stomatitis/mucosi
tis 
NS, trend for an 
increase, p=0.09 
4.2% 
dehydration NS 2.3% 





NS, trend for an 
increase, p=0.07 
1.6% 
anorexia NS 1.5% 
pain NS 0.8% 
thrombocytopeni
a 






x 1.7 (S) 26% 
dose modification NS 74% 
   disease free 
survival 
after 3 year 
NS 73% 
When restricting the analysis to Caucasians, sex or 
treatment, the association between *2A and 
grade ≥ 3 5-FU toxicity remained significant, 
whereas the association between *2A and grade ≥ 














































Risk of grade ≥ 3 toxicity, premature treatment 
termination and disease free survival for 










any toxicity ORadj = 5.43 (95% 
CI: 1.52-19.43) (S) 
62%  
any 5-FU toxicity ORadj = 10.24 (95% 
CI: 3.57-29.40) (S) 
33% 
   diarrhoea x 2.8 (S) 12% 
neutropenia x 4.9 (S)  11% 
nausea/vomiting NS 5.0% 




dehydration x 5.0 (S)  2.2% 
leukopenia x 8.2 (S)  1.8% 
febrile 
neutropenia 
NS, trend for an 
increase, p=0.08 
1.6% 
anorexia NS 1.5% 
pain NS 0.8% 
thrombocytopeni
a 





dose modification NS 74% 
   disease free 
survival after 3 
year 
NS 73% 
When restricting the analysis to Caucasians, sex or 
treatment, the association between c.2846A>T 
and grade ≥ 3 5-FU toxicity remained significant. 
The association between c.2846A>T and grade ≥ 3 
overall toxicity remained significant in the 
subgroups of Caucasians and males, but not in the 




- Because of its low frequency, a statistically 
significant association could not be demonstrated 
between *13 and either 5-FU or overall grade ≥ 3 
toxicity (NS). 
- The *2A/c.2846A>T-patient had a grade 5 
adverse event. The patient was only able to 
receive one cycle of FOLFOX + cetuximab. 




























































outcomes were not. In addition, this indicates that 
adverse events common to 5-fluorouracil are not the 
same as 5-FU-induced adverse events. 
 
Genotyping: 
- 2532x *1/*1 
- 24x *1/*2A  
- 26x *1/c.2846A>T 
- 1x *2A/c.2846A>T 
- 1x *1/274C  
- 5x *2A-genotyping failed 
- 5x c.2846A>T-genotyping failed 
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any toxicity ORadj = 3.58 (95% 
CI: 1.01-12.64) (S) 
62%  
any 5-FU toxicity ORadj = 14.91 (95% 
CI: 4.26-52.18) (S) 
33% 
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neutropenia x 5.7 (S) 11% 
nausea/vomiting x 4.2 (S) 4.8% 
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NS, trend for an 
increase, p=0.09 
4.2% 
dehydration NS 2.3% 
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CI: 1.52-19.43) (S) 
62%  
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CI: 3.57-29.40) (S) 
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   diarrhoea x 2.8 (S) 12% 
neutropenia x 4.9 (S)  11% 
nausea/vomiting NS 5.0% 




dehydration x 5.0 (S)  2.2% 
leukopenia x 8.2 (S)  1.8% 
febrile 
neutropenia 
NS, trend for an 
increase, p=0.08 
1.6% 
anorexia NS 1.5% 
pain NS 0.8% 
thrombocytopeni
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dose modification NS 74% 
   disease free 
survival after 3 
year 
NS 73% 
When restricting the analysis to Caucasians, sex or 
treatment, the association between c.2846A>T 
and grade ≥ 3 5-FU toxicity remained significant. 
The association between c.2846A>T and grade ≥ 3 
overall toxicity remained significant in the 
subgroups of Caucasians and males, but not in the 




- Because of its low frequency, a statistically 
significant association could not be demonstrated 
between *13 and either 5-FU or overall grade ≥ 3 
toxicity (NS). 
- The *2A/c.2846A>T-patient had a grade 5 
adverse event. The patient was only able to 
receive one cycle of FOLFOX + cetuximab. 





- The gene variants *2A, *13 and c.2846A>T 
together predicted 5-FU grade ≥ 3 toxicity with a 
sensitivity of 5.3%, specificity of 99.4%, positive 
predictive value of 81.8% and negative predictive 
value of 68%. The low sensitivity and negative 
predictive value might be attributed to the 
combination chemotherapy, which may add to the 
5-FU toxicity. 
 
NOTE: Genotyping was for 25 gene variants of which 
only 4 (*2A, *13, c.2846A>T and 274G>C) were found 
in this population from the USA. 
ref. 11 – 
CAP/FU, 
comb 


















































After colorectal cancer excision, 927 patients received 
adjuvant therapy with capecitabine 1250 mg/m2 
twice daily on days 1-14 of a 3-week cycle either as 
monotherapy (n = 436) or in combination with 
bevacizumab (n = 491). Grade III-V toxicity comprised 
hand-foot syndrome (n = 206), diarrhoea (n = 97) and 
neutropenia (n = 19). 
 
Variant c.2846A>T:  
- Associated with grade III-V toxicity (OR = 9.35; 95% 
CI: 2.01-43.4) (S) 
- No association with grade III-V diarrhoea and grade 
III-V hand-foot syndrome (NS). 
Given the allele frequency found, this is apparently 
based on 5 defect alleles. 
 
Variants *2A, 496A>G, c.1236G>A: 
- No association with grade III-V toxicity, grade III-V 
diarrhoea and grade III-V hand-foot syndrome (NS). 
Given the allele frequency found, this is apparently 
based on 4 defect alleles for *2A, 83 for 496A>G and 
18 for c.1236G>A. 
 
Variant c.2846A>T and/or *2A: 
- Associated with grade III-V toxicity (OR = 5.51; 95% 
CI: 1.95-15.5) (S) 
- No association with grade III-V diarrhoea and grade 
III-V hand-foot syndrome (NS) 
- Both patients who died were carriers of *2A or 
c.2846A>T  
 
Meta-analysis of 6 studies during which Caucasian 
patients received capecitabine or 5-FU-based 
therapy. Of these 6 studies, the study covered in the 
paragraph above and Schwab, 2008, were also 
included separately in this risk analysis. 
 
Variant *2A: 
- No association with grade III-V toxicity for 
capecitabine (2 studies, n = 1035) (NS) 
- No significant association with grade III-V toxicity for 
5-FU infusion, but there was a trend (2 studies, n = 
Authors’ conclusion: 
“Global capecitabine 
toxicity (grades 0/1/2 
v grades 3/4/5) was 
associated with the 
rare, functional DPYD 
alleles c.2846A>T>A 
and *2A (combined 
































732) (NS; p=0.0075, whilst this should be less than 
0.0048 due to multiple testing) 
- No significant association with grade III-V toxicity for 
5-FU bolus injection, but increased risk of grade III-V 
neutropenia (OR = 12.9; 95% CI: 3.13-53.3) (1 study, n 
= 338) (S) 
 
Variant c.2846A>T: 
- No meta-analysis for capecitabine, 5-FU infusion and 
5-FU bolus injection (1 study each time) 
 
Variant 496G>A: 
- No meta-analysis for capecitabine and 5-FU infusion 
(in both cases only 1 study) 
- No association with grade III-V toxicity for 5-FU 
bolus injection (2 studies, n = 379) (NS) 
 
Variant c.1236G>A: 
- No meta-analysis for capecitabine, 5-FU infusion and 
5-FU bolus injection (1 study each time) 
 
Variant c.2846A>T and/or *2A: 
- No meta-analysis for capecitabine (only 1 study) 
- There was a significant association (p=0.05) with 
grade III-V toxicity for 5-FU infusion and 5-FU bolus 
injection (S) 
 
NOTE: No association was found for the gene variants 
*4, *5, *6 and *9A. However, associations with 
severe toxicity have never been found in studies 
concerning these gene variants. 










































Meta-analysis of 15 studies investigating patients 
treated with fluorouracil, capecitabine or tegafur-
uracil (1 study). Data on *2A (IVS14+1G>A) were 
derived from 15 studies including a total of 4,094 
patients and 60 carriers of *2A. Data on c.2846A>T 
were derived from 7 studies including a total of 2,308 
patients and 34 carriers of c.2846A>T. These 15 
studies include 8 studies that have also been included 
separately in this risk analysis: Salgueiro 2004, Morel 
2006, Largillier 2006, Boisdron-Celle 2007, Schwab 
2008, Sulzyc-Bielicka 2008, Kristensen 2010 and 
Deenen 2011.  
 
*2A versus (no *2A): 
Increased risk of grade III-V toxicity (OR = 5.42; 95% 
CI: 2.79-10.52; increase in the percentage of patients 
with grade III-V toxicity from 39% to 68%) (S) 
Exclusion of each of the studies from the meta-
analysis did not lead to substantially different results 
(OR = 4.05 - 7.32 (S)). 
The risk was increased in studies in which the 
percentage of patients with grade III-V toxicity was 
less than 40% (OR = 8.31; 95% CI: 3.63-19.06) (S). 
Authors’ conclusion: 
“The results of this 
meta-analysis 
confirm clinical 
validity of DPYD 
IVS14+1 G>A and 
2846A>T as risk 










- The gene variants *2A, *13 and c.2846A>T 
together predicted 5-FU grade ≥ 3 toxicity with a 
sensitivity of 5.3%, specificity of 99.4%, positive 
predictive value of 81.8% and negative predictive 
value of 68%. The low sensitivity and negative 
predictive value might be attributed to the 
combination chemotherapy, which may add to the 
5-FU toxicity. 
 
NOTE: Genotyping was for 25 gene variants of which 
only 4 (*2A, *13, c.2846A>T and 274G>C) were found 
in this population from the USA. 
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adjuvant therapy with capecitabine 1250 mg/m2 
twice daily on days 1-14 of a 3-week cycle either as 
monotherapy (n = 436) or in combination with 
bevacizumab (n = 491). Grade III-V toxicity comprised 
hand-foot syndrome (n = 206), diarrhoea (n = 97) and 
neutropenia (n = 19). 
 
Variant c.2846A>T:  
- Associated with grade III-V toxicity (OR = 9.35; 95% 
CI: 2.01-43.4) (S) 
- No association with grade III-V diarrhoea and grade 
III-V hand-foot syndrome (NS). 
Given the allele frequency found, this is apparently 
based on 5 defect alleles. 
 
Variants *2A, 496A>G, c.1236G>A: 
- No association with grade III-V toxicity, grade III-V 
diarrhoea and grade III-V hand-foot syndrome (NS). 
Given the allele frequency found, this is apparently 
based on 4 defect alleles for *2A, 83 for 496A>G and 
18 for c.1236G>A. 
 
Variant c.2846A>T and/or *2A: 
- Associated with grade III-V toxicity (OR = 5.51; 95% 
CI: 1.95-15.5) (S) 
- No association with grade III-V diarrhoea and grade 
III-V hand-foot syndrome (NS) 
- Both patients who died were carriers of *2A or 
c.2846A>T  
 
Meta-analysis of 6 studies during which Caucasian 
patients received capecitabine or 5-FU-based 
therapy. Of these 6 studies, the study covered in the 
paragraph above and Schwab, 2008, were also 
included separately in this risk analysis. 
 
Variant *2A: 
- No association with grade III-V toxicity for 
capecitabine (2 studies, n = 1035) (NS) 
- No significant association with grade III-V toxicity for 
5-FU infusion, but there was a trend (2 studies, n = 
Authors’ conclusion: 
“Global capecitabine 
toxicity (grades 0/1/2 
v grades 3/4/5) was 
associated with the 
rare, functional DPYD 
alleles c.2846A>T>A 
and *2A (combined 
































732) (NS; p=0.0075, whilst this should be less than 
0.0048 due to multiple testing) 
- No significant association with grade III-V toxicity for 
5-FU bolus injection, but increased risk of grade III-V 
neutropenia (OR = 12.9; 95% CI: 3.13-53.3) (1 study, n 
= 338) (S) 
 
Variant c.2846A>T: 
- No meta-analysis for capecitabine, 5-FU infusion and 
5-FU bolus injection (1 study each time) 
 
Variant 496G>A: 
- No meta-analysis for capecitabine and 5-FU infusion 
(in both cases only 1 study) 
- No association with grade III-V toxicity for 5-FU 
bolus injection (2 studies, n = 379) (NS) 
 
Variant c.1236G>A: 
- No meta-analysis for capecitabine, 5-FU infusion and 
5-FU bolus injection (1 study each time) 
 
Variant c.2846A>T and/or *2A: 
- No meta-analysis for capecitabine (only 1 study) 
- There was a significant association (p=0.05) with 
grade III-V toxicity for 5-FU infusion and 5-FU bolus 
injection (S) 
 
NOTE: No association was found for the gene variants 
*4, *5, *6 and *9A. However, associations with 
severe toxicity have never been found in studies 
concerning these gene variants. 










































Meta-analysis of 15 studies investigating patients 
treated with fluorouracil, capecitabine or tegafur-
uracil (1 study). Data on *2A (IVS14+1G>A) were 
derived from 15 studies including a total of 4,094 
patients and 60 carriers of *2A. Data on c.2846A>T 
were derived from 7 studies including a total of 2,308 
patients and 34 carriers of c.2846A>T. These 15 
studies include 8 studies that have also been included 
separately in this risk analysis: Salgueiro 2004, Morel 
2006, Largillier 2006, Boisdron-Celle 2007, Schwab 
2008, Sulzyc-Bielicka 2008, Kristensen 2010 and 
Deenen 2011.  
 
*2A versus (no *2A): 
Increased risk of grade III-V toxicity (OR = 5.42; 95% 
CI: 2.79-10.52; increase in the percentage of patients 
with grade III-V toxicity from 39% to 68%) (S) 
Exclusion of each of the studies from the meta-
analysis did not lead to substantially different results 
(OR = 4.05 - 7.32 (S)). 
The risk was increased in studies in which the 
percentage of patients with grade III-V toxicity was 
less than 40% (OR = 8.31; 95% CI: 3.63-19.06) (S). 
Authors’ conclusion: 
“The results of this 
meta-analysis 
confirm clinical 
validity of DPYD 
IVS14+1 G>A and 
2846A>T as risk 

















































However, the increase was non-significant in studies 
including ³40% of patients with toxicity. 
The results were similar if only prospective studies, 
only higher quality studies or only studies including ³ 
200 patients were analysed. In prospective studies, 
the risk also increased as the incidence of grade III-V 
toxicity decreased in the study. 
The risk was also increased when only studies 
investigating 5-FU-based therapy or 5-FU 
monotherapy were analysed. 
Increased risk of grade III-V haematological toxicity 
(OR = 15.77; 95% CI: 6.36-39.06) (S) 
Increased risk of grade III-V diarrhoea (OR = 5.54; 95% 
CI: 2.31-13.29) (S) 
Increased risk of grade III-V mucositis (OR = 7.48; 95% 
CI: 3.03-18.47) (S) 
*2A had a sensitivity of 5.2% (95% CI: 3.0-8.9) and a 
specificity of 99.2% (95% CI: 98.8-99.4) for predicting 
grade III-V toxicity (S)  
The sensitivity was 9.0% for studies that showed less 
than 40% grade III-V toxicity (95% CI: 5.7-13.9) (S). 
There was study heterogeneity in the overall group, 
but not in the group with less than 40% toxicity. 
*2A had a sensitivity of 13% (95% CI: 6.6-24.1) for 
predicting grade III-V haematological toxicity (S)  
*2A had a sensitivity of 5.6% (95% CI: 3.2-9.7) for 
predicting grade III-V diarrhoea (S)  
*2A had a sensitivity of 11.5% (95% CI: 6.2-20.5) for 
predicting grade III-V mucositis (S)  
 
c.2846A>T versus (no c.2846A>T): 
Increased risk of grade III-V toxicity (OR = 8.18; 95% 
CI: 2.65-25.25; increase in the percentage of patients 
with grade III-V toxicity from 34% to 71%) (S) 
Exclusion of each of the studies from the meta-
analysis did not lead to substantially different results 
(OR = 6.20 - 12.88 (S)). 
The risk was increased in studies in which the 
percentage of patients with grade III-V toxicity was 
less than 40% (OR = 16.59; 95% CI: 5.06-54.43) (S). 
However, the increase was non-significant in studies 
including ³40% of patients with toxicity. 
The results were similar if higher only quality studies 
or only studies including ³ 200 patients were 
analysed.  
The risk was also increased when only prospective 
studies were analysed (OR = 18.14; 95% CI: 6.26-
52.58) (S) or only studies investigating 5-FU-based 
therapy (OR = 21.38; 95% CI: 6.71-68.15) (S). 
There was moderate study heterogeneity in the 
overall group, but not in the low or high toxicity 
subgroups, among prospective studies or among 
those investigating 5-fluorouracil-based therapy. 
There may have been publication bias. 
Increased risk of grade III-V diarrhoea (OR = 6.04; 95% 
CI: 1.77-20.66) (S) 
c.2846A>T had a sensitivity of 5.4% (95% CI: 1.7-16.1) 
and a specificity of 99.1% (95% CI: 98.7-99.4) for 
predicting grade III-V toxicity (S)  
The sensitivity was 11.2% for studies that showed less 
than 40% grade III-V toxicity (95% CI: 2.8-35.1) (S). 
There was heterogeneity between the studies. 
c.2846A>T had a sensitivity of 4.6% (95% CI: 2.2-9.4) 
for predicting grade III-V diarrhoea (S)  
ref. 13 – 
FU/CAP, 
comb 
Magnani E et 
al. 
Fluoropyrimid


































3 patients with genotype *1/*2A with gastrointestinal 
or head and neck tumours received 5-FU or 
capecitabine-based therapy (adjuvant or metastatic 
therapy). A 4th patient with genotype *1/*2A was not 
given adjuvant therapy.  
 
A 43-year-old colon cancer patient was given 
adjuvant therapy with capecitabine/oxaliplatin and a 
50% dose of capecitabine (500 mg/m2 twice daily for 
14 days, followed by a week-long rest period). The 
patient developed diarrhoea, grade 4 neutropenia 
and grade 3 thrombocytopenia after 19 days. The 
adjuvant therapy was discontinued. 
 
A 71-year-old colon cancer patient received the same 
adjuvant therapy including 40% of the normal 
capecitabine dose (400 mg/m2 twice daily). After 1 
day, the patient started vomiting and developed 
grade 3 abdominal pain. The adjuvant therapy was 
discontinued. 
A 68-year-old patient with metastatic maxillary sinus 
cancer initially received 5-FU/carboplatin/folinic acid 
with standard-dose 5-FU (3000 mg/m2 continuous 
infusion + 400 mg/m2 bolus every 3 weeks). After 15 
days, he developed grade 4 neutropenia and 
thrombocytopenia, and grade 3 sepsis and ulceration 
of the palate. After recovery, the treatment was 
restarted at 44% of the original dose (1500 mg/m2 by 
continuous infusion) and prophylactic growth factors. 
There was no toxicity for 2 cycles. In the third cycle, 
the dose was increased to 59% of the standard dose 
(2000 mg/m2 bolus) and no growth factors were 
given. After 14 days, the patient developed grade 4 
febrile neutropenia and grade 2 anaemia. He was 
henceforth given non-fluoropyrimidine-based 
therapy. 
The authors indicated that a 50% dose decrease in 
gene activity score 1 is not always adequate. 
Authors’ conclusion: 
“Our data suggest 
that greater dose 
reductions or 
alternative therapies 
are needed for 
patients with DPD 
IVS14+1 G>A 
mutations.” 
ref. 14 – FU, 
comb 










1012 breast cancer patients received 
neoadjuvant/adjuvant therapy with 5-FU, epirubicin 
and cyclophosphamide. The 5-FU dose was 500 
mg/m2 every 3 weeks with a maximum of 1000 mg 
(n=902) or 600 mg/m2 with a maximum of 1200 mg (n 
= 110).  
Authors’ conclusion: 
“In our study, we did 
not observe any 
association with 
toxicity and IVS14+1 













































However, the increase was non-significant in studies 
including ³40% of patients with toxicity. 
The results were similar if only prospective studies, 
only higher quality studies or only studies including ³ 
200 patients were analysed. In prospective studies, 
the risk also increased as the incidence of grade III-V 
toxicity decreased in the study. 
The risk was also increased when only studies 
investigating 5-FU-based therapy or 5-FU 
monotherapy were analysed. 
Increased risk of grade III-V haematological toxicity 
(OR = 15.77; 95% CI: 6.36-39.06) (S) 
Increased risk of grade III-V diarrhoea (OR = 5.54; 95% 
CI: 2.31-13.29) (S) 
Increased risk of grade III-V mucositis (OR = 7.48; 95% 
CI: 3.03-18.47) (S) 
*2A had a sensitivity of 5.2% (95% CI: 3.0-8.9) and a 
specificity of 99.2% (95% CI: 98.8-99.4) for predicting 
grade III-V toxicity (S)  
The sensitivity was 9.0% for studies that showed less 
than 40% grade III-V toxicity (95% CI: 5.7-13.9) (S). 
There was study heterogeneity in the overall group, 
but not in the group with less than 40% toxicity. 
*2A had a sensitivity of 13% (95% CI: 6.6-24.1) for 
predicting grade III-V haematological toxicity (S)  
*2A had a sensitivity of 5.6% (95% CI: 3.2-9.7) for 
predicting grade III-V diarrhoea (S)  
*2A had a sensitivity of 11.5% (95% CI: 6.2-20.5) for 
predicting grade III-V mucositis (S)  
 
c.2846A>T versus (no c.2846A>T): 
Increased risk of grade III-V toxicity (OR = 8.18; 95% 
CI: 2.65-25.25; increase in the percentage of patients 
with grade III-V toxicity from 34% to 71%) (S) 
Exclusion of each of the studies from the meta-
analysis did not lead to substantially different results 
(OR = 6.20 - 12.88 (S)). 
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less than 40% (OR = 16.59; 95% CI: 5.06-54.43) (S). 
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The results were similar if higher only quality studies 
or only studies including ³ 200 patients were 
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The risk was also increased when only prospective 
studies were analysed (OR = 18.14; 95% CI: 6.26-
52.58) (S) or only studies investigating 5-FU-based 
therapy (OR = 21.38; 95% CI: 6.71-68.15) (S). 
There was moderate study heterogeneity in the 
overall group, but not in the low or high toxicity 
subgroups, among prospective studies or among 
those investigating 5-fluorouracil-based therapy. 
There may have been publication bias. 
Increased risk of grade III-V diarrhoea (OR = 6.04; 95% 
CI: 1.77-20.66) (S) 
c.2846A>T had a sensitivity of 5.4% (95% CI: 1.7-16.1) 
and a specificity of 99.1% (95% CI: 98.7-99.4) for 
predicting grade III-V toxicity (S)  
The sensitivity was 11.2% for studies that showed less 
than 40% grade III-V toxicity (95% CI: 2.8-35.1) (S). 
There was heterogeneity between the studies. 
c.2846A>T had a sensitivity of 4.6% (95% CI: 2.2-9.4) 
for predicting grade III-V diarrhoea (S)  
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3 patients with genotype *1/*2A with gastrointestinal 
or head and neck tumours received 5-FU or 
capecitabine-based therapy (adjuvant or metastatic 
therapy). A 4th patient with genotype *1/*2A was not 
given adjuvant therapy.  
 
A 43-year-old colon cancer patient was given 
adjuvant therapy with capecitabine/oxaliplatin and a 
50% dose of capecitabine (500 mg/m2 twice daily for 
14 days, followed by a week-long rest period). The 
patient developed diarrhoea, grade 4 neutropenia 
and grade 3 thrombocytopenia after 19 days. The 
adjuvant therapy was discontinued. 
 
A 71-year-old colon cancer patient received the same 
adjuvant therapy including 40% of the normal 
capecitabine dose (400 mg/m2 twice daily). After 1 
day, the patient started vomiting and developed 
grade 3 abdominal pain. The adjuvant therapy was 
discontinued. 
A 68-year-old patient with metastatic maxillary sinus 
cancer initially received 5-FU/carboplatin/folinic acid 
with standard-dose 5-FU (3000 mg/m2 continuous 
infusion + 400 mg/m2 bolus every 3 weeks). After 15 
days, he developed grade 4 neutropenia and 
thrombocytopenia, and grade 3 sepsis and ulceration 
of the palate. After recovery, the treatment was 
restarted at 44% of the original dose (1500 mg/m2 by 
continuous infusion) and prophylactic growth factors. 
There was no toxicity for 2 cycles. In the third cycle, 
the dose was increased to 59% of the standard dose 
(2000 mg/m2 bolus) and no growth factors were 
given. After 14 days, the patient developed grade 4 
febrile neutropenia and grade 2 anaemia. He was 
henceforth given non-fluoropyrimidine-based 
therapy. 
The authors indicated that a 50% dose decrease in 
gene activity score 1 is not always adequate. 
Authors’ conclusion: 
“Our data suggest 
that greater dose 
reductions or 
alternative therapies 
are needed for 
patients with DPD 
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mutations.” 
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1012 breast cancer patients received 
neoadjuvant/adjuvant therapy with 5-FU, epirubicin 
and cyclophosphamide. The 5-FU dose was 500 
mg/m2 every 3 weeks with a maximum of 1000 mg 
(n=902) or 600 mg/m2 with a maximum of 1200 mg (n 
= 110).  
Authors’ conclusion: 
“In our study, we did 
not observe any 
association with 
toxicity and IVS14+1 


































Variant *2A (c.1905+1G>A, rs3918290): 
No significant association with serious adverse events 
(febrile neutropenia, prolonged grade III-IV 
neutropenia or severe neutropenia, grade III-IV 
anaemia, grade III-IV thrombocytopenia or grade III-IV 
non-haematological toxicity) (NS) 
 
The authors indicated that the lack of association is 
likely due to the fact that 5-FU toxicity is not common 
among breast cancer patients treated with this 
combination therapy. The 5-FU dose in this 
combination therapy is much lower than the dose in 
combination therapies used for colorectal cancer. 
 
NOTE: Associations were also not found for gene 
variants *5 (1627A>G), *6 (2194G>A) and *9A 
(85T>C). However, associations with severe toxicity 





probably relates to 
the fact that 5-FU 
toxicity is not 
frequent in breast 
cancer patients 
treated with FEC due 
to a much lower 5-FU 
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Clinical aspects were determined in 20 patients who 
had been genotyped as *1/*2A beforehand and were 
treated with 5-FU. Kinetics were determined in 30 
*1/*2A (c.1905+1G>A) and 18 *1/*1, who received a 
5-FU bolus injection of 300 mg/m2 and/or 450 mg/m2. 
Treatment regimens were not given. 
 
Clinical 
- All 7 *1/*2A receiving a standard dose of 5-FU 
showed grade III-V toxicity, of which 3 showed grade 
IV neutropenia 
The severe toxicity occurred in the first cycle each 
time and 1 patient died. 
- Among 13 *1/*2A receiving low-dose 5-FU, 4 had 
grade III toxicity and none had grade IV toxicity 
The patients with grade III toxicity received on 
average 74% of the standard dose, and those with 
grade II or lower toxicity received 61% of the dose.  
 
Kinetics 
*1/*2A versus *1/*1: 
- The 5-FU AUC increased by 52% for the 300 mg/m2 
dose (from 6.0 to 9.1 mg.hour/L) and by 32% for the 
450 mg/m2 dose (from 13.4 to 17.7 mg.hour/L) (S) 
The dose-corrected AUC increased by 32% (from 
0.026 to 0.034 mg.hour/L per mg/m2; 45 and 25 
patient/dose combinations respectively) (S). 
The AUC seems to be predictive of the first 2 hours 
after the injection and may therefore cause an 
Authors’ conclusion: 
“Profound 
differences in the 
elimination of 5FU 
could be detected 
between DPD-
deficient patients 













(Vmax for 300 mg/m2) 
versus EM: 
gene activity 1: 54%  
 
AUCt versus EM: 








underestimate for *1/ *2A. The 5-FU concentration 1 
hour after injection was around the detection limit for 
*1/*1.  
- The terminal half-life of 5-FU increased by 109% for 
the 300 mg/m2 dose (from 0.128 to 0.268 hours) and 
by 69% for the 450 mg/m2 dose (from 0.181 to 0.306 
hours) (S) 
- The maximum enzymatic metabolic capacity (Vmax) 
calculated in a multi-compartment model decreased 
by 46% for the 300 mg/m2 dose (from 1749 to 942 
mg/hour) and by 34% for the 450 mg/m2 dose (from 
1370 to 900 mg/hour) (S) 
ref. 16 – CAP, 
comb 



























































568 patients with advanced colorectal cancer were 
treated with capecitabine 1000 mg/m2 twice daily for 
14 days every 3 weeks, in combination with 
oxaliplatin and bevacizumab, with or without 
cetuximab. Oxaliplatin was discontinued from cycle 7 
and the capecitabine dose increased to 1250 mg/m2. 
Grade III-IV toxicity occurred in 85% of the patients. 
 
*1/*2A versus *1/*1: 
- Factor 3.0 increase in the percentage of patients 
with grade III-IV diarrhoea (from 24% to 71%) (S; 
strong association: false discovery rate < 0.3) 
The sensitivity of *2A for predicting grade III-IV 
diarrhoea was 4% and the specificity 100%.  
- No increase in the percentage of patients with grade 
II-III hand-foot syndrome and no significant increase 
in the percentage of patients with grade III-IV toxicity 
(NS) 
All 7 *1/*2A developed grade III-IV toxicity (including 
3 women), and 1 patient died during the 3rd cycle. 
- Decrease in the cumulative dose over the first 6 
cycles (S): the average dose decrease increased from 
10% to 51% in the lowest-dose cycle and from 10% to 
44% in cycle 6. 
- No difference in mortality or progression-free 
survival (NS) 
 
(*1/c.1236A>G + c.1236A>G/c.1236A>G) versus 
*1/*1: 
- Factor 2.2 increase in the percentage of patients 
with grade III-IV diarrhoea (from 23% to 50%) (S; 
strong association: false discovery rate < 0.3) 
The sensitivity of c.1236G>A for predicting grade III-IV 
diarrhoea was 10% and the specificity 97%.  
- No significant increase in the percentage of patients 
with grade II-III hand-foot syndrome or with grade III-
IV toxicity (NS). 
- No significant increase in dose decreases (NS) 
- No difference in mortality or progression-free 
survival (NS) 
 
*1/c.2846A>T versus *1/*1: 
Authors’ conclusion: 




c.1236G>A, 71% (5 of 
7), 63% (5 of 8), and 
50% (14 of 28) 
developed grade 3 to 
4 diarrhoea, 
respectively, 
compared with 24% 




and 2846A>T predict 






The data suggest that 
initial dose 
reductions of 50% in 
IVS14+1 G>A and 
25% in c.2846A>T 
variant allele carriers 
with further dose 
titration would 
significantly reduce 
the total number of 
severe toxicity 
events, thereby 




































Variant *2A (c.1905+1G>A, rs3918290): 
No significant association with serious adverse events 
(febrile neutropenia, prolonged grade III-IV 
neutropenia or severe neutropenia, grade III-IV 
anaemia, grade III-IV thrombocytopenia or grade III-IV 
non-haematological toxicity) (NS) 
 
The authors indicated that the lack of association is 
likely due to the fact that 5-FU toxicity is not common 
among breast cancer patients treated with this 
combination therapy. The 5-FU dose in this 
combination therapy is much lower than the dose in 
combination therapies used for colorectal cancer. 
 
NOTE: Associations were also not found for gene 
variants *5 (1627A>G), *6 (2194G>A) and *9A 
(85T>C). However, associations with severe toxicity 
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Clinical aspects were determined in 20 patients who 
had been genotyped as *1/*2A beforehand and were 
treated with 5-FU. Kinetics were determined in 30 
*1/*2A (c.1905+1G>A) and 18 *1/*1, who received a 
5-FU bolus injection of 300 mg/m2 and/or 450 mg/m2. 
Treatment regimens were not given. 
 
Clinical 
- All 7 *1/*2A receiving a standard dose of 5-FU 
showed grade III-V toxicity, of which 3 showed grade 
IV neutropenia 
The severe toxicity occurred in the first cycle each 
time and 1 patient died. 
- Among 13 *1/*2A receiving low-dose 5-FU, 4 had 
grade III toxicity and none had grade IV toxicity 
The patients with grade III toxicity received on 
average 74% of the standard dose, and those with 
grade II or lower toxicity received 61% of the dose.  
 
Kinetics 
*1/*2A versus *1/*1: 
- The 5-FU AUC increased by 52% for the 300 mg/m2 
dose (from 6.0 to 9.1 mg.hour/L) and by 32% for the 
450 mg/m2 dose (from 13.4 to 17.7 mg.hour/L) (S) 
The dose-corrected AUC increased by 32% (from 
0.026 to 0.034 mg.hour/L per mg/m2; 45 and 25 
patient/dose combinations respectively) (S). 
The AUC seems to be predictive of the first 2 hours 
after the injection and may therefore cause an 
Authors’ conclusion: 
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differences in the 
elimination of 5FU 
could be detected 
between DPD-
deficient patients 
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underestimate for *1/ *2A. The 5-FU concentration 1 
hour after injection was around the detection limit for 
*1/*1.  
- The terminal half-life of 5-FU increased by 109% for 
the 300 mg/m2 dose (from 0.128 to 0.268 hours) and 
by 69% for the 450 mg/m2 dose (from 0.181 to 0.306 
hours) (S) 
- The maximum enzymatic metabolic capacity (Vmax) 
calculated in a multi-compartment model decreased 
by 46% for the 300 mg/m2 dose (from 1749 to 942 
mg/hour) and by 34% for the 450 mg/m2 dose (from 
1370 to 900 mg/hour) (S) 
ref. 16 – CAP, 
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568 patients with advanced colorectal cancer were 
treated with capecitabine 1000 mg/m2 twice daily for 
14 days every 3 weeks, in combination with 
oxaliplatin and bevacizumab, with or without 
cetuximab. Oxaliplatin was discontinued from cycle 7 
and the capecitabine dose increased to 1250 mg/m2. 
Grade III-IV toxicity occurred in 85% of the patients. 
 
*1/*2A versus *1/*1: 
- Factor 3.0 increase in the percentage of patients 
with grade III-IV diarrhoea (from 24% to 71%) (S; 
strong association: false discovery rate < 0.3) 
The sensitivity of *2A for predicting grade III-IV 
diarrhoea was 4% and the specificity 100%.  
- No increase in the percentage of patients with grade 
II-III hand-foot syndrome and no significant increase 
in the percentage of patients with grade III-IV toxicity 
(NS) 
All 7 *1/*2A developed grade III-IV toxicity (including 
3 women), and 1 patient died during the 3rd cycle. 
- Decrease in the cumulative dose over the first 6 
cycles (S): the average dose decrease increased from 
10% to 51% in the lowest-dose cycle and from 10% to 
44% in cycle 6. 
- No difference in mortality or progression-free 
survival (NS) 
 
(*1/c.1236A>G + c.1236A>G/c.1236A>G) versus 
*1/*1: 
- Factor 2.2 increase in the percentage of patients 
with grade III-IV diarrhoea (from 23% to 50%) (S; 
strong association: false discovery rate < 0.3) 
The sensitivity of c.1236G>A for predicting grade III-IV 
diarrhoea was 10% and the specificity 97%.  
- No significant increase in the percentage of patients 
with grade II-III hand-foot syndrome or with grade III-
IV toxicity (NS). 
- No significant increase in dose decreases (NS) 
- No difference in mortality or progression-free 
survival (NS) 
 
*1/c.2846A>T versus *1/*1: 
Authors’ conclusion: 




c.1236G>A, 71% (5 of 
7), 63% (5 of 8), and 
50% (14 of 28) 
developed grade 3 to 
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respectively, 
compared with 24% 
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The data suggest that 
initial dose 
reductions of 50% in 
IVS14+1 G>A and 
25% in c.2846A>T 
variant allele carriers 
with further dose 
titration would 
significantly reduce 
the total number of 
severe toxicity 
events, thereby 








































- Factor 2.6 increase in the percentage of patients 
with grade III-IV diarrhoea (from 24% to 62%) (S; 
medium association: false discovery rate 0.3-0.4) 
The sensitivity of c.2846A>T for predicting grade III-IV 
diarrhoea was 4% and the specificity 99%.  
- No significant increase in the percentage of patients 
with grade II-III hand-foot syndrome or with grade III-
IV toxicity (NS). 
- Decrease in the cumulative dose over the first 6 
cycles (S): the average dose decrease increased from 
10% to 27% in the lowest-dose cycle and from 10% to 
24% in cycle 6. 
- No difference in mortality or progression-free 
survival (NS) 
 
(*1/*6 + *6/*6) versus *1/*1: 
- Factor 1.8 increase in the percentage of patients 
with grade III-IV diarrhoea (from 23% to 41%) (S; 
medium association: false discovery rate 0.3-0.4) 
The sensitivity of *6 (2194G>A) for predicting grade 
III-IV diarrhoea was 12% and the specificity 95%.  
- No significant increase in the percentage of patients 
with grade II-III hand-foot syndrome or with grade III-
IV toxicity (NS). 
- No significant increase in dose decreases (NS) 
- No difference in mortality or progression-free 
survival (NS) 
 
(*1/496G + 496G/496G) versus *1/*1: 
- Factor 1.4 increase in the percentage of patients 
with grade III-IV diarrhoea (from 23% to 33%) (S; 
weak association: false discovery rate < 0.3) 
The sensitivity of 496A>G for predicting grade III-IV 
diarrhoea was 24% and the specificity 84%.  
- Factor 1.3 increase in the percentage of patients 
with grade II-III hand-foot syndrome (from 41% to 
53%) (S; weak association: false discovery rate < 0.3) 
The sensitivity of 496A>G for predicting grade II-III 
hand-foot syndrome was 22% and the specificity 85%.  
- No significant increase in the percentage of patients 
with grade III-IV toxicity (NS). 
- No significant increase in dose decreases (NS) 




- The percentage *1/*13 was 0% among 43 patients 
with grade IV-V toxicity or two forms of grade III-V 
toxicity and 1% in 99 randomly selected patients (NS) 
 
The authors indicated that the lack of association 
with grade III-IV toxicity for each of the investigated 
SNPs is likely caused by the high risk in the overall 
population.  
 
NOTE: No associations were found for gene variants 
*4 (1601 G>A), *5 (1627A>G) and *9A (85T>C). 
However, associations with severe toxicity have never 
been found in studies concerning these gene variants. 





































68 patients with advanced colorectal cancer were 
given adjuvant or palliative treatment with 
fluoropyrimidine-based therapy. Therapy consisted of 
either a 5-FU bolus injection 500 mg/m2 every 2 
weeks plus folinic acid (n=24) or fluorouracil (400 
mg/m2 bolus plus 600 mg/m2 by infusion every 2 
weeks) plus folinic acid and oxaliplatin (n=27) or 
capecitabine 1250 mg/m2 twice daily for 14 days 
every 3 weeks (n=17). There was no significant 
difference between incidences of grade I-IV toxicity in 
the first 2 cycles caused by the different 
chemotherapies. However, the proportion of grade 




- Higher frequency of 1896C>T in the group with 
grade I-IV toxicity than in the group without toxicity 
(13% versus 2% 1896T heterozygotes; there were no 
homozygotes; RR = 6) (S) 
- Of the 4 1896T heterozygotes, 2 developed grade III-
IV toxicity, 1 developed grade I toxicity and 1 did not 
develop toxicity; the number of patients with toxicity 
was 24, the number of patients without was 44. 
This is equivalent to 8.3% 1896T heterozygotes in the 
group with grade III-IV toxicity and 4.5% in the group 
with < grade III toxicity. This is equivalent to an RR of 
1.8 for grade III-IV toxicity.  
Authors’ conclusion: 
“Patients with the 
genetic variant 
IVS14+1 G/A or 
c1896 C/T in the 
DPYD gene had a 
statistically 
significant increased 
risk of experiencing 
toxicity (RR 2 and 6, 
respectively), both 
having a high 
specificity (0.97 and 
0.98, respectively) 
and low sensitivity 
(0.04 and 0.13, 
respectively). It is 
concluded that pre-
treatment detection 
of genetic variants 






ref. 18 – 
FU/CAP, 
comb 




























128 Caucasian patients including 39 with poor 
tolerance to FU combination therapy (grade III or IV 
toxicity). 2 of the patients with poor tolerance died as 
a result of FU-associated toxicity. Independent group 
of 53 patients with poor tolerance to FU (n=39) or 
capecitabine combination therapy (n=14). The 
presence of variants was investigated by fully 
sequencing the DPD alleles. 
 
Variant 496A>G: 
Strongest association with grade III and IV toxicity: OR 
= 4.42 [95% CI = 2.12-9.23] for 92 patients with 
toxicity. 
The polymorphism attributable risk was 56.9%. 
The association was significant in patients with breast 
and gastro-oesophageal cancer (n=56 and n=158), but 
was non-significant in colon cancer patients n=128). 
1 of the fatalities was heterozygous. 
All 3 homozygotes had grade III or IV toxicity. 
Grade III and IV toxicity (especially diarrhoea and 
hand-foot syndrome) also occurred in carriers using 
Authors’ conclusion: 
“Our results show 
compelling evidence 
that, at least in 
distinct tumour 
types, a common 
DPYD polymorphism 
strongly contributes 
to the occurrence of 
fluoropyrimidine-
related drug adverse 
events. Carriers of 
this variant could 
benefit from 
individual dose 
adjustment of the 
fluoropyrimidine 









































- Factor 2.6 increase in the percentage of patients 
with grade III-IV diarrhoea (from 24% to 62%) (S; 
medium association: false discovery rate 0.3-0.4) 
The sensitivity of c.2846A>T for predicting grade III-IV 
diarrhoea was 4% and the specificity 99%.  
- No significant increase in the percentage of patients 
with grade II-III hand-foot syndrome or with grade III-
IV toxicity (NS). 
- Decrease in the cumulative dose over the first 6 
cycles (S): the average dose decrease increased from 
10% to 27% in the lowest-dose cycle and from 10% to 
24% in cycle 6. 
- No difference in mortality or progression-free 
survival (NS) 
 
(*1/*6 + *6/*6) versus *1/*1: 
- Factor 1.8 increase in the percentage of patients 
with grade III-IV diarrhoea (from 23% to 41%) (S; 
medium association: false discovery rate 0.3-0.4) 
The sensitivity of *6 (2194G>A) for predicting grade 
III-IV diarrhoea was 12% and the specificity 95%.  
- No significant increase in the percentage of patients 
with grade II-III hand-foot syndrome or with grade III-
IV toxicity (NS). 
- No significant increase in dose decreases (NS) 
- No difference in mortality or progression-free 
survival (NS) 
 
(*1/496G + 496G/496G) versus *1/*1: 
- Factor 1.4 increase in the percentage of patients 
with grade III-IV diarrhoea (from 23% to 33%) (S; 
weak association: false discovery rate < 0.3) 
The sensitivity of 496A>G for predicting grade III-IV 
diarrhoea was 24% and the specificity 84%.  
- Factor 1.3 increase in the percentage of patients 
with grade II-III hand-foot syndrome (from 41% to 
53%) (S; weak association: false discovery rate < 0.3) 
The sensitivity of 496A>G for predicting grade II-III 
hand-foot syndrome was 22% and the specificity 85%.  
- No significant increase in the percentage of patients 
with grade III-IV toxicity (NS). 
- No significant increase in dose decreases (NS) 




- The percentage *1/*13 was 0% among 43 patients 
with grade IV-V toxicity or two forms of grade III-V 
toxicity and 1% in 99 randomly selected patients (NS) 
 
The authors indicated that the lack of association 
with grade III-IV toxicity for each of the investigated 
SNPs is likely caused by the high risk in the overall 
population.  
 
NOTE: No associations were found for gene variants 
*4 (1601 G>A), *5 (1627A>G) and *9A (85T>C). 
However, associations with severe toxicity have never 
been found in studies concerning these gene variants. 





































68 patients with advanced colorectal cancer were 
given adjuvant or palliative treatment with 
fluoropyrimidine-based therapy. Therapy consisted of 
either a 5-FU bolus injection 500 mg/m2 every 2 
weeks plus folinic acid (n=24) or fluorouracil (400 
mg/m2 bolus plus 600 mg/m2 by infusion every 2 
weeks) plus folinic acid and oxaliplatin (n=27) or 
capecitabine 1250 mg/m2 twice daily for 14 days 
every 3 weeks (n=17). There was no significant 
difference between incidences of grade I-IV toxicity in 
the first 2 cycles caused by the different 
chemotherapies. However, the proportion of grade 




- Higher frequency of 1896C>T in the group with 
grade I-IV toxicity than in the group without toxicity 
(13% versus 2% 1896T heterozygotes; there were no 
homozygotes; RR = 6) (S) 
- Of the 4 1896T heterozygotes, 2 developed grade III-
IV toxicity, 1 developed grade I toxicity and 1 did not 
develop toxicity; the number of patients with toxicity 
was 24, the number of patients without was 44. 
This is equivalent to 8.3% 1896T heterozygotes in the 
group with grade III-IV toxicity and 4.5% in the group 
with < grade III toxicity. This is equivalent to an RR of 
1.8 for grade III-IV toxicity.  
Authors’ conclusion: 
“Patients with the 
genetic variant 
IVS14+1 G/A or 
c1896 C/T in the 
DPYD gene had a 
statistically 
significant increased 
risk of experiencing 
toxicity (RR 2 and 6, 
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and low sensitivity 
(0.04 and 0.13, 
respectively). It is 
concluded that pre-
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128 Caucasian patients including 39 with poor 
tolerance to FU combination therapy (grade III or IV 
toxicity). 2 of the patients with poor tolerance died as 
a result of FU-associated toxicity. Independent group 
of 53 patients with poor tolerance to FU (n=39) or 
capecitabine combination therapy (n=14). The 
presence of variants was investigated by fully 
sequencing the DPD alleles. 
 
Variant 496A>G: 
Strongest association with grade III and IV toxicity: OR 
= 4.42 [95% CI = 2.12-9.23] for 92 patients with 
toxicity. 
The polymorphism attributable risk was 56.9%. 
The association was significant in patients with breast 
and gastro-oesophageal cancer (n=56 and n=158), but 
was non-significant in colon cancer patients n=128). 
1 of the fatalities was heterozygous. 
All 3 homozygotes had grade III or IV toxicity. 
Grade III and IV toxicity (especially diarrhoea and 
hand-foot syndrome) also occurred in carriers using 
Authors’ conclusion: 
“Our results show 
compelling evidence 
that, at least in 
distinct tumour 
types, a common 
DPYD polymorphism 
strongly contributes 
to the occurrence of 
fluoropyrimidine-
related drug adverse 
events. Carriers of 
this variant could 
benefit from 
individual dose 
adjustment of the 
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capecitabine-based chemotherapy. Chemotherapy 
was discontinued in 2 of these. 
The association seems stronger with combination 
therapy than with monotherapy. 
 
Variant IVS10-15T>C: 
Association with grade III and IV toxicity: OR = 3.38 
[95% CI = 1.71-8.78] for 39 patients with toxicity. 
The association was significant in patients with breast 
and gastro-oesophageal cancer (n=46 and n=146), but 
was non-significant in colon cancer patients (n=58). 
 
Variant *2A (IVS14+1G>A): 
Low allele frequency in these groups (0.03 in patients 
with severe toxicity; 0 in healthy people and patients 
without severe toxicity) (NS difference). 
 
16 other variants identified: 
No significant association with severe toxicity. 
ref. 19 – FU, 
mono 





























76 French patients with advanced colon cancer 
received weekly or two-weekly FU plus folinic acid 
(initial FU dose 1200 and 2500 mg/m2 respectively; by 
continuous infusion, two-weekly regimen partially 
using a bolus (400 mg/m2); dose adjustments based 
on a target AUC of 25 mg.h/L; dose reduction of 10% 
in the event of significant grade II toxicity, 
discontinuation and dose decrease of 25% in the 
event of grade III toxicity and discontinuation of 
therapy in the event of grade IV toxicity), screening 
for *2A (IVS14+1G>A), c.2846A>T, *13 (1679 T>G) 
and 464T>A and for DPD-deficient patients and also 
for 19 other variants.  
 
- 11.8% of the patients (n=9) displayed abnormally 
low clearance of FU associated with abnormal 
dihydrouracil/uracil plasma ratio prior to therapy. An 
SNP was found in 3 of these (2x c.2846A>T, 1x *2A).  
- Despite pharmacological dose adjustments, the 
incidence of grade III and IV toxicity was higher in the 
group with reduced DPD activity (n=9) than in the 
group with normal DPD activity (33.3% versus 7.5%; S 
by 347%; OR = 6.20 [95% CI = 1.18-32.56]). 
- The incidence of grade III and IV toxicity was higher 
in the group with SNPs (n=3) than in the group 
without SNPs (66.7% versus 8.2%; S by 711%). 
- The authors indicated that the increased toxicity in 
DPD-deficient patients may have been prevented by 
reduced initial doses followed by pharmacokinetic 
dose adjustments. 
Authors’ conclusion: 
“Toxicity was linked 
to low UH2/U ratio, 
c.2846 A>T, IVS14+1 
G>A for DPD.” 
ref. 20 – FU 
Sulzyc-






252 Polish colon cancer patients received FU 
chemotherapy and screening for *2A (IVS14+1G>A). 
 
- 1 patient was heterozygous. This patient was 1 of 
the 4 patients with grade III-IV neutropenia. 
Authors’ conclusion: 
“We conclude that 
IVS14 + 1G > A DPYD 
(DPYD*2A) variant 




IVS14 + 1G > 

















 population and is 
responsible for a 
significant proportion 
of life-threatening 
toxicity of 5-FU.” 
ref. 21 – FU, 
mono 









































683 German patients (670x *1/*1, 13x *1/*2A), of 
whom 110 with grade III/IV toxicity; FU monotherapy 
with folinic acid or levamisole; screening for *2A 
(IVS14+1G>A) and also sequencing of exons and 
exon/intron transitions in 28 patients with grade IV 
toxicity, grade III toxicity or grade 0-II toxicity.  
 
*1/*2A versus *1/*1: 
Increased risk of grade III/IV toxicity: OR = 4.67 [95% 
CI = 1.54-14.2]. 
Significantly increased risk of grade III/IV leukopenia 
and mucositis (OR = 10.19 [95% CI = 3.0-35.1] and OR 
= 5.8 [95% CI = 1.71-19.4] respectively), but not of 
grade III/IV diarrhoea. 
Significantly increased risk of grade III/IV toxicity in 
men (OR = 41.8 [95% CI = 9.2-190]), but not in 
women.  
The sensitivity of *2A genotyping for overall toxicity 
was 5.5% [95% CI = 0.02-0.11] with a positive 
predictive value of 0.46 [95% CI = 0.19-0.75]. 
 
Sequencing of 3x 28 patients with different toxicity 
classes: 
12 additional SNPs, including 4 new ones. 
5 variants (623G>A, *4 (1601G>A), *6 (2194G>A), 
c.2846 A>T and 2585G>C) further investigated in ³ 
250 patients. 
2585G>C was found in 1 patient with grade IV 
mucositis, but not in other patients (NS). 
The percentage of patients with toxicity was 
increased for c.2846A>T (60% versus 16.1% in the 
overall population) (NS).  
All other variants did not show a significant 
association with toxicity. 
Authors’ conclusion: 
“DPYD, TYMS, and 
MTHFR play a limited 
role for FU related 




















capecitabine-based chemotherapy. Chemotherapy 
was discontinued in 2 of these. 
The association seems stronger with combination 
therapy than with monotherapy. 
 
Variant IVS10-15T>C: 
Association with grade III and IV toxicity: OR = 3.38 
[95% CI = 1.71-8.78] for 39 patients with toxicity. 
The association was significant in patients with breast 
and gastro-oesophageal cancer (n=46 and n=146), but 
was non-significant in colon cancer patients (n=58). 
 
Variant *2A (IVS14+1G>A): 
Low allele frequency in these groups (0.03 in patients 
with severe toxicity; 0 in healthy people and patients 
without severe toxicity) (NS difference). 
 
16 other variants identified: 
No significant association with severe toxicity. 
ref. 19 – FU, 
mono 





























76 French patients with advanced colon cancer 
received weekly or two-weekly FU plus folinic acid 
(initial FU dose 1200 and 2500 mg/m2 respectively; by 
continuous infusion, two-weekly regimen partially 
using a bolus (400 mg/m2); dose adjustments based 
on a target AUC of 25 mg.h/L; dose reduction of 10% 
in the event of significant grade II toxicity, 
discontinuation and dose decrease of 25% in the 
event of grade III toxicity and discontinuation of 
therapy in the event of grade IV toxicity), screening 
for *2A (IVS14+1G>A), c.2846A>T, *13 (1679 T>G) 
and 464T>A and for DPD-deficient patients and also 
for 19 other variants.  
 
- 11.8% of the patients (n=9) displayed abnormally 
low clearance of FU associated with abnormal 
dihydrouracil/uracil plasma ratio prior to therapy. An 
SNP was found in 3 of these (2x c.2846A>T, 1x *2A).  
- Despite pharmacological dose adjustments, the 
incidence of grade III and IV toxicity was higher in the 
group with reduced DPD activity (n=9) than in the 
group with normal DPD activity (33.3% versus 7.5%; S 
by 347%; OR = 6.20 [95% CI = 1.18-32.56]). 
- The incidence of grade III and IV toxicity was higher 
in the group with SNPs (n=3) than in the group 
without SNPs (66.7% versus 8.2%; S by 711%). 
- The authors indicated that the increased toxicity in 
DPD-deficient patients may have been prevented by 
reduced initial doses followed by pharmacokinetic 
dose adjustments. 
Authors’ conclusion: 
“Toxicity was linked 
to low UH2/U ratio, 
c.2846 A>T, IVS14+1 
G>A for DPD.” 
ref. 20 – FU 
Sulzyc-






252 Polish colon cancer patients received FU 
chemotherapy and screening for *2A (IVS14+1G>A). 
 
- 1 patient was heterozygous. This patient was 1 of 
the 4 patients with grade III-IV neutropenia. 
Authors’ conclusion: 
“We conclude that 
IVS14 + 1G > A DPYD 
(DPYD*2A) variant 
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 population and is 
responsible for a 
significant proportion 
of life-threatening 
toxicity of 5-FU.” 
ref. 21 – FU, 
mono 









































683 German patients (670x *1/*1, 13x *1/*2A), of 
whom 110 with grade III/IV toxicity; FU monotherapy 
with folinic acid or levamisole; screening for *2A 
(IVS14+1G>A) and also sequencing of exons and 
exon/intron transitions in 28 patients with grade IV 
toxicity, grade III toxicity or grade 0-II toxicity.  
 
*1/*2A versus *1/*1: 
Increased risk of grade III/IV toxicity: OR = 4.67 [95% 
CI = 1.54-14.2]. 
Significantly increased risk of grade III/IV leukopenia 
and mucositis (OR = 10.19 [95% CI = 3.0-35.1] and OR 
= 5.8 [95% CI = 1.71-19.4] respectively), but not of 
grade III/IV diarrhoea. 
Significantly increased risk of grade III/IV toxicity in 
men (OR = 41.8 [95% CI = 9.2-190]), but not in 
women.  
The sensitivity of *2A genotyping for overall toxicity 
was 5.5% [95% CI = 0.02-0.11] with a positive 
predictive value of 0.46 [95% CI = 0.19-0.75]. 
 
Sequencing of 3x 28 patients with different toxicity 
classes: 
12 additional SNPs, including 4 new ones. 
5 variants (623G>A, *4 (1601G>A), *6 (2194G>A), 
c.2846 A>T and 2585G>C) further investigated in ³ 
250 patients. 
2585G>C was found in 1 patient with grade IV 
mucositis, but not in other patients (NS). 
The percentage of patients with toxicity was 
increased for c.2846A>T (60% versus 16.1% in the 
overall population) (NS).  
All other variants did not show a significant 
association with toxicity. 
Authors’ conclusion: 
“DPYD, TYMS, and 
MTHFR play a limited 
role for FU related 









Inclusion of the additional variants only led to a 
marginal improvement in the prediction of overall 
toxicity. 
 
The method of administration is an independent risk 
factor: the risk of grade III/IV toxicity was greater for 
the bolus Mayo regimen than for the high-dose 
infusion (OR=2.44 [95% CI 1.52-3.91]). 
ref. 22 – FU, 
comb 
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59 French patients with inoperable head and neck 
cancer; determination of DPD activity 
(dihydrouracil/uracil ratio) prior to FU combination 
therapy or radio-chemotherapy; mild DPD deficiency 
(dihydrouracil/uracil ratio < 0.5): FU dose was 80% of 
the standard dose, severe DPD deficiency (ratio < 
0.33): FU dose was 50% of the standard dose, 
complete DPD deficiency: no FU.  
 
- 25% of the patients had mild and 22% severe DPD 
deficiency. 
- 12% of the patients with DPD deficiency and dose 
reduction showed severe toxicity. The incidence of 
severe toxicity was twofold lower in the overall group 
compared to the regimen without dose reduction. 
- There were no toxicity-induced fatalities. 
- The effectiveness was similar to the regimen 
without dose reduction (percentages of responders 
64% and 81% for first-line chemotherapy and radio-
chemotherapy and 50% and 38% for treatment for 
relapsed cancer).  
Authors’ conclusion: 
“5-FU dose tailoring 
based upon DPD 
status evaluation led 
to 2 fold decrease in 
occurrence of severe 
toxicities without 
impairing efficacy.” 
ref. 23 – FU, 
comb 


































50 American patients with locally advanced 
oesophageal cancer (11x *1/*1, 1x *1/*2A, 16x 
*1/*5, 3x *1/*6, 13x *1/*9A, 4x *9A/*9A, 1x *5/*5) 
participating in a phase II study received FU 225 
mg/m2 per day by continuous infusion in combination 
with carboplatin, paclitaxel and radiotherapy; FU was 
temporarily discontinued in the event of FU-related 
grade III-IV toxicity, after which the dose was 
decreased by 20%; patients received median 81% and 
66% of the standard FU dose during 1 and 2 cycles 
respectively; screening for *2A (IVS14+1G>A), *5 
(1627A>G), *6 (2194G>A) and *9A (85T>C). 
 
- Almost all patients (94%) had at least 1 incident of 
grade III-IV toxicity, including 3 fatalities. 
- No significant associations of the polymorphisms 
with pathological complete response, time to 
progression/relapse of cancer, overall survival or 
grade III/IV toxicity.  
 








transferase did not 
predict tumour 
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comb 


























131 French patients with poor tolerance to FU 
combination or monotherapy (grade II neurotoxicity 
or grade III-IV toxicity), including 9 fatalities, and 185 
unselected patients; screening for DPD activity in 
peripheral mononuclear blood cells and for *2A 
(IVS14+1G>A).   
 
- 81% of the toxicity occurred during the 1st cycle of 
FU chemotherapy. 
- Inverse association between DPD activity and 
toxicity score (sum of the different toxicity grades per 
patient) (S). 
- Percentage of patients with clear or severe DPD 
deficiency was higher in the case group than in the 
control group (17% versus 2.7% and 6% versus 0% 
respectively).   
- Inverse association between lethal toxicity and DPD 
activity (S). 
- Inverse association between the severity of the 
individual types of toxicity (grade II central 
neurotoxicity; grade IV mucositis, diarrhoea, 
neutropenia or thrombocytopenia) and DPD activity 
(all five S). Median DPD activity was 1.6-3.2x lower in 
patients with severe toxicity. 
- Only 2 in 93 screened cases (2.2%) had *2A (both 
*1/*2A). Both had low DPD activity and high toxicity 
scores during the 1st cycle. Neither died. 
Authors’ conclusion: 
“Present data 
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23 patients with excessive toxicity on FU (n=8) or 
capecitabine therapy (n=15), including 16 Caucasians, 
3 Afro-Americans and 3 South-Asians; screening for 
DPD activity in peripheral mononuclear blood cells 
and by genotyping.  
 
- 30% of the patients had DPD deficiency (n=7), 
including 3 who were treated with FU (500 mg/m2 per 
week or 425 mg/m2 per week) and folinic acid, 2 who 
were treated with capecitabine 1800 mg/m2 and 2 
who were treated with high-dose bolus FU (1400 
mg/m2) in combination with the uridine prodrug 
2’,3’,5’-tri-O-acetyluridine. The deficiency was 
confirmed by genotyping in 1 patient: he was *1/*2A. 
- 28% of the DPD-deficient patients died due to 
toxicity (n=2), including 1 to capecitabine and 1 to 
high-dose bolus FU. 
- Re-challenge with capecitabine of a patient treated 




for DPD deficiency 
prior to 
administration of 5-
FU or capecitabine 
using 2-13C uracil 
breath test could 
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marginal improvement in the prediction of overall 
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infusion (OR=2.44 [95% CI 1.52-3.91]). 
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59 French patients with inoperable head and neck 
cancer; determination of DPD activity 
(dihydrouracil/uracil ratio) prior to FU combination 
therapy or radio-chemotherapy; mild DPD deficiency 
(dihydrouracil/uracil ratio < 0.5): FU dose was 80% of 
the standard dose, severe DPD deficiency (ratio < 
0.33): FU dose was 50% of the standard dose, 
complete DPD deficiency: no FU.  
 
- 25% of the patients had mild and 22% severe DPD 
deficiency. 
- 12% of the patients with DPD deficiency and dose 
reduction showed severe toxicity. The incidence of 
severe toxicity was twofold lower in the overall group 
compared to the regimen without dose reduction. 
- There were no toxicity-induced fatalities. 
- The effectiveness was similar to the regimen 
without dose reduction (percentages of responders 
64% and 81% for first-line chemotherapy and radio-
chemotherapy and 50% and 38% for treatment for 
relapsed cancer).  
Authors’ conclusion: 
“5-FU dose tailoring 
based upon DPD 
status evaluation led 
to 2 fold decrease in 
occurrence of severe 
toxicities without 
impairing efficacy.” 
ref. 23 – FU, 
comb 


































50 American patients with locally advanced 
oesophageal cancer (11x *1/*1, 1x *1/*2A, 16x 
*1/*5, 3x *1/*6, 13x *1/*9A, 4x *9A/*9A, 1x *5/*5) 
participating in a phase II study received FU 225 
mg/m2 per day by continuous infusion in combination 
with carboplatin, paclitaxel and radiotherapy; FU was 
temporarily discontinued in the event of FU-related 
grade III-IV toxicity, after which the dose was 
decreased by 20%; patients received median 81% and 
66% of the standard FU dose during 1 and 2 cycles 
respectively; screening for *2A (IVS14+1G>A), *5 
(1627A>G), *6 (2194G>A) and *9A (85T>C). 
 
- Almost all patients (94%) had at least 1 incident of 
grade III-IV toxicity, including 3 fatalities. 
- No significant associations of the polymorphisms 
with pathological complete response, time to 
progression/relapse of cancer, overall survival or 
grade III/IV toxicity.  
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131 French patients with poor tolerance to FU 
combination or monotherapy (grade II neurotoxicity 
or grade III-IV toxicity), including 9 fatalities, and 185 
unselected patients; screening for DPD activity in 
peripheral mononuclear blood cells and for *2A 
(IVS14+1G>A).   
 
- 81% of the toxicity occurred during the 1st cycle of 
FU chemotherapy. 
- Inverse association between DPD activity and 
toxicity score (sum of the different toxicity grades per 
patient) (S). 
- Percentage of patients with clear or severe DPD 
deficiency was higher in the case group than in the 
control group (17% versus 2.7% and 6% versus 0% 
respectively).   
- Inverse association between lethal toxicity and DPD 
activity (S). 
- Inverse association between the severity of the 
individual types of toxicity (grade II central 
neurotoxicity; grade IV mucositis, diarrhoea, 
neutropenia or thrombocytopenia) and DPD activity 
(all five S). Median DPD activity was 1.6-3.2x lower in 
patients with severe toxicity. 
- Only 2 in 93 screened cases (2.2%) had *2A (both 
*1/*2A). Both had low DPD activity and high toxicity 
scores during the 1st cycle. Neither died. 
Authors’ conclusion: 
“Present data 
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23 patients with excessive toxicity on FU (n=8) or 
capecitabine therapy (n=15), including 16 Caucasians, 
3 Afro-Americans and 3 South-Asians; screening for 
DPD activity in peripheral mononuclear blood cells 
and by genotyping.  
 
- 30% of the patients had DPD deficiency (n=7), 
including 3 who were treated with FU (500 mg/m2 per 
week or 425 mg/m2 per week) and folinic acid, 2 who 
were treated with capecitabine 1800 mg/m2 and 2 
who were treated with high-dose bolus FU (1400 
mg/m2) in combination with the uridine prodrug 
2’,3’,5’-tri-O-acetyluridine. The deficiency was 
confirmed by genotyping in 1 patient: he was *1/*2A. 
- 28% of the DPD-deficient patients died due to 
toxicity (n=2), including 1 to capecitabine and 1 to 
high-dose bolus FU. 
- Re-challenge with capecitabine of a patient treated 




for DPD deficiency 
prior to 
administration of 5-
FU or capecitabine 
using 2-13C uracil 
breath test could 
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252 French patients with advanced colon cancer 
(163x *1/*1, 6x *1/c.2846A>T, 1x *9A/c.2846A>T, 1x 
*1/*2A, 1x -1590C/*2A, 1x *2A/c.2846A>T+85C, 1x 
*1/-1590C, 67x *1/*9A, 1x -1590C/*9A, 10x *9A/*9A) 
received either FU 400 mg/m2 bolus + 2500 mg/m2 by 
46-hour infusion every 2 weeks (n=168) or FU 1200 
mg/m2 by 4-hour infusion per week (n=84) (both 
regimens: plus folinic acid); dose adjustment from the 
second cycle based on the FU plasma concentration 
at the end of the previous infusion (Css); 
discontinuation of treatment in the event of grade IV 
toxicity; screening for *2A (IVS14+1G>A), c.2846A>T, 
*7 (295-298delTCAT), 1156G>T, *9A (85T>C), *9B 
(2657G>A), *10 (2983G>T), -1590T>C. 
 
(*1/*2A + -1590C/*2A) versus *1/*1: 
Clearance decreased by 80% (S; from 104.7 to 21.22 
L/h per m2) 
Increase in the percentage of patients with grade III-
IV toxicity by 793% (S; from 5.6% to 50.0%). 
 
(*1/c.2846A>T + 1x *9A/c.2846A>T) versus *1/*1: 
Clearance decreased by 40% and 58% for the two-
weekly and weekly regimens respectively (both S; 
from 136.0 to 81.2 L/h per m2 and from 104.7 to 43.9 
L/h per m2). 
Increase in the percentage of patients with grade III-
IV toxicity by 1175% (S; from 5.6% to 71.4%). 
 
*2A/c.2846A>T+85T versus *1/*1: 
Clearance decreased to almost 0 (NS; by almost 
100%). 
Increase in the percentage of patients with grade III-
IV toxicity by 1686% (NS; from 5.6% to 100%). 
The patient had grade IV multi-organ toxicity and died 
after 40 days in Intensive Care. 
 
(1x *9A + 2x *9A) versus *1/*1: 
No difference in clearance and incidence of toxicity 
(NS). 
 
1x -1590C versus *1/*1: 
No difference in clearance and incidence of toxicity 
(NS). 
 
Analysis of relevant SNPs had a high specificity 
(98.3%), but a low sensitivity (47.1%) for detecting 
DPD deficiency. 
Authors’ conclusion: 




because the 5-FU 
metabolism is close 
to zero, IVS14 + 1G>A 
or 2846A>T 
heterozygote are not 
strict contra-
indications to 5-FU 
treatment, provided 
that the physician is 
aware of it and that 
added precautions 
are taken, such as an 
initial 5-FU dose 
reduction and an 
individual dose 
adjustment based on 
a close clinical and 
pharmacokinetic 
follow-up.”  
“In the case of a 
homozygous status 
for a relevant SNP, 
with a uracil plasma 
level higher than 100 
lg/L or a UH2/U ratio 
below 1, then 
fluoropyrimidine 
administration must 





gene activity 2: 
gene act.1.5: 55% 
gene act.1:    20% 
gene act.0.5: almost 
0% 
ref. 27 – FU, 
mono 










21 Korean colon cancer patients with grade III-IV 
toxicity on FU therapy (500 mg/m2 by continuous 
infusion on days 1-5, plus folinic acid) and 100 healthy 
volunteers; screening by sequencing all exons and 
flanking introns.  
 
Authors’ conclusion: 
“The findings, from 
Korean patients with 
colon cancer, suggest 
that polymorphisms 



























- Very common variants (allele frequency 14-22%) in 
this Korean group were *5, 1737T>C and 1896T>C. No 
*2A was found. 
- The percentage of patients without SNPs was similar 
to that in healthy volunteers (9.5% versus 10%). 
- There was no significant correlation between 
specific genotypes and toxic response.    
 
NB: *5 does not have reduced DPD activity. 
not associated with 
an in-creased risk for 
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comb 
Salgado J et 
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58 Spanish patients with advanced colon cancer 
received capecitabine (1000 mg/m2 twice daily for 14 
days) and raltitrexed every 3 weeks; screening for *2A 
(IVS14+1G>A). 
1 patient was *1/*2A. This patient developed severe 
toxicity after the first cycle, after which FU was 





common use of 
fluoropyrimidines, 
genetic screening 
would be highly 
recommendable for 
the presence of the 
DPD gene mutation 
(IVS14+1G>A) related 
to toxicity, prior to 5-
FU administration.” 
 
ref. 29 – FU, 
comb 




























487 French patients (300x *1/*1, 10x *1/c.2846A>T, 
8x *1/*2A, 1x -1590C/*2A, 1x *2A/*2A, 6x *1/-1590C, 
144x *1/*9A, 15x *9A/*9A, 1x *1/*13) received FU 
monotherapy (n=168) or one of 4 different FU 
combination therapies (n=319); dose adjustment 
from the second cycle based on the FU plasma 
concentration at the end of the previous infusion 
(Css); discontinuation of treatment or continuation 
with individual dose adjustment in the event of grade 
III/IV toxicity; screening for 22 relevant SNPs, 
including 9 in all patients *2A (IVS14+1G>A), 
c.2846A>T, *7 (295-298delTCAT), 1156G>T, *9A 
(85T>C), *9B (2657G>A), *10 (2983G>T), -1590T>C 
and *13 (1679T>G)) in 171 patients with or without 
toxicity. 5 variants were found in the population. 
Authors’ conclusion: 
“Pretreatment 
detection of three 
DPYD SNPs could 
help to avoid serious 
toxic adverse events. 
This approach is 
suitable for clinical 
practice and should 
be compared or 
combined with 
pharmacologic 
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252 French patients with advanced colon cancer 
(163x *1/*1, 6x *1/c.2846A>T, 1x *9A/c.2846A>T, 1x 
*1/*2A, 1x -1590C/*2A, 1x *2A/c.2846A>T+85C, 1x 
*1/-1590C, 67x *1/*9A, 1x -1590C/*9A, 10x *9A/*9A) 
received either FU 400 mg/m2 bolus + 2500 mg/m2 by 
46-hour infusion every 2 weeks (n=168) or FU 1200 
mg/m2 by 4-hour infusion per week (n=84) (both 
regimens: plus folinic acid); dose adjustment from the 
second cycle based on the FU plasma concentration 
at the end of the previous infusion (Css); 
discontinuation of treatment in the event of grade IV 
toxicity; screening for *2A (IVS14+1G>A), c.2846A>T, 
*7 (295-298delTCAT), 1156G>T, *9A (85T>C), *9B 
(2657G>A), *10 (2983G>T), -1590T>C. 
 
(*1/*2A + -1590C/*2A) versus *1/*1: 
Clearance decreased by 80% (S; from 104.7 to 21.22 
L/h per m2) 
Increase in the percentage of patients with grade III-
IV toxicity by 793% (S; from 5.6% to 50.0%). 
 
(*1/c.2846A>T + 1x *9A/c.2846A>T) versus *1/*1: 
Clearance decreased by 40% and 58% for the two-
weekly and weekly regimens respectively (both S; 
from 136.0 to 81.2 L/h per m2 and from 104.7 to 43.9 
L/h per m2). 
Increase in the percentage of patients with grade III-
IV toxicity by 1175% (S; from 5.6% to 71.4%). 
 
*2A/c.2846A>T+85T versus *1/*1: 
Clearance decreased to almost 0 (NS; by almost 
100%). 
Increase in the percentage of patients with grade III-
IV toxicity by 1686% (NS; from 5.6% to 100%). 
The patient had grade IV multi-organ toxicity and died 
after 40 days in Intensive Care. 
 
(1x *9A + 2x *9A) versus *1/*1: 
No difference in clearance and incidence of toxicity 
(NS). 
 
1x -1590C versus *1/*1: 
No difference in clearance and incidence of toxicity 
(NS). 
 
Analysis of relevant SNPs had a high specificity 
(98.3%), but a low sensitivity (47.1%) for detecting 
DPD deficiency. 
Authors’ conclusion: 




because the 5-FU 
metabolism is close 
to zero, IVS14 + 1G>A 
or 2846A>T 
heterozygote are not 
strict contra-
indications to 5-FU 
treatment, provided 
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reduction and an 
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a close clinical and 
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homozygous status 
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with a uracil plasma 
level higher than 100 
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below 1, then 
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21 Korean colon cancer patients with grade III-IV 
toxicity on FU therapy (500 mg/m2 by continuous 
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- Very common variants (allele frequency 14-22%) in 
this Korean group were *5, 1737T>C and 1896T>C. No 
*2A was found. 
- The percentage of patients without SNPs was similar 
to that in healthy volunteers (9.5% versus 10%). 
- There was no significant correlation between 
specific genotypes and toxic response.    
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58 Spanish patients with advanced colon cancer 
received capecitabine (1000 mg/m2 twice daily for 14 
days) and raltitrexed every 3 weeks; screening for *2A 
(IVS14+1G>A). 
1 patient was *1/*2A. This patient developed severe 
toxicity after the first cycle, after which FU was 
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487 French patients (300x *1/*1, 10x *1/c.2846A>T, 
8x *1/*2A, 1x -1590C/*2A, 1x *2A/*2A, 6x *1/-1590C, 
144x *1/*9A, 15x *9A/*9A, 1x *1/*13) received FU 
monotherapy (n=168) or one of 4 different FU 
combination therapies (n=319); dose adjustment 
from the second cycle based on the FU plasma 
concentration at the end of the previous infusion 
(Css); discontinuation of treatment or continuation 
with individual dose adjustment in the event of grade 
III/IV toxicity; screening for 22 relevant SNPs, 
including 9 in all patients *2A (IVS14+1G>A), 
c.2846A>T, *7 (295-298delTCAT), 1156G>T, *9A 
(85T>C), *9B (2657G>A), *10 (2983G>T), -1590T>C 
and *13 (1679T>G)) in 171 patients with or without 
toxicity. 5 variants were found in the population. 
Authors’ conclusion: 
“Pretreatment 
detection of three 
DPYD SNPs could 
help to avoid serious 
toxic adverse events. 
This approach is 
suitable for clinical 
practice and should 
be compared or 
combined with 
pharmacologic 






















(*1/*2A + *2A/*2A + *1/c.2846A>T + *1/*13) versus 
*1/*1: 
Clearance decreased by 43% (S; from 132.3 to 74.9 
L/h per m2) 
Increase in the percentage of patients with grade III-
IV toxicity by 838% (S; from 6.6% to 61.9%). 
One *1/*2A patient died due to toxicity. 
The *2A/*2A patient developed grade IV diarrhoea, 
neutropenia and mucositis a few days after initiation 
of low-dose bolus FU in combination with epirubicin 
and cyclophosphamide. She was treated in Intensive 
Care for 15 days. 
Patients with SNPs: treatment was discontinued in 
40% of the patients with severe toxicity and 
continued with a 25-50% dose reduction and 
pharmacokinetic follow-up in the other 60%. 
 
(*1/*2A + *1/*13) versus *1/*1: 
Clearance decreased by 54% (NS; from 132.5 to 60.8 
L/h per m2)  
 
*1/c.2846A>T versus *1/*1: 
Clearance decreased by 45% (NS; from 132.5 to 72.3 
L/h per m2)  
 
(*1/*9A + *9A/*9A + *1/-1590C) versus *1/*1: 
No difference in clearance (NS, increased by 3%).  
No significant difference in the percentage of patients 
with grade III-IV toxicity (NS). 
None of the homozygous patients had grade III/IV 
toxicity. 
 
The sensitivity and specificity of the analysis of the 3 
most important SNPs for predicting toxicity were 0.31 
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gene activity 2: 
gene act.1.5: 55% 
gene act.1:    46% 
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105 French patients with advanced breast cancer 
received capecitabine monotherapy; screening for 
*2A (IVS14+1G>A). 
1 patient was *1/*2A. This patient died due to 
haematological toxicity after treatment with 
capecitabine 1820 mg/m2 per day for 12 days. 
Authors’ conclusion: 
“Our case report 
clearly identifies DPD 
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73 Portuguese colon cancer patients (71x *1/*1, 1x 
*1/*2A, 1x *1/1845T), including 8 with grade III/IV 
toxicity; various FU regimens; sequencing of exon 14. 
 
Authors’ conclusion: 
“We conclude that 
mutations in exon 14 
of DPYD gene are 
Mutations in 
















SNPs in exon 14 (n=2) versus no SNPs in exon 14: 
Increase in the percentage of patients with grade III-
IV toxicity by 1076% (S; from 8.5% to 100%). 
 
responsible for a 
significant proportion 
of life-threatening 
toxicity to 5-FU, and 
should therefore be 
excluded before its 
administration to 
cancer patients.” 




























1 + gene 
act. 0): 
CTC-AE 4 
60 Dutch patients with grade III/IV toxicity on FU 
therapy (43x *1/*1, 16x *1/*2A, 1x *2A/*2A) and 54 
controls, including 35 cancer patients; screening for 
DPD activity in peripheral mononuclear blood cells 
and for *2A.  
 
- 60% of the cases had reduced DPD activity (< 70% of 
the average activity in controls). 
- 29% of the cases had 1 or 2 *2A alleles. 
- Significantly higher *2A allele frequency in the cases 
than in the general population (S; increase by 1548% 
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25 German patients (19x *1/*1, 5x *1/*2A, 1x 
*2A/*2A) with grade III/IV toxicity on FU 
monotherapy (n=20), FU chemo-radiotherapy (n=2) 
or FU combination therapy (n=3) and 851 controls, 
including 800 cancer patients; screening for *2A.  
 
- 24% of the cases had 1 or 2 *2A alleles. 
- Higher *2A allele frequency in the cases than in the 
controls (NS; increase by 2879% from 0.47% to 14%). 
- The homozygous patient and two heterozygous 












patients provides a 
concept of 
individualized 
therapy and allows 























(*1/*2A + *2A/*2A + *1/c.2846A>T + *1/*13) versus 
*1/*1: 
Clearance decreased by 43% (S; from 132.3 to 74.9 
L/h per m2) 
Increase in the percentage of patients with grade III-
IV toxicity by 838% (S; from 6.6% to 61.9%). 
One *1/*2A patient died due to toxicity. 
The *2A/*2A patient developed grade IV diarrhoea, 
neutropenia and mucositis a few days after initiation 
of low-dose bolus FU in combination with epirubicin 
and cyclophosphamide. She was treated in Intensive 
Care for 15 days. 
Patients with SNPs: treatment was discontinued in 
40% of the patients with severe toxicity and 
continued with a 25-50% dose reduction and 
pharmacokinetic follow-up in the other 60%. 
 
(*1/*2A + *1/*13) versus *1/*1: 
Clearance decreased by 54% (NS; from 132.5 to 60.8 
L/h per m2)  
 
*1/c.2846A>T versus *1/*1: 
Clearance decreased by 45% (NS; from 132.5 to 72.3 
L/h per m2)  
 
(*1/*9A + *9A/*9A + *1/-1590C) versus *1/*1: 
No difference in clearance (NS, increased by 3%).  
No significant difference in the percentage of patients 
with grade III-IV toxicity (NS). 
None of the homozygous patients had grade III/IV 
toxicity. 
 
The sensitivity and specificity of the analysis of the 3 
most important SNPs for predicting toxicity were 0.31 
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gene activity 2: 
gene act.1.5: 55% 
gene act.1:    46% 
 
ref. 30 – CAP, 
mono 



















105 French patients with advanced breast cancer 
received capecitabine monotherapy; screening for 
*2A (IVS14+1G>A). 
1 patient was *1/*2A. This patient died due to 
haematological toxicity after treatment with 
capecitabine 1820 mg/m2 per day for 12 days. 
Authors’ conclusion: 
“Our case report 
clearly identifies DPD 
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73 Portuguese colon cancer patients (71x *1/*1, 1x 
*1/*2A, 1x *1/1845T), including 8 with grade III/IV 
toxicity; various FU regimens; sequencing of exon 14. 
 
Authors’ conclusion: 
“We conclude that 
mutations in exon 14 
of DPYD gene are 
Mutations in 
















SNPs in exon 14 (n=2) versus no SNPs in exon 14: 
Increase in the percentage of patients with grade III-
IV toxicity by 1076% (S; from 8.5% to 100%). 
 
responsible for a 
significant proportion 
of life-threatening 
toxicity to 5-FU, and 
should therefore be 
excluded before its 
administration to 
cancer patients.” 
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act. 0): 
CTC-AE 4 
60 Dutch patients with grade III/IV toxicity on FU 
therapy (43x *1/*1, 16x *1/*2A, 1x *2A/*2A) and 54 
controls, including 35 cancer patients; screening for 
DPD activity in peripheral mononuclear blood cells 
and for *2A.  
 
- 60% of the cases had reduced DPD activity (< 70% of 
the average activity in controls). 
- 29% of the cases had 1 or 2 *2A alleles. 
- Significantly higher *2A allele frequency in the cases 
than in the general population (S; increase by 1548% 




demonstrates that a 
DPD deficiency is the 




prevalence of the 
IVS14 + 1G>A 
mutation warrants 
genetic screening for 





ref. 33 – FU, 
mono 









e (DPD) gene 
within the 5'-
splice donor 
site of intron 












25 German patients (19x *1/*1, 5x *1/*2A, 1x 
*2A/*2A) with grade III/IV toxicity on FU 
monotherapy (n=20), FU chemo-radiotherapy (n=2) 
or FU combination therapy (n=3) and 851 controls, 
including 800 cancer patients; screening for *2A.  
 
- 24% of the cases had 1 or 2 *2A alleles. 
- Higher *2A allele frequency in the cases than in the 
controls (NS; increase by 2879% from 0.47% to 14%). 
- The homozygous patient and two heterozygous 
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69 Japanese patients (61x *1/*1, 4x *1/*9A; 1x 
*1/*5; 1x *1/74G, 1x *1/812delT, 1x *1/1714G); FU 
combination therapy or monotherapy (FU: either 800 
mg/m2 by 1-hour infusion or 500 mg/m2 per day on 
days 1 and 5 by continuous infusion); screening by 
PCR and sequencing.  
 
- The percentage of patients with grade III/IV toxicity 
was lower among the 8 heterozygous patients than 
among the *1/*1 patients (NS; decrease by 18% to 
0%). 
 
NB: *5 and *9A do not have reduced DPD activity. 
Authors’ conclusion: 
“Our observations of 
Japanese patients 
implied that the 
heterozygote is not 
associated with 
increased toxic 
response to 5FU.” 


































37 Dutch patients with grade III/IV toxicity on FU 
therapy and 22 controls; sequencing of introns and 
intron-exon transitions.  
 
- 59% of the cases had reduced DPD activity (< 70% of 
the average activity in controls). 
- Weak but significant correlation between DPD 
activity and time to toxicity. 
- Higher prevalence of grade IV neutropenia in 
patients with reduced DPD activity compared to those 
with normal DPD activity (S; increased by 323%, from 
13% to 55%). No higher prevalence of other types of 
toxicity. 
- 79% of 14 patients with reduced DPD activity had 1 
or 2 allele variants (3x *1/*1, 4x *1/*2A, 1x *2A/*9A, 
1x *2A/*5, 1x *9A/496G, 1x *9A/496G/c.2846A>T, 1x 
*1/*5, 1x *5/*9A, 1x *6/*6). 
 
NB: *5, *6 and *9A do not have reduced DPD activity. 
Authors’ conclusion: 
“Our results 
demonstrated that at 
least 57% (8 of 14) of 
the patients with a 
reduced DPD activity 
have a molecular 
basis for their 
deficient 
phenotype.” 



























A 76-year-old white man developed severe stomatitis, 
severe inflammatory colitis, erythematous rash, 
neutropenia 0.6x109/L and thrombocytopenia 
57x109/L one week after initiation of 5% FU cream 
twice daily on the scalp for the treatment of basal cell 
cancer. FU was discontinued and the patient made a 
gradual recovery over 3 weeks. 
The patient was *2A/*2A and had no detectable DPD 
enzyme activity in peripheral mononuclear blood 
cells.  
Assuming 10% cutaneous absorption, the authors 
estimate that application of 2 g of 5% FU cream leads 
to a total absorbed dose of ~20 mg/day (~0.33 mg/kg 
for this patient). This is much lower than the IV bolus 




represents the first 
characterization of a 
DPD deficient patient 
who developed life-
threatening toxicity 






(~10%) of topical 5-
FU, we suggest that 
life-threatening 
toxicity in the 
population of 
patients receiving 
topical 5-FU will be 

















Warning: There have been reports of increased 5-FU 
toxicity in patients with partially functional or non-
functional dihydropyrimidine dehydrogenase (DPD). If 
appropriate, DPD enzyme activity should be 
determined prior to treatment with 5-
fluoropyrimidines. 
 

















Warning: Individuals with a defective 
dihydropyrimidine dehydrogenase (DPD) enzyme may 
be susceptible to severe systemic toxicity on use of 
standard doses of Efudix due to an increased systemic 
5-FU concentration. Evaluation of DPD activity may be 
considered in patients with confirmed or suspected 
systemic toxicity. Due to the relationship between 
DPD deficiency and systemic toxicity, individuals 
known to have DPD enzyme deficiency should be 
intensively monitored for systemic toxicity during 
Efudix treatment. 
Adverse events: Frequency not known: 
haematological conditions, such as pancytopenia, 
neutropenia, thrombocytopenia, leukocytosis; 
haemorrhagic diarrhoea, diarrhoea, vomiting, 
stomach pain, stomatitis, rash, nasal mucositis.* 
* Haematological conditions, stomatitis, rash, nasal 
mucositis (associated with systemic toxicity to 
medicinal products).  
 
ref. 39 - CAP  Level of 
evidence 
score: 0 
Contraindications: Patients with known complete 
















































69 Japanese patients (61x *1/*1, 4x *1/*9A; 1x 
*1/*5; 1x *1/74G, 1x *1/812delT, 1x *1/1714G); FU 
combination therapy or monotherapy (FU: either 800 
mg/m2 by 1-hour infusion or 500 mg/m2 per day on 
days 1 and 5 by continuous infusion); screening by 
PCR and sequencing.  
 
- The percentage of patients with grade III/IV toxicity 
was lower among the 8 heterozygous patients than 
among the *1/*1 patients (NS; decrease by 18% to 
0%). 
 
NB: *5 and *9A do not have reduced DPD activity. 
Authors’ conclusion: 
“Our observations of 
Japanese patients 
implied that the 
heterozygote is not 
associated with 
increased toxic 
response to 5FU.” 


































37 Dutch patients with grade III/IV toxicity on FU 
therapy and 22 controls; sequencing of introns and 
intron-exon transitions.  
 
- 59% of the cases had reduced DPD activity (< 70% of 
the average activity in controls). 
- Weak but significant correlation between DPD 
activity and time to toxicity. 
- Higher prevalence of grade IV neutropenia in 
patients with reduced DPD activity compared to those 
with normal DPD activity (S; increased by 323%, from 
13% to 55%). No higher prevalence of other types of 
toxicity. 
- 79% of 14 patients with reduced DPD activity had 1 
or 2 allele variants (3x *1/*1, 4x *1/*2A, 1x *2A/*9A, 
1x *2A/*5, 1x *9A/496G, 1x *9A/496G/c.2846A>T, 1x 
*1/*5, 1x *5/*9A, 1x *6/*6). 
 
NB: *5, *6 and *9A do not have reduced DPD activity. 
Authors’ conclusion: 
“Our results 
demonstrated that at 
least 57% (8 of 14) of 
the patients with a 
reduced DPD activity 
have a molecular 
basis for their 
deficient 
phenotype.” 



























A 76-year-old white man developed severe stomatitis, 
severe inflammatory colitis, erythematous rash, 
neutropenia 0.6x109/L and thrombocytopenia 
57x109/L one week after initiation of 5% FU cream 
twice daily on the scalp for the treatment of basal cell 
cancer. FU was discontinued and the patient made a 
gradual recovery over 3 weeks. 
The patient was *2A/*2A and had no detectable DPD 
enzyme activity in peripheral mononuclear blood 
cells.  
Assuming 10% cutaneous absorption, the authors 
estimate that application of 2 g of 5% FU cream leads 
to a total absorbed dose of ~20 mg/day (~0.33 mg/kg 
for this patient). This is much lower than the IV bolus 
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Warning: There have been reports of increased 5-FU 
toxicity in patients with partially functional or non-
functional dihydropyrimidine dehydrogenase (DPD). If 
appropriate, DPD enzyme activity should be 
determined prior to treatment with 5-
fluoropyrimidines. 
 

















Warning: Individuals with a defective 
dihydropyrimidine dehydrogenase (DPD) enzyme may 
be susceptible to severe systemic toxicity on use of 
standard doses of Efudix due to an increased systemic 
5-FU concentration. Evaluation of DPD activity may be 
considered in patients with confirmed or suspected 
systemic toxicity. Due to the relationship between 
DPD deficiency and systemic toxicity, individuals 
known to have DPD enzyme deficiency should be 
intensively monitored for systemic toxicity during 
Efudix treatment. 
Adverse events: Frequency not known: 
haematological conditions, such as pancytopenia, 
neutropenia, thrombocytopenia, leukocytosis; 
haemorrhagic diarrhoea, diarrhoea, vomiting, 
stomach pain, stomatitis, rash, nasal mucositis.* 
* Haematological conditions, stomatitis, rash, nasal 
mucositis (associated with systemic toxicity to 
medicinal products).  
 
ref. 39 - CAP  Level of 
evidence 
score: 0 
Contraindications: Patients with known complete 



















Warning: Rarely, unexpected, severe toxicity (e.g. 
stomatitis, diarrhoea, mucosal inflammation, 
neutropenia and neurotoxicity) associated with 5-FU 
has been attributed to a deficiency of DPD activity. 
Patients with low or absent DPD activity, an enzyme 
involved in 5-FU degradation, are at increased risk for 
severe, life-threatening, or fatal adverse reactions 
caused by 5-FU. Although DPD deficiency cannot be 
precisely defined, it is known that patients with 
certain homozygous or certain compound 
heterozygous mutations in the DPYD gene locus, 
which can cause complete or near complete absence 
of DPD enzymatic activity (as determined from 
laboratory assays), have the highest risk of life-
threatening or fatal toxicity and should not be treated 
with Xeloda. No dose has been proven safe for 
patients with complete absence of DPD activity. For 
patients with partial DPD deficiency (such as those 
with heterozygous mutations in the DPYD gene) and 
where the benefits of Xeloda are considered to 
outweigh the risks (taking into account the suitability 
of an alternative non-fluoropyrimidine 
chemotherapeutic regimen), these patients must be 
treated with extreme caution and frequent 
monitoring with dose adjustment according to 
toxicity. There is insufficient data to recommend a 
specific dose in patients with partial DPD activity as 
measured by specific test. In patients with 
unrecognised DPD deficiency treated with 
capecitabine, life-threatening toxicities manifesting as 
acute overdose may occur. In the event of grade 2-4 
acute toxicity, treatment must be discontinued 
immediately. 




















Based on post-marketing reports, patients with 
certain homozygous or certain compound 
heterozygous mutations in the DPD gene that result 
in complete or near complete absence of DPD activity 
are at increased risk for acute early-onset of toxicity 
and severe, life-threatening, or fatal adverse 
reactions caused by 5-FU (e.g., mucositis, diarrhoea, 
neutropenia, and neurotoxicity). Patients with partial 
DPD activity may also have increased risk of severe, 
life-threatening, or fatal adverse reactions caused by 
5-FU. 
Withhold or permanently discontinue 5-FU based on 
clinical assessment of the onset, duration and severity 
of the observed toxicities in patients with evidence of 
acute early-onset or unusually severe toxicity, which 
may indicate near complete or total absence of DPD 
activity. No 5-FU dose has been proven safe for 
patients with complete absence of DPD activity. There 
is insufficient data to recommend a specific dose in 
 
patients with partial DPD activity as measured by any 
specific test. 













Contraindications: Carac should not be used in 
patients with dihydropyrimidine dehydrogenase 
(DPD) deficiency. DPD deficiency may lead to 5-FU 
entering the anabolic route, resulting in cytotoxic 
activity and possible toxicity. 
Warning: Patients should discontinue treatment with 
Carac if symptoms of DPD deficiency develop.  
Rare, unexpected systemic toxicity (e.g. stomatitis, 
diarrhoea, neutropenia and neurotoxicity) associated 
with parenteral administration of 5-FU has been 
attributed to DPD deficiency. A case of life-
threatening systemic toxicity has been reported 
following topical use of 5% 5-FU by a patient with 
fully non-functional DPD. Symptoms included severe 
abdominal pain, haemorrhagic diarrhoea, vomiting, 
fever and chills. Physical examination showed 
stomatitis, erythematous rash, neutropenia, 
thrombocytopenia, inflammation of the oesophagus, 
stomach and small intestine. Although this patient 
had used 5% 5-FU cream, it is not known whether 
patients with severe DPD deficiency develop systemic 
toxicity in response to lower concentrations of 




















Warning: Rarely, unexpected, severe toxicity (e.g. 
stomatitis, diarrhoea, mucosal inflammation, 
neutropenia and neurotoxicity) associated with 5-FU 
has been attributed to a deficiency of DPD activity. 
Patients with low or absent DPD activity, an enzyme 
involved in 5-FU degradation, are at increased risk for 
severe, life-threatening, or fatal adverse reactions 
caused by 5-FU. Although DPD deficiency cannot be 
precisely defined, it is known that patients with 
certain homozygous or certain compound 
heterozygous mutations in the DPYD gene locus, 
which can cause complete or near complete absence 
of DPD enzymatic activity (as determined from 
laboratory assays), have the highest risk of life-
threatening or fatal toxicity and should not be treated 
with Xeloda. No dose has been proven safe for 
patients with complete absence of DPD activity. For 
patients with partial DPD deficiency (such as those 
with heterozygous mutations in the DPYD gene) and 
where the benefits of Xeloda are considered to 
outweigh the risks (taking into account the suitability 
of an alternative non-fluoropyrimidine 
chemotherapeutic regimen), these patients must be 
treated with extreme caution and frequent 
monitoring with dose adjustment according to 
toxicity. There is insufficient data to recommend a 
specific dose in patients with partial DPD activity as 
measured by specific test. In patients with 
unrecognised DPD deficiency treated with 
capecitabine, life-threatening toxicities manifesting as 
acute overdose may occur. In the event of grade 2-4 
acute toxicity, treatment must be discontinued 
immediately. 




















Based on post-marketing reports, patients with 
certain homozygous or certain compound 
heterozygous mutations in the DPD gene that result 
in complete or near complete absence of DPD activity 
are at increased risk for acute early-onset of toxicity 
and severe, life-threatening, or fatal adverse 
reactions caused by 5-FU (e.g., mucositis, diarrhoea, 
neutropenia, and neurotoxicity). Patients with partial 
DPD activity may also have increased risk of severe, 
life-threatening, or fatal adverse reactions caused by 
5-FU. 
Withhold or permanently discontinue 5-FU based on 
clinical assessment of the onset, duration and severity 
of the observed toxicities in patients with evidence of 
acute early-onset or unusually severe toxicity, which 
may indicate near complete or total absence of DPD 
activity. No 5-FU dose has been proven safe for 
patients with complete absence of DPD activity. There 
is insufficient data to recommend a specific dose in 
 
patients with partial DPD activity as measured by any 
specific test. 













Contraindications: Carac should not be used in 
patients with dihydropyrimidine dehydrogenase 
(DPD) deficiency. DPD deficiency may lead to 5-FU 
entering the anabolic route, resulting in cytotoxic 
activity and possible toxicity. 
Warning: Patients should discontinue treatment with 
Carac if symptoms of DPD deficiency develop.  
Rare, unexpected systemic toxicity (e.g. stomatitis, 
diarrhoea, neutropenia and neurotoxicity) associated 
with parenteral administration of 5-FU has been 
attributed to DPD deficiency. A case of life-
threatening systemic toxicity has been reported 
following topical use of 5% 5-FU by a patient with 
fully non-functional DPD. Symptoms included severe 
abdominal pain, haemorrhagic diarrhoea, vomiting, 
fever and chills. Physical examination showed 
stomatitis, erythematous rash, neutropenia, 
thrombocytopenia, inflammation of the oesophagus, 
stomach and small intestine. Although this patient 
had used 5% 5-FU cream, it is not known whether 
patients with severe DPD deficiency develop systemic 
toxicity in response to lower concentrations of 
topically administered 5-FU. 
 
  
# For studies that did not show significant differences for intermediate metabolizers (IM) or poor 
metabolizers (PM) due to very low numbers of IM or PM in the study (<4), the effect for IM or PM was 
scored as if this concerned a case. This was indicated by placing the case code (2) behind the score. 
a SPC Xeloda (capecitabine) 14-12-16 (USA). 
Abbreviations: 5-FU: 5-fluorouracil; 95% CI: 95% confidence interval; CAP: capecitabine; Cl: clearance; 
comb: combination therapy (≥ 2 oncolytic drugs), Css: steady-state plasma concentration; DPD: 
dihydropyrimidine dehydrogenase; gene act.: gene activity score; gene activity score 2: two fully 
functional alleles (extensive metaboliser); gene activity score 1.5: one fully functional and one partially 
functional allele; gene activity score 1: one fully functional and one non-functional allele or two 
partially functional alleles; gene activity score 0.5: one non-functional and one partially functional 
allele; gene activity score 0: two non-functional alleles; mono: monotherapy (one oncolytic drug); NS: 
non-significant; RR: relative risk; S: significant; SNP: single nucleotide polymorphism.
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Supplementary Table 2. Literature review of DPYD/[tegafur with DPD inhibitor] interactions to 
support the therapeutic dose guidelines to optimize dose
Reference Code Effect Comments
ref. 1  
Cubero DI et al. 
Tegafur-uracil is 
a safe alternative 
for the treatment 
of colorectal 




deficiency: a proof 
of principle.  








gene act. 1: 
AA
Four patients with colorectal cancer developed grade 
3-4 toxicity after the first cycle of chemotherapy with 
5-FU (intravenous bolus of 425 mg/m2 on days 1 and 
5, in combination with folinic acid). They were found 
to be *1/*2A. After recovery, treatment with tegafur-
uracil in combination with folinic acid was initiated. A 
full dose (100%) was tegafur 100 mg/m2 three times 
daily for 21 days followed by a week-long rest period. 
Doses were rounded down to multiples of 100 mg 
tegafur. Doses were guided by adverse events.
The first patient received 60% in the first cycle, 80% 
in the second cycle, 100% in the third cycle and 
90% in the fourth and fifth cycles of the full dose of 
tegafur without development of grade 3-4 toxicity. 
This patient had developed grade 4 mucositis, 
diarrhoea and myelotoxicity on 5-FU. 
The following 3 patients received 90% of the full 
dose of tegafur during 5 cycles without development 
of grade 3-4 toxicity in any of the cycles. Of the three 
patients, one developed grade 4 diarrhoea and grade 
3 mucositis on 5-FU, the second grade 3 diarrhoea 
and myelotoxicity, and the third grade 3 mucositis, 
diarrhoea and myelotoxicity.
The best response in the first and the last patient, 
who both had metastatic disease, was achieving 
stable disease. The second and third patients 
receiving adjuvant chemotherapy were disease-free 




complete absence of 
severe toxicity in all 
patients and cycles 
analysed. We believe 
that UFT is a safe 
alternative for the 
treatment of patients 
with partial DPD 
deficiency.”
ref. 2 
Deenen MJ et al. 
Standard-dose 
tegafur combined 
with uracil is not 
safe treatment 
after severe toxicity 
from 5-fluoro-uracil 
or capecitabine.








gene act. 1: E
gene act. 
1,5: E
- One patient developed severe abdominal cramps, 
grade 4 diarrhoea, grade 4 neutropenia, dehydration 
and severe mucositis 10 days after initiation of 
capecitabine 1000 mg/m2 BSA twice daily (in 
combination with oxaliplatin and bevacizumab). 
She recovered after discontinuation of capecitabine 
and 25 days at the hospital. A few months later 
she received tegafur-uracil 300 mg/m2 per day in 
combination with folinic acid. After 10 days, she 
developed severe diarrhoea, mucositis, fever, 
dehydration and grade 4 neutropenia. She recovered 
after 25 days at the hospital. 
The patient was *1/*2A.
- Three other patients requiring hospitalisation due 
to severe toxicity on 5-FU or capecitabine therapy 
also developed severe toxicity following treatment 
with standard-dose tegafur-uracil. The patients 
were *1/*2A, *1/c.2846A>T and *1/c.1236G>A 
respectively. The DPD activity was approximately 
50% in the latter two patients. This confirms that
Authors’ conclusion:
“The standard dose 
of UFT is not safe 
after severe toxicity to 







they were heterozygous and did not have a second 
unknown non-functional allele. 
The authors stated that tegafur-uracil is probably not 
safe in patients with partial DPD deficiency due to 
the greater effect of the DPD inhibitor uracil in these 
patients. They referred to an article that showed 
that uracil increases the half-life of fluorouracil to a 
greater extent in DPD-deficient patients, which leads 
to an increased risk of toxicity. 
The authors also stated that the tegafur dose 
in tegafur-gimeracil-oteracil is 3x as low as in 
tegafur-uracil, while the DPD inhibitor is 200x more 
potent. However, 5-FU is still metabolised by DPD 
after administration of tegafur-gimeracil-oteracil. 
This means that DPD also remains essential for 













Known dihydropyrimidine dehydrogenase (DPD) 
deficiency. 
History of severe and unexpected reactions to 
fluoropyrimidine therapy.
Pharmacodynamics: Mean 5-FU maximum 
plasma concentration (C
max) and area under 
the concentration-time curve (AUC) values 
were approximately 3-fold higher after Teysuno 
administration than after administration of tegafur 
alone, despite a 16-fold lower Teysuno dose (50 mg 
of tegafur) compared to tegafur alone (800 mg), 
and are attributed to inhibition of DPD by gimeracil. 
Maximum plasma uracil concentration was observed 
at 4 hours, with a return to baseline levels within 
approximately 48 hours after dosing, indicating the 
reversibility of DPD inhibition by gimeracil. In man, 
the apparent terminal elimination half-life (T1/2) 
of 5-FU observed after administration of Teysuno 
(containing tegafur, a 5-FU prodrug) was longer 
(approximately 1.6-1.9 hours) than that previously 
reported after intravenous administration of 5-FU 
(10 to 20 minutes). Following a single dose of 
Teysuno, T1/2 values ranged from 6.7 to 11.3 hours 
for tegafur, from 3.1 to 4.1 hours for gimeracil and 
from 1.8 to 9.5 hours for oteracil.
Interactions: Sorivudine or its chemically related 
analogues such as brivudine irreversibly inhibit DPD, 
resulting in a significant increase in 5-FU exposure. 
This may lead to increased clinically significant 
fluoropyrimidine-related toxicities with potentially 
fatal outcomes.
Abbreviations: 5-FU: 5-fluorouracil; DPD: dihydropyrimidine dehydrogenase; gene act.: gene activity 
score; gene activity score 2: two fully functional alleles (extensive metaboliser); gene activity score 1.5: 
one fully functional and one partially functional allele; gene activity score 1: one fully functional and 
one non-functional allele or two partially functional alleles; gene activity score 0.5: one non-functional 
and one partially functional allele; gene activity score 0: two non-functional alleles.
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Supplementary Table 3. Relationship between genotype result and predicted phenotype in patients 
carrying no variants or one or more variants leading to decreased DPD enzyme activity
Patients carrying no or one variant(s)
Genotype result Genotype (given as 
functionality of both alleles)
Predicted Phenotype
No aberrant variant (*1/*1) Full functionality/ 
full functionality 
Gene activity score 2 
(100% of normal DPD enzyme activity)
Heterozygous for variant 
with reduced functionality 
(*1/c.2846A>T or 
*1/c.1236G>A)
Fully functionality/ reduced 
functionality
Gene activity score 1.5 
(75% of normal DPD enzyme activity)
Heterozygous for variant with 
inactive functionality (*1/*2A 
or *1/*13)
Full functionality/ inactive 
functionality
Gene activity score 1 
(50% of normal DPD enzyme activity)
Homozygous for variant 





Gene activity score 1 
(50% of normal DPD enzyme activity)
Homozygous for variant with 
inactive functionality (*2A/*2A 
or*13/*13)
Inactive functionality/ inactive 
functionality
Gene activity score 0 
(0% of normal DPD enzyme activity)
Patients carrying two variants
Genotype result Possible predicted phenotype Reasoning
Heterozygous for two different 




Gene activity score 1 to 1.5 
(50% to 75% of normal DPD 
enzyme activity), phenotyping 
is required to quantify DPD 
enzyme activity
When two variants are located on different 
alleles the predicted gene activity score is 1. 
   When two variants are located on the same 
allele the predicted gene activity score is 
dependent on the effect that the two variants 
have on each other. This effect is unknown. 
If one of the two variants has no additional 
effect on the functionality, then the activity of 
the allele is equal to that without the second 
variant, thus 0.5, and the gene activity score is 
1.5.
   When the two variants act synergistic and the 
allele becomes fully inactive, then the activity 
ofthe allele is 0 and the gene activity score is 1.
   Since the c.2846A>T and c.1236G>A variants 
result in reduced DPD enzyme activity through 
different biological mechanisms (Asp949Val 
amino acid substitution and an mRNA splicing-
defect, respectively), it is probable that they 
are independent of each other regarding their 
effect on the allele’s functionality. This would 
result in an allele activity of 0.25 (each variant 
resulting in half of the allele functionality) and 
thus a gene activity score of 1.25. Unfortunately 
there is no recommendation available for gene 





However, other factors than genetic variants 
can also affect the DPD enzyme activity. 
For this reason, one should resort to the 
recommendation for the gene activity score 
of 1 when the measured DPD enzyme activity 
is approximately equal to 50% of normal DPD 
enzyme activity and to the recommendation 
for the gene activity score of 1.5 when the 
measured DPD enzyme activity is approximately 
equal to 75% of normal DPD enzyme activity.  
   When the measured DPD enzyme activity is 
between 50% and 75% (e.g. 63%) one should 
resort to the recommendation for gene activity 
score 1. In this case, one should record a gene 
activity score of 1.25 in the patients’ medical 
record. 
Heterozygous for variants 
with reduced functionality 









Gene activity score 0.5 or 1 
(25% or 50% of normal DPD 
enzyme activity), phenotyping 
is required to quantify DPD 
enzyme activity
When two variants are located on different 
alleles the gene activity score is 0.5 (one allele 
with reduced functionality and one allele with 
inactive functionality).
   When two variants are located on the same 
allele, the gene activity score is 1 (one allele 
with full functionality and one allele with 
inactive functionality). 
Heterozygous for two 
different variants with inactive 
functionality 
(*2A/*13 or *1/*2A+*13)
Gene activity score 0 or 1 
(0% or 50% of normal DPD 
enzyme activity), phenotyping 
is required to quantify DPD 
enzyme activity
When two variants are located on different 
alleles the gene activity score is 0 (two alleles 
with inactive functionality). 
   When two variants are located on the same 
allele the gene activity score is 1 (one allele with 
full functionality and one allele with inactive 
functionality).
Homozygous for one variant 
with reduced functionality 
and heterozygous for the 
other variant with reduced 
functionality 
Gene activity score 0.5 to 1 
(25% to 50% of normal DPD 
enzyme activity), phenotyping 
is required to quantify DPD 
enzyme activity
One of the alleles has an activity of 0.5. The 
activity of the other allele is unknown, but 
lies between 0 and 0.5 (see reasoning for 
heterozygous for two different alleles with 
reduced functionality). 
One should resort to the recommendation for 






DPD enzyme activity is approximately 25% 
of normal DPD enzyme activity and to the 
recommendation of gene activity score 1 when 
the DPD enzyme activity is 50% of normal DPD 
enzyme activity. 
When the measured DPD enzyme activity is 
between 25% and 50% (e.g. 38%) one should 
resort to the recommendation for gene activity 
score 0.5. In this case, one should record a gene 





Homozygous for a variant 
with reduced functionality 
and heterozygous for a variant 







Gene activity score 0.5 One of the alleles has an activity of 0.5, the 
activity of the other allele is 0. Therefore the 
gene activity score is 0.5. 
Heterozygous for a variant 
with reduced functionality 
and homozygous for a variant 
with inactive functionality 
2A/*2A+c.2846A>Tc.2846A>T 




Gene activity score 0 Both alleles have an activity of 0. Therefore the 
gene activity score is 0. 
Homozygous for a variant 
with inactive functionality 
and heterozygous for the 
other variant with inactive 
functionality (*2A/*2A+*13 or 
*13/*2A+*13)
Gene activity score 0 Both alleles have an activity of 0. Therefore the 
gene activity score is 0. 
Homozygous for two different 




Gene activity score 0 to 1 
(0% to 50% of normal DPD 
enzyme activity), phenotyping 
is required to quantify DPD 
enzyme activity
The activity of both alleles is unknown, but 
lies between 0 and 0.5 (see reasoning for 
heterozygous for two different reduced 
functionality alleles).
   One should resort to the recommendation for 
gene activity score 0 when the measured DPD 
enzyme activity is approximately 0% of normal 
DPD enzyme activity and the recommendation 
of gene activity score 1 when the DPD enzyme 
activity is 50% of normal DPD enzyme activity.
   When the measured DPD enzyme activity is 
between 0% and 50% (e.g. 25%) one should 
resort to the recommendation for gene activity 
score 0.5. 
Homozygous for a variant 
with reduced functionality 
and a variant with 
inactive functionality 
+c.2846A>T/*2A+c.2846A>T 






Gene activity score 0 Both alleles have an activity of 0. Therefore the 





Homozygous for two different 
variants with inactive 
functionality 
(*2A+*13/*2A+ *13)
Gene activity score 0 Both alleles have an activity of 0. Therefore the 
gene activity score is 0. 
Patients carrying three or more variants
Genotype result Reasoning for finding the possible predicted phenotype
Three or more variants Since patients carrying three or more different variants are rare, only a general 
explanation of how to predict the phenotype is given. If one does encounter a 
patient carrying three or more variants, one must determine how these variants 
can be located among two alleles and determine if this leads to different 
predicted phenotypes.
   Since there are only two validated variants which result in a reduced 
functionality, an allele with three different variants will always have a variant 
with an inactive functionality and therefore the allele will have an activity of 0. 
The predicted allele activities for alleles with 0, 1 or 2 variants are indicated in 
the tables above. 
   If all possible distributions of the variants across the alleles lead to the same 
gene activity score of the genotype (i.e. the sum of allele activities), then one 
can conclude this as the patient’s gene activity score.
   If different distributions lead to genotypes with different gene activity scores, 
phenotyping is required to quantify DPD enzyme activity.
Abbreviation: DPD: dihydropyrimidine dehydrogenase.
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Supplementary Table 4. Genotype to predicted phenotype translation to be programmed into 
laboratory information system
Genotype rs number variants Nucleotide at 
position
















































































































Unable to predict the gene activity score. 
Phenotyping should distinguish if both 
variants are present on separate alleles 
(GENE ACTIVITY SCORE 0) or on the same 












Unable to predict the gene activity score. 
Phenotyping should distinguish if both 
variants are present on separate alleles 
(GENE ACTIVITY SCORE 0.5) or on the same 
















Unable to predict the gene activity score. 
Phenotyping should distinguish if both 
variants are present on separate alleles 
(GENE ACTIVITY SCORE 0.5) or on the same 












Unable to predict the gene activity score. 
Phenotyping should distinguish if both 
variants are present on separate alleles 
(GENE ACTIVITY SCORE 0.5) or on the same 












Unable to predict the gene activity score. 
Phenotyping should distinguish if both 
variants are present on separate alleles 
(GENE ACTIVITY SCORE 0.5) or on the same 












Unable to predict the gene activity score. 
Phenotyping should distinguish if both 
variants are present on separate alleles 
(GENE ACTIVITY SCORE 1) or on the same 
allele (GENE ACTIVITY SCORE 1 to 1.5). 
When both variants are located on the 
same allele, it is not known whether the 
variants have an independent or synergistic 
effect or whether the second variant does 












Unable to predict the gene activity score 
(GENE ACTIVITY SCORE 0 to 1). Both 
variants are located on the same allele, but 
it is not known whether the variants have 
an independent or synergistic effect or 
whether the second variant does not have 












Unable to predict the gene activity score 
(GENE ACTIVITY SCORE 0.5 to 1). There is 
one allele with one variant and one allele 
with two variants, but it is not known 
whether the two variants on the same allele 
have an independent or synergistic effect or 













Unable to predict the gene activity score 
(GENE ACTIVITY SCORE 0.5 to 1). There is 
one allele with one variant and one allele 
with two variants, but it is not known 
whether the two variants on the same allele 
have an independent or synergistic effect or 





























































































































































































































































Unable to predict the gene activity score 
(GENE ACTIVITY SCORE 0 to 0.5). The 
activity of the allele with two variants 
(c.1236G>A and c.2846A>T) is not known, 
because it is not known whether the 
variants have an independent or synergistic 
effect or whether the second variant does 













Unable to predict the gene activity score. 
Phenotyping should distinguish if *13 and 
c.1236G>A are present on separate alleles 
(GENE ACTIVITY SCORE 0 to 0.5) or on the 
same allele (GENE ACTIVITY SCORE 0.5). 
When both variants are located on separate 
alleles, the activity of the allele with the 
two variants c.1236G>A and c.2846A>T 
is not known, because it is not known 
whether the variants have an independent 
or synergistic effect or whether the second 













Unable to predict the gene activity score. 
Phenotyping should distinguish if *13 and 
c.2846A>T are present on separate alleles 
(GENE ACTIVITY SCORE 0 to 0.5) or on the 
same allele (GENE ACTIVITY SCORE 0.5). 
When both variants are located on separate 
alleles, the activity of the allele with the 
two variants c.1236G>A and c.2846A>T 
is not known, because it is not known 
whether the variants have an independent 
or synergistic effect or whether the second 
















Unable to predict the gene activity score 
(GENE ACTIVITY SCORE 0 to 1). Phenotyping 
should distinguish which variants are 
present on the same allele. The activity of 
an allele with the two variants c.1236G>A 
and c.2846A>T is not known, because it 
is not known whether the variants have 
an independent or synergistic effect or 














































































































































































Unable to predict the gene activity score 
(GENE ACTIVITY SCORE 0 to 0.5). The 
activity of the allele with two variants 
(c.1236G>A and c.2846A>T) is not known, 
because it is not known whether the 
variants have an independent or synergistic 
effect or whether the second variant does 













Unable to predict the gene activity score. 
Phenotyping should distinguish if *2A and 
c.1236G>A are present on separate alleles 
(GENE ACTIVITY SCORE 0 to 0.5) or on the 
same allele (GENE ACTIVITY SCORE 0.5). 
When both variants are located on separate 
alleles, the activity of the allele with the 
two variants c.1236G>A and c.2846A>T 
is not known, because it is not known 
whether the variants have an independent 
or synergistic effect or whether the second 













Unable to predict the gene activity score. 
Phenotyping should distinguish if *2A and 
c.2846A>T are present on separate alleles 
(GENE ACTIVITY SCORE 0 to 0.5) or on the 
same allele (GENE ACTIVITY SCORE 0.5). 
When both variants are located on separate 
alleles, the activity of the allele with the 
two variants c.1236G>A and c.2846A>T 
is not known, because it is not known 
whether the variants have an independent 
or synergistic effect or whether the second 













Unable to predict the gene activity score 
(GENE ACTIVITY SCORE 0 to 1). Phenotyping 
should distinguish which variants are 
present on the same allele. The activity of 
an allele with the two variants c.1236G>A 
and c.2846A>T is not known, because it 
is not known whether the variants have 
an independent or synergistic effect or 





































































Unable to predict the gene activity score. 
Phenotyping should distinguish if *2A and 
*13 are present on separate alleles (GENE 
ACTIVITY SCORE 0) or on the same allele 













Unable to predict the gene activity score 
(GENE ACTIVITY SCORE 0 to 1). Phenotyping 
should distinguish which variants are 













Unable to predict the gene activity score. 
Phenotyping should distinguish if *2A and 
*13 are present on separate alleles (GENE 
ACTIVITY SCORE 0) or on the same allele 













Unable to predict the gene activity score 
(GENE ACTIVITY SCORE 0 to 1). Phenotyping 
should distinguish which variants are 
present on the same allele.
#NOTE: In patients with two different gene variants, the gene activity score is dependent on location 
of the variants on the alleles. The variants can either be located on the same allele (resulting in one 
affected allele with reduced or absent DPD activity and one fully functional allele) or located on 




Supplementary Table 5. Dutch Pharmacogenetics Working Group (DPWG) Guideline for DPYD and 
5-FU/capecitabine: the therapeutic recommendation and its rationale, and the kinetic and clinical 
consequences for each aberrant gene activity score




SYSTEMIC ROUTE OF ADMINISTRATION:
Choose an alternative. 
Tegafur is not an alternative, as this is also metabolised by DPD.
If an alternative is not available: determine the residual DPD activity in mononuclear cells 
from peripheral blood and adjust the initial dose accordingly. 
A patient with 0.5% of normal DPD activity tolerated 0.8% of the standard dose (150 mg 
capecitabine every five days). A patient with undetectable DPD activity tolerated 0.43% of 
the standard dose (150 mg capecitabine every 5 days with every third dose skipped)
The average Caucasian DPD activity is 9.9 nmol/hour per mg protein. Adjust the initial dose 
based on toxicity and efficacy.
NOTE: If a patient carries two different genetic variations that lead to a non-functional 
DPD enzyme (e.g. *2A and *13), this recommendation only applies if the variations are 
on different alleles. If both variations are on the same allele, the patient is assigned a 
gene activity score of 1 and the recommendation for that gene activity score should be 
followed. These two situations can only be distinguished by determining the enzyme activity 
(phenotyping).
CUTANEOUS ROUTE OF ADMINISTRATION:
Choose an alternative 
NOTE: If a patient has two different genetic variations that lead to a non-functional DPD 
enzyme (e.g. *2A and *13), this recommendation only applies if the variations are on a 
different allele. If both variations are on the same allele, this patient is assigned a gene 
activity score of 1, for which no increased risk of severe, potentially fatal toxicity has been 
found with cutaneous use. These two situations can only be distinguished by determining 




There are not enough data available to be able to make a substantiated recommendation 
on dose adjustments for patients assigned gene activity score 0. The recommendation for 
*1/*2A is a dose reduction by 50%. This would be equivalent to a dose reduction by 100% 
for *2A/*2A and therefore a dose reduction to 0%. This is equivalent to severe toxicity 
found in one patient with genotype *2A/*2A when using 5-FU cream on the scalp. Because 
of the indications that the tolerated dose is close to zero and the scarce data on tolerated 
doses in patients assigned a gene activity score of 0 (see below), an alternative is advised.
The calculated dose reduction based on two patients is a reduction to 0.81% of the normal 
dose (0.72-0.89%; median 0.81%). However, this is based on too few patients to be used 
for a substantiated dose recommendation. In addition, in one of these patients, having 
undetectable DPD activity, the dose had to be reduced from 0.65% to 0.43% of the normal 
dose during treatment. However, there is a fairly good correlation between the residual DPD 
enzyme activity in peripheral blood mononuclear cells and the tolerated dose (Meulendijks 
2016, Deenen 2016, Henricks 2017 JCO Precis Oncol and Henricks 2017 Int J Cancer). 
Therefore, if an alternative is not possible, adjusting the dose according to the residual DPD 
enzyme activity in peripheral blood mononuclear cells is advised. This strategy has been 
shown to be feasible in two patients with genotype *2A/*2A. A patient with 0.5% of the 
normal DPD activity tolerated 0.8% of the normal dose (150 mg capecitabine every five 
days) (Henricks 2017 Int J Cancer). A patient with undetectable DPD activity, tolerated 0.43% 
of the normal dose (150 mg capecitabine every five days with every third dose skipped) 






For two patients with genotype *2A/*2A the dose-corrected AUC of 5-FU increased by a 
factor 113 and 138 respectively after the first systemic capecitabine dose. Extrapolation of 
the decrease in clearance by 50% identified for *1/*2A would suggest a clearance of 0% for 
*2A/*2A (gene activity score 0). This is equivalent to severe toxicity found in one patient 
with *2A/*2A after using 5-FU cream on the scalp and the two previously described patients 
using very low tolerated systemic doses (0.8% and 0.43% of the standard dose). 
Clinical 
consequence
SYSTEMIC ROUTE OF ADMINISTRATION: 
All patients assigned a gene activity score of 0 with known toxicity (n=2, both *2A/*2A), 
had grade III/IV toxicity and 50% died due to toxicity. Moreover, a patient with *2A/*2A 
developed severe toxicity after treatment with cutaneous 5-FU cream.
CUTANEOUS ROUTE OF ADMINISTRATION:
A patient with *2A/*2A developed severe toxicity after treatment with cutaneous 5-FU 
cream. All patients using systemic 5-FU assigned a gene activity score of 0 with known 
toxicity (n=2, both *2A/*2A), had grade III/IV toxicity and 50% died due to toxicity.




Start with 25% of the standard dose or choose an alternative. 
Adjustment of the initial dose should be guided by toxicity and effectiveness.
Tegafur is not an alternative, as this is also metabolised by DPD.
NOTE: This recommendation only applies if the two genetic variations are on a different 
allele. If both variations are on the same allele, this patient has gene activity score 1 and the 
recommendation for that gene activity score should be followed. These two situations can 




Clearance has only been determined for one patient assigned a gene activity score of 0.5 
(Boisdron-Celle, 2007). The clearance found for this patient with genotype *2A/c.2846A>T 
was almost zero. 
Extrapolation of the required dose reduction by 50% for *1/*2A and the required dose 
reduction by 25% for *1/c.2846A>T and *1/c.1236G>A would, however, lead to a required 
dose reduction by 75% for *2A/c.2846A>T. The dose reductions for *1/*2A, *1/2486T and 
*1/c.1236G>A are based on more than one patient. Moreover, the Boisdron-Celle article 
found a much lower clearance for one patient with genotype *1/*2A than the weighted 
average for this genotype (reduction by 80% instead of by 50%). For this reason, the 
recommendation given is based on extrapolation and therefore constitutes a dose reduction 
to 25% of the normal dose. 
Instead of dose adjustment, physicians may also choose an alternative.
Kinetic 
consequence 
Clearance decreased by almost 100% in one patient assigned a gene activity score of 0.5 
(*2A/c.2846A>T). Extrapolation of the dose reductions identified for *1/*2A, *1/c.2846A>T 
and *1/c.1236G>A would, however, lead to a dose reduction by 75%.
Clinical 
consequence
Clinical consequences are only known for three patients (all genotype *2A/c.2846A>T). 
The first patient developed grade III/IV toxicity and died due to toxicity. The second patient 
developed grade V toxicity and tolerated only one cycle of FOLFOX plus cetuximab. The third 
patient received half of the standard dose, but despite this the fluoropyrimidine therapy 
was stopped after the first cycle due to side effects (≤ grade 3).




Start with 50% of the standard dose or choose an alternative. 
Adjustment of the initial dose should be guided by toxicity and effectiveness. Tegafur is not 





NOTE 1: The dose reduction described here is well substantiated for *1/*2A and c.1236G>A/
c.1236G>A. The dose reduction for patients with c.2846A>T (c.2846A>T/c.2846A>T or 
c.1236G>A/c.2846A>T) is based on, among other factors, the dose reductions identified for 
*1/c.2846A>T.
NOTE 2: If a patient has two different genetic variations that result in a partially functional 
DPD enzyme (e.g. c.2846A>T and c.1236G>A), this recommendation applies if the variations 
are on a different allele. If both variations are on the same allele, the gene activity score is 
between 1 and 1.5, depending on whether and how the two gene variations influence each 
other and on other factors that influence the DPD activity. Whether a gene activity score 
of 1 or 1.5 needs to be assigned in the case of two different genetic variations can only be 




For 25 patients with genotype  *1/*2A, one with genotype *1/*13, one with genotype 
c.2846A>T/c.2846A>T and one with genotype c.1236G>A/c.2846A>T, the weighted average 
of the dose adjustments calculated based on 5-FU clearance or AUC was a reduction to 
45% (18-49%, median 33%). Because the relatively low median was caused by the low 
values found in the two smallest studies (n = 1 and n = 2 respectively), it was decided to 
base the dose recommendation on the weighted mean. The weighted mean of 45% was 
translated to 50% to be more achievable in clinical practice. This is similar to the dose 
reduction to 56% and 60% of the standard dose found by Deenen 2011 and Meulendijks 
2016 when investigating patients with respectively *1/*2A and c.1236G>A/c.1236G>A in 
whom toxicity-guided dose adjustments were made. It is also similar to the mean tolerated 
dose of 55% found by Henricks 2017 JCO Precis Oncol for 2x c.1236G>A/c.1236G>A, 1x 
c.1236G>A/c.2846A>T and 1x c.2846A>T/c.2846A>T, although in this study a strongvariation 
between patients (and genotypes) was found. In addition, Deenen 2016 found no difference 
in toxicities between 18 patients with *1/*2A on an initial dose of maximally 50% of the 
standard dose and *1/*1-patients on the standard dose. Lunenburg 2016 found no grade 
≥ 3 toxicity when treating three patients with *1/*2A with an initial dose of 50% of the 
standard dose.  
There are no data on clearance or AUC for c.1236G>A/c.1236G>A and only scarce data 
on clearance or AUC or on maximum tolerated dose in clinical practice for c.2846A>T/
c.2846A>T and c.1236G>A/c.2846A>T. Deenen 2011 found a dose reduction to 74% of 
the standard dose for patients with *1/c.2846A>T when toxicity-guided dose adjustments 
were made. Extrapolation of the required dose reduction for *1/c.2846A>T would lead to 
a required dose reduction to 50% for c.2846A>T/c.2846A>T. This is equivalent to the dose 
reduction for *1/*2A and c.1236G>A/c.1236G>A, which are also in the gene activity score 1 
group.
Instead of dose adjustment, physicians may also choose an alternative.
Kinetic 
consequence 
Increase in the AUC of 5-FUby 103% (16x *1/*2A), 127% (1x c.1236G>A/c.2846A>T) or 766% 
(1x c.2846A>T/c.2846A>T).
52-80% decrease in clearance.
69-109% increase in half-life.
Clinical 
consequence
7 of the 10 studies and two meta-analyses found an increased risk of grade ≥ 3 toxicity. 
Increased grade ≥ 3 toxicity: OR = 4.67-24.9; RR = 4.40-9.76. The highest ORs were found for 
haematological toxicity. There was a 74-793% increase in the percentage of patients with 
grade ≥ 3 toxicity. Out of 48 patients with genotype *1/*2A in published cohort studies, 73% 
developed grade ≥ 3 toxicity. The allele frequency of *2A in a group with grade III/IV toxicity 
was 1548-2879% higher. Toxicity generally occurred in the first cycle. Six patients died due 
to toxicity, including two that had used capecitabine.
No association with grade ≥ 3 toxicity was found for breast cancer patients receiving 
adjuvant/neoadjuvant therapy with 5-FU, epirubicin and cyclophosphamide in a phase II 
study that showed 94% grade ≥ 3 toxicity and in a small study of 21 patients with grade ≥ 3 





A large study found that the *2A allele only increased the risk of grade ≥ 3 toxicity in men 
(OR = 41.8) and not in women. Other studies did not find any differences between men and 
women.
When the dose was guided by toxicity, the average dose in the sixth cycle was 56% of the 
standard dose in seven patients with genotype  *1/*2A. Dose reduction down to 40% or 
50% of the standard dose was not adequate in two *1/*2A patients in another study. There 
was no difference in grade ≥ 3 toxicity between 18 patients with genotype *1/*2A at ≤ 50% 
of the standard dose and non-selected patients on the standard dose. In another study, four 
patients with genotype *1/*2A did not develop grade ≥ 3 toxicity at 50% of the standard 
dose. One of them had previously developed grade ≥ 3 toxicity during the first cycle at 
the standard dose. One of them tolerated a dose increase to 60%, the other two did not 
tolerate a dose increase to 80% and 100% respectively. Of the three patients with genotype 
c.1236G>A/c.1236G>A, one tolerated a standard dose. A second patient tolerated the 
treatment after dose reduction to 60% of the standard dose. Another study found a mean 
tolerated dose of 55% of the standard dose for 2x c.1236G>A/c.1236G>A, 1x c.1236G>A/
c.2846A>T and 1x c.2846A>T/c.2846A>T, although in this study a strong variation between 
patients (and genotypes) was found (17-100% of the standard dose).




Start with 75% of the standard dose or choose an alternative. 
Adjustment of the initial dose should be guided by toxicity and effectiveness.




For *1/c.2846A>T, the weighted average of the calculated dose adjustments was a reduction 
to 55%. However, Deenen 2011 investigated 8 patients with *1/c.2846A>T and found a 
toxicity-guided dose reduction to 74% of the standard dose. In addition, Lunenburg 2016 
found no grade ≥ 3 toxicity when treating five patients with *1/c.1236G>A with an initial 
dose of 75% of the standard dose. As  oncolytic under dosing should be avoided, the dose 
adjustment determined in clinical practice has been included in the recommendation. 
Instead of dose adjustment, physicians may also choose an alternative.
Kinetic 
consequence 
40-58% decrease in clearance.
Clinical 
consequence
Four of the five studies and one meta-analysis found an increased risk of grade ≥ 3 toxicity. 
Increased grade ≥ 3 toxicity: OR = 4.42-9.35. The percentage of patients with grade ≥ 3 
toxicity was 109-1175% higher. One patient (*1/496G) died due to toxicity.
No association with grade ≥ 3 toxicity was found in one small study of 21 patients with 
grade ≥ 3 toxicity.
When the dose for eight patients with genotype *1/c.2846A>T was guided by toxicity, the 
average dose in the sixth cycle was 76% of the standard dose. Five patients with genotype 
*1/c.1236G>A did not develop grade ≥ 3 toxicity at 75 % of the standard dose. The two 
patients for who the dose was then increased tolerated the standard dose. One patient 
with genotype *1/c.1236G>A, who was started at the standard dose, developed grade 3-4 
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Supplementary Table 6. Dutch Pharmacogenetics Working Group (DPWG) Guideline for DPYD and 
tegafur with DPD inhibitors: the therapeutic recommendation and its rationale, and the kinetic and 
clinical consequences for each aberrant gene activity score




Choose an alternative. 
Do not choose 5-FU or capecitabine, as these are also metabolised by DPD.
If an alternative is not possible: start with a very low dose and adjust the initial dose 
based on toxicity and efficacy.
A substantiated recommendation for dose reduction cannot be made based on the 
literature. The recommendation for 5-FU and capecitabine is to determine the residual 
DPD activity in mononuclear cells from peripheral blood and to adjust the initial dose 
accordingly. A patient with 0.5% of the normal DPD activity tolerated 0.8% of the 
standard capecitabine dose (150 mg every 5 days). A patient with undetectable DPD 
activity tolerated 0.43% of the standard capecitabine dose (150 mg every five days with 
every third dose skipped)
The average Caucasian DPD activity is 9.9 nmol/hour per mg protein.
NOTE: If a patient carries two different gene variations that lead to a non-functional 
DPD enzyme (e.g. *2A and *13), this recommendation only applies if the variations are 
on different alleles. If both variations are on the same allele, this patient is assigned a 
gene activity score of 1 and the recommendation for that gene activity score should be 





There are no data available on the use of tegafur in combination with a DPD inhibitor 
for patients assigned a gene activity score of 0. The SPCs state that tegafur in 
combination with a DPD inhibitor is contraindicated in patients with dihydropyrimidine 
dehydrogenase deficiency, but do not substantiate this.
However, two patients using standard doses of tegafur-uracil, who developed severe 
toxicity, were found to be assigned  partially deficient phenotypes (gene activity scores 
of 1 and 1.5). The toxicity was similar to that found in patients treated with capecitabine 
or 5-FU, both of which are given without a DPD inhibitor. 
The DPD inhibitor is 200 times more potent in the tegafur-gimeracil-oteracil 
combination. However, 5-FU is still metabolised by DPD after administration of this 
combination and DPD is therefore also involved in 5-FU clearance.
For 5-FU and capecitabine, the maximally tolerated dose of 50% of the normal dose for 
*1/*2A indicates that the maximally tolerated dose for *2A/*2A (gene activity score 0) 
is close to zero, as do the scarce data on tolerated doses in patients with gene activity 
score 0. For this reason, an alternative is advised.
There is a fairly good correlation between the residual DPD enzyme activity in peripheral 
blood mononuclear cells and the tolerated 5-FU or capecitabine dose. Therefore, if an 
alternative is not available, adjusting the dose according to the residual DPD enzyme 
activity in peripheral blood mononuclear cells is advised. This strategy has been shown 
to be feasible for capecitabine in two patients with genotype *2A/*2A. A patient with 
0.5% of the normal DPD activity tolerated 0.8% of the normal capecitabine dose (150 mg 
every five days). A patient with undetectable DPD activity, tolerated 0.43% of the normal 
capecitabine dose (150 mg every five days with every third dose skipped).This is why this 





Kinetic consequence Studies regarding the kinetic consequences are unavailable.
Clinical consequence Studies regarding the clinical consequences are unavailable. The SmPC states that 
this combination is contraindicated in patients with DPD deficiency. This probably 
refers to gene activity score 0. No safe dose for 5-FU (the metabolite of tegafur) has 
been found for patients assigned a gene activity score of 0. In addition, four patients 
with a less deficient DPD activity (assigned a gene activity score of 1 or 1.5) had a 
comparable toxicity for treatment with tegafur/uracil as found for treatment with 5-FU 
or capecitabine.




Choose an alternative or start with a low dose and adjust the initial dose based on 
toxicity and efficacy. 
Do not choose 5-FU or capecitabine, as these are also metabolised by DPD.
A substantiated recommendation for dose reduction cannot be made based on 
the literature. For 5-FU and capecitabine, starting with 25% of the standard dose is 
recommended.
NOTE: This recommendation only applies if the two gene variations are on different 
alleles. If both variations are on the same allele, this patient is assigned a gene activity 
score of 1 and the recommendation for that gene activity score should be followed. 





There are no data available on the use of tegafur in combination with a DPD inhibitor 
for gene activity score 0.5. The SPCs state that tegafur in combination with a DPD 
inhibitor is contraindicated in patients with a history of serious and unexpected 
reactions to fluoropyrimidine therapy, but do not substantiate this.
However, two patients using standard doses of tegafur-uracil who developed severe 
toxicity were found to be assigned partially deficient phenotypes of gene activity scores 
of 1 and 1.5. The toxicity was similar to that found in patients treated with capecitabine 
or 5-FU, both of which are given without a DPD inhibitor. The recommendation for 
5-FU and capecitabine in patients with gene activity score 0.5 is to reduce the dose to 
25% of the standard dose or to choose an alternative. This is why a dose reduction or 
alternative is also recommended for tegafur.
Kinetic consequence Studies regarding the kinetic consequences are unavailable.
Clinical consequence Studies regarding the clinical consequences are unavailable. However, four patients 
with a less deficient DPD activity (assigned a gene activity score of 1 or 1.5) had a 
comparable toxicity for treatment with tegafur/uracil as found for treatment with 
5-FU or capecitabine. In addition to this, four patients assigned a gene activity score 
of 1 could be treated with 90 % of the standard tegafur/uracil dose without grade 3-4 
toxicity occurring.




Choose an alternative or start with a low dose and adjust the initial dose based on 
toxicity and efficacy.
Do not choose 5-FU or capecitabine, as these are also metabolised by DPD.
A substantiated recommendation for dose reduction cannot be made based on 
the literature. For 5-FUand capecitabine, starting with 50 % of the standard dose is 
recommended.
NOTE: If a patient has two different gene variations that result in a partially functional 




only applies if the variations are on different alleles. If both variations are on the 
same allele, the gene activity score assigned is between 1 and 1.5, depending on 
whether and how the two gene variations influence each other and on other factors 
that influence the DPD activity. Whether a gene activity score of 1 or 1.5 needs to be 
assigned in the case of two different genetic variations can only be determined by 




Treatment with tegafur in combination with the DPD inhibitor uracil in two patients 
with gene activity score 1 led to similar toxicity as found after treatment with 5-FU or 
capecitabine.  However, four patients with an assigned gene activity score of 1 could 
be treated with 90% of the standard tegafur-uracil dose without grade 3-4 toxicity 
occurring. Similar to data found for 5-FU and capecitabine, treatment with a reduced 
dose of tegafur-uracil seems possible for patients who are assigned a gene activity 
score of 1. This is why a dose reduction or alternative is recommended.
Kinetic consequence Studies regarding the kinetic consequences are unavailable.
Clinical consequence In a study, two patients had a comparable toxicity for treatment with tegafur/uracil as 
found for treatment with 5-FU or capecitabine. In another study, four patients could 
be treated with 90 % of the standard tegafur/uracil dose without grade 3-4 toxicity 
occurring. All six patients had the genotype *1/*2A.




Choose an alternative or start with a low dose and adjust the initial dose based on 
toxicity and efficacy.
Do not choose 5-FU or capecitabine, as these are also metabolised by DPD.
A substantiated recommendation for dose reduction cannot be made based on 





Treatment with tegafur in combination with the DPD inhibitor uracil in two patients 
with gene activity score 1.5 led to similar toxicity as found after treatment with 5-FU 
or capecitabine. However, four patients with the more deficient phenotype (gene 
activity score 1) could be treated with 90% of the standard tegafur-uracil dose without 
grade 3-4 toxicity occurring. Similar to data found for 5-fluorouracil and capecitabine, 
treatment with a reduced dose of tegafur-uracil seems possible for patients with gene 
activity score 1 or higher. This is why a dose reduction or alternative is recommended.
Kinetic consequence Studies regarding the kinetic consequences are unavailable.
Clinical consequence Two patients with gene activity score 1.5 had a comparable toxicity for treatment with 
tegafur/uracil as found for treatment with 5-FU or capecitabine. Four patients with 
gene activity score 1 could be treated with 90 % of the standard tegafur/uracil dose 
without grade 3-4 toxicity occurring.
Abbreviations: Ref.: References; 5-FU: 5-fluorouracil; AUC: Area Under the Curve; DPD: 
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Supplementary Table 7. Suggested clinical decision support texts for various health care professionals 
for 5-FU/capecitabine
DPD gene act. 0: 5-fluorouracil (5-FU)/capecitabine, SYSTEMIC 
Pharmacist text / Hospital text / Prescriber text
Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of 5-fluorouracil/
capecitabine to inactive metabolites means that the standard dose is a more than 100-fold  overdose. 
  
Recommendation:
- Choose an alternative 
Tegafur is not an alternative, as this is also metabolised by DPD.
- If an alternative is not possible: 
o Determine the residual DPD activity in mononuclear cells from peripheral blood and adjust 
the initial dose accordingly. 
A patient with 0.5% of the normal DPD activity tolerated 0.8% of the standard dose (150 
mg capecitabine every 5 days). A patient with undetectable DPD activity tolerated 0.43% of 
the standard dose (150 mg capecitabine every 5 days with every third dose skipped)
The average Caucasian DPD activity is 9.9 nmol/hour per mg protein.
o Adjust the initial dose based on toxicity and efficacy.
NOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. *2A and 
*13), this recommendation only applies if the variations are on a different allele. If both variations are on the 
same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be 




5-Fluorouracil and its prodrug capecitabine are mainly converted by dihydropyrimidine dehydrogenase (DPD) 
to inactive metabolites. Genetic variations result in reduced DPD activity and thereby to reduced conversion 
of 5-fluorouracil to inactive metabolites. As a result, the intracellular concentration of the active metabolite of 
5-fluorouracil can increase, resulting in severe, potentially fatal toxicity. 
For more information about the phenotype gene activity score 0: see the general background information about 
DPD on the KNMP Knowledge Bank or on www.knmp.nl (search for DPD). 
  
Clinical consequences: 
All patients with gene activity score 0 with known toxicity (n=2, both *2A/*2A), had grade III/IV toxicity and 50% 




For 2 patients with genotype *2A/*2A the dose-corrected AUC of 5-fluorouracil increased by a factor 113 and 
138 respectively after the first systemic capecitabine dose. Extrapolation of the decrease in clearance by 50% 
identified for *1/*2A would suggest a clearance of 0% for *2A/*2A (gene activity score 0). This is equivalent 
to severe toxicity found in one patient with *2A/*2A after using 5-fluorouracil cream on the scalp and the two 
previously described patients using very low tolerated systemic doses (0.8% and 0.43% of the standard dose). 
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10. SPC Carac cream (VS), Efudix crème, Fluorouracil P and Xeloda.
DPD gene act. 0: 5-fluorouracil (5-FU) CUTANEOUS
Pharmacist text/ Hospital text / Prescriber text
Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of 5-fluorouracil/
capecitabine to inactive metabolites means that the normal dose is an overdose.
Recommendation:
- Choose an alternative 
NOTE: If a patient has two different genetic variations that lead to a non-functional DPD enzyme (e.g. 
*2A and *13), this recommendation only applies if the variations are on a different allele. If both 
variations are on the same allele, this patient has gene activity score 1, for which no increased risk of 
severe, potentially fatal toxicity has been found with cutaneous use. These two situations can only be 
distinguished by determining the enzyme activity (phenotyping).
Background information
Mechanism: 
5-Fluorouracil is mainly converted by dihydropyrimidine dehydrogenase (DPD) to inactive metabolites. Genetic 
variations result in reduced DPD activity and thereby to reduced conversion of 5-fluorouracil to inactive 
metabolites. As a result, the intracellular concentration of the active metabolite of 5-fluorouracil can increase, 
resulting in severe, potentially fatal toxicity.
For more information about the phenotype gene activity score 0: see the general background information about 
DPD on the KNMP Knowledge Bank or on www.knmp.nl (search for DPD).
Clinical consequences: 
A patient with *2A/*2A developed severe toxicity after treatment with cutaneous 5-fluorouracil cream. All 
patients using systemic 5-fluorouracil with gene activity score 0 with known toxicity (n=2, both *2A/*2A), had 
grade III/IV toxicity and 50% died due to toxicity.
Kinetic consequences: 
For 2 patients with genotype *2A/*2A the dose-corrected AUC of 5-fluorouracil increased by a factor 113 and 138 
respectively after the first systemic capecitabine dose.  
Extrapolation of the decrease in clearance by 50% identified for *1/*2A would suggest a clearance of 0% for 
*2A/*2A (gene activity score 0). This is equivalent to severe toxicity found in one patient with *2A/*2A after using 
5-fluorouracil cream on the scalp and the two previously described patients using very low tolerated systemic 
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9. SPC Carac cream (VS) en Efudix crème.
DPD gene act. 0.5: 5-fluorouracil (5-FU)/capecitabine 
Pharmacist text / Hospital text / Prescriber text
Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of 5-fluorouracil/
capecitabine to inactive metabolites means that the normal dose is an overdose. 
  
Recommendation:
- Start with 25% of the standard dose or choose an alternative. 
Adjustment of the initial dose should be guided by toxicity and effectiveness. 
Tegafur is not an alternative, as this is also metabolised by DPD. 
NOTE: This recommendation only applies if the two genetic variations are on a different allele. If both 
variations are on the same allele, this patient has gene activity score 1 and the recommendation 
for that gene activity score should be followed. These two situations can only be distinguished by 




5-Fluorouracil and its prodrug capecitabine are mainly converted by dihydropyrimidine dehydrogenase (DPD) 
to inactive metabolites. Genetic variations result in reduced DPD activity and thereby to reduced conversion 
of 5-fluorouracil to inactive metabolites. As a result, the intracellular concentration of the active metabolite of 
5-fluorouracil can increase, resulting in severe, potentially fatal toxicity. 
For more information about the phenotype gene activity score 0.5: see the general background information 
about DPD on the KNMP Knowledge Bank or on www.knmp.nl (search for DPD). 
  
Clinical consequences: 
Clinical consequences are only known for 3 patients (all genotype *2A/2846T). The first patient developed 
grade III/IV toxicity and died due to toxicity. The second patient developed grade V toxicity and tolerated only 
one cycle of FOLFOX plus cetuximab. The third patient received half the standard dose, but despite this the 
fluoropyrimidine therapy was stopped after the first cycle due to side effects (≤ grade 3). 
  
Kinetic consequences: 
Clearance decreased by almost 100% in one patient with gene activity score 0.5 (*2A/2846T). Extrapolation of the 
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4. SPC Efudix crème and Fluorouracil PCH.
DPD gene act. 1: 5-fluorouracil (5-FU)/capecitabine 
Pharmacist text / Hospital text / Prescriber text
Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of 5-fluorouracil/
capecitabine to inactive metabolites means that the normal dose is an overdose. 
  
Recommendation:
- Start with 50% of the standard dose or choose an alternative. 
Adjustment of the initial dose should be guided by toxicity and effectiveness. 
Tegafur is not an alternative, as this is also metabolised by DPD. 
NB1: The dose reduction described here is well substantiated for *1/*2A and 1236A/1236A. The dose 
reduction for patients with 2846T (2846T/2846T or 1236A/2846T) is based on, among other factors, 
the dose reductions identified for *1/2846T. 
NB2: If a patient has two different genetic variations that result in a partially functional DPD enzyme 
(e.g. 2846T and 1236A), this recommendation applies if the variations are on a different allele. If both 
variations are on the same allele, the gene activity score is between 1 and 1.5, depending on whether 
and how the two gene variations influence each other and on other factors that influence the DPD 
activity. Whether a gene activity score of 1 or 1.5 needs to be assigned in the case of two different 




5-Fluorouracil and its prodrug capecitabine are mainly converted by dihydropyrimidine dehydrogenase (DPD) 
to inactive metabolites. Genetic variations result in reduced DPD activity and thereby to reduced conversion 
of 5-fluorouracil to inactive metabolites. As a result, the intracellular concentration of the active metabolite of 
5-fluorouracil can increase, resulting in severe, potentially fatal toxicity. 
For more information about the phenotype gene activity score 1: see the general background information about 
DPD on the KNMP Knowledge Bank or on www.knmp.nl (search for DPD). 
  
Clinical consequences: 
7 of the 10 studies and two meta-analyses found an increased risk of grade ≥ 3 toxicity. Increased grade ≥ 3 
toxicity: OR = 4.67-24.9; RR = 4.40-9.76. The highest ORs were found for haematological toxicity. There was a 74-
793% increase in the percentage of patients with grade ≥ 3 toxicity. Out of 48 patients with genotype *1/*2A in 
published cohort studies, 73% developed grade ≥ 3 toxicity. The allele frequency of *2A in a group with grade III/
IV toxicity was 1548-2879% higher. Toxicity generally occurred in the first cycle. Six patients died due to toxicity, 
including two that had used capecitabine. 
No association with grade ≥ 3 toxicity was found for breast cancer patients receiving adjuvant/neoadjuvant 
therapy with 5-fluorouracil, epirubicin and cyclophosphamide in a phase II study that showed 94% grade ≥ 3 
toxicity and in a small study of 21 patients with grade ≥ 3 toxicity. 5-Fluorouracil toxicity is not common in breast 
cancer patients treated with this combination therapy. 
A large study found that the *2A allele only increased the risk of grade ≥ 3 toxicity in men (OR = 41.8) and not in 
women. Other studies did not find any differences between men and women.
When the dose was guided by toxicity, the average dose in the sixth cycle was 56% of the standard dose in 7 
*1/*2A. Dose reduction down to 40% or 50% of the standard dose was not adequate in two *1/*2A patients in 
another study. There was no difference in grade ≥ 3 toxicity between 18 *1/*2A at ≤ 50% of the standard
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dose and non-selected patients on the standard dose. In another study, 4 *1/*2A did not develop grade ≥ 3 
toxicity at 50% of the standard dose. One of them had previously developed grade ≥ 3 toxicity during the first 
cycle at the standard dose. One of them tolerated a dose increase to 60%, the other two did not tolerate a dose 
increase to 80% and 100% respectively. Of the 3 patients with genotype 1236A/1236A, one tolerated a standard 
dose. A second patient tolerated the treatment after dose reduction to 60% of the standard dose. Another 
study found a mean tolerated dose of 55% of the standard dose for 2x 1236A/1236A, 1x 1236A/2846T and 1x 
2846T/2846T, although in this study a strong variation between patients (and genotypes) was found (17-100% of 
the standard dose). 
  
Kinetic consequences:
Increase in the AUC of 5-fluorouracil by 103% (16x *1/*2A), 127% (1x 1236A/2846T) or 766% (1x 2846T/2846T). 
 
52-80% decrease in clearance. 
69-109% increase in half-life. 
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DPD gene act. 1.5: 5-fluorouracil (5-FU)/capecitabine 
Pharmacist text / Hospital text / Prescriber text
Genetic variation increases the risk of severe, potentially fatal toxicity. A reduced conversion of 5-fluorouracil/
capecitabine to inactive metabolites means that the normal dose is an overdose. 
  
Recommendation:
• Start with 75% of the standard dose or choose an alternative. 
Adjustment of the initial dose should be guided by toxicity and effectiveness. 




5-Fluorouracil and its prodrug capecitabine are mainly converted by dihydropyrimidine dehydrogenase (DPD) 
to inactive metabolites. Genetic variations result in reduced DPD activity and thereby to reduced conversion 
of 5-fluorouracil to inactive metabolites. As a result, the intracellular concentration of the active metabolite of 
5-fluorouracil can increase, resulting in severe, potentially fatal toxicity. 
For more information about the phenotype gene activity score 1.5: see the general background information 
about DPD on the KNMP Knowledge Bank or on www.knmp.nl (search for DPD). 
  
Clinical consequences: 
4 of the 5 studies and one meta-analysis found an increased risk of grade ≥ 3 toxicity. Increased grade ≥ 3 toxicity: 
OR = 4.42-9.35. The percentage of patients with grade ≥ 3 toxicity was 109-1175% higher. One patient (*1/496G) 
died due to toxicity.
No association with grade ≥ 3 toxicity was found in one small study of 21 patients with grade ≥ 3 toxicity. 
When the dose for 8 *1/2846T was guided by toxicity, the average dose in the sixth cycle was 76% of the standard 
dose. 5 patients with genotype *1/1236A did not develop grade ≥ 3 toxicity at 75 % of the standard dose. The two 
patients for who the dose was then increased tolerated the standard dose. One patient with genotype *1/1236A, 
who was started at the standard dose, developed grade 3-4 toxicity in the first cycle. 
  
Kinetic consequences: 
40-58% decrease in clearance. 
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Supplementary Table 8. Suggested clinical decision support texts for health care professionals for 
tegafur with DPD inhibitors
DPD gene act. 0: tegafur
Pharmacist text / Hospital text / Prescriber text 
Genetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive 
metabolites means that the normal dose is an overdose. 
  
Recommendation:
- Choose an alternative 
Do not choose 5-fluorouracil or capecitabine, as these are also metabolised by DPD.
- If an alternative is not possible: start with a very low dose and adjust the initial dose based on toxicity 
and efficacy. 
A substantiated recommendation for dose reduction cannot be made based on the literature. The 
recommendation for 5-fluorouracil and capecitabine is to determine the residual DPD activity in 
mononuclear cells from peripheral blood and to adjust the initial dose accordingly. A patient with 0.5% 
of the normal DPD activity tolerated 0.8% of the standard capecitabine dose (150 mg every 5 days). 
A patient with undetectable DPD activity tolerated 0.43% of the standard capecitabine dose (150 mg 
every 5 days with every third dose skipped)
The average Caucasian DPD activity is 9.9 nmol/hour per mg protein.
NOTE: If a patient has two different gene variations that lead to a non-functional DPD enzyme (e.g. *2A and 
*13), this recommendation only applies if the variations are on a different allele. If both variations are on the 
same allele, this patient has gene activity score 1 and the recommendation for that gene activity score should be 
followed. These two situations can only be distinguished by determining the enzyme activity (phenotyping).
Background information
Mechanism: 
Tegafur is mainly converted by CYP2A6 to 5-fluorouracil. 5-Fluorouracil is mainly (> 80 %) converted by 
dihydropyrimidine dehydrogenase (DPD) to inactive metabolites. Genetic variations result in reduced DPD 
activity and thereby to reduced conversion of 5-fluorouracil to inactive metabolites. As a result, the intracellular 
concentration of the active metabolite of 5-fluorouracil can increase, resulting in severe, potentially fatal toxicity. 
Tegafur is used in combination with the DPD inhibitor gimeracil (molar ratio 1:0.4) and was used in combination 
with the DPD inhibitor uracil (molar ratio 1:4). Both DPD inhibitors exhibit competitive inhibition of DPD. This is 
why efficacy is achieved at lower concentrations of the metabolites formed by DPD, which seem to contribute to 
the toxicity. Inhibition by DPD inhibitors is reversible and reduces over time. 
For more information about the phenotype gene activity score 0: see the general background information about 





There are no studies into the clinical consequences of tegafur in combination with a DPD inhibitor for gene 
activity score 0. The SmPC states that this combination is contra-indicated in patients with DPD deficiency. This 
probably refers to gene activity score 0. No safe dose has been found for gene activity score 0 for 5-fluorouracil 
(the metabolite of tegafur). In addition to this, four patients with a less strongly reduced DPD activity (gene 
activity score 1 or 1.5) had a comparable toxicity for treatment with tegafur/uracil as found for treatment with 
5-fluorouracil or capecitabine. 
  
Kinetic consequences: 
There are no studies into the kinetic consequences. 
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DPD gene act. 0.5: tegafur
Pharmacist text / Hospital text / Prescriber text
Genetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur to inactive 
metabolites means that the normal dose is an overdose. 
  
Recommendation:
- Choose an alternative or start with a low dose and adjust the initial dose based on toxicity and efficacy 
5-fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. 
It is not possible to offer substantiated advice for dose reduction based on the literature. For 
5-fluorouracil and capecitabine, starting with 25% of the standard dose is recommended. 
NOTE: This recommendation only applies if the two gene variations are on a different allele. If both 
variations are on the same allele, this patient has gene activity score 1 and the recommendation 
for that gene activity score should be followed. These two situations can only be distinguished by 
determining the enzyme activity (phenotyping).
Background information
Mechanism: 
Tegafur is mainly converted by CYP2A6 to 5-fluorouracil. 5-Fluorouracil is mainly (> 80 %) converted by 
dihydropyrimidine dehydrogenase (DPD) to inactive metabolites. Genetic variations result in reduced DPD 
activity and thereby to reduced conversion of 5-fluorouracil to inactive metabolites. As a result, the intracellular 
concentration of the active metabolite of 5-fluorouracil can increase, resulting in severe, potentially fatal toxicity. 
Tegafur is used in combination with the DPD inhibitor gimeracil (molar ratio 1:0.4) and was used in combination 
with the DPD inhibitor uracil (molar ratio 1:4). Both DPD inhibitors exhibit competitive inhibition of DPD. This is 
why efficacy is achieved at lower concentrations of the metabolites formed by DPD, which seem to contribute to 
the toxicity. Inhibition by DPD inhibitors is reversible and reduces over time. 
For more information about the phenotype gene activity score 0.5: see the general background information 
about DPD on the KNMP Knowledge Bank or on www.knmp.nl (search for “DPD”). 
 
Clinical consequences: 
There are no studies into the clinical consequences of tegafur in combination with a DPD inhibitor for gene 
activity score 0.5. However, four patients with a less strongly reduced DPD activity (gene activity score 1 or 
1.5) had a comparable toxicity for treatment with tegafur/uracil as found for treatment with 5-fluorouracil 
or capecitabine. In addition to this, four patients with gene activity score 1 could be treated with 90 % of the 
standard tegafur/uracil dose without grade 3-4 toxicity occurring. 
  
Kinetic consequences: 
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DPD gene act. 1.0: tegafur
Pharmacist text / Hospital text / Prescriber text
Genetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur into inactive 
metabolites means that the normal dose is an overdose. 
  
Recommendation:
- Choose an alternative or start with a low dose and adjust the initial dose based on toxicity and efficacy 
5-Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. 
It is not possible to offer substantiated advice for dose reduction based on the literature. For 
5-fluorouracil and capecitabine, starting with 50 % of the standard dose is recommended. 
NOTE: If a patient has two different gene variations that result in a partially functional DPD enzyme 
(e.g. 2846T and 1236A), this recommendation only applies if the variations are on a different allele. 
If both variations are on the same allele, the gene activity score is between 1 and 1.5, depending on 
whether and how the two gene variations influence each other and on other factors that influence 
the DPD activity. Whether a gene activity score of 1 or 1.5 needs to be assigned in the case of two 




Tegafur is mainly converted by CYP2A6 to 5-fluorouracil. 5-Fluorouracil is mainly (> 80 %) converted by 
dihydropyrimidine dehydrogenase (DPD) to inactive metabolites. Genetic variations result in reduced DPD 
activity and thereby to reduced conversion of 5-fluorouracil to inactive metabolites. As a result, the intracellular 
concentration of the active metabolite of 5-fluorouracil can increase, resulting in severe, potentially fatal toxicity. 
Tegafur is used in combination with the DPD inhibitor gimeracil (molar ratio 1:0.4) and was used in combination 
with the DPD inhibitor uracil (molar ratio 1:4). Both DPD inhibitors exhibit competitive inhibition of DPD. This is 
why efficacy is achieved at lower concentrations of the metabolites formed by DPD, which seem to contribute to 
the toxicity. Inhibition by DPD inhibitors is reversible and reduces over time. 
For more information about the phenotype gene activity score 1: see the general background information about 
DPD on the KNMP Knowledge Bank or on www.knmp.nl (search for “DPD”). 
 
Clinical consequences: 
In a study, two patients had a comparable toxicity for treatment with tegafur/uracil as found for treatment with 
5-fluorouracil or capecitabine. In another study, four patients could be treated with 90 % of the standard tegafur/
uracil dose without grade 3-4 toxicity occurring. All six patients had the genotype *1/*2A. 
  
Kinetic consequences: 
There are no studies into the kinetic consequences. 
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DPD gene act. 1.5: tegafur
Pharmacist text / Hospital text / Prescriber text
Genetic variation increases the risk of severe, possibly fatal toxicity. A reduced conversion of tegafur into inactive 
metabolites means that the normal dose is an overdose. 
  
Recommendation:
- Choose an alternative or start with a low dose and adjust the initial dose based on toxicity and efficacy 
5-Fluorouracil and capecitabine are not alternatives, as these are also metabolised by DPD. 
It is not possible to offer substantiated advice for dose reduction based on the literature. For 5-fluorouracil and 




Tegafur is mainly converted by CYP2A6 to 5-fluorouracil. 5-Fluorouracil is mainly (> 80 %) converted by 
dihydropyrimidine dehydrogenase (DPD) to inactive metabolites. Genetic variations result in reduced DPD 
activity and thereby to reduced conversion of 5-fluorouracil to inactive metabolites. As a result, the intracellular 
concentration of the active metabolite of 5-fluorouracil can increase, resulting in severe, potentially fatal toxicity. 
Tegafur is used in combination with the DPD inhibitor gimeracil (molar ratio 1:0.4) and was used in combination 
with the DPD inhibitor uracil (molar ratio 1:4). Both DPD inhibitors exhibit competitive inhibition of DPD. This is 
why efficacy is achieved at lower concentrations of the metabolites formed by DPD, which seem to contribute to 
the toxicity. Inhibition by DPD inhibitors is reversible and reduces over time. 
For more information about the phenotype gene activity score 1.5: see the general background information 
about DPD on the KNMP Knowledge Bank or on www.knmp.nl (search for “DPD”). 
  
Clinical consequences: 
Two patients with gene activity score 1.5 had a comparable toxicity for treatment with tegafur/uracil as found for 
treatment with 5-fluorouracil or capecitabine. Four patients with gene activity score 1 could be treated with 90 % 
of the standard tegafur/uracil dose without grade 3-4 toxicity occurring. 
  
Kinetic consequences: 
There are no studies into the kinetic consequences. 
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Supplementary Table 9. The clinical implication score of DPYD-fluoropyrimidines is “essential”, 
based on the criteria and corresponding scores given by the DPWG
Clinical Implication Score Criteria Possible score Given score
Clinical effect associated with gene/drug interaction 
   3 (D) ≤ CTCAE Grade ≤4 (E)
   4 (E) < CTCAE Grade ≤5 (F)





Level of evidence supporting the associated clinical effect 
   One study with level of evidence score 3
   At least two studies with level of evidence score 3




Effectiveness of the intervention 
Number needed to genotype (NNG)
   100 < NNG ≤ 1000
   10 <  NNG ≤ 100





PGx information in the drug-label
   Recommendation to genotype 
   At least one genotype/phenotype mentioned as a contraindication 
+
+ +d
Total Score 9+ 8+
Corresponding Clinical Implication Scoree Essential
a Patients assigned to be DPD deficient but have received normal doses of fluoropyrimidines been 
associated with CTCAE grade 5 toxicity;  
b Eight studies of sufficient quality have shown an association with CTCAE grade 5 toxicity (references 
in Supplementary Table 1: 10, 15, 16, 18, 26, 29, 30 and 33);
c The NNG was calculated using the “Calculations of the number of adverse events prevented with 
an effective pre-emptive genotyping program”.1 The pooled odds ratios and relative risks for*2A, 
1236A, 2846T and *13 was 5.2, extracted from meta-analyses Meulendijks et al., Terrazzino et al., and 
Rosmarin et al.2-4 The calculated NNG was 53.9; 
d In the European Union, DPD deficiency is mentioned in the current version of the summary of 
product characteristics (SPC) of capecitabine in the sections Contraindications and Special Warnings 
and Precautions for Use.5 Similar information on DPD deficiency is provided in the United States by 
the Food and Drug Administration (FDA) for capecitabine.6 Comparable reports are made in SPCs of 
5-FU;7,8
e essential, beneficial, potentially beneficial or not required.
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Fluoropyrimidine treatment can result in severe toxicity in up to 30% of patients and is often 
the result of reduced activity of the key metabolic enzyme dihydropyrimidine dehydrogenase 
(DPD), mostly caused by genetic DPYD variants. In a prospective clinical trial, we investigated 
whether upfront screening for four DPYD variants and DPYD-guided dose individualization 
can reduce fluoropyrimidine-induced toxicity. 
 Prospective genotyping of DPYD*2A, c.2846A>T, c.1679T>G, and c.1236G>A was 
performed in adult cancer patients for which fluoropyrimidine-based chemotherapy 
was considered in their best interest. All patients about to start with a fluoropyrimidine 
regimen (capecitabine or 5-fluorouracil as single agent or in combination with other 
chemotherapeutic agents and/or radiotherapy) could be included in the study. Heterozygous 
DPYD variant allele carriers received an initial dose reduction of 25% (c.2846A>T, c.1236G>A) 
or 50% (DPYD*2A, c.1679T>G), DPYD wild-type patients were treated according to standard 
of care. The primary endpoint of the study was the incidence of severe (CTC-AE grade≥3) 
overall fluoropyrimidine-related toxicity. This toxicity incidence was compared between 
DPYD variant allele carriers and DPYD wild-type patients in the study in an intention-to-treat 
analysis, and relative risks for severe toxicity were compared between the current study and 
a historical cohort of DPYD variant allele carriers treated with full dose fluoropyrimidine-
based therapy (derived from a previously published meta-analysis). This trial is registered 
under clinicaltrials.gov identifier NCT02324452 and is completed.
 In total, 1,103 evaluable patients were enrolled, of whom 85 DPYD variant carriers (7.7%). 
Overall grade≥3 toxicity was higher in DPYD variant carriers than in wild-type patients (39% vs 
23%, p=0.0013). The relative risk (RR) for grade≥3 toxicity was 1.31 (95% confidence interval 
[95%CI]:0.63–2.73) for genotype-guided dosing vs 2.87(95%CI:2.14–3.86) in the historical 
cohort for DPYD*2A, no toxicity vs 4.30(95%CI:2.10–8.80) in c.1679T>G, 2.00(95%CI:1.19–
3.34) vs 3.11(95%CI:2.25–4.28) for c.2846A>T, and 1.69(95%CI:1.18–2.42) vs 1.72(95%CI: 
1.22–2.42) for c.1236G>A. 
 Upfront DPYD genotyping was feasible in routine clinical practice, and improved patient 
safety of fluoropyrimidine treatment. For DPYD*2A and c.1679T>G carriers, a 50% initial dose 
reduction seems adequate. For c.1236G>A and c.2846A>T carriers, a larger dose reduction 
of 50% (instead of 25%) needs to be investigated. As fluoropyrimidines are among the most 
commonly used anticancer agents, the findings of this study are of high clinical importance, 
as they endorse implementing DPYD genotype-guided dosing as the new standard of care. 
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Fluoropyrimidine anticancer drugs, including 5-fluorouracil (5-FU) and its oral prodrug 
capecitabine, have been widely used for over sixty years in the treatment of different 
solid tumor types, such as colorectal, breast, and gastric cancer. Although these drugs are 
relatively well tolerated, up to 30% of patients experience severe treatment-related toxicity, 
including diarrhea, mucositis, myelosuppression, and hand-foot syndrome.1-3 In addition, 
severe fluoropyrimidine-related toxicity can lead to treatment-related death in up to 1% of 
patients.4,5 The occurrence of these severe side-effects can lead to treatment discontinuation 
and toxicity-related hospitalization, which in addition puts a heavy burden on health-care 
costs. 
 Fluoropyrimidine-related toxicity is often caused by reduced activity of the enzyme 
dihydropyrimidine dehydrogenase (DPD), the main metabolic enzyme for fluoropyrimidine 
inactivation.6,7 A partial DPD deficiency (e.g. a ~50% reduced DPD activity compared to 
normal) is present in 3─5% of the Western population. These DPD deficient patients have 
a highly increased risk of developing severe treatment-related toxicity when treated with 
a standard dose of fluoropyrimidines.8-10 Complete DPD deficiency is much rarer, with an 
estimated prevalence of 0.01─0.1%.8,11,12 DPD deficiency is most often caused by genetic 
variants in DPYD, the gene encoding DPD. The four DPYD variants currently considered 
most clinically relevant and with convincingly demonstrated association with severe toxicity 
are DPYD*2A (rs3918290, c.1905+1G>A, IVS14+1G>A), c.2846A>T (rs67376798, D949V), 
c.1679T>G (rs55886062, DPYD*13, I560S), and c.1236G>A (rs56038477, E412E, in haplotype 
B3).10,13,14 For these variants, available evidence suggests that heterozygous carriers of these 
variants have an average reduction in DPD enzyme activity of approximately 25% (c.2846A>T, 
c.1236G>A) to 50% (DPYD*2A, c.1679T>G).14 
 Prospective DPYD genotyping and dose reduction in heterozygous DPYD variant allele 
carriers is a promising strategy for preventing severe and potentially fatal fluoropyrimidine-
related toxicity without affecting treatment efficacy. In a previous study prospective 
genotyping and dose-individualization for one DPYD variant, DPYD*2A, in a cohort of 1,631 
patients showed that severe fluoropyrimidine-related toxicity could be decreased from 73% 
in DPYD*2A carriers receiving a standard fluoropyrimidine dose (N=48) to 28% by genotype-
guided dosing, i.e. DPYD*2A carriers receiving a 50% dose reduction (N=18, p<0.001).15 This 
study showed that by reducing the fluoropyrimidine dose by 50% in DPYD*2A variant allele 
carriers, severe toxicity was reduced to a frequency (28%) comparable to that in DPYD*2A 
wild-type patients treated with a standard fluoropyrimidine dose (23%). 
 It is expected that patient safety can be further improved by expanding the number of 
prospectively tested DPYD variants beyond DPYD*2A alone. The objective of the current 
study was to assess the impact on patient safety of prospective screening for the four most 
relevant DPYD variants and subsequent DPYD genotype-guided dose individualization in 




Study design and participants
This study was a prospective multicenter clinical trial in which 17 hospitals in the Netherlands 
participated. The study was approved by the institutional review board of The Netherlands 
Cancer Institute, Amsterdam, the Netherlands, and approval from the board of directors 
of each individual hospital was obtained for all participating centers. All patients provided 
written informed consent before enrollment in the study. Additional informed consent was 
obtained for DPYD variant allele carriers who participated in pharmacokinetic and DPD 
enzyme activity measurements.
 The study population consisted of adult cancer patients (≥18 years) intended to start with 
a fluoropyrimidine-based anticancer therapy, either as single agent or in combination with 
other chemotherapeutic agents and/or radiotherapy. Patients with all tumor types for which 
fluoropyrimidine-based therapy was considered in their best interest could be included. 
Prior chemotherapy was allowed, except for prior use of fluoropyrimidines. Patients had 
to have a WHO performance status of 0, 1 or 2, a life expectancy of at least 12 weeks, and 
acceptable safety laboratory values (Supplementary methods). There were no restrictions 
on comorbidities, except for diseases expected to interfere with study or the patient’s safety. 
Full inclusion and exclusion criteria can be found in the Supplementary methods.
Procedures
Treatment 
Patients were genotyped before start of fluoropyrimidine therapy for the previously 
mentioned four DPYD variants. Heterozygous DPYD variant allele carriers received an 
initial dose reduction of either 25% (for c.2846A>T and c.1236G>A) or 50% (for DPYD*2A 
and c.1679T>G), in line with current recommendations from Dutch and international 
pharmacogenomic guidelines.13,16 To achieve a maximal safe exposure, dose escalation 
was allowed after the first two cycles provided that treatment was well tolerated, and the 
decision to escalate was left to the discretion of the treating physician. The dose of other 
anticancer agents or radiotherapy were left unchanged at start of treatment. Homozygous 
or compound heterozygous DPYD variant allele carriers were excluded from the study and 
could be treated with personalized regimens outside this protocol.17 Non-carriers of the 
above mentioned DPYD variants are considered wild-type patients in this study and were 
treated according to existing standard of care. 
Assessments
Toxicity was graded by participating centers according to the National Cancer Institute 
common terminology criteria for adverse events (CTC-AE),18 and severe toxicity was defined 
as grade 3 or higher. Patients were followed for toxicity during the entire treatment period 
and until toxicity was resolved. Toxicity scored by the treating physician or qualified nurse 
practitioner as possibly, probably or definitely related to fluoropyrimidine-treatment was 
considered treatment-related toxicity (definitions in the Supplementary methods). Toxicity-
related hospitalization and treatment discontinuation due to adverse events were also 
investigated. Standard laboratory assessments were performed prior to start of treatment 
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and each new cycle according to routine clinical care, for evaluation of treatment safety. 
DPYD genotyping
Genotyping of the four DPYD variants DPYD*2A, c.2846A>T, c.1679T>G and c.1236G>A was 
performed before start of treatment. Genotyping was performed in a clinical laboratory of 
the local hospital or in one of the other participating centers of this trial. Validated assays 
were used and all laboratories participated in a Dutch national proficiency testing program 
for all four DPYD variants.19 
Pharmacokinetics and DPD enzyme activity
In DPYD variant allele carriers who provided written informed consent for additional tests, 
plasma levels of capecitabine, 5-FU, and their metabolites were determined at the first day 
of a capecitabine/5-FU cycle (preferably the first cycle) to assess the pharmacokinetic profile 
in these patients. A validated ultra-performance liquid chromatography tandem mass-
spectrometry (UPLC-MS/MS) method was used (details in the Supplementary methods). 
Results of pharmacokinetic parameters, including the area under the plasma concentration-
time curve (AUC) and half-life (t1/2) were calculated using non-compartmental analysis, and 
compared to control values derived from literature.20 
 DPD enzyme activity in peripheral blood mononuclear cells (PBMCs) was determined in 
a pretreatment sample in the DPYD variant allele carriers and compared to DPD enzyme 
activity measured in wild-type patients in this study, using a validated assay.21 
Outcomes
The primary endpoint of the study was the frequency of severe overall fluoropyrimidine-
related toxicity across the entire treatment duration. A comparison was made between the 
incidence of severe toxicity in DPYD variant allele carriers treated with reduced dose and in 
wild-type patients treated with standard dose in this study. In addition to this, the relative risk 
for severe toxicity of these DPYD variant allele carriers treated with reduced dose compared 
to non-carriers in the study was calculated. A comparison between this calculated relative 
risk and a similarly calculated relative risk for DPYD variant allele carriers treated with full 
dose in a historical cohort derived from a previously published meta-analysis10 was made. 
Secondary endpoints included pharmacokinetics of capecitabine and 5-FU in DPYD variant 
allele carriers and measurements of DPD enzyme activity. Another secondary endpoint was 
a cost analysis on individualized dosing based on upfront DPYD genotyping, of which results 
will be reported separately. 
Statistical analysis 
The sample size was based on a one stage A’Hern (phase II) design22 and calculated under 
the assumption that overall fluoropyrimidine-related severe toxicity could be reduced from 
60% (in DPYD variant allele carriers receiving standard dose)10,15 to 20% by individualized 
dosing in DPYD variant allele carriers. This resulted in a required sample size of eleven 
variant carriers. To reach this number of variant carriers, we used a single DPYD variant 
(c.2846A>T, assumed variant frequency of 1%) to calculate the total sample size, resulting in 
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a total expected sample size of 1,100 evaluable patients. Detailed information on the sample 
size calculation can be found in the Supplementary methods. Patients were considered 
evaluable when meeting the inclusion and exclusion criteria, and if they received at least 
one fluoropyrimidine drug administration.
 Associations between dichotomous outcomes, e.g. occurrence of severe toxicity or 
hospitalization, and genotype status were tested using χ2 or Fisher’s exact test (Fisher’s exact 
test was chosen when the smallest cell count was 5 or lower; for this test the double one-
tailed exact probability was reported). Baseline characteristics between DPYD variant allele 
carriers and wild-type patients in the study were compared using either χ2 test, Fisher’s 
exact test or Kruskal-Wallis rank sum test depending on the type of variable. DPD enzyme 
activity was compared between carriers of individual DPYD variants and wild-type patients 
using Student’s t-tests. P-values <0.05 were considered statistically significant. Statistical 
analyses on an intention-to-treat population were performed using SPSS (version 23.0) and 
R (version 3.1.2). This study is registered with ClinicalTrials.gov, number NCT02324452. 
 
Results 
Patient and treatment characteristics
Between April 30th, 2015 and December 21st, 2017, a total of 1,181 patients intended to start 
fluoropyrimidine-based treatment were enrolled in this study. In total, 78 patients were 
considered non-evaluable (Figure 1), as they retrospectively were identified as not meeting 
the inclusion criteria (N=48), did not start fluoropyrimidine-based treatment (N=26), or were 
homozygous or compound heterozygous DPYD variant allele carriers (N=4). This resulted 
in a total of 1,103 evaluable patients, of whom 85 were heterozygous DPYD variant allele 
carriers (7.7%). Baseline characteristics of DPYD variant allele carriers and DPYD wild-type 
patients are described in Table 1 and in the Supplementary Table 1. The most common 
tumor type was colorectal cancer (64%). In total, 83% of patients were treated with a 
capecitabine-based regimen. 
 Mean relative dose intensities for each patient group are presented in Table 2. In general, 
dose recommendations as described in the study protocol were followed by the treating 
physicians, which resulted in mean dose intensities in the first cycle of 74%, 73%, 51%, 
and 50% for c.1236G>A, c.2846A>T, DPYD*2A and c.1679T>G, respectively. The performed 
dose reductions were therefore in line with the pre-specified dose reductions of 25% 
(for c.1236G>A and c.2846A>T) or 50% (for DPYD*2A and c.1679T>G). However, for four 
patients carrying DPYD variants, dose reductions were not applied at start of treatment 
(Supplementary results). One of these patients, (c.2846A>T carrier) was treated by mistake 
with a full capecitabine dose for the first two cycles, which resulted in fatal fluoropyrimidine-
related toxicity. Although dosing recommendations were not followed in these four patients, 
all results were included in the analysis (intention-to-treat analysis). 
 Doses were escalated during treatment in eleven out of 85 DPYD variant allele carriers 
(13%). In five of these patients (two DPYD*2A and three c.1236G>A carriers) the higher 
dose was not well tolerated, leading to a dose reduction. Also, one patient (c.2846A>T 
carrier) discontinued treatment after the dose escalation due to toxicity. Five patients 
(one c.2846A>T, one c.1236G>A, one c.1679T>G, and two DPYD*2A carriers) were able to 
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continue treatment with the escalated dose. 
 The median follow-up period (similar to the entire treatment duration or when toxicity 
was resolved) was 71 days (interquartile range [IQR]: 36─161 days). For wild-type patients 
median follow-up was 69 days (IQR 36─161 days) and for DPYD variant allele carriers 90 
days (IQR 35─168 days). 
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Figure 1. Consort diagram of included patients 
Toxicity in DPYD variant allele carriers versus wild-type patients
Frequencies of severe toxicity for DPYD variant allele carriers who received genotype-
guided dosing and wild-type patients who received standard dosing are depicted in Table 
2. A total of 33 out of 85 (39%) DPYD variant allele carriers experienced severe (grade ≥3) 
fluoropyrimidine-related toxicity, which was significantly higher than the frequency in 
wild-type patients (23%, p=0.0013). The incidence of grade ≥4 toxicity was low but was 
comparable between both groups as well (four out of 85 (5%) for DPYD variant allele carriers 
vs 29 out of 1,018 3% for wild-type patients, p=0.49, Table 2). 
 The percentage of toxicity in DPYD variant allele carriers was mainly driven by the two 
most common variants, who also had higher toxicity frequencies. In total, 20 out of 51 
c.1236G>A carriers experienced severe toxicity (39%) and eight out of 17 c.2846A>T carriers 
(47%). For DPYD*2A carriers, five out of 16 patients (31%) experienced severe toxicity. The 
single c.1679T>G carrier, who did receive reduced-dose treatment, tolerated the treatment 
well and did not experience severe treatment-related toxicity over the course of treatment 
(three cycles). 
 For 16 out of 85 DPYD variant allele carriers (19%) fluoropyrimidine-related toxicity resulted 
in hospitalization, compared to 140 out of 1,018 wild-type patients (14%, p=0.26). Median 
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duration of hospitalization was five days for both DPYD variant allele carriers and wild-type 
patients (IQR 3─7 days, and 3─10 days, respectively). For 15 out of 85 DPYD variant allele 
carriers (18%) fluoropyrimidine treatment was stopped due to fluoropyrimidine-related 
toxicity, compared to 175 out of 1,018 wild-type patients (17%), which was comparable 
between both groups (p=1.0). 
 As described above, one c.2846A>T carrier experienced fatal fluoropyrimidine-related 
toxicity, but the intended dose reductions were not applied for this patient. When 
disregarding this patient for the critical protocol violation, no treatment-related death 
occurred in DPYD variant allele carriers. In the wild-type cohort, three patients died due to 
fluoropyrimidine-related toxicity (0.3%), which is comparable to literature.4,5 
Table 1. Demographic and clinical characteristics of patients







     Male 48 (56%) 545 (54%) 593 (54%)
0.68     Female 37 (44%) 473 (46%) 510 (46%)
Age
     Median [IQR] 63 [54─71] 64 [56─71] 64 [56─71] 0.61
Ethnic origin
     Caucasian 84 (99%) 964 (95%) 1,048 (95%)
0.61
     African 0 19 (2%) 19 (2%)
     Asian 1 (1%) 23 (2%) 24 (2%)
     Otherb 0 12 (1%) 12 (1%)
Tumor type
     Non-metastatic CRC 32 (38%) 440 (43%) 472 (43%)
0.48
     Metastatic CRC 24 (28%) 208 (20%) 232 (21%)
     BC 10 (12%) 131 (13%) 141 (13%)
     GC 6 (7%) 57 (6%) 63 (6%)
     Otherc 13 (15%) 182 (18%) 195 (18%)
Type of treatment regimen
     CAP mono 14 (16%) 191 (19%) 205 (19%)
0.40
     CAP + RT 18 (21%) 246 (24%) 264 (24%)
     CAPOX 31 (36%) 343 (34%) 374 (34%)
     CAP other 5 (6%) 67 (7%) 72 (7%)
     5-FU mono 1 (1%) 1 (0%) 2 (0%)
     5-FU + RT 6 (7%) 57 (6%) 63 (6%)
     FOLFOX 5 (6%) 38 (4%) 43 (4%)
0.40     5-FU other 5 (6%) 75 (7%) 80 (7%)
BSA
     Median [IQR] 1.9 [1.8─2.1] 1.9 [1.8─2.1] 1.9 [1.8─2.1] 0.60
table continues
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     0 39 (46%) 515 (51%) 554 (50%)
0.68
     1 36 (42%) 412 (40%) 448 (41%)
     2 4 (5%) 38 (4%) 42 (4%)
     NS d 6 (7%) 53 (5%) 59 (5%)
Number of treatment cycles
      Median [IQR] 4 [1─8] 3 [1─8] 3 [1─8] 0.97
DPYD status
     Wild-type 0 1,018 (100%) 1,018 (92%)
NA
     c.1236G>A heterozygous 51 (60%) 0 51 (5%)
     c.2846A>T heterozygous 17 (20%) 0 17 (2%)
     DPYD*2A heterozygous 16 (19%) 0 16 (1%)
     c.1679T>G heterozygous 1 (1%) 0 1
a P-value comparing DPYD variant allele carriers to DPYD wild-type patients. A Kruskal-Wallis rank sum 
test was used for age, BSA, and number of treatment cycles, a Fisher’s exact test was used for ethnic 
origin and WHO performance status and a χ2 test for sex, tumor type, and treatment regimen;
b Other ethnic origins included Hispanic descent, mixed-racial parentage and unknown ethnic origin;
c Other tumor types included anal cancer, esophageal cancer, head and neck cancer, pancreas cancer, 
bladder cancer, unknown primary tumor, vulva carcinoma, and several rare tumor types;
d WHO performance status was not specified for these patients, but was either 0, 1, or 2, as this was 
required by the inclusion criteria of the study.
Abbreviations: 5-FU mono: 5-fluorouracil monotherapy; 5-FU other: 5-fluorouracil combined with 
other anticancer drugs (excluding the FOLFOX regimen); 5-FU + RT: 5-fluorouracil combined with 
radiotherapy (with or without mitomycin); BC: breast cancer; BSA: body surface area; CAP mono: 
capecitabine monotherapy (with or without bevacizumab); CAPOX: capecitabine combined with 
oxaliplatin (with or without bevacizumab); CAP other: capecitabine combined with other anticancer 
drugs; CAP + RT: capecitabine combined with radiotherapy (with or without mitomycin); CRC: 
colorectal cancer; DPYD: gene encoding dihydropyrimidine dehydrogenase; FOLFOX: 5-fluorouracil 
combined with oxaliplatin and leucovorin (with or without bevacizumab); GC: gastric cancer; IQR: 
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e Defined as palmar-plantar erythrodysesthesia syndrome by the common terminology criteria for 
adverse events (CTC-AE) version 4.03;18
f This patient (c.2846A>T carrier) was wrongly treated with a full capecitabine dose for two cycles, 
which resulted in fatal fluoropyrimidine-related toxicity. 
Abbreviations: DPYD: gene encoding dihydropyrimidine dehydrogenase; FP: fluoropyrimidines; NA: 
not applicable. 
Toxicity of genotype-guided dosing versus standard dosing in DPYD variant allele carriers
As another primary comparison, the relative risk for severe toxicity of DPYD variant allele 
carriers with genotype-guided dosing was compared with the corresponding relative risk 
for severe toxicity of DPYD variant allele carriers from a historical cohort of a previously 
performed meta-analysis.10 DPYD variant allele carriers described in the meta-analysis 
were not identified prior to start of treatment and were therefore treated with a full dose. 
Relative risks for severe toxicity for each DPYD variant obtained in the meta-analysis10 are 
described in Table 3 (incidences of toxicity can be found in the Supplementary Table 2) and 
were compared to calculated relative risks in the current study. This analysis showed that 
genotype-guided dosing reduced the relative risk for severe toxicity in DPYD*2A carriers 
from 2.87 (95% confidence interval [95%CI]: 2.14─3.86)10 when treated with full dose to 
1.31 (95%CI: 0.63─2.73) when treated with individualized dose, thus showing a clinically 
relevant reduction of toxicity risk. 
Table 3. Relative risk for severe toxicity of DPYD variant carriers compared to a historical cohort
DPYD variant DPYD variant carriers treated with 
reduced dose (this study)
DPYD variant carriers treated with full 
dose (meta-analysis)
Relative risk overall grade≥3 toxicity 
(95%CI)a
Relative risk overall grade≥3 toxicity 
(95%CI)b
c.1236G>A 1.69 (1.18–2.42) 1.72 (1.22–2.42)
c.2846A>T 2.00 (1.19–3.34) 3.11 (2.25–4.28)
DPYD*2A 1.31 (0.63–2.73) 2.87 (2.14–3.86)
c.1679T>G NAc 4.30 (2.10–8.80)
a Relative risk for overall grade ≥3 fluoropyrimidine-related toxicity compared to non-carriers of this 
variant as described in Table 2; 
b Relative risk for overall grade ≥3 fluoropyrimidine-related toxicity compared to non-carriers of this 
variant, as determined in a random-effects meta-analysis by Meulendijks et al.10 Unadjusted relative 
risks for the meta-analysis are depicted, as the relative risk in the current study was also calculated as 
an unadjusted value (as patient numbers were low); 
c Relative risk cannot be calculated as only one patient who carried c.1679T>G was present. This 
patient did not experience severe toxicity. 
Abbreviations: 95%CI: 95% confidence interval; NA: not applicable. 
Interestingly, for c.1236G>A and c.2846A>T, a reduction in toxicity risk comparable to 
that of DPYD wild-type patients could not be demonstrated. The risk for c.1236G>A in 
the historical cohort was 1.72 (95%CI: 1.22─2.42),10 and in our study it was 1.69 (95%CI: 
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1.18─2.42), showing that the toxicity risk was still increased even when applying a 25% 
dose reduction. For c.2846A>T, the risk of severe toxicity determined in the meta-analysis 
was 3.11 (95%CI: 2.25─4.28),10 which was decreased to 2.00 (95%CI: 1.19─3.34) after 25% 
dose reduction. However, this risk was still higher compared to non-carriers of this variant. 
For the c.1679T>G variant no relative risk could be calculated, as only one patient with this 
variant was included. 
Pharmacokinetics of DPYD-guided dosing
A total of 26 DPYD variant allele carriers (of which 16 c.1236G>A carriers, five c.2846A>T 
carriers, four DPYD*2A carriers and one c.1679T>G carrier) treated with a reduced 
fluoropyrimidine dose gave informed consent to draw blood for pharmacokinetic analysis. 
Mean AUC values of the DPYD variant allele carriers and control values are depicted in Figure 
2. Mean exposure to capecitabine and all metabolites, including 5-FU, was comparable 
between patients dosed based on DPYD genotype and control values,20 suggesting that 
mean drug exposure of all combined DPYD variant allele carriers treated with a reduced 
dose was adequate. However, in line with toxicity data, AUC values for 5-FU were markedly 
higher for c.1236G>A carriers and especially for c.2846A>T carriers, compared to DPYD*2A 








































Figure 2. Pharmacokinetics of DPYD-guided capecitabine dosing
Depicted are the mean AUCs of capecitabine, and the metabolites 5’DFCR, 5’DFUR, 5-FU and FBAL of 
the DPYD variant allele carriers treated with DPYD-genotype guided dose (blue) and control values 
from wild-type patients from a published study (red).20 Error bars represent the standard deviation. 
Abbreviations:  5’DFCR: 5-deoxy-5-fluorocytidine; 5’DFUR: 5-deoxy-5-fluorouridine; 5-FU: 
5-fluorouracil; AUC: area under the plasma concentration-time curve; CAP: capecitabine; FBAL: fluoro-
β-alanine.
DPD enzyme activity 
In 56 DPYD variant allele carriers and 82 wild-type patients (participating in a subgroup 
of the study where DPD phenotyping tests were investigated), pretreatment DPD enzyme 
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activity was determined (Figure 3). Mean DPD activity (with standard deviation) in DPYD 
wild-type patients was 9.4 (3.6) nmol/(mg*h), similar to as previously published.23 For the 
c.1236G>A variant (N=35), the mean DPD activity was 7.5 (2.8) nmol/(mg*h) (i.e. a 20% 
reduction compared to wild-type). The mean DPD activity for c.2846A>T (N=12) was 6.2 
(1.9) nmol/(mg*h) (34% reduction), and for DPYD*2A (N=8) 5.2 (0.6) nmol/(mg*h) (45% 
reduction). The single patient carrying c.1679T>G had a DPD enzyme activity of 3.8 nmol/
(mg*h) (60% reduction). For c.1236G>A, c.2846A>T, and DPYD*2A, the mean DPD enzyme 
activity was significantly lower than the mean for wild-type patients. Statistical analysis was 
not possible for c.1679T>G. No correlation between DPD enzyme activity and the occurrence 
of severe fluoropyrimidine-related toxicity in DPYD variant allele carrying patients was seen 












































Figure 3. DPD enzyme activity in DPYD variant allele carriers and wild-type patients
Wild-type patients were wild-type for the four DPYD variants that were prospectively tested. Mean 
DPD enzyme activity was statistically significantly lower than wild-type (mean 9.4 (3.6) nmol/[mg*h]) 
for the DPYD variants as determined by a t-test: c.1236G>A (7.5 (2.8) nmol/[mg*h], p=0.0050), 
c.2846A>T (6.2 (1.9) nmol/[mg*h], p=0.0034), and DPYD*2A (5.2 (0.6) nmol/[mg*h], p=0.0012). As 
only one patient carried c.1679T>G, no statistical test could be performed for this variant. However, 
the single measurement in this patient was in the range of DPD deficiency (3.8 nmol/[mg*h]). Patients 
with grade ≥3 fluoropyrimidine-related toxicity are depicted by closed triangles, patients without 
grade <3 toxicity by open circles; wild-type patients are treated with standard fluoropyrimidine doses, 
DPYD variant allele carriers with initially reduced doses according to protocol. 
Abbreviations: DPD: dihydropyrimidine dehydrogenase; PBMCs: peripheral blood mononuclear cells. 
Discussion 
This is, to our knowledge, the first prospective study to investigate the effect on 
fluoropyrimidine-related toxicity by dose individualization based on four DPYD variants. 
Our results demonstrate that genotype-guided dosing is feasible in clinical practice. Dose 
individualization markedly decreased the risk of severe toxicity for DPYD*2A carriers, was 
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safe in the single c.1679T>G carrier, and moderately decreased the toxicity risk in c.2846A>T 
carriers. For c.1236G>A carriers, a 25% dose reduction was not enough to decrease severe 
treatment-related toxicity. This shows that DPYD genotype-guided dose-individualization is 
able to improve patient safety, as toxicity risk was reduced for three of the four variants in 
our study. Although sample sizes of variant allele carriers were modest and not all reductions 
in toxicity risk were statistically significant, these findings imply high clinical relevance. Also, 
implementation of DPYD genotype-guided dosing resulted in similar frequencies of toxicity-
related hospitalization and discontinuation of treatment due to fluoropyrimidine-related 
toxicity for wild-type patients and DPYD variant allele carriers. 
 Interestingly, for DPYD*2A carriers, the frequency of severe toxicity found in this study was 
31%; drastically lower than the frequency in the historical cohort (72%). DPD enzyme activity 
measurements in this study showed that activity for DPYD*2A carriers was approximately 
50% reduced compared to wild-type patients, which endorses the dose recommendation of 
50% for this variant. 
 As only one carrier of the rare c.1679T>G variant was identified in our current study, this 
made statistical comparisons impossible. However, while a relative risk for severe toxicity 
of 4.30 has been reported in literature, we showed that this patient did not experience 
severe toxicity in a completed treatment with 50% reduced dose. The DPD enzyme activity 
was about 50% decreased as well in this patient, which is in line with expectations based on 
previous studies.24
 For carriers of the c.1236G>A and c.2846A>T variant, risk of severe toxicity remained 
relatively high despite dose individualization based on our dosing recommendations (25% 
reduction). In this study, 39% of the c.1236G>A carriers experienced severe toxicity and 
47% of the c.2846A>T carriers. For these two variants, an initial dose reduction of 25% was 
applied in this study, because these variants are considered to have a less deleterious effect 
on DPD activity than the non-functional variants DPYD*2A and c.1679T>G.14,16 However, the 
Clinical Pharmacogenetics Implementation Consortium (CPIC) mentions that evidence is 
limited regarding the optimal degree of dose reduction for the decreased function variants 
c.1236G>A and c.2846A>T, and a 25% dosing recommendation is mainly based on one small 
retrospective study. Therefore, they advise a 25%─50% dose reduction in heterozygous 
c.1236G>A and c.2846A>T carriers.13 Our current results suggest that applying 25% dose 
reduction might be insufficient for some patients, as toxicity risk was increased for carriers 
of c.1236G>A and c.2846A>T, compared to wild-type patients. In line with these findings, our 
pharmacokinetic analyses showed that exposure to 5-FU was markedly higher in c.2846A>T 
carriers than in DPYD wild-type controls. Exposure to 5-FU in the variant allele carriers was 
at least equal to levels observed in wild-type patients receiving standard dose, which is 
circumstantial evidence that the applied genotype-guided dose-reduction will not result 
in under-treatment. However, these pharmacokinetic results need to be interpreted with 
caution for some reasons. In patients with reduced DPD activity, 5-FU metabolism is affected, 
with 5-FU being the third metabolite derived from the parent compound capecitabine, which 
limits the interpretation of 5-FU exposure. Furthermore, pharmacokinetics of capecitabine 
and its metabolites exhibit a high inter-individual variability in exposure –even in wild-
type patients– and are therefore difficult to interpret. In addition, based on the limited 
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number of patients with a DPYD variant of whom we also obtained pharmacokinetic data 
(Supplementary Table 3) firm conclusions on the basis of pharmacokinetic measurements 
alone cannot be drawn. 
 The mean DPD enzyme activity for c.1236G>A was approximately 20% reduced, but a 
large variation in DPD activity was found (Figure 3), which suggests that a proportion of 
patients needs a larger dose reduction, while other patients might even tolerate a full dose. 
This is also in line with the large variation in pharmacokinetic exposure seen in c.1236G>A 
carriers. Individual dose titration is important to ensure an adequate and safe dose for all 
patients. Therefore, we recommend a more cautious initial dose reduction of 50%, followed 
by close monitoring and individual dose titration. 
 The mean value for c.2846A>T DPD enzyme activity was approximately 35% reduced 
compared to normal. These DPD activity measurements show that 25% dose reduction 
might not be sufficient for most of the patients, and this could be an explanation for the 
higher toxicity risk in this patient group. A more cautious initial dose reduction of 50% 
should be considered in these patients as well. 
 In this study, initially reduced doses were escalated in eleven out of 85 (13%) DPYD 
variant allele carriers, although only five patients were able to tolerate this escalated dose. 
In DPYD wild-type patients dose escalations are uncommon in clinical practice (3% in our 
study, mostly patients who started with an initially reduced dose as a precaution measure). 
 Our study was performed in a daily clinical care setting in general regional hospitals and 
a few academic centers, demonstrating the feasibility of implementation of upfront DPYD 
screening. In order to make DPYD-guided dosing feasible in all hospitals, it is important 
that the turn-around time for DPYD genotyping is short to prevent a delay in the start of 
treatment. Participating laboratories in our study had a turn-around time of a few days to a 
maximum of a week. 
 A limitation of this study is that a historical cohort of DPYD variant allele carriers treated 
with full dose was used as control, and no direct comparison was made with a control 
cohort within the study. Inherently to this chosen design, differences between the study 
populations could have influenced the observed toxicity outcomes. However, this study 
design was chosen as a randomized clinical trial is considered unethical in this context, since 
it is known that DPYD variant allele carriers are at increased risk of severe toxicity when 
treated with a full dose of fluoropyrimidines.25 A previously performed clinical study was 
stopped prematurely as a patient in the arm without dose individualization died due to 
treatment-related toxicity.26 
 This study focused on toxicity and did not evaluate survival or other effectiveness 
outcomes, as this was considered not feasible due to the large variation in tumor types 
and treatment regimens. We did, however, perform pharmacokinetic measurements, which 
suggest that applied dose reductions in DPYD variant allele carriers did not result in under-
dosing.
 The four DPYD variants investigated in this study are especially relevant to Caucasian 
populations. For ethnicities other than Caucasians, more research on the frequency and 
clinical relevance of these and other DPYD variants is recommended.27 In our current study, 
homozygous and compound heterozygous DPYD variant allele carriers were not included and 
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were treated with individualized fluoropyrimidine dosing or alternative treatment outside 
this study.17 However, for this group of patients DPYD genotype-guided dosing is of even 
greater importance than for heterozygous DPYD variant allele carriers, as these patients in 
general have less remaining DPD activity or even complete absence of DPD activity, and a 
full fluoropyrimidine dose, when not identified as DPD deficient patients, is therefore likely 
to be fatal. 
 Although our study revealed that the applied approach of genotype-guided adaptive 
dosing significantly reduced severe fluoropyrimidine-induced toxicity and prevented 
treatment related death, additional methods should be explored and prospectively tested 
to further reduce treatment related toxicity not only in poor metabolizers, but also in DPYD 
wild-type patients.
 In conclusion, we showed safety of patients treated with fluoropyrimidines was improved 
by dose individualization based on DPYD genotype. Dose reduction of 50% in heterozygous 
DPYD*2A and c.1679T>G carriers reduced toxicity risk markedly. The applied dose reductions 
of 25% in heterozygous c.1236G>A and c.2846A>T carriers appear to be insufficient to lower 
the risk of fluoropyrimidine-related toxicity to the background risk in wild-type patients. A 
larger initial dose reduction of 50% for c.2846A>T and c.1236G>A carriers with subsequent 
individual dose titrations should therefore be considered. 
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Inclusion and exclusion criteria
Patients with a pathologically confirmed malignancy for which treatment with a 
fluoropyrimidine drug was considered to be in the patient’s best interest could be included 
in this study. Eligible patients were 18 years or older and were willing to undergo blood 
sampling for the purpose of this study (pharmacogenetic and phenotyping analysis). Patients 
had to have a WHO performance status of 0, 1 or 2, a life expectancy of at least 12 weeks, 
and acceptable safety laboratory values (neutrophil count of ≥1.5 x 109/L, platelet count of 
≥100 x 109/L, hepatic function as defined by serum bilirubin ≤1.5 x upper limit of normal 
(ULN), alanine aminotransferase (ALAT), and aspartate aminotransferase (ASAT) ≤2.5 x ULN, 
or in case of liver metastases ALAT and ASAT≤5 x ULN, renal function as defined by serum 
creatinine ≤1.5 x ULN, or creatinine clearance ≥60 ml/min (by Cockcroft-Gault formula).
 Exclusion criteria were prior treatment with fluoropyrimidines, patients with known 
substance abuse, psychotic disorders, and/or other diseases expected to interfere with 
study or the patient’s safety, women who were pregnant or breast feeding, man and women 
who refused to use reliable contraceptive methods throughout the study, and patients with 
a homozygous polymorphic DPYD genotype or compound heterozygous DPYD genotype. 
Toxicity assessments
For causality assessment of toxicity the following definitions were used: 
- Possible: the event follows a reasonable temporal sequence from the time of drug 
administration, but could have been produced by other factors such as the patient’s 
clinical state, other therapeutic interventions or concomitant drugs.
- Probable: the event follows a reasonable temporal sequence from the time of drug 
administration, and follows a known response pattern to the study drug. The toxicity 
cannot be reasonably explained by other factors such as the patient’s clinical state, 
therapeutic interventions or concomitant drugs.
- Definite: the event follows a reasonable temporal sequence from the time of drug 
administration, and follows a known response pattern to the study drug, cannot be 
reasonably explained by other factors such as the patient’s condition, therapeutic 
interventions or concomitant drugs; AND occurs immediately following study drug 
administration, improves on stopping the drug, or reappears on re-exposure.
Sample size calculation
A sample size calculation was made based on the primary aim of the study, which was to 
determine whether fluoropyrimidine-related severe toxicity can be reduced by individualized 
dosing in DPYD variant allele carriers compared to standard dosing in these patients. Using 
a one stage A’Hern (phase II) design and a null hypothesis of a probability of toxicity of 
60% (the estimated severe treatment-related toxicity probability if DPYD variant allele 
carriers received standard dose)1,2 and an alternative hypothesis of 20% (estimated toxicity 
probability of DPYD variant allele carriers receiving individualized dose), a sample size of 
eleven DPYD variant allele carriers would give a one-sided type I error probability α of 2.93% 




1.0%)3 would determine the total number of patients required in the study. These patients 
would then arise from an expected minimum population of 1,100 treated patients. To 
account for a proportion of patients not evaluable for the study, the target accrual was 
set at 1,250 patients. Given the very low allele frequency of the c.1679T>G variant, it 
was considered not feasible to power this study for this particular variant. The estimated 
frequency of c.1236G>A is 3% and of DPYD*2A 1%, which means that the calculated sample 
size would be adequate for those individual variants, or when analyzing all four variants 
together (estimated frequency of 5%). 
Pharmacokinetic analyses
For pharmacokinetic analyses, peripheral blood was collected on the first day of treatment. 
Blood was collected in lithium heparin tubes at nine different time points up to eight hours 
after capecitabine intake (pre-dose, 0.25, 0.5, 1, 2, 3, 4, 6, and 8 hours after capecitabine 
intake). Samples were centrifuged immediately after the blood was drawn and plasma was 
stored at -80°C until analysis. 
 Capecitabine and the metabolites 5’-deoxy-5-fluorocytidine (5’DFCR), 5’-deoxy-5-
fluorourdine (5’DFUR), 5-fluorouracil (5-FU), and fluoro-β-alanine (FBAL) were quantified in 
plasma samples using a validated ultra-performance liquid chromatography (UPLC)-tandem 
mass spectrometry (MS/MS) method. Lower limit of quantifications were 25 ng/ml for 
capecitabine, 10 ng/ml for 5’DFCR, 5’DFUR and 5-FU, and 50 ng/ml for FBAL. Stable isotopes 
were used as internal standard for all analytes. To a sample volume of 300 μl  of plasma, 900 μl 
of methanol-acetonitrile (50:50 v/v) was added to precipitate the plasma proteins. Samples 
were vortex-mixed for 10 seconds, shaken for 10 minutes at 1,250 rpm and centrifuged at 
14,000 rpm for 10 minutes. The clear supernatants were dried under a stream of nitrogen 
at 40°C and reconstituted in 100 μl of 0.1% formic acid in water. An Acquity UPLC® HSS T3 
column (150 x 2.1 mm ID, 1.8 μlm particles) was used for chromatographic separation, at 
a flow rate of 300 μl/min and a gradient of 0.1% formic acid in water (mobile phase A) and 
0.1% formic acid in acetonitrile (mobile phase B). The following gradient was applied: 100% 
A from 0─2.5 minutes, an increase from 0% to 90% B from 2.5─7.5 minutes, and 100% A 
from 7.5─9 minutes. For detection an API5500 triple quadruple mass spectrometer (Sciex) 
equipped with a turbo ionspray interphase was used, using optimized mass transitions m/z 
360.0  243.9 for capecitabine, 244.9  128.8 for 5’DFUR, 128.9  42.1 for 5-FU, and 
105.9  85.9 for FBAL. 
 Pharmacokinetic parameters were calculated using non-compartmental analysis and 
the calculated area under the plasma concentration-time curve (AUC) and half-life (t1/2) 
were compared with pharmacokinetic data described in literature,4 measured at the same 
laboratory as the current study. 
Data sharing statement
Data collected in the study, including individual participant data, will not be made available 
to others, except to researchers involved in the study. However, upon request, data sharing 
for additional research is possible and will be supported. Requests will be judged on scientific 
and clinical rationale and may need to be reviewed by an authorized institutional review 
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board (IRB) prior to data sharing. The study protocol of this study is publicly available (as 
online supplement available with this publication).
Supplementary results
Detailed information of DPYD variant allele carriers not treated according to dosing 
recommendations
For four patients dosing recommendations were not followed according to protocol. One 
patient carrying DPYD*2A started with a full dose as genotyping results were not awaited 
before start of treatment. After one week of treatment the DPYD genotyping result became 
available and the dose was reduced to 50%. The patient did not experience severe treatment-
related toxicity in this course. However, from the third cycle onwards the dose was quickly 
titrated upwards (75% in the third cycle and 90% in the fourth cycle), hereafter treatment-
related toxicity (anorexia grade 2, fatigue grade 3) occurred and the dose was reduced again. 
A second patient (DPYD*2A carrier) also started with a full dose as genotyping results were 
not awaited before starting treatment. As results were known the following day, the patient 
had only taken a full dose for one day, which did not result in severe toxicity. The patient was 
treated with a 50% dose from the second day onwards. A third patient carrying c.2846A>T, 
used a full dose for four days, but continued with a 50% dose after an interruption of 5 days. 
The overall dose intensity of this cycle was approximately 55% and no toxicity occurred. The 
fourth patient (c.2846A>T carrier) was wrongly treated with a full dose for two cycles due to 
miscommunication with the patient. The patient experienced severe diarrhea, pancytopenia 
and sepsis, and passed away. 
Pharmacokinetic analyses
A total of 26 DPYD variant allele carriers treated with reduced dose of capecitabine was 
included in the analysis. Pharmacokinetic results are shown in Supplementary Table 3. In 24 
out 26 patients (92%) pharmacokinetic sampling was performed at day 1 of cycle 1. In two 
patients this was done at day 1 of another cycle, after a resting period of one week without 
capecitabine intake. 
 Of five patients who were treated with 5-FU, pharmacokinetic blood samplings was 
performed as well, but results were considered unreliable, most likely as drawing of blood 





Supplementary Table 1. Demographic and clinical characteristics of DPYD variant allele carriers
Characteristics DPYD variant 
allele carriers 
c.1236G>A c.2846A>T DPYD*2A c.1679T>G
N=85 N=51 N=17 N=16 N=1
Sex
     Male 












     Median [IQR] 63 [54─71] 62 [52─71] 62 [53─72] 64 [58─70] 70
Ethnic origin
     Caucasian
     African 
     Asian
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Type of treatment regimen
     CAP mono 
     CAP + RT
     CAPOX
     CAP other
     5-FU mono 
     5-FU + RT
     FOLFOX
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Number of treatment cycles
     Median [IQR] 4 [1─8] 4 [2─8] 3 [1─7] 3 [1─7] 3
a Other ethnic origins included Hispanic descent, mixed-racial parentage and unknown ethnic origin; 
b Other tumor types included anal cancer, esophageal cancer, head and neck cancer, pancreas cancer, 
bladder cancer, unknown primary tumor, vulva carcinoma, and several rare tumor types; 
c WHO performance status was not specified for these patients, but was either 0, 1, or 2, as this was 
required by the inclusion criteria of the study. 
Abbreviations: 5-FU mono: 5-fluorouracil monotherapy; 5-FU other: 5-fluorouracil combined with 
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other anticancer drugs (excluding the FOLFOX regimen); 5-FU + RT: 5-fluorouracil combined with 
radiotherapy (with or without mitomycin); BC: breast cancer; BSA: body surface area; CAP mono: 
capecitabine monotherapy (with or without bevacizumab); CAPOX: capecitabine combined with 
oxaliplatin (with or without bevacizumab); CAP other: capecitabine combined with other anticancer 
drugs; CAP + RT: capecitabine combined with radiotherapy (with or without mitomycin); CRC: 
colorectal cancer; DPYD: gene encoding dihydropyrimidine dehydrogenase; FOLFOX: 5-fluorouracil 
combined with oxaliplatin and leucovorin (with or without bevacizumab); GC: gastric cancer; IQR: 
interquartile range; NS: not specified. 
Supplementary Table 2. Incidences of severe toxicity in DPYD variant allele carriers in this study and 
the historical cohort
DPYD variant DPYD variant carriers treated with 
reduced dose 
(this study)
DPYD variant carriers treated with full 
dose
(meta-analysis)
N of patients with overall grade ≥3 
toxicity / total N of patients with this 
variant (%)
N of patients with overall grade ≥3 
toxicity / total N of patients with this 
variant (%)
c.1236G>A 20 / 51 (39%) 65 / 177 (37%)
c.2846A>T 8 / 17 (47%) 53 / 85 (62%)
DPYD*2A 5 / 16 (31%) 43 / 60 (72%)
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table 4. DPD enzyme activity in patients with and without severe toxicity
DPYD genotype Patients without severe toxicitya Patients with severe toxicitya P-valueb
Mean activity (SD) N of patients Mean activity (SD) N of patients
Wild-type 9.6 (3.6) 67 8.7 (3.7) 15 0.36
c.1236G>A 7.6 (3.0) 22 7.3 (2.6)       13 0.79
c.2846A>T 6.8 (1.9) 6 5.7 (1.8)       6 0.33
DPYD*2A 4.9 (0.7) 5 5.5 (1.1)       3 0.22
c.1679T>G NA 1 NA                 0 NA
a Severe toxicity is defined as CTC-AE grade 3 or higher; 
b P-value determined with t-test. 





Supplementary Table 5. Overview of participating centers in this study
Center Principal investigator Number of 
eligible patients 
included
Erasmus Medical Center, Rotterdam, the 
Netherlands
Prof. Ron H.J. Mathijssen, 
MD
264
The Netherlands Cancer Institute, Amsterdam, the 
Netherlands
Prof. Jan H.M. Schellens, 
MD
210
Catharina Hospital, Eindhoven, the Netherlands Geert-Jan Creemers, MD 118
Leiden University Medical Center, Leiden, the 
Netherlands
Prof. Hans Gelderblom, 
MD
93
Hospital Gelderse Vallei, Ede, the Netherlands Arnold Baars, MD 88
Reinier de Graaf Hospital, Delft, the Netherlandsa Vincent O. Dezentjé, MD / 
Annelie J.E. Vulink, MD
79
Haaglanden Medical Center, the Hague, the 
Netherlands
Frank J.F. Jeurissen, MD 46
Deventer Hospital, Deventer, the Netherlands Alexander L.T. Imholz, MD 41
Haga Hospital, the Hague, the Netherlandsa Prof. Johanna E.A. 
Portielje, MD / Danny 
Houtsma, MD
35
Maastricht University Medical Center, Maastricht, 
the Netherlands
Rob L.H. Jansen, MD 28
Franciscus Gasthuis and Vlietland, Rotterdam, the 
Netherlands
Paul Hamberg, MD 24
Amphia Hospital, Breda, the Netherlands Albert J. ten Tije, MD 20
Bravis Hospital, Roosendaal, the Netherlands Helga J. Droogendijk, MD 17
University Medical Center, Utrecht, the Netherlands Prof. Miriam Koopman, 
MD
14
Wilhelmina Hospital, Assen, the Netherlands Peter Nieboer, MD 13
Laurentius Hospital, Roermond, the Netherlands Marlène H.W. van de Poel, 
MD
9
Canisius-Wilhelmina Hospital, the Netherlands Caroline M.P.W. 
Mandigers, MD
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Fluoropyrimidine therapy including capecitabine or 5-fluorouracil can result in severe 
treatment-related toxicity in up to 30% of patients. Toxicity is often related to reduced 
activity of dihydropyrimidine dehydrogenase (DPD), the main metabolic fluoropyrimidine 
enzyme, primarily caused by genetic DPYD polymorphisms. In a large prospective study, it 
was concluded that upfront DPYD-guided dose individualization is able to improve safety of 
fluoropyrimidine-based therapy. In our current analysis, we evaluated whether this strategy 
is cost-saving. 
 A cost-minimization analysis from a health care payer perspective was performed 
as part of the prospective clinical trial (NCT02324452) in which patients prior to start of 
fluoropyrimidine-based therapy were screened for the DPYD variants DPYD*2A, c.2846A>T, 
c.1679T>G, and c.1236G>A, and received an initial dose reduction of 25% (c.2846A>T, 
c.1236G>A) or 50% (DPYD*2A, c.1679T>G). Data on treatment, toxicity, hospitalization 
and other toxicity-related interventions were collected. The model compared prospective 
screening for these DPYD variants with no DPYD screening. One-way and probabilistic 
sensitivity analyses were also performed. 
 Expected total costs of the screening strategy were €2,599 per patient, compared to 
€2,650 for non-screening, resulting in a net cost-saving of €51 per patient. Results of the 
probabilistic sensitivity and one-way sensitivity analysis demonstrated that the screening 
strategy was very likely to be cost-saving or worst case cost-neutral.
 Upfront DPYD-guided dose individualization, improving patient safety, is cost-saving or cost 
neutral, but is not expected to yield additional costs. These results endorse implementing 
DPYD screening before start of fluoropyrimidine treatment as standard of care. 
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The class of fluoropyrimidine anticancer drugs includes 5-fluorouracil (5-FU) and its oral 
prodrug capecitabine. These drugs are used by approximately two million patients yearly 
worldwide,1 and are the cornerstone of chemotherapeutic treatment for several solid tumor 
types, including colorectal, breast, gastric and head- and neck cancer. While fluoropyrimidine 
drugs are highly valuable treatment options, severe and potential fatal fluoropyrimidine-
related toxicity remains a major clinical limitation. Around 15─30% of the patients develop 
severe treatment-related toxicity,2,3 usually associated with interruption or discontinuation 
of therapy and often hospitalization, resulting in increased health care costs. 
 During the last decades it has become clear that safety of patients treated with 
fluoropyrimidine-based anticancer therapy is strongly affected by inter-individual variability 
in the enzyme dihydropyrimidine dehydrogenase (DPD), which is the main metabolic 
enzyme of fluoropyrimidines. The DPD enzyme is present in the liver and inactivates over 
80% of 5-FU.4 DPD enzyme activity varies widely between patients, with an estimated 3 to 
8% of the population having a reduced DPD activity.5,6 DPD deficiency results in reduced 5-FU 
clearance, and as a direct consequence, highly increased risk of severe treatment-related 
toxicity when DPD-deficient patients are treated with standard doses of a fluoropyrimidine 
drug.7
 DPD deficiency can be caused by genetic polymorphisms in DPYD, the gene encoding 
DPD. Currently, four DPYD variants are considered as being clinically relevant and dosing 
recommendations are provided for these variants: DPYD*2A, c.1679T>G, c.2846A>T and 
c.1236G>A).8,9 Upfront genotyping followed by a fluoropyrimidine dose reduction in carriers 
in any of these four variants has proven a useful strategy to improve patient safety.10,11 
However, this strategy has not yet been universally implemented in daily clinical care. 
 One of the potential barriers that can make physicians reluctant to implement upfront 
DPYD screening as a routine test, is uncertainty on the cost-effectiveness of a DPYD 
screening strategy.12 Deenen et al. previously showed that upfront screening for one DPYD 
variant, DPYD*2A, is cost-saving, as average total medical costs in the screening arm were 
€2,772 per patient and therefore lower than the non-screening arm, for which the average 
total medical costs were €2,817 per patient. This shows that the reduction in toxicity-
related costs outweighs the screening costs.10 In our current study, we aimed to investigate 
the medical costs associated with upfront screening for the four DPYD variants currently 
considered clinically relevant and dose individualization in heterozygous carriers of a DPYD 
variant, therefore evaluating the net cost effects of this expanded DPYD genotyping strategy. 
Patients and methods
Study design and participants
The cost analysis was performed as part of a recently published clinical trial.11 This was a 
multicenter study in which 17 hospitals in the Netherlands participated (NCT02324452). 
Study approval was obtained by the institutional review board of The Netherlands Cancer 
Institute, Amsterdam, the Netherlands, and approval from the board of directors of each 
individual hospital was obtained for all participating centers. All patients provided written 
informed consent before inclusion in the study. 
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The study population consisted of patients treated with a fluoropyrimidine-based anticancer 
therapy, either as single agent or in combination with other chemotherapeutic agents and/
or radiotherapy. Prior chemotherapy was allowed, except for prior use of fluoropyrimidines. 
Before start of fluoropyrimidine therapy, patients were genotyped for four DPYD variants 
(DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A). Heterozygous DPYD variant allele 
carriers received an initial dose reduction of either 25% (for c.2846A>T and c.1236G>A) 
or 50% (for DPYD*2A and c.1679T>G), in line with current recommendations from Dutch 
and international pharmacogenomic guidelines.9,13 To achieve maximal safe exposure, dose 
escalation was allowed after the first two cycles, provided that treatment was well tolerated 
and was left at the discretion of the physician. The dose of other chemotherapeutic agents 
or radiotherapy was left unchanged at the start of treatment. Homozygous or compound 
heterozygous DPYD variant allele carriers were not included in the study. Non-carriers of the 
above mentioned DPYD variants were considered wild-type patients in this study, and were 
treated according to existing standard of care. 
 Toxicity was graded by participating centers according to the National Cancer Institute 
common terminology criteria for adverse events (CTC-AE),14 and severe toxicity was defined 
as grade 3 or higher. Patients were followed for toxicity during the entire treatment period. 
Toxicity defined as possibly, probably or definitely related to fluoropyrimidine-treatment 
was considered treatment-related toxicity. Toxicity-related hospitalization and treatment 
discontinuation due to adverse events were also investigated. 
 The primary end point of the prospective study was the frequency of severe overall 
fluoropyrimidine-related toxicity across the entire treatment duration. A comparison was 
made between DPYD variant allele carriers treated with reduced dose and wild-type patients 
treated with standard dose in this study, and also with DPYD variant allele carriers treated 
with full dose in a historical cohort derived from a previously published meta-analysis.8 
Secondary endpoints of the prospective study included a cost analysis of individualized 
dosing based on upfront genotypic assessment, and pharmacokinetics of capecitabine and 
5-FU in DPYD variant allele carriers.
Cost analysis 
To compare the prospective screening for four DPYD variants (screening strategy) with no 
DPYD screening (non-screening strategy), a cost analysis model was composed. This analysis 
consisted of a cost-minimization analysis using a decision analytical model from a health 
care payer perspective. 
 A previously published model by Deenen et al.10 was used and updated with data from 
the current study and current prices. Estimated parameters incorporated in the model were 
derived from data of the present trial and relevant data from literature.15,16 Interventions for 
treatment-related toxicity were prospectively collected for all patients during the trial. An 
overview of the decision tree is depicted in Figure 1. In the model, a comparison between 
the screening strategy (prospective screening for four DPYD variants and dose adjustments 
in heterozygous DPYD variant allele carriers) and the non-screening strategy was made. 
Expected differences in costs of both strategies were calculated. 
 Costs included were restricted to direct medical costs only and included costs for 
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genotyping, fluoropyrimidine drug therapy including visits to the medical doctor and day 
care, costs for treatment of adverse events (e.g. extra medication, extra doctor visits, extra 
assessments), and costs for hospitalization due to adverse events. Costs for other anticancer 
drugs than the fluoropyrimidine drugs were not included in the model, as they were 
expected to be equal in both arms. Cost-saving was calculated as the difference between 
the net direct costs of the DPYD screening strategy versus the non-screening strategy. 
 To examine the effects on variations in parameter values, one-way and probabilistic 
sensitivity analyses were performed. In the one-way sensitivity analysis, each parameter 
was varied individually at ±20% of the baseline value. In the probabilistic sensitivity analysis, 
all parameters were varied simultaneously by running 1,000 simulations (Monte Carlo). 
Since the parameter values of the wild-type patients for both the screening and the non-
screening arm are identical, these parameters remained fixed in the probabilistic sensitivity 
analysis.
Figure 1. Decision tree for cost analysis
Results
Patient characteristics and toxicity incidence 
The study was open for inclusion between April 30th, 2015 and December 21st, 2017. In 
this period, a total of 1,103 evaluable patients were enrolled in this study, of whom 85 
heterozygous DPYD variant allele carriers (7.7%) and 1,018 wild-type patients (92.3%). 
The group of DPYD variant allele carriers included 51 c.1236G>A carriers, 17 c.2846A>T 
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carriers, 16 DPYD*2A carriers and one c.1679T>G carrier. Details on patient characteristics, 
treatment and toxicity incidence are published separately.11 In short, 33 out of 85 DPYD 
variant allele carriers (39%) experienced grade ≥3 treatment-related toxicity, while this was 
significantly lower in the group of wild-type patients with 231 out of 1,018 patients (23%) 
experiencing severe toxicity (p=0.001). Compared to the historical cohort of DPYD variant 
allele carriers treated with full dose, DPYD genotype-guided dosing markedly decreased 
the risk of severe fluoropyrimidine-related toxicity for three out of four variants (DPYD*2A, 
c.1679T>G and c.2846A>T; Figure 2). No reduction in severe treatment-related toxicity was 
shown for c.1236G>A. 
Figure 2. Relative risk for severe treatment-related toxicity of DPYD variant allele carriers receiving 
dose-reduction (this study) and DPYD variant allele carriers treated with full dose (historical cohort)
The relative risk for overall grade ≥3 fluoropyrimidine-related toxicity compared to non-carriers of this 
variant was calculated with data from this study11 and for the historical cohort with data derived from 
a previously published random-effects meta-analysis.8 Unadjusted relative risks for the meta-analysis 
are depicted, as the relative risk in the current study was also calculated as an unadjusted value. For 
c.1679T>G no relative risk could be calculated in this study, as only one patient who carried c.1679T>G 
was present. This patient did not experience severe toxicity.
Abbreviations: 95%CI: 95% confidence interval. 
Cost analysis 
All parameter estimates used in the model are provided in Table 1. In the cost analysis the 
expected total costs for the screening strategy were €2,599 per patient, compared to €2,650 
per patient for the non-screening strategy, resulting in a net cost-saving of €51 per patient 
treated. 
 Results of the one-way sensitivity analysis are depicted in Figure 3, demonstrating that 
the frequency of the DPYD variant allele genotype had the largest influence on outcome of 
the cost analysis, followed by the risk of hospitalization at the nursing ward for DPYD variant 
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allele carrier receiving standard dose, and DPYD genotyping costs. However, in all cases, the 
cost-saving remained positive. 
 Results of the simulations for the probabilistic sensitivity analysis are depicted in Figure 4. 
Average cost-savings from the simulation in the probabilistic sensitivity analysis were €52 per 
patient (95%-interval range -€38 to €176). Average gain in safety was 0.89% (95%-interval 
range -0.04% to 1.79%). This gain in safety represents the difference between the proportion 
of patients treated without severe toxicity (both wild-type patients and DPYD variant allele 
carriers taken together) in the screening strategy and the non-screening strategy.
Figure 3. One-way sensitivity analysis of upfront DPYD genotyping versus non-screening
All parameters were individually varied by ±20% (-20% depicted in blue, +20% depicted in green), 
effects of which cost-savings are indicated by horizontal bars. The vertical line indicates the baseline 
costs savings of €50.
Figure 4. Probabilistic sensitivity analysis of the cost analysis 
For this sensitivity analysis, all parameters were varied simultaneously by running 1,000 Monte Carlo 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The cost analysis performed in this study showed that prospective DPYD screening for 
these four variants and dose individualization is cost-saving. This confirms that upfront 
DPYD screening does not result in an increase in healthcare costs, while it can significantly 
improve patient safety and prevent toxicity-related deaths, as shown previously.11 Results of 
the probabilistic sensitivity analysis and one-way sensitivity demonstrated that, even when 
varying parameters in the model, the screening strategy is unlikely to result in an increase 
in costs.
 However, the net saving for the screening strategy in our cost analysis was with €51 
relatively small. One of the determinants for this finding is that in our clinical study patients 
carrying a DPYD variant were still at increased risk of developing severe treatment-related 
toxicity, compared to wild-type patients (39% versus 23%, p=0.001).11 The higher incidence 
of toxicity in DPYD variant allele carriers was mainly driven by carriers of the variants 
c.1236G>A and c.2846A>T. For these two variants a 25% dose reduction was applied in the 
study, which was concluded to be probably insufficient to reduce the incidence of toxicity to 
the background incidence in wild-type patients. 
 Our results are in line with four previous studies investigating costs of DPYD genotyping 
and toxicity.10,17 Deenen et al. previously confirmed that upfront screening for one DPYD 
variant (DPYD*2A) is cost-saving.10 Another study, by Cortejoso et al. investigated screening 
for three variants (DPYD*2A, c.2846A>T, c.1679T>G) and compared genotyping costs and 
costs for treating severe neutropenia in a retrospective analysis. Occurrence of severe 
neutropenia resulted in average costs for treatment for this side effect of €3,044 per patient 
(drug and hospitalization costs). Genotyping costs for the three DPYD variants were only 
€6.40 per patient (approximately 16 times less expensive than in our study). The authors 
calculated that DPYD genotyping would be cost-effective, provided that at least 2.1 cases of 
severe neutropenia per 1,000 treated patients are prevented by upfront genotyping of the 
three variants.17 This was, however, not validated in a prospective setting. 
 The third study, by Murphy et al., investigated the cost implications for reactive DPYD 
screening (i.e. screening patients for DPYD variants after experiencing severe toxicity) 
versus prospective screening.18 In a period of three years, all patients experiencing severe 
(grade ≥3) fluoropyrimidine-related toxicity in an Irish hospital were screened for four DPYD 
variants (DPYD*2A, c.2846A>T, c.1679T>G and c.1601G>A). Genotyping costs if prospective 
DPYD screening for all patients would have been performed were calculated. Total costs 
of hospitalization for five DPYD variant allele carriers (identified after experiencing severe 
toxicity) were €232,061, while prospectively testing would have cost in total €23,718 for the 
134 included patients (€177 per patient), showing that hospitalization costs are significantly 
higher than costs for prospective DPYD screening.18 The main difference between their study 
and our study was that the study by Murphy et al. did not collect data on the prospective 
DPYD screening strategy, but only on reactive DPYD screening. 
 The fourth study was a retrospective study as well, performed by Toffoli et al.19 Toxicity-
related costs on 550 colorectal cancer patients were investigated and genotyping of the 
same four variants as in our study was performed, but this was done retrospectively and not 
used for dose adjustments. This showed that average costs for treatment of toxicity were 
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higher in DPYD variant allele carriers (€2,972) than in non-carriers (€825), p<0.0001.19 
 To conclude, in addition to the important finding that upfront DPYD genotype-guided dose 
individualization is able to markedly increase patient safety, this study now confirms that 
this upfront DPYD screening strategy does not result in an increase in direct medical costs. 
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Prospective DPYD genotyping prevents severe fluoropyrimidine-induced toxicity 
by decreasing dosages in DPYD variant allele carriers. Fluoropyrimidine dosages in 
chemoradiation therapy (CRT) are lower compared to other fluoropyrimidine-containing 
regimens. Pharmacogenetic guidelines do not distinguish between regimens, leaving 
physicians in doubt to apply dose reductions. Our aim was to investigate severe toxicity in 
DPYD variant allele carriers receiving CRT.
 Medical records of 828 patients who received fluoropyrimidine-based CRT were reviewed 
from three centers. Severe (grade ≥3) toxicity in DPYD variant allele carriers receiving upfront 
fluoropyrimidine dose reductions according to pharmacogenetic dosing guidelines and 
DPYD variant allele carriers not receiving fluoropyrimidine dose reductions was compared 
with DPYD wild-type patients receiving standard dose of fluoropyrimidines in CRT. 
 DPYD variant allele carriers treated with standard dosages (N=34) showed an increased 
risk of severe gastrointestinal (adjusted OR: 2.58, 95% confidence interval [95%CI]: 
1.02─6.53, p=0.045) or severe haematological (adjusted OR: 4.19, 95%CI: 1.32─13.25, 
p=0.015) toxicity compared with wild-type patients (N=771). DPYD variant allele carriers who 
received dose reductions (N=22) showed a comparable frequency of severe gastrointestinal 
toxicity compared with wild-type patients, but more (not statistically significant) severe 
haematological toxicity. Hospitalisations for all DPYD variant allele carriers were comparable, 
independent of dose adjustments; however, the mean duration of hospitalisation was 
significantly shorter in the dose reduction group (p=0.010). 
 Standard fluoropyrimidine dosages in CRT resulted in an increased risk of severe toxicity in 
DPYD variant allele carriers. We advise to apply fluoropyrimidine dose reductions according 
to current guidelines in DPYD variant allele carriers starting CRT.
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Fluoropyrimidines, such as 5-fluorouracil (5-FU) and capecitabine, are the backbone of 
chemotherapy regimens for solid tumours such as colorectal and breast cancer.1-3 Since 
the 90’s, 5-FU has been in use in neoadjuvant chemoradiation therapy (CRT) for patients 
with stages 2-3 rectal cancer.4,5 Fluoropyrimidines affect nucleotide metabolism and inhibit 
the repair of radiation-induced DNA damage in patients and act as a radiation sensitiser.6 
Fluoropyrimidines in combination with radiotherapy are used at lower dosages than those 
in other treatment regimens. An example; for patients with advanced colorectal cancer 
capecitabine, dosages are usually 1,250 mg/m2 bid (twice daily) for two weeks followed 
by one week rest, repeated every three weeks.7 In combination with radiotherapy, a 
continuous regimen is preferred to optimise radio-sensitisation. The maximum tolerated 
dose of capecitabine was 825 mg/m2 bid for patients with rectal cancer.8,9 
 Adverse events are well known in fluoropyrimidine treatment and differ between 
treatment regimens. Severe (grade ≥3) side-effects in stage 3 or 4 colorectal cancer patients 
treated with capecitabine monotherapy dosed 1,250 mg/m2 bid in three-week cycles, 
were hand-foot syndrome (~18%), diarrhoea (~14%), stomatitis (~3%), vomiting (~3%) 
and neutropenia (~3%).10-12 Severe side-effects in locally advanced rectal cancer patients 
treated with CRT, including 825 mg/m2 capecitabine continuously for five weeks, were grade 
≥3 radiation dermatitis (~9%), diarrhoea (~2-7%), fatigue (~2%), neutropenia (~2%) and 
anaemia (~2%).13,14
 Over 80% of 5-FU is degraded into inactive metabolites by the key enzyme dihydropyrimidine 
dehydrogenase (DPD).15 DPD is encoded by the gene DPYD. DPD and variants in DPYD are 
associated with the onset of severe fluoropyrimidine-induced toxicity. To prevent severe 
fluoropyrimidine-induced toxicity prospective DPYD genotyping is increasingly used in 
clinical practice, followed by dose reductions in patients who carry a DPYD variant. For four 
variants (DPYD*2A, c.1905+1G>A, rs3918290; DPYD*13, c.1679T>G, rs55886062; c2846A>T, 
rs67376798; c.1236G>A/HapB3, rs56038477) individual dosing guidelines are currently 
given by the Dutch Pharmacogenetics Working Group and Clinical Pharmacogenetics 
Implementation Consortium.16,17 Dosing guidelines advise that DPYD variant allele carriers 
should receive a percentage of the standard dose, for example 50 or 75%, depending on 
the specific variant.18 These guidelines do not distinguish between treatment regimens in 
which different fluoropyrimidine dosages are given. Because fluoropyrimidine dosages in 
CRT regimens are lower than those in other treatment regimens, it is questioned if dose 
adjustments in dosing guidelines should be applied in patients receiving fluoropyrimidines 
in CRT. The objective of this study was to investigate the frequency of severe treatment-
related toxicity in DPYD variant allele carriers receiving reduced or standard fluoropyrimidine 
dosages in CRT, to determine whether dose reductions are required.
Methods
Study population
The study population consisted of three combined databases. All patients were treated with 
fluoropyrimidine-based CRT according to the various tumour types and were genotyped for 
the aforementioned four variants in DPYD. 
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At the Netherlands Cancer Institute (NKI), Amsterdam, the Netherlands, a prospective clinical 
trial was executed in which patients were prospectively genotyped for DPYD*2A followed 
by dose reductions of ≥50% in DPYD*2A carriers (NCT00838370).19 The trial was approved 
by the institutional review board (IRB) of all participating institutes, and all DPYD*2A 
carriers provided written informed consent before study registration. The patients were 
retrospectively genotyped for the three other variants (DPYD*13, c.2846A>T, c.1236G>A). A 
total of 497 patients received CRT and were selected for the present study. Two patients had 
missing genotypes and were excluded. Radiation dose in Gray (Gy) and fractions (Fr) given to 
the patient could be collected retrospectively for 425 patients. 
 At Leiden University Medical Center (LUMC), Leiden, the Netherlands, a retrospective 
database was created for the purpose of this study. The study was reviewed and approved 
by the IRB. All patients scheduled to start fluoropyrimidine-based CRT between April 2013 
and September 2017 were evaluated. In total, 253 patients started therapy. In April 2013, 
only DPYD*2A was genotyped; DPYD*13 and c.2846A>T were added to the genotyping 
panel in October, and c.1236G>A was added in May 2014. Some patients were prospectively 
genotyped for DPYD*2A alone (N=20) or DPYD*2A, DPYD*13 and c.2846A>T (N=35). Missing 
genotypes were determined retrospectively. Thirteen patients could not be genotyped and 
were excluded. Data were collected from the electronic patient files. Ten percent of the data 
was checked by an independent data manager. Ten percent of toxicity data was checked by 
an oncologist and radiation oncologist. Limited discrepancies were discussed and similar 
errors were searched and corrected. 
 At CRO-Aviano National Cancer Institute, Northern Italy, 207 patients were enrolled in a 
study from December 1993 to April 2016. All procedures were reviewed and approved by 
the IRB and patients signed written informed consent for research purposes. Ninety-five 
patients were included in the present study of whom additional chemotherapy treatment 
details could be collected. Sixteen patients were prospectively tested for DPYD*2A, DPYD*13 
and c.2846A>T, and 79 patients were tested after start of treatment. Missing genotypes of 
c.1236G>A were determined retrospectively. Two patients had incomplete genotype data 
and were excluded.  
Groups
All included patients in the combined database were grouped into wild-types receiving 
standard fluoropyrimidine dosages in CRT, DPYD variant allele carriers receiving standard 
fluoropyrimidine dosages in CRT or DPYD variant allele carriers receiving upfront reduced 
fluoropyrimidine dosages in CRT. DPYD variant allele carriers are heterozygous or homozygous 
for a DPYD variant (DPYD*2A, DPYD*13, c.2846A>T or c.1236G>A). Initial dose reductions 
(25 or 50%) were applied corresponding to pharmacogenetic guidelines.16,17
Toxicity
Treatment-related toxicity data were scored prospectively according to the National Cancer 
Institute common terminology criteria for adverse events (CTC-AE) v3.020 for the NKI and 
CRO databases, and retrospectively using CTC-AE v4.0321 for the LUMC database. It was 
not possible to determine missing toxicities retrospectively. In CRT a continuous regimen 
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is used, and there are no cycles; therefore, the highest toxicity grade over the entire 
treatment period was used. Gastrointestinal toxicity included diarrhoea, mucositis, nausea 
and vomiting (nausea or vomiting were not scored by all databases). Haematological toxicity 
included leukopenia, thrombocytopenia and neutropenia. 
Statistics
To study the association between study groups and severe gastrointestinal or haematological 
toxicity multivariable logistic regression models with grouped diagnosis as covariate were 
estimated. Gastrointestinal and haematological toxicity outcomes were dichotomised 
(grades 0─2 versus grades 3─5). Diagnoses were grouped according to tumour location, 
either pelvic or non-pelvic region (grouped diagnosis). Differences in baseline characteristics 
between study groups were tested using Pearson Chi-square or Kruskal Wallis tests. Owing 
to the retrospective character of this study, there was no protocol on how to deal with 
additional dose adjustments during treatment in the analysis. A Mann–Whitney U test was 
applied to compare duration of hospitalisation between DPYD variant allele carriers who 
received dose reductions or standard dosages. P-values of <0.05 were considered statistically 
significant. Statistical analyses were performed using SPSS (v23, Chicago, IL, USA).
Results
Study population
The combined database of 828 patients was divided into three study groups. Seven hundred 
seventy-one patients were wild-types, 34 patients were DPYD variant allele carriers who 
received standard fluoropyrimidine dosages in CRT and 23 patients were DPYD variant allele 
carriers who received upfront reduced (50 or 75%) fluoropyrimidine dosages in CRT. Baseline 
characteristics per database and study group are shown in Tables 1 and 2. Each original 
database included patients in each study group, described in Table 2. Cancer of the rectum 
was the most present in 71.7% of the patients. 86.6% of the patients received capecitabine. 
Baseline characteristics between study groups showed no significant differences. 
 In one DPYD *2A carrier, dose reductions were applied during treatment but not at the 
first drug administration. In three DPYD*2A carriers initial reduced dosages were increased 
during treatment. Three out of four patients had a total dose intensity of approximately 50% 
(according to current dosing guidelines). The fourth patient was excluded from statistical 
analyses. These four patients were described in Table 2.
Toxicity
Toxicity of patients from this study treated with comparable treatment schedules was 
similar to toxicity of rectal cancer patients described in literature (Supplementary Table 1). 
Differences in toxicity between databases were observed. Grade 2 radiation dermatitis and 
grade 2 ‘other toxicity’ were very high in the LUMC and CRO database, respectively, resulting 
in a high overall toxicity percentage in these databases (Supplementary Table 2). Toxicity 
separated per study group is shown in Table 3. 
 Percentages of severe gastrointestinal and haematological toxicity were 8 and 2.9% for 
wild-types, 17.6 and 11.8% for DPYD variant allele carriers treated with a standard dose, 
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Sex, male 283 (57.2) 122 (50.8) 60 (64.5) 465 (56.2)
Age, median [range] 62 [32-86] 65 [23-86] 63 [33-88] 63 [23-88]
BSA, median [range] 1.9 [1.38-2.71] 1.89 [1.39-2.54] 1.85 [1.4-2.2] 1.9 [1.38-2.71]
Diagnosis 
     Rectum cancer
     Anus cancer
     Vulva/vagina cancer
     Pancreas cancer
     Upper GI cancer
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50 [7.2-78]c  
25 [4-39]e
DPYD carriers total
     DPYD*2A
     DPYD*13
     c.2846A>T


























a Included are cancers of the colon sigmoidal, rectum, anus, vulva, vagina, cervix, uterus, endometrium, 
bladder, urethra, prostate and double tumours with one tumour in the pelvic area;
b Included are cancers of the breast, stomach, oesophagus, pancreas, skin, tongue;
c Seventy-one patients have missing data;
d One patient has missing data;
e Seventy-two patients have missing data.
Abbreviations: BSA: body surface area; CRO: Aviano National Cancer Institute; DB: database; DPYD: 
gene encoding dihydropyrimidine dehydrogenase; 5-FU: 5-fluorouracil; Fr: fractions; GI: gastro-
intestinal tract; Gy: gray; LUMC: Leiden University Medical Center; NKI: Netherlands Cancer Institute.
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and 9.1 and 9.1% for DPYD variant allele carriers who received a reduced dose, respectively 
(Figure 1, Table 3). DPYD variant allele carriers treated with a standard dose had a significantly 
increased risk to develop severe gastrointestinal toxicity (adjusted OR: 2.58, 95% confidence 
interval [95%CI]: 1.023─6.534, p=0.045) and severe haematological toxicity (adjusted 
OR:4.19, 95%CI: 1.323─13.253, p=0.015) compared with DPYD wild-type patients treated 
with standard dose. No statistical significant difference was found for the risk of developing 
severe gastrointestinal toxicity (adjusted OR: 1.10, 95%CI: 0.250─4.804, p=0.904) or severe 
haematological toxicity (adjusted OR: 3.88, 95%CI: 0.837─18.016, p=0.083) in DPYD variant 
allele carriers who received an initially reduced dose compared with wild-types. Grouped 
diagnosis was not significantly associated with the development of severe gastrointestinal 
toxicity (adjusted OR: 0.26, 95%CI: 0.061─1.069), while it was for severe haematological 
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Figure 1. Percentages of severe toxicity
Shown are the percentages of severe gastrointestinal and severe haematological toxicity of DPYD 
variant allele carriers with and without fluoropyrimidine dose reductions and wild-type patients in 
chemoradiation treatment. 
Abbreviations: OR: adjusted odds ratio; DPYD: gene encoding dihydropyrimidine dehydrogenase; GI= 
gastrointestinal; HEM: haematological.
Included in Table 3 are any changes applied in chemotherapy during treatment due to ad-
verse events, such as dose interruptions. Compared with wild-type patients, DPYD variant 
allele carriers had more dose reductions during treatment, stopped treatment prematurely 
and were hospitalised more often, regardless of any received dose reductions. However, 
the mean duration of hospitalisation of DPYD variant allele carriers who received a dose re-
duction was notably shorter (4 days) compared with the DPYD variant allele carriers treated 
with a standard dose (23 days, p=0.010).
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Table 2. Baseline characteristics per study group
No significant differences between study groups in baseline characteristics were found. Differences 
in median dose intensity, treatment date and DPYD carriers were not tested. All original databases 
were able to include patients in each study group. Of the 34 DPYD variant allele carriers who received 
standard fluoropyrimidine dosages in CRT, 29 patients were included from NKI, three patients from 
LUMC (2x DPYD*2A, 1x c.1236G>A) and two c.1236G>A carriers from the CRO database. Of the 23 
DPYD variant allele carriers who received upfront dose reductions in CRT, 15 patients were included 
from LUMC, seven DPYD*2A carriers from NKI and one c.2846A>T carrier from the CRO database. 
Characteristics WT + standarda 
(N=771)
N (%)
DPYD + standardb 
(N=34) 
N (%)
DPYD + reducedc 
(N=23) 
N (%)
Sex, male 432 (56) 20 (58.8) 13 (56.5)
Age, median [range] 63 [23-88] 64 [45-79] 66 [50-78]
BSA, median [range] 1.89 [1.38-2.71] 1.93 [1.51-2.34] 2 [1.50-2.44]
Diagnosis
     Rectum cancer
     Anus cancer
     Vulva/vagina cancer
     Pancreas cancer
     Upper GI cancer
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Median dose intensityf 97% 91% 61%









25 [23-39]   
DPYD carriers
     DPYD*2A
     DPYD*13
     c.2846A>T
     c.1236G>A

















a Wild-type patients receiving standard fluoropyrimidine dosages in chemoradiation therapy;
b DPYD variant allele carriers receiving standard fluoropyrimidine dosages in chemoradiation therapy;
c DPYD variant allele carriers receiving initially reduced fluoropyrimidine dosages according to current 
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guidelines compared with standard fluoropyrimidine dosages used in chemoradiation therapy. One 
DPYD*2A variant carrier started intravenous 5-FU therapy at a 100% dose before the genotype result 
became available. When the genotype was known, the administration of 5-FU was prematurely 
stopped after 2 instead of 4 days. In the second cycle a 50% dose reduction over 4 days was applied. 
The overall dose intensity of this patient was 49%. In three DPYD*2A carriers initial reduced dosages 
were increased during treatment. One patient was included in the clinical trial (NCT00838370) before 
existence of dosing guidelines and started with 30% of the standard total dose, which was increased 
to 46%. One patient went from 50 to 60% of the standard total dose and for another patient the dose 
was increased from 50 to 83%. The latter patient was excluded from statistical analyses, due to the 
substantial dose increase. The c.2846A>T variant carrier who received a dose reduction, was treated 
with a 60% dose;
d Included are cancers of the colon sigmoidal, rectum, anus, vulva, vagina, cervix, uterus, endometrium, 
bladder, urethra, prostate and double tumours with one tumour in the pelvic area; 
e Included are cancers of the breast, stomach, oesophagus, pancreas, skin and tongue;
f Dose intensity was calculated by dividing the received amount of mg of chemotherapy by the initial 
scheduled amount of mg of chemotherapy. 
Abbreviations: BSA: body surface area; DPYD: gene encoding dihydropyrimidine dehydrogenase; 5-FU: 
5-fluorouracil; Fr: fractions; GI: gastro-intestinal tract; Gy: gray; WT: wild-type patients.
Table 3. Toxicity of patients per study group
Shown per study group are percentages of several types of (grouped) toxicity after chemoradiation 
therapy and actions following toxicity. P-values are shown for executed statistical tests.
Type of event WT + standarda 
(N=771) N (%)
DPYD + standardb 
(N=34) N (%)
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Type of event WT + standarda 
(N=771) N (%)
DPYD + standardb 
(N=34) N (%)
DPYD + reducedc 
(N=22) N (%)
Grade 2 Cardio toxicity















Grouped type of events
Grade 2 GI toxicityf




6 (17.6)     p=0.045g
6 (27.3)
2 (9.1)    p=0.904g
Grade 2 HEM toxicityh




4 (11.8)     p=0.015g
2 (9.1)
2 (9.1)    p=0.083g
Grade 2 Overall toxicityi 

























Treatment-related hospitalization 60 (7.8) 6 (17.6) 4 (18.2)
Days of hospitalization, mean 
[range]
13 [1─76] 23 [6─36] 4 [2─5]    p=0.010m
a Wild-type patients receiving standard fluoropyrimidine dosages in chemoradiation therapy;
b DPYD variant allele carriers receiving standard fluoropyrimidine dosages in chemoradiation therapy;
c DPYD variant allele carriers receiving initially reduced fluoropyrimidine dosages according to current 
guidelines compared with standard fluoropyrimidine dosages used in chemoradiation therapy;
d   Data of 332 patients in total, data of 5 patients in the group of DPYD variant allele carriers treated with a stand-
ard dose  and data of 15 patients in the group of DPYD variant allele carriers who received dose reductions; 
e     Data of 239 patients in total, data of 3 patients in the group of DPYD variant allele carriers treated with a stand-
ard dose and data of 14 patients in the group of DPYD variant allele carriers who received dose reductions; 
f GI toxicity includes diarrhoea, mucositis, nausea, vomiting;
g P-values shown are compared with wild-type patients;
h HEM toxicity includes neutropenia, thrombocytopenia, leukocytopenia;
i Overall toxicity includes diarrhoea, mucositis, nausea, vomiting, neutropenia, thrombocytopenia, 
leukocytopenia, anaemia, radiation dermatitis, HFS, cardio toxicity, fatigue and other toxicity;
j Dosages were reduced from 100 to 60-77%;
k Dosages were reduced from 70 to 45% and 100 to 50% (applying dosing guidelines 2 days after start 
of therapy); 
l Dosages were increased from 30 to 46% and from 50 to 60%;
m P-values shown are compared with DPYD variant allele carriers who received a standard dose. 
Abbreviations:  DPYD: gene encoding dihydropyrimidine dehydrogenase; GI: gastrointestinal; HFS: 
hand-foot syndrome; HEM: haematological; WT: wild-type patients.




To illustrate the importance of dose reductions in DPYD variant allele carriers, we have 
shown the course of one DPYD*2A carrier in Figure 2. This patient was excluded from the 
statistical analyses due to a substantially increased dose during treatment. Being one of 
the first DPYD variant allele carriers who received 50% dosed CRT, it was decided that the 
fluoropyrimidine dose would be titrated up to 100% if the patient would have no side-effects 
after two weeks. However, diarrhoea grade 1─2 was present, and the dose was increased to 
83%. After four weeks, severe toxicity (diarrhoea, vomiting, nausea grade 3 and dermatitis 
grade 2) occurred and chemotherapy, and later radiotherapy, was stopped prematurely. The 
patient was hospitalised for 31 days, of which three days at the intensive care unit. After 
hospitalisation, the patient had to recover completely from toxicity for 39 days in a nursing 
home (rehabilitation). Although it cannot be excluded that toxicity would have evolved in 
the severity as was now shown at an 83% dose level when treated entirely with a 50% dose 
level, it is clear that the dose increase was most likely a reason for the development of 
severe toxicity.  
Figure 2. Course of treatment and toxicity
Shown is the course of an ideal treatment, and the treatment and toxicity for one patient (#1). The 
patient is a carrier of the DPYD*2A variant and started therapy on a 50% dose. After two weeks, 
the dose was increased to 83%. Thereafter, the patient developed severe toxicity, and therapy was 
discontinued. The patient was hospitalised for 31 days (including three days at the intensive care unit) 
and had to recover completely from toxicity for 39 days in a nursing home (rehabilitation). 
Abbreviations: CT: chemotherapy; RT: radiotherapy. 
Discussion
Fluoropyrimidine dosages are lower in CRT compared with other fluoropyrimidine treatment 
regimens, and it is unclear if pharmacogenetic dose adjustments should be made for DPYD 
variant allele carriers receiving CRT. Dose titration in CRT is more difficult compared with other 
treatment regimens where the schedule contains so-called stop weeks. To our knowledge, 
this is the first study specifically investigating DPYD pharmacogenetics of fluoropyrimidines 
in CRT. DPYD variant allele carriers treated with standard fluoropyrimidine dosages in CRT 
showed a significantly increased risk to develop severe toxicity compared with wild-type 
patients. This indicates the need for pharmacogenetic dose reductions in CRT, despite the 
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lower standard dosages. 
 Although over 800 patients are considered, the number of patients with a DPYD variant 
remains limited due to the low prevalence of DPYD variants. We were unable to show 
that the risk of toxicity in DPYD variant allele carriers who received dose reductions was 
equivalent to the risk of wild-type patients. Also, 85% of the DPYD variant allele carriers 
treated with a standard dose were carriers of the c.1236G>A and c.2846A>T variants. 
DPYD*2A and DPYD*13 carriers have a higher risk of toxicity when treated with standard 
dosages compared with c.1236G>A and c.2846A>T carriers. Therefore, it is possible that 
more toxicity could have occurred in this group if DPYD variants would have been equally 
distributed, increasing the difference in toxicity compared with the other study groups. 
Moreover, in the DPYD group with initial dose reductions, DPYD variants and corresponding 
dose reductions (25 versus 50%) were equally distributed. 
 Noteworthy, the number of hospitalisations due to toxicity was similar in both groups 
of DPYD variant allele carriers, yet the duration of hospitalisation was significantly shorter 
in DPYD variant allele carriers treated with a reduced fluoropyrimidine dose. A possible 
explanation for this could be that treating physicians are alarmed of a potentially increased 
risk of toxicity because of DPD deficiency and more rapidly decide to hospitalise a patient 
in response to signs of potential toxicity. A second explanation is that DPYD variant allele 
carriers who received dose reductions recovered faster of toxicity. 
 In two DPYD variant allele carriers who received initially reduced dosages and did 
not experience (severe) toxicity, the dose was increased during treatment. This shows 
that physicians might still have fear of underdosing patients and reducing efficacy of the 
treatment. 
 Grouped diagnosis was significantly associated to severe haematological toxicity, with 
more severe toxicity in pelvic malignancies. A possible explanation may be that more bone 
marrow is exposed to radiation in the pelvic area compared with other areas, increasing the 
chance of myelosuppression. 
 With over 800 patients included, this study provides a large amount of toxicity data of 
wild-type patients and DPYD variant allele carriers receiving CRT. However, our study has 
several limitations. First, three databases were combined and were partly retrospective, 
possibly introducing bias. However, each database included patients in each study group, 
limiting bias. General differences in scoring toxicity per database could exist; however, 
criteria for toxicity grades are well marked and should therefore be limited. One database 
used the new version of CTC-AE; however, updates did not influence the grading of toxicity 
of interest for this study. 
 Second, not all databases contained the full toxicity spectrum of interest in this study 
(e.g. nausea, vomiting, radiation dermatitis, fatigue); therefore, overall toxicity consisted of 
different toxicities per original database and was not used as a primary end-point. 
And third, pharmacokinetic sampling was not executed in this study, which could have shown 
that dose reductions in DPYD variant allele carriers result in equivalent fluoropyrimidine 
metabolite plasma levels compared with wild-types treated with standard dosages, as was 
done previously for DPYD*2A variant allele carriers.19 




Our study is the first to show that DPYD variant allele carriers have an increased risk of 
severe toxicity when treated with standard dosages in CRT, indicating that dose reductions 
are necessary in these patients as well. The present study provides the only evidence at 
this time, and based on these data we advise that fluoropyrimidine dose reductions 
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Supplementary table 1. Toxicity of study patients compared to patients from literature
Selected studies from literature had relatively large patient cohorts and reported toxicity extensively. 






















Grade 2 Radiation dermatitisb









































a Selected from this study are all patients with a similar capecitabine schedule to referenced locally 
advanced rectal patients from literature (825 mg/m2 twice daily, for 5 weeks with or without 
weekends);
b Data of 266 patients;
c Data of 172 patients.




Supplementary table 2. Toxicity of patients from three original databases and of the combined 
database (total)
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Grade 2 Cardio toxicity



















Grade 2 Other toxicityc









Grouped type of events
Grade 2 GI toxicityd









Grade 2 HEM toxicitye









Grade 2 Overall toxicityf









a Data of 332 patients;
b Data of 239 patients;
c Other toxicity includes anal pain, chronic enteritis, cystitis (genitourinary tract), dizziness, dysgeusia, 
enterocolitis, fever, headache, multi-organ failure, papulopustular rash, proctitis, radio-enteritis, skin 
hyperpigmentation, stomatitis, thromboembolic event, ulcer of the small intestine;
d GI toxicity includes diarrhoea, mucositis, nausea, vomiting;
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e HEM toxicity includes neutropenia, thrombocytopenia, leukocytopenia;
f Overall toxicity includes diarrhoea, mucositis, nausea, vomiting, neutropenia, thrombocytopenia, 
leukocytopenia, anaemia, radiation dermatitis, HFS, cardio toxicity, fatigue and other toxicity.
Abbreviations: CRO: Aviano National Cancer Institute; DB: database; GI: gastrointestinal; HFS: hand-
foot syndrome; HEM: haematological; LUMC: Leiden University Medical Center; ND: not defined in 
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treated patients
Pharmacogenomics. 2016;17(7):721-9
Carin A.T.C. Lunenburg*, Maurice C. van Staveren*, Hans Gelderblom, 





Fluoropyrimidines are commonly used anti-cancer drugs, but lead to severe toxicity in 
10─30% of patients. Prospective DPYD screening identifies patients at risk for toxicity 
and leads to a safer treatment with fluoropyrimidines. This study evaluated the routinely 
application of prospective DPYD screening at the Leiden University Medical Center. 
 Prospective DPYD screening as part of routine patient care was evaluated by 
retrospectively screening databases and patient files to determine genotype, treatment, 
dose recommendations and dose adjustments. 
 86,9% of all patients with a first fluoropyrimidine prescription were screened. Fourteen 
out of 275 patients (5.1%) carried a DPYD variant and received a 25─50% dose reduction 
recommendation. None of the patients with a DPYD variant treated with a reduced dose 
developed toxicities. 
 Prospective DPYD screening can be implemented successfully in a real world clinical 
setting, is well accepted by physicians and results in low toxicity. 
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Fluoropyrimidines such as 5-fluorouracil (5-FU) and its oral prodrug capecitabine are the 
cornerstone anticancer drugs for several types of cancer such as colorectal cancer, head–
neck cancer and breast cancer. Approximately 10–30% of the patients receiving 5-FU or 
capecitabine experience severe (grade ≥3) toxicity, such as diarrhea, mucositis and hand-foot 
syndrome.1 5-FU is extensively metabolized (>80%) by the liver enzyme dihydropyrimidine 
dehydrogenase (DPD). DPD is encoded by the gene DPYD for which more than 160 genetic 
variants are known, some of them being pathogenic by reducing enzyme function.2,3 There 
is a strong correlation between reduced DPD activity and increased risk for severe and 
potentially lethal toxicity following treatment with a normal dose of 5-FU.4-7 Toxicity occurred 
in 73% of DPYD*2A carriers, compared with 23% of wild-types.8 Several meta-analyses 
have consistently shown that DPYD*2A, c.2846A>T, DPYD*13 and c.1236C>G/HapB3 are 
associated with toxicity.1,6,9 Although the sensitivity of DPYD genotyping is low (<14.5% for 
DPYD*2A and c.2846A>T combined), prospective screening for genetic variants in DPYD 
is a well-known strategy to detect patients who have reduced DPD enzyme activity (DPD 
deficient).8,10,11 Patients with no or reduced DPD enzyme activity can be treated more safely 
when applying a 25–50% dose reduction of 5-FU or capecitabine, or using an alternative 
drug.10,12,13 Recently it was shown that prospective screening for DPYD*2A followed by a 50% 
dose reduction significantly reduces the number of severe toxicities and is cost-effective.8 
Several pharmacogenetic guidelines are available that provide dose recommendations 
when a reduced function DPYD variant is present. The pharmacogenetic guidelines of the 
Dutch Pharmacogenetic Working Group (DPWG), recommend a 25–50% dose reduction of 
5-FU or capecitabine for the first treatment cycle followed by dose titration guided upon 
toxicity during subsequent cycles for patients with a variant in DPYD (DPYD*2A, DPYD*13, 
c.2846A>T or c.1236G>A). A minimum of 50% reduction or alternative therapy is advised 
for homozygous patients, depending on the variant.14 The Clinical Pharmacogenetics 
Implementation Consortium (CPIC)15,16 recommends a 50% dose reduction of 5-FU or 
capecitabine for patients with DPYD*2A, DPYD*13 and c.2846A>T and alternative therapy 
for patients who are homozygous for these variants. While these guidelines are very useful 
for dose adjustments in patients with a genetic variant, they do not advocate prospective 
DPYD testing prior to initiation of therapy. 
 At Leiden University Medical Center (LUMC; Leiden, The Netherlands), a routine DPYD 
screening program prior to prescribing 5-FU or capecitabine was initiated in April 2013. In this 
retrospective study we evaluated the physician’s acceptance of prospective DPYD screening 
for patients who were prescribed 5-FU or capecitabine in LUMC and the adherence of the 
recommended dose reduction. 
Methods
Setting
At LUMC all patients with an indication for a fluoropyrimidine containing therapy were 
routinely screened for DPYD variants by the laboratory of the department of Clinical 
Pharmacy and Toxicology (CPT) using two independent techniques (TaqMan® Genotyping 
SNP assay from Thermo Fisher Scientific [MA USA], and a home-brew pyrosequencing (PSQ), 
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described previously).17 Within LUMC the Electronic Medication Record (EMR) system EZIS 
(version 5.2, Chipsoft) is used, which can be consulted by physicians, pharmacists and nurses. 
DPYD genotyping results are communicated electronically by the responsible pharmacist 
into the EMR and are visible for other users of the EMR. 
 The prospective screening program was initiated on 15 April 2013. During a kick-off 
meeting attended by medical oncologists and fellows, the staff was informed and agreed 
on the prospective program. New medical oncologists and fellows were informed about 
the prospective screening program during the regular introduction program for new staff 
members. Genotyping was performed three times per week (Monday, Wednesday and 
Friday) in order to minimize the lag time between sampling and test. This resulted in a 
turnaround time of 2 days, allowing rapid start of treatment if needed. Ethical approval by 
the Institutional Review Board of LUMC was not required for the current study as it evaluates 
standard care. Patient data from the EMR was handled following the Codes of Proper Use 
and Proper Conduct in the Self-Regulatory Codes of Conduct.18
Study end points
Three study end points were evaluated to determine the successfulness of the screening 
program that was introduced at LUMC. We evaluated: 
- The ‘implementation’, in other words, requests of the DPYD tests as standard care in 
daily practice;
- The proportion of test results with a dose recommendation provided by the pharmacist;
- The follow-up of the dose recommendations by oncologists, calculated as the number 
of follow-ups of dose recommendations by prescribers, excluding the patients in which 
a follow-up was not possible (e.g., no therapy).
Study procedures
The implementation, or routinely application of the prospective (pretreatment) DPYD 
screening in daily practice was evaluated by determining the proportion of patients who 
were screened for DPYD variants when an incident prescription for 5-FU or capecitabine was 
given. The data were extracted from two electronic databases. The first database contains 
data of all patients who are genotyped for DPYD variants. The second database (EMR EZIS) 
contains individual patient medical records. This system is also used by oncologists to 
electronically prescribe 5-FU and capecitabine. Prescription data prior to the start of the 
study was studied as well, to ascertain that 5-FU or capecitabine prescription was indeed 
the first prescription for the patient. The patient identification number was used to connect 
data from both databases. Discrepancies between information in the queried databases 
were resolved by manually checking the individual electronic patient records to identify the 
reason of their absence in one of the two searches. After connecting the data from both 
databases, all patient data were anonymized. All manual changes (additional information, 
removal of duplicates, among others) to the queries were double checked by the two first 
authors (CL and MvS). 
 To evaluate the follow up of the recommended dose reductions by the oncologists, 
medical records of patients carrying a variant in DPYD were inventoried as to determine 
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if the oncologist followed the dose advice. The genotyping data of the laboratory of CPT 
was used to determine the patients carrying a DPYD variant. Prospective execution of the 
genotyping could be determined by comparing the genotyping date and start date of the 
therapy. Regular drug regimens and notations of dose reductions in the medical records 
were searched to check applied dose reductions.
 After completion of the study, an explorative analysis was executed in order to describe 
the course of toxicity in relation to the provided dose recommendations. In order to perform 
this analysis, toxicity information regarding the 5-FU or capecitabine therapy was retrieved 
from the EMR for patients with a DPYD variant. Toxicity was scored by the oncologists using 
the National Cancer Institute common terminology criteria for adverse events (CTC-AE), 
version 4.03.19
Results
The implementation of the prospective screening program for DPYD 
The prospective DPYD screening program was implemented on 15 April 2013 (study start 
date) at LUMC. From this date until 13 December 2014 (study end date) 540 patients 
were genotyped for DPYD variants at LUMC. Initially, patients were screened only for the 
presence of the DPYD*2A variant. Later on DPYD*13, c.2846A>T and c.1236G>A were added 
to the DPYD screening. An overview is shown in Table 1. After removal of duplicate or invalid 
records, 529 evaluable genotyped patients remained. Of these 529 patients, 275 patients 
were patients treated at the LUMC and 254 patients were treated at other hospitals, but 
genotyped as a service provided by the department of CPT of the LUMC. The dose reductions 
that were advised for each individual DPYD variant are displayed in Table 1.
Table 1. Recommended reductions of initial 5-fluorouracil or capecitabine dose
Advice given by CPIC and DPWG guidelines at the time the variant was added to the routine screening.
DPYD variant Initial dose reduction 
(%)
Inclusion in screening 
program
Patients screened
DPYD*2A (c.1905+1G>A) 50 April 15th, 2013 529
DPYD*13 (c.1679T>G) 50 October 10th, 2013 440
c.2846A>T 50  25a October 10th, 2013 440
c.1236G>A 25 May 28th, 2014 254
a The dose reduction advice for c.2846A>T has been updated to 25% in February 2015.
A total of 2,498 records of 5-FU or capecitabine prescriptions prior to 31 December 2014 
were found. After removal of duplicates, invalid records (e.g., incomplete data) or patients 
not meeting eligibility criteria (e.g., prescription prior to April 2013), 337 patients remained 
who were prescribed 5-FU (16%) or capecitabine (84%) for the first time at LUMC within the 
study period. 
 Genotyped patients were compared with patients who were prescribed 5-FU or 
capecitabine, resulting in 236 matching patients. Thirty-nine patients were genotyped for 
DPYD, but were not prescribed 5-FU or capecitabine. Also, 101 patients were prescribed 
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5-FU or capecitabine, but were not genotyped for DPYD variants (Figure 1). 
 Two patients, who received 5-FU or capecitabine and were genotyped, were excluded 
because their medical records revealed they had received 5-FU or capecitabine prior to 15 
April 2013. Of the 39 patients who were genotyped without receiving 5-FU or capecitabine 
therapy, 33 patients eventually did not start their therapy, although there was an intention to 
treat at the time of requesting the screening test. Six patients started their therapy after 31 
December 2014 and were therefore not identified by the search. Of the 101 patients with a 
5-FU or capecitabine prescription and no DPYD-genotyping record, the medical records were 
screened resulting in a legitimate reason not to genotype in 60 cases (Table 2). Legitimate 
reasons included; any notes on prior treatment with 5-FU or capecitabine (e.g., outside 
LUMC) or invalid patient files (e.g., no medical dossier found for the oncology department). 
For 41 patients who had a prescription for newly 5-FU or capecitabine no reason was found 
to neglect genotyping. After data cleaning, 314 patients with a newly 5-FU or capecitabine 
prescription remained in the dataset and 273 of these patients were genotyped as depicted 
in Figure 1. The clinical acceptance of the prospective DPYD screening program is displayed 
as percentage per month in Figure 2. The average clinical acceptance was 86.9%. 
Figure 1. Patient selection
Flowchart following the results from the two searches. Patients could be both genotyped and 
prescribed 5-FU or capecitabine, or only genotyped, or only prescribed 5-FU or capecitabine. If the 
intention to treat was present, patients should have been genotyped and these patients are ‘eligible 
for evaluation’.
a These two patients were excluded because their medical records revealed they had received 5-FU or 
capecitabine prior to April 15th 2013;
b Legitimate reasons were: e.g., any notes on prior treatment with 5-FU or capecitabine (e.g., outside 
LUMC) or invalid patient files (e.g., no medical dossier found for the oncology department).
Abbreviations: 5-FU: 5-fluorouracil, CAP: capecitabine.
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Table 2. Excluded patients
Patients (N=60) with legitimate reasons not to screen were excluded from analysis.
Patients (N) Reason not to perform DPYD genotyping
8 5-FU or CAP therapy started just prior to the start date of 15 April 2013
30 5-FU or CAP was used before April 2013 without problems and would start again 
after 15 April 2013 
20 No medical dossier at the Medical Oncology department was found, therefore the 
patient was not treated at the LUMC
2 These dossiers were fake patients used for education purposes







































































































































Intention to start Genotyping Percentage
Figure 2. Proportion of eligible patients that were genotyped
The figure shows the eligible patients for evaluation per month in actual patient numbers. If the 
intention to treat with 5-FU or capecitabine was present, patients were eligible. Also the actual 
patient numbers of the genotyped patients per month are shown and the calculated percentage which 
represents the clinical acceptance, or how well implemented the prospective DPYD screening is.
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Table 3. DPYD variants
DPYD variant SNPs (N) Tested patients (N) LUMC (%) Literature (%) Ref.
DPYD*2A (c.1905+1G>A) 6 275 2.2 ~1.0–1.8 10,20
DPYD*13 (c.1679T>G) 0 214 0 ~0.1 12
c.2846A>T 1 214 0.5 ~1.0–1.4 10,12
c.1236G>A 8 109 7.3 ~2.6–4.9 10,21
Total 15 (N=14) 275 5.1 4.7–8.2
DPYD variants found in LUMC patients and these numbers compared with frequencies in the literature. 
The follow-up of the dose recommendations by oncologists
Dose reduction was advised after the first administration of 5-FU or capecitabine (post-
dose) for two patients. The medical record of the first patient showed that the initial 
screening result became available after the start of therapy. Dose adjustments could not be 
applied, toxicity occurred and the advised dose reduction was applied in the second cycle 
(Table 4, patient 12). The other patient was screened after start of therapy, but stopped 
therapy completely due to toxicity, thus applying a dose reduction was not applicable. For 
this patient the reason not to screen prospectively was absent in the medical record (Table 
4, patient 2). 
 For eleven patients a dose reduction was recommended prior to the start of therapy 
(prospective). This resulted in an initial dose reduction in eight of 11 patients. For one patient 
the recommend dose reduction was not applied and full dose was given (Table 4, patient 
13). In two patients the recommended dose reduction could not be applied since they did 
not start therapy. One patient did not start therapy due to renal failure and the presence 
of a DPYD variant (Table 4, patient 14), and one patient refused to start therapy (Table 4, 
patient 5). Also one patient was genotyped prospectively, but received a recommendation 
for phenotyping due to compound heterozygosity (Table 4, patient 9). This patient started 
treatment with a 50% reduced dose at the oncologists discretion. An overview of the above 
mentioned data are displayed in Table 4. The adherence to the dose recommendations (pre- 
and post-dose) is 90% (9 out of 10).
Analysis of results on clinical outcomes 
The explorative analysis showed that the prospective dose recommendations given, 
resulted in initial dose reductions in eight patients. None of these eight patients developed 
severe toxicity (grade ≥3) during the first cycle. After the first or second cycle it was possible 
to increase the dosages, guided by toxicity. Dosages were increased in four patients (from 
50% up to 60, 80 and 100%, and from 75 to 100%, respectively, all receiving capecitabine). 
However, this led to the development of severe toxicity in two DPYD*2A carrying patients 
(80% capecitabine led to diarrhea grade 3 followed by 31 days of hospitalization and 100% 
capecitabine led to hand-foot syndrome grade 3). Toxicity data can be found in Table 4. 
 In one patient with a DPYD*2A variant who received capecitabine in combination with 
radiotherapy, the dose recommendation was not followed by the physician and this patient 
experienced diarrhea (grade 4), enteritis and leukopenia, for which hospitalization of 18 
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days was required and capecitabine therapy was permanently terminated (Table 4, patient 
13). 
Discussion
In this study, the successfulness of routine application of a prospective DPYD screening 
program followed by pharmacogenetically guided dose recommendations was studied. 
The percentage of patients in which screening was performed was relatively high: 86.9% of 
all eligible (newly prescribed 5-FU or capecitabine) patients. In the study period, 13.1% of 
the patients were not screened prior to receiving 5-FU or capecitabine therapy, which on 
average comes down to one patient per month. Follow-up of dose recommendations given 
by the pharmacist were applied in all cases except one, resulting in a high acceptance.
 Our study has several limitations. Due to the retrospective design of our study, available 
data may not always have been fully complete. For example for some patients, it was not 
possible to retrieve why DPYD screening was not requested or whether a patient actually 
started fluoropyrimidine therapy. In addition, the study was performed with data obtained 
in a real world clinical setting instead of a regulated and controlled case report form. We 
had to manually check patient files to obtain specific information and not all physicians may 
have systematically annotated CTC-AE grading continuously to describe toxicity. Due to the 
low number of DPYD variant carriers our study was not powered to formally test the effect 
of DPYD screening on fluoropyrimidine-induced toxicity and only explorative analyses could 
be performed.
 In this study, we determined the level of routine application of DPYD screening in daily 
practice, which increased at the end of the study period to 90–100%. This might indicate 
that prescribers were undergoing a learning or acceptance curve following the initial start, 
and were getting used to apply DPYD genotyping increasingly in their daily routine.
 We believe patients do not need to be genotyped if previous 5-FU or capecitabine usage 
without toxicity is known or if patients were genotyped (DPYD) or phenotyped (DPD) 
previously. However, within the 41 (13.1%) remaining patients legitimate reasons can still 
exist (e.g., well-tolerated treatment before 2013 with 5-FU or capecitabine), but might not 
have been filed in the medical record. Therefore we can conclude the 90–100% (≤ 1 patient 
not tested per month) rate was an effective prospective DPYD screening implementation. 
Disputable is, if this clinical acceptance can become 100% continuously. In order to support 
the clinical implementation, the use of a clinical decision support system might be suitable. 
In LUMC a clinical decision support system entitled adverse drug event alerting system 
(ADEAS) is used in daily practice in the hospital pharmacy of LUMC.22 This system is used 
by hospital pharmacists to systematically select patients at risk of possible adverse drug 
events. It retrieves data from several information systems, and uses clinical rules to select 
the patient at risk of adverse drug events. 
 As mentioned before, sensitivity of genotyping is relatively low (<14.5% for DPYD*2A and 
c.2846A>T combined).11 Even if all patients with a DPYD variant are identified and treated with 
an appropriately reduced dose, not all fluoropyrimidine-related toxicity can be prevented. 
Adding a DPD phenotyping test may increase sensitivity, but is expensive and logistically 
challenging to implement in clinical practice.13 SNPs located in other genes than DPYD 
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(e.g., TYMS) have been associated with fluoropyrimidine-induced toxicity with conflicting 
results. However, testing for these SNPs holds the potential to increase sensitivity.23 Even 
though DPYD screening cannot prevent all fluoropyrimidine-related toxicity, we feel that 
the available evidence strongly supports implementation in clinical practice and can prevent 
fluoropyrimidine-induced deaths.8,11,24 
 The presence of one of the four DPYD variants that were pre-emptively tested resulted 
in a recommendation to the oncologist to reduce the initial dose of 5-FU or capecitabine 
by 25–50% depending on the identified variant. In February 2015 the recommended dose 
reduction for c.2846A>T was changed from 50 to 25%, following the updated guidelines of 
the DPWG.25,26
 One patient (Table 4, patient 13) received full capecitabine dose, since the treating 
oncologist argued that she was afraid of under dosing the patient as the dosage of 
capecitabine in chemoradiation schemes is already lower compared with other treatments 
and there is less opportunity to increase the dose in subsequent treatment cycles. The 
patient developed severe toxicity illustrating that the recommended dose reductions 
should also be applied to lower capecitabine doses used in chemoradiation, despite lack of 
published data about capecitabine toxicity during chemoradiation therapy.
Conclusion
This study for the first time shows that systematic prospective DPYD screening can be 
implemented successfully in real world daily clinical practice. The applied 25–50% dose 
reduction for patients with a DPYD variant resulted in absence of toxicity. However, a more 
active follow-up of adherence to provided dose recommendations might improve patient 
safety even further. 
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Confirmation practice in pharmacogenetic testing; 
how good is good enough? 
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Pharmacogenetic testing is increasingly implemented in routine diagnostics. However, 
quality control measures, in particular confirmation practices e.g. the use of two independent 
genotyping techniques, are subject of debate and there are no clear guidelines. The aim of 
the current paper is to discuss the current practice in confirmation testing in the field of 
pharmacogenetics and draw attention to this situation. DPYD genotyping is used as a case 
example to highlight the importance of assigning the correct genotype. Current confirmation 
practices in laboratories were explored through a survey. Substantial heterogeneity was 
observed with 54% of the laboratories applying different forms of confirmation practice. 
Finally, we evaluated over ten years of genotyping results from two large genotyping 
facilities, which both use a second, independent genotyping technique. Discrepancies 
between tests were identified in nine patients (0.01%), possibly due to allele dropout. We 
feel that a second, independent technique is useful for genetic tests with a high clinical 
impact, such as DPYD testing. Guidelines can help to align confirmatory laboratory practices 
for pharmacogenetics, which may need to be specified per gene and test.
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Over the past ten years, our knowledge of pharmacogenetics (PGx) has increased 
significantly. With decreasing assay costs, availability of PGx dosing guidelines and inclusion 
of PGx information in drug labels PGx testing has become an attractive strategy for routine 
diagnostics.1 For some diseases and drugs (pharmaco)genetic testing to predict therapeutic 
response is already widely accepted in clinical practice (e.g. lung cancer and EGFR status) 
or even mandatory (e.g. abacavir and HLA-B*5701 allele carriers).2 For a limited number of 
(pharmaco)genetic tests approval of the Food and Drug Administration (FDA) is available, 
e.g. CYP2D6 (Luminex) and INFINITI CYP2C19 assays, possibly increasing its use in clinical 
care.3-5 The Roche AmpliChip for cytochrome p450 CYP2D6 and CYP2C19 (Roche Molecular 
Diagnostics, Pleasanton, CA, USA) was the first FDA approved (December 24th, 2004) and 
commercially available PGx test.6 If no FDA-approved assay is available, laboratory developed 
tests (LDTs) can be used.7 
 Many laboratories use LDTs. It is important to have quality assurance of the PGx test 
results from these LDTs, which can be achieved by participating in a proficiency testing 
program. Proficiency testing programs are regulated by independent organizations, such 
as the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC),8 the 
German Reference Institute for Bioanalytics (RfB),9 the European Molecular Genetics Quality 
Network (EMQN) in the UK,10 or the Dutch Foundation for Quality Assessment in Medical 
Laboratories (SKML).11 In addition, the Genetic Testing Reference Material Coordination 
Program (GeT-RM) was set-up to guard quality assurance, assay development, validation 
and proficiency testing.12 Another less commonly applied quality control measure used by 
laboratories to ensure quality of PGx test results is confirmation practice, e.g. the use of two 
independent genotyping techniques. However, these measures have disadvantages, such 
as increased costs and labour, and are subject of debate. It is yet unknown if differences in 
laboratory practices exist as there are no clear guidelines on this particular quality control 
aspect. 
 The aim of the current paper is to discuss the current practice in confirmation testing in 
PGx and draw attention to this situation. We first assess current confirmation practices to 
assure the validity of PGx test results, by means of a questionnaire using DPYD genotyping 
as an impactful case. Secondly, we evaluate genotyping results from Leiden University 
Medical Center (LUMC) and Erasmus Medical Center Rotterdam (Erasmus MC), where two 
independent genotyping methods are applied to confirm results. 
Importance of analytical validity and assigning the correct genotype
The number of executed PGx tests is rapidly increasing, partly due to incorporation of 
PGx information in drug labels ─currently over 260─ some of them strongly suggesting 
or demanding a priori PGx testing (e.g. abacavir, clopidogrel, eliglustat).13 For some other 
diseases or drugs, which have a (pharmaco)genetic application available, the use in clinical 
practice remains limited and is subject to debate (e.g. bupropion, tamoxifen).1,14 By contrast 
to many other clinical laboratory tests, a (pharmaco)genetic test is usually performed only 
once in the lifespan of a patient. As a result, it is of utmost importance that the correct 
result is reported. Consequences of a false positive or false negative result could be 
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fatal, as is explained in the following example of DPYD genotyping for fluoropyrimidines 
(5-fluorouracil/5-FU, and capecitabine).15 There is compelling evidence on the reduction of 
severe fluoropyrimidine-induced toxicity when using prospective PGx for four DPYD variants, 
and dosing recommendations for these four DPYD variants have been published by the Clinical 
Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics 
Working Group (DPWG).16-19 Despite this, clinical implementation is not yet part of routine 
clinical care in many hospitals.20 When exposed to standard dosages of fluoropyrimidines, 
carriers of a DPYD variant are at high risk for severe, or even fatal, toxicity. Despite the low 
frequency of DPYD variants, prospective genotyping of DPYD variants in all patients prior to 
initiating fluoropyrimidine treatment was shown to be cost-saving.21 Thus, it is safer, but not 
more expensive to genotype patients. Misclassification of the DPYD genotype can result in 
suboptimal therapy (false positive) or even have lethal consequences from fluoropyrimidine 
treatment in standard dosages (false negative). In addition, therapeutic drug monitoring 
(TDM) could be used to monitor the 5-FU dose during treatment, but is rarely executed. For 
capecitabine, the oral pro-drug of 5-FU, TDM protocols need to be developed. This particular 
example shows the clinical importance and substantial consequences of PGx testing and 
illustrates why it is of utmost importance to report the correct result. 
The dilemma
Laboratories apply different genotyping techniques to generate PGx results. Sanger 
sequencing remains the gold standard for DNA sequencing,22 even though this can be prone 
to errors.23 In general, PCR-based assays (including Sanger sequencing) are considered a 
robust methodology with reliable results. Each assay is subjected to extensive validation 
by the company or laboratory to reduce the risk of a priori errors. However, after the 
implementation of a test in clinical practice, it is still possible to have false positive or false 
negative results, e.g. due to allele dropout.24 Allele dropout can be caused by a newly 
acquired variant located at the site of a primer, causing the binding of this primer to fail. 
A genetic variant located on that DNA strand will not be genotyped, and the patient is 
misclassified as homozygous carrier of the variant on the other strand.
 To mitigate the risk of allele dropout a laboratory can use a second, independent method 
that uses different primers to confirm results. However, this results in increased costs, 
labour and turn-around-time. Should laboratories execute a second method to confirm 
results, or not? The dilemma of the quality control aspect of PGx testing is based on the 
probability of a genotyping error to occur, the level of increased effort and costs to detect 
the error and the consequence of not detecting the error. A genotyping error, e.g. due to 
allele dropout, can be detected by a second, independent genotyping assay, which is the 
most adequate, but comprehensive, available method. Abolishing a second method or 
repetition can thus save both time and costs, possibly increasing the likeliness of use of 
PGx testing since cost-effectiveness is often reported as a barrier for implementing PGx 
testing.15 The consequence of an error in PGx can be substantial, yet it is unrealistic to aim to 
never have an incorrect result. This dilemma is why differences in confirmation practices in 
laboratories could exist and why guidelines are required to align laboratory practices. These 
differences could be overcome by clear guidelines from regulatory authorities, however, 
Confirmation practice in pharmacogenetic testing
233
9
notifications from regulatory authorities are also not conclusive about this dilemma. In 
January 2017, the FDA discussed that regulatory aspects on the quality control of LDTs are 
still under debate.25 In Europe, guidelines on good pharmacogenomics practice (GPP) by the 
European Medicines Agency (EMA) issued in September 2018 include a chapter on quality 
aspects on PGx analyses. They describe the importance of proper validation prior to using 
genetic tests in clinical trials or a diagnostic setting and the detection of respective allele-
drop-outs, as primer-based technologies are prone for these artefacts. However, no specific 
standpoint is taken regarding the use of a second, independent technique.26 Also, the In 
Vitro Diagnostic Regulation (IVDR) of the European Parliament and of the Council on in vitro 
diagnostic medical devices has recently been updated and will come into force in 2022. Yet, 
these guidelines do not explicitly state what actions to guarantee quality are required in the 
laboratory.
Confirmation practice
Current confirmation practice in laboratories
In order to investigate the consequences of the lack of clear guidelines we assessed the 
current confirmation practices of laboratories. A short questionnaire comprising three 
general questions on DPYD genotyping and confirmation practices in the laboratory was 
sent to laboratories in Europe and the Netherlands participating in the proficiency testing 
program of the RfB and SKML, respectively. Details on the set-up of the questionnaire can 
be found in the Supplementary Material. Out of the 475 laboratories, 35 completed the 
questionnaire. One laboratory participated in both the European (RfB) and Dutch (SKML) 
questionnaire. 28 laboratories executed genotyping tests. Of all laboratory techniques, the 
TaqMan assay and melting curve analyses were most frequently used. A large variation 
between laboratories in confirmation practice was observed. Almost half of the laboratories 
did not execute a second test (either independent or repetition). 
Two independent genotyping methods as confirmation practice
In addition, we assessed the impact of confirmation methods in PGx. At LUMC and the 
IFCC PGx reference laboratory at Erasmus MC, the most elaborate confirmation method, 
executing two independent genotyping tests using two different platforms, are used. We 
evaluated over ten years of aggregated genotyping data of these two large genotyping 
laboratories performing duplicate analyses on two independent platforms. Details of the 
two laboratories can be found in the Supplementary Material. In total, 89,842 duplicate 
tests were executed for patient care in over ten years of genotyping. Nine discrepancies 
(0.01%) between tests were observed. One discrepancy in CYP3A5*3 was the result of 
chimerism due to allogeneic hematopoietic stem cell transplantations, which resulted 
in the determination of the genotype of both patient and donor.27,28 Four discrepancies 
in CYP3A5*3, one discrepancy in DPYD*13 and three discrepancies in CYP2D6*6 were 
identified, possibly due to allele dropout. The probability of finding a discrepant result when 




The topic of confirmatory testing in the rapidly growing field of PGx deserves attention. At 
this moment, there are no clear guidelines on the required confirmation practice aspects 
of PGx testing. Should laboratories execute a second method to confirm results, or not? 
The FDA is in debate on this dilemma and the current guidelines of the EMA are not very 
precise on the use of confirmation methods. Our supporting data show that there is great 
heterogeneity between laboratories in confirmation practice. Discrepant results were 
identified between two tests in about 0.01% of samples. 
 Our data show a substantial variation of approaches for DPYD genotyping used in 
laboratories across Europe as well as a limited use of second, independent techniques as 
a confirmation method to assure the correctness of genotyping results. Almost half of the 
responders do not apply any of the suggested confirmation or replication methods, and 
implies the need for centrally organized guidelines. We selected DPYD as an example for its 
clinical relevance, as a false negative result or misclassification can have a fatal outcome. 
The number of centres which routinely test for DPYD is relatively low and it is possible that 
a questionnaire focussing on a gene that is more commonly tested would have resulted in a 
higher response rate. However we do not expect major differences in confirmation practice 
between genes within a laboratory.
 To assess the usefulness of applying two independent genotyping techniques for 
confirmatory testing we evaluated genotyping results of almost 90,000 samples tested 
in two laboratories in over ten years of genotyping. We identified nine discrepant results 
(0.01%) between the two independent genotyping techniques. One discrepant result was 
caused by chimerism following allogeneic hematopoietic stem cell transplantations, and is 
thus not due to analytical failure. To prevent this particular type of error, a check-box for 
“transplantation patient” was added to the genotyping request form. Two other stem cell 
transplantation patients were correctly genotyped after the check-box was added. For the 
other eight samples, misclassification due to allele dropout was the most probable cause 
of the discrepancies. In this study, a frequency of 0.01% of misclassification was shown, 
whereas previous publications show higher frequencies of misclassification (0.27% in 365 
patients, Scantamburlo et al.29 and 0.44% in 30,769 genotypes, Blais et al.).24 A difference 
in discrepant results between the two genotyping centres was identified and might be 
explained by the different genotyping techniques used in each centre, as the call rate and 
accuracy of the techniques can be different. Additionally, CYP2D6 data of one centre was not 
included, as this centre did not use a second, independent genotyping platform to confirm 
genotyping results for CYP2D6. CYP2D6 is a highly polymorphic gene and CYP2D6-assays 
could be more prone to allele dropout.
 Another important aspect to consider is that allele dropout is test specific: it depends 
on the positions of variants and the primer positions of the assay. Therefore, caution 
should be taken in generalizing our results. Specific quality control analyses per assay 
may be warranted. One could envision for example a minimum amount of samples to be 
tested to show that allele dropout for that particular assay and primers is low, possibly 
as a requirement for diagnostic companies to demonstrate. This brings along a second 
important consideration, which is that the sensitivity of detecting allele dropouts is directly 
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proportional to the amount of heterozygotes present. In other words, discrepancies for 
CYP2D6*4 (allele frequency 23%)30 will be detected much earlier than discrepancies for, 
e.g. CYP2D6*7 (allele frequency 0.05%).30 In this aspect, the determined discrepancy rate of 
0.01% might actually be higher for specific variants. In addition, the tests in this study were 
mainly executed in patients with a Caucasian ethnic background. As frequencies of genetic 
variants can vary between different ethnic populations, results could be different in another 
population.
 The large number of genotyping test results is a strength of this study. However, specific 
allele dropout will depend on the number of samples with a particular variant. The low 
discrepancy rate shows high concordance and robustness of the methods used. As 
described before, the consequence of a misclassified genotype can be substantial, resulting 
in either underdosing or overdosing, sub sequentially leading to inefficacy or, potentially 
lethal, toxicity (e.g. DPYD genotyping). We expect that next generation sequencing (NGS) 
might replace some of the current assays in the upcoming years. NGS is also subject to allele 
dropout as it is PCR based, but possibly less compared to current techniques. This is caused 
by the fact that NGS has multiple coverage depth of the same variants, thus a failed reaction 
of one primer will not directly results in a misclassification of the variant.
 Differences exist between laboratories in which DPYD variants are genotyped, or they 
might not genotype for DPYD variants at all. This could have great impact on patient care 
as DPD phenotypes might be predicted differently between laboratories. The impact could 
be greater compared to the impact due to differences between laboratories in confirmation 
practice as quality control of these tests. This also accounts for other variants in other genes, 
and for the fact that not all associated variants per gene are discovered yet. Besides assay 
errors, human errors (switch of samples) might also occur. However, this discussion is out of 
the scope of this paper, were we focus on the dilemma of confirmation practice.
Conclusions
We have shown substantial variability between laboratories in the use of a second 
confirmatory technique for PGx testing. The risk of a discrepancy may differ between assays 
and the clinical implications will depend on the gene tested. Therefore we feel that a second, 
independent technique is useful for genetic tests with a high clinical impact, such as DPYD 
testing. Guidelines can help to align confirmatory laboratory practices for PGx, however, 
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Laboratories participating in the largest European proficiency testing program organized 
by the RfB received the questionnaire by hard-copy. Laboratories in the Netherlands 
participating in the national proficiency testing program organized by SKML were contacted 
via e-mail with the questionnaire. Questionnaires were sent via RfB and SKML via their 
respective subscriber lists. Responding to the invitation was completely voluntary, results 
were collected by RfB (hard-copy) and SKML (e-mail) and were processed anonymously. Data 
were collected in Microsoft Excel 2010. The questionnaire contained the three following 
general questions; 
 1) Which SNPs in DPYD are currently tested in your lab?
 2) Which techniques are used for these SNPs?
 3) How is quality controlled? By using:
 *two independent techniques, *two technicians using the same technique, *one 
technician using the same technique on two independent days, *using two independent 
samples per patient, *other; namely:, *none
The third question was used to identify which confirmation or replication methods for the 
current genotyping are used. 
Two independent genotyping methods as confirmation practice
Two large genotyping laboratories (LUMC and Erasmus MC) performed two independent 
genotyping tests for over ten years. 
 At LUMC, both a commercially available TaqMan assay and a home-brew pyrosequencing 
method were employed to determine the patient’s genotype. The results of each 
independent method were checked by two independent technicians, and approved by a 
hospital pharmacist. When results between two methods were concordant, results were 
added to the digital system. Results and additional notes on results are then automatically 
available for physicians to consult. From January 2009 results were recorded electronically 
in a Global Laboratory Information Management System (GLIMS, version 8.10.6, MIPS©). 
For CYP2D6, the FDA-approved AmpliChip (Hoffmann-La Roche, Basle, Switzerland)1 was 
used, until discontinuation of the AmpliChip by Roche forced switching to the GenoChip 
CYP2D6 macroarray (PharmGenomics GmbH, Mainz, Germany) in April 2015.2 No second 
independent genotyping platform was used for the AmpliChip and GenoChip variants.
 At Erasmus MC, commercially available TaqMan assays and Polymerase Chain Reaction-
Restriction Fragment Length Polymorphism (PCR-RFLP) were used, in addition to AmpliChip, 
CYP2D6 kit (Luminex Corporation, Austin, TX, USA), CYP2C19 INFINITI (AutoGenomics, 
Carlsbad, CA, USA), DMET (Affymetrix/Thermo Fisher Scientific, Waltham, MA, USA). The 
results of each method were checked by two independent technicians, and approved by 
a clinical chemist. Results were recorded in the electronic hospital information systems 
EZIS and HiX (ChipSoft©) from April 2005. For CYP2D6, the FDA-approved AmpliChip was 
used, until discontinuation of the AmpliChip by Roche forced switching to the FDA-approved 
Luminex CYP2D6 Assay3 and CE-IVD marked INFINITI CYP450 2D6-BC Assay.4 
 The AmpliChip included 25 SNPs in CYP2D6, copy number variation in CYP2D6, and 




CYP2D6 and gene duplication. The Luminex and INFINITI assays include 15 SNPs and 
gene duplications. At Eramsus MC Taqman or PCR-RFLP were used to determine 15 and 
25 variants from the Luminex/INFINITI assays and AmpliChip assay respectively. CYP2D6 
and CYP2C19 are involved in different drug metabolisms.5 The other routinely tested SNPs 
are SNPs in genes coding for enzymes involved in drug metabolism from the cytochrome 
P450 (CYP2C19*17, CYP2C19*2, CYP2C19*3, CYP2C9*2, CYP2C9*3, CYP3A4*22, CYP3A5*3, 
CYP3A5*6), SNPs correlated to fluoropyrimidine-induced toxicity (DPYD*2A, DPYD*13, 
c.2846A>T, c.1236G>A),6 simvastatin-induced toxicity (SLCO1B1  rs4149056),7 calcineurin 
inhibitors pharmacokinetics (ABCB1-c1236t, ABCB1-g2677t, ABCB1-t129c, ABCB1-t3435c),8 
warfarin-induced toxicity (VKORC1 rs9934438)9 and thiopurines-induced toxicity (TPMT*2, 
TPMT*3A/*3B/*3C).10 All results of which a second independent genotyping test was 
executed were reviewed. For Erasmus MC CYP2D6 genotypes were taken into account. 
Mismatches between two tests were directly investigated upon discovery and summarized 
in this study. 
Supplementary Results
Current confirmation practice
The 460 laboratories participating in the proficiency testing program organized by RfB 
received the hard-copy questionnaire focusing on DPYD. In addition, the questionnaire was 
also sent by e-mail to 16 Dutch laboratories participating in the proficiency testing program 
of SKML. In total, we received 35 completed questionnaires, of which six laboratories do not 
execute genotyping assays. Of 63 of the 460 European laboratories it is known that they test 
for DPYD and these laboratories were more likely to reply to our questionnaire compared to 
laboratories not testing for DPYD. Response rate in European laboratories testing for DPYD 
was 27% (17 out of 63) compared to 75% response (twelve out of 16) in Dutch laboratories 
testing for DPYD. One laboratory responded to both Dutch and European questionnaires, 
and was only taken into account once. Supplemental Figure 1 shows the flowchart of invited 
laboratories and their responses. 
 The first question was asked to determine which DPYD SNPs are currently tested in 
different laboratories. 16 out of 22, and eleven out of twelve responders in Europe and the 
Netherlands execute DPYD genotyping, respectively. Of all centres genotyping for DPYD, 
only one centre did not test for the most-described DPYD variant in literature: DPYD*2A. 
Five centres genotyped only one variant (DPYD*2A), whereas the other centres combined 
multiple SNPs in their genotyping program. The four variants for which dosing guidelines are 
available, were most frequently tested. The different genotyped DPYD variants against the 
total number of responders are shown in Supplemental Figure 2.
 The second question aimed at gaining insight into which techniques were used for 
genotyping. Only answers of laboratories testing for DPYD (N=27) were included in the 
evaluation of questions 2 and 3. Multiple answers could be given to questions 2 and 3. Of all 
laboratory techniques, the TaqMan assay and melting curve analyses were most frequently 
used. There were no considerable frequency differences of the applied techniques between 
Europe and the Netherlands. An overview of all applied genotyping techniques is shown in 
Supplemental Figure 3. 
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A large variation in confirmation practice was observed (Supplemental Figure 4). The specific 
answer ‘one technician using the same technique on two independent days’ was only given 
by European laboratories. 
 Answers from ‘other’ included e.g. “use of a heterozygous positive control DNA” or “two 
persons judge the result”, which we consider as part of the genetic analysis or regular 
checks, not confirmation methods. Supplemental Figure 4 shows the diversity in answers.
Participants from RfB (N=460)
Do not test for DPYD (N=397)
Participants from SKML(N=16)
Test for DPYD (N=63)
Responders (N=12)Responders (N=6) Responders (N=17)
Total responders (N=34)    (-1 duplicate)
Supplemental Figure 1. Invited laboratories and responders


























Supplemental Figure 2. Different DPYD SNPs tested in PGx
Overview of 34 responders, shown as percentages. ‘Other’ includes: c.496A>G (rs2297595), DPYD*4 
















Supplemental Figure 3. Different genotyping techniques used in PGx
Overview of 32 answers from 27 responders, shown as percentages. 
Abbreviations: PCR: Polymerase Chain Reaction; RFLP: Restriction Fragment Length Polymorphism; 
Melting Curve: Melting curve analyses, including High Resolution Melt, ‘LightCycler’, ‘Rotorgene Melt 








two technicians using the same technique,
one technician using the same technique on two independent days,
using two independent samples per patient,
none
other
Supplemental Figure 4. Confirmation practice in PGx 
Overview of 34 answers from 27 responders, shown as percentages. ‘Other’ includes: “two 
technicians judge the results”, “new sample is requested with divergent result”, “two persons judge”, 
“authorized by Clinical Chemistry”, “phenotyping if necessary”, “use of synthetic controls”, “use of 
internal sequenced controls”, “use of heterozygous positive control DNA”. In this study these are not 
considered a (cost inducing) confirmation or replication method.
Two independent genotyping methods as confirmation practice
Since 2005 (Erasmus MC) and 2010 (LUMC) PGx tests are executed as a part of routine 
diagnostics in clinical care. Digitally stored results were included in the analysis. For LUMC 
and Erasmus MC data on 16,932 and 72,910 SNP tests were available, making the sample 
size a total of 89,842 tests. Results are shown for each SNP and separated per laboratory in 
Supplemental Table 1. Results of CYP2D6 are shown in Supplemental Table 2. 
 At LUMC, in 2011 a single discrepancy was observed as previously described.11,12 Briefly; 
the TaqMan assay identified a patient as CYP3A5*3/*3, while results from PSQ showed that 
the patient was CYP3A5*1/*3. A second blood sample was obtained and genotyped. Results 
from the second analysis (both Taqman as PSQ) classified the patient as CYP3A5*1/*3. 
However, the PSQ results showed some inconsistencies, making the results questionable. 
Chapter 9
244
After further investigations and consult with the attending nephrologist, it appeared that 
this patient had a history with allogeneic hematopoietic stem cell transplantations. Saliva 
samples from both patient and stem cell donor were obtained and genotyped, which 
showed a CYP3A5*1/*3 genotype for the patient and CYP3A5*3/*3 genotype for the donor.
At Erasmus MC, in 2011 a discrepancy for CYP3A5*3 was found. Thereafter, 300 patients 
were genotyped at Erasmus MC in a single run, using TaqMan. Comparing the outcome with 
PCR-RFLP revealed three discrepancies. Upon sequencing, the TaqMan assay appeared to 
have been wrongly addressing the wild type status, possibly due to allele dropout caused by 
a variant located at one of the TaqMan primers. 
 At Erasmus MC, in 2016 a DPYD result was found discrepant between PCR-RFLP and 
TaqMan-based validated assays, PCR-RFLP giving heterozygosity *1/*13, indicating a 50% 
dose reduction, whereas the other assay indicated wild type for the four SNPs tested 
(regular starting dose). Both methods were repeated, confirming the earlier results. Direct 
sequencing revealed that wild type was the correct outcome. This was the only discrepant 
finding for DPYD. 
 At Erasmus MC, the genotype of three patients showed discrepancies for CYP2D6*6. The 
AmpliChip assay showed wildtype for CYP2D6*6, whereas TaqMan determined CYP2D6*6. 
The tests were repeated, and sequencing of the samples revealed the correct genotype 
(CYP2D6*6). Like the CYP3A5*3 discrepancies, a possible explanation was a variant located 
at one of the AmpliChip primers, resulting in allele dropout and thereby misclassification, 
missing the CYP2D6*6 allele. Previously, another discrepancy for CYP2D6*6, possibly caused 
by allele dropout, was described by Rasmussen et al.13 We are not aware of publications on 
other discrepancies of CYP3A5*3 or DPYD*13. 
 In total, eight discrepancies were found at Erasmus MC in 72,910 SNPs tested in duplo 
(0.01%). For LUMC, one discrepancy was found in 16,932 SNPs tested in duplo (0.006%), 
which could be attributed to chimerism in a patient with previous stem cell transplantation. 
In total, the probability of finding a discrepant result when using two independent techniques 
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BEYOND CURRENT DPYD PHARMACOGENETICS
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Fluoropyrimidines are widely used anticancer drugs. Prospective DPYD (encoding 
dihydropyrimidine dehydrogenase, DPD, the key metabolic enzyme for degradation of 
fluoropyrimidines) genotyping followed by dose adjustments in DPYD variant allele carriers 
reduces severe fluoropyrimidine-induced toxicity. However, when using this approach still 
~20% of patients experience severe toxicity. We evaluated four DPD phenotyping assays, 
aiming to determine which is most suitable for identifying patients at risk for severe 
fluoropyrimidine-induced toxicity, and identifying DPD deficient patients. 
 Study participants underwent testing of two, three or four DPD phenotyping assays before 
starting fluoropyrimidine-based therapy; the endogenous dihydrouracil/uracil (DHU/U) 
ratio, endogenous uracil levels, the oral uracil loading dose, and the 2-13C-uracil breath test. 
Phenotyping results were associated with the onset of severe toxicity and DPD deficiency 
according to the DPD enzyme activity measurement in peripheral blood mononuclear cells. 
Sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV) and 
F1-score (harmonic mean of sensitivity and PPV) were calculated per phenotyping assay 
as predictive measures for severe (grade ≥3) fluoropyrimidine-induced toxicity and DPD 
deficiency.
 In total, 1,037 patients participated in this study. Of these, 1,037, 92 and 82 patients 
underwent two, three or four DPD phenotyping assays, respectively. Two phenotyping 
assays were analysed on their performance for the prediction of severe fluoropyrimidine-
induced toxicity. No differences were identified between wild-type patients who did or did 
not experience severe toxicity in the mean endogenous DHU/U ratio or mean endogenous 
uracil levels. The F1-scores of both assays were 10 and 24%, respectively. In the comparison 
of phenotyping assays in performance for prediction of DPD deficiency, four phenotyping 
assays were analysed in both wild-type patients and DPYD variant allele carriers. The highest 
F1-score of the phenotyping assays in predicting DPD deficiency was 40% for the oral uracil 
loading dose.
 All four investigated DPD phenotyping assays in this study have been favourably 
evaluated as predictive test for the occurrence of severe fluoropyrimidine-induced toxicity 
in previous studies. However, in a first-time prospective head-to-head comparison study 
we could not show associations with the onset of severe fluoropyrimidine-induced toxicity 
or DPD deficiency. In order to determine the true clinical value of DPD phenotyping assays, 
additional research is required.




Fluoropyrimidines, including 5-fluorouracil (5-FU) and its oral pro-drug capecitabine, play 
a key role in the treatment of multiple types of cancer.1 Although 5-FU has been used 
for over 60 years, toxicity remains a major clinical problem, as severe fluoropyrimidine-
induced side effects occur in up to 30% of patients, resulting in lethal outcome in up to 1% 
of these patients.1,2 With over two million patients treated with fluoropyrimidines each year 
worldwide, many patients are at risk of developing severe toxicity.3 
 Abundant research has been carried out on dihydropyrimidine dehydrogenase (DPD), the 
key metabolic enzyme of fluoropyrimidines, and the gene DPYD encoding DPD. Low DPD 
activity itself and several DPYD variants resulting in low DPD activity have both individually 
been associated with severe fluoropyrimidine-induced toxicity.4-6 Prospective phenotyping 
or genotyping, followed by dose adjustments in DPD deficient patients or DPYD variant 
allele carriers, can reduce the risk for severe toxicity. This was shown for prospective 
genotyping of DPYD*2A, c.1679T>G, c.2846A>T and c.1236G>A/HapB3, followed by initially 
reduced dosages in DPYD variant allele carriers.7,8 However, genotyping to predict severe 
fluoropyrimidine-induced toxicity has an inherently limited sensitivity, as other genetic and 
also non-genetic factors are known to play a role in the variability in DPD activity and the 
onset of severe fluoropyrimidine-induced toxicity. Phenotyping of the DPD enzyme, as a 
way to determine the DPD activity, can potentially better predict severe fluoropyrimidine-
induced toxicity as it takes both pharmacogenetic and other factors influencing DPD activity 
into account. 
 A well-established method to determine DPD activity is measurement of DPD enzyme 
activity in peripheral blood mononuclear cells (PBMCs). The activity in PBMCs is well-
correlated to the DPD enzyme activity in the liver, and reference values have been 
established.6,9 However, the method is not widely used since feasibility in clinical practice 
remains challenging due to substantial costs, complex sample logistics and specific 
equipment required for the radio assay. In addition, the results are influenced by the 
distribution of blood cells (e.g. monocytes, granulocytes) in the sample,10 and there is a 
substantial intra patient variability (up to 25%) in DPD enzyme activity, possibly caused by 
circadian rhythm.11,12
 Several DPD phenotyping assays have previously been investigated, focussing on the 
metabolism of uracil (U) and dihydrouracil (DHU), the endogenous substrate and product 
of DPD, respectively. Two of these assays are the determination of the endogenous uracil 
levels and the DHU/U ratio. Several studies have shown an association between the pre-
treatment endogenous DHU/U ratio in plasma and 5-FU pharmacokinetics,13-16 and also with 
severe fluoropyrimidine-induced toxicity.15,17-19 In addition, Meulendijks et al. have recently 
shown that high pre-treatment serum uracil concentrations were also strongly related to 
severe and fatal fluoropyrimidine-induced toxicity.20 Another DPD phenotyping assay for 
estimating the in vivo DPD activity is the oral uracil loading dose assay.21,22 In this assay, a high 
dose of uracil is administered orally, and uracil and DHU levels are measured using a limited 
sampling strategy.21 In this way, the DPD enzyme function is utilized to the full capacity. In 
case of reduced uracil conversion, also partially DPD deficient patients can be identified. 
Finally, the in vivo DPD activity can also be determined using the 2-13C-uracil breath test.23 
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This assay uses a personalized dose of 2-13C uracil, a stable isotope of uracil, and is based on 
the conversion of 2-13C uracil into 13CO2 which can be measured in exhaled breath.
23 
 Several of these assays have been evaluated in head-to-head comparisons to DPD 
enzyme activity measurements in PBMCs in healthy volunteers, or patients selected after 
experiencing severe toxicity.11,21,23-27 However, when using an enriched patient cohort for 
severe toxicity, calculated assay characteristics such as sensitivity or specificity will be biased 
and not representative for routine clinical care. Strengths and weaknesses of these assays 
have been reviewed independently of each other;28,29 however, a head-to-head comparison 
in clinical practice has never been investigated. Therefore, in this prospective study, we 
evaluated four DPD phenotyping assays in patients prior to treatment with fluoropyrimidines 
in order to determine the association with the onset of severe fluoropyrimidine-induced 
toxicity and detecting DPD deficiency, defined as DPD enzyme activity in PBMCs below the 
cut-off value.
Materials and methods
Study design and patients
This study was a pre-planned analysis in a large prospective multi-centre clinical trial 
(clinicaltrials.gov identifier NCT02324452, here referred to as main study cohort or clinical 
trial) improving the safety of fluoropyrimidines by prospective DPYD genotyping.7 Two out 
of four phenotyping assays (endogenous DHU/U ratio and endogenous uracil levels) were 
executed in patients recruited in the seventeen Dutch hospitals participating in the clinical 
trial. All four DPD phenotyping assays were executed in three hospitals, and three out of four 
assays were executed in another hospital (excluding the 2-13C-uracil breath test). Patient 
recruitment for this study was open from 30 April, 2015, until 21 December, 2017. Ethical 
approval of this study was granted by the medical ethical committee of The Netherlands 
Cancer Institute, Amsterdam, the Netherlands. All patients provided written informed 
consent before enrollment in this study. 
 All assays were executed before start of fluoropyrimidine therapy. 92 patients were 
asked to participate in all four phenotyping assays, which made intra-patient comparisons 
possible. Results of the DPD phenotyping assays were determined after start of treatment 
and were not used for dose individualization. Dose adjustments of the fluoropyrimidine 
drug were done based on DPYD genotype only as per protocol of the clinical trial. 
 Toxicity was graded according to the National Cancer Institute common terminology 
criteria for adverse events (CTCAE; version 4.03)30 and severe toxicity was defined as CTCAE 
grade ≥3. Only toxicity defined by the treating physician as definitely, probably and possibly 
related to fluoropyrimidine treatment was taken into account. Patients were followed for 
toxicity during the entire treatment period and were evaluated for toxicity if they received 
at least one fluoropyrimidine drug administration. The endpoints of this study were the 
association of each DPD phenotyping assay with the onset of severe fluoropyrimidine-
induced toxicity and DPD deficiency, defined as low DPD activity levels in PBMCs (≤5.9 nmol/
[mg*h]).6 
 Inclusion and exclusion criteria for this study were the same as in the clinical trial; eligibility 
to start with fluoropyrimidine-based therapy, 18 years or older, an adequate performance 
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status, adequate renal and liver biochemistry and haematological values, and no prior 
treatment with fluoropyrimidines.  
Study procedures
One blood draw for the endogenous DHU/U ratio and endogenous uracil level assays was taken 
prior to start of treatment. For patients participating in three or four DPD phenotyping assays 
the study scheme was as follows. During two random days prior to start of fluoropyrimidine-
based treatment, all three or four phenotyping assays were performed in each patient (study 
scheme in Figure 1). On the first day, blood draws for the DPD enzyme activity in PBMCs and 
two DPD phenotyping assays (endogenous DHU/U ratio and endogenous uracil levels) were 
taken prior to 9 am. Immediately thereafter, the third phenotyping assay (oral uracil loading 
dose of 1000 mg uracil) was performed. The U/DHU ratio was assessed at 120 minutes after 
administration of uracil. At least one day later, but prior to start of fluoropyrimidines, the 
fourth phenotyping assay (2-13C-uracil breath test with 6 mg/kg 2-13C-uracil) was performed 
including blood draws for 13C-uracil and 13C-dihydrouracil plasma measurements. The 
DOB50 value from breath samples was correlated to 
13C-dihydrouracil plasma levels and the 
13C-DHU/U ratio. The oral uracil loading dose and 2-13C-uracil breath test were performed 
on two separate days to exclude any interference, as uracil was administered orally for both 
assays. Also, a minimum time interval of 24 hours between the phenotyping assays and 
start of fluoropyrimidine treatment was taken into account as a safety precaution, although 
it was expected that the administered uracil would not affect the efficacy and safety of 
patients when starting their fluoropyrimidine-based treatment, since uracil has a very short 




Start with FPDPD enzyme activity
Endogenous DHU/U ratio
Endogenous uracil levels
Oral uracil loading dose
2-13C-uracil breath  
test
≥24 hours interval ≥24 hours interval
Figure 1. Study scheme 
The study scheme per patient. Minimum interval between the tests and between tests and start of 
fluoropyrimidine-therapy was 24 hours. There was no predefined maximum number of days between 
assays as patients usually started relatively quickly with therapy when the decision to start was made.
Abbreviations: FP: fluoropyrimidines; DHU: dihydrouracil; U: uracil.
DPD phenotyping assays
Patients underwent the DPD phenotyping assays in the hospital of their recruitment. 
Protocols for each DPD phenotyping assay were made available and discussed with 
executive personnel. In four hospitals, trained personnel was available to execute three or 
four DPD phenotyping assays. Each DPD phenotyping assay is described in more detail in the 
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supplementary material. In addition, the time of last food intake prior to the blood draw for 
the endogenous DHU/U ratio was collected in all patients. 
Sample size calculation and statistical analyses
The sample size for comparison of the four phenotyping assays was based on the co-primary 
aim (the association between the result of a phenotyping assay and severe fluoropyrimidine-
induced toxicity). It was calculated to be 240 patients (see detailed description in the 
supplementary material). The association between the result of a phenotyping assay and 
DPD deficiency (as determined by the DPD enzyme activity in PBMCs) was investigated as 
secondary aim. 
 Patient characteristics or toxicity differences between patient groups were tested using 
χ² test or non-parametric test. The DPD phenotyping assays were executed for the first 
time in the participating centres, i.e. in a research setting and were not cross-validated. 
To investigate the effect of centres on the outcome per assay, a mixed model analysis 
was executed to demonstrate the general reliability of the assay. A univariate analysis of 
variance was done to compare outcomes per centre. In this analysis, the centre with the 
highest recruitment rate was chosen as the reference centre. DPYD variant allele carriers 
were excluded in these analyses, as they are underwent a per protocol dose adjustment and 
hence are at lower risk for toxicity. Age, gender and baseline BSA were additionally taken 
into account as possible covariates to minimize the risk of biased results of the analyses. 
When age, gender or baseline BSA were associated with the outcome of the phenotyping 
assay, the distribution of the covariate was checked between centres using Chi-Square tests 
or univariate analysis of variance. The possible clinical consequence of the divergent results 
was discussed per assay and data could be excluded from further analyses. 
 For assessing clinical validity, measures to determine diagnostic performance (i.e. 
sensitivity, specificity, positive predictive value [PPV], negative predictive value [NPV] and 
F1-score [harmonic mean of sensitivity and PPV]) of the assays with regard to the onset of 
severe toxicity or DPD deficiency were determined. DPYD variant allele carriers who received 
dose reductions based on their identified genotype could only be included in an analysis for 
association with DPD activity, not for the association with onset of severe toxicity. The level 
of significance was set at p<0.05. Analyses were performed using SPSS, version 23 (IBM SPSS 
Inc., Chicago, IL, USA). 
Results
Patients
In total, 1,037 patients participated in the phenotyping study of which 1,037, 92 and 
82 patients underwent two, three and four phenotyping assays, respectively. Patient 
and treatment characteristics of the 92 patients were similar to those of the main study 
(N=1,103), with the exception that the 92 patients were slightly younger (median age of 
60 versus 64 years, p=0.011, Table 1). Details on fluoropyrimidine-induced toxicity are 
depicted in Supplementary Table 1. In total, 19 out of 92 patients (21%) experienced severe 
fluoropyrimidine-induced toxicity, which is comparable to the main study in which 264 out 
of 1,103 patients (24%) experienced severe toxicity (p=0.477). 





For the DPD enzyme activity measurements, the variance was estimated to be 8.6 ± 1.4 nmol/
(mg*h). For centre as covariate, the variance was estimated to be 6.5 ± 5.7 nmol/(mg*h). 
The deviations between centres in general (intra class variation) was 43.0%, therefore the 
general reliability of the DPD enzyme activity measurements was 57%. For the endogenous 
DHU/U ratio, endogenous uracil levels, 2-13C-uracil breath test and the oral uracil loading 
dose assay the general reliabilities were 74.1%, 92.9%, 73.5%, and 94.3%, respectively. 
Endogenous DHU/U ratio 
The endogenous DHU/U ratio was determined in 1,037 patients. Results of wild-type patients 
(non-carriers of the four DPYD variants, N=955) were compared between seventeen study 
centres. The endogenous DHU/U ratio differed significantly in nine study centres compared 
to the reference centre (lowest divergent mean DHU/U ratio 5.9, to the highest divergent 
mean DHU/U ratio 13.9, p<0.001). It appeared that age was significantly associated with 
the outcome of the DHU/U ratio (p<0.001). Age was differently distributed between the 
centres (p<0.001). The lowest statistically divergent mean DHU/U ratio was not as low as 
the suggested DHU/U ratio cut-off value (4.31)20 for DPD deficient patients, therefore no 
patients were excluded. The median, interquartile range (IQR) and standard deviation (SD) 
of each assay are shown in Table 2.
Endogenous uracil levels 
Endogenous uracil levels were determined in 1,037 patients. Results of wild-type patients 
(N=955) were compared between seventeen study centres. The endogenous uracil levels 
differed significantly in four study centres compared to the reference centre (lowest divergent 
mean uracil level 8.3 ng/ml, to the highest divergent mean uracil level 18.8 ng/ml, p<0.001). 
It appeared that gender was significantly associated with the outcome of the uracil levels 
(p=0.030), with lower uracil levels in females. Males and females were significant differently 
distributed between the centres (p=0.046). The divergent results were substantially higher, 
even higher than the previously suggested cut-off value (13.9 ng/ml)20 for DPD deficient 
patients, therefore the data were considered unreliable and patients recruited in these 
centres (N=172) were excluded from further analyses. The endogenous uracil levels and 
endogenous DHU/U ratio were correlated to time of last meal that was eaten, to study the 
influence of food on the uracil levels. No correlation was found (Supplementary Figure 1), 
therefore time of food intake was not taken into account as covariate in further analyses. 
DPD enzyme activity
The DPD enzyme activity in PBMCs was determined in 92 patients. Results of 82 wild-
type patients were compared between study centres. The mean DPD enzyme activity was 
significantly lower in one of the four participating centres (5.23 nmol/(mg*h) versus 10.89 
nmol/(mg*h) in the reference centre, p<0.001). These results were substantially lower, even 
lower than the cut-off value (≤5.9 nmol/[mg*h])6 for DPD deficiency, therefore the data 
were considered unreliable and patients recruited in this centre (N=19) were excluded from 
further analyses in which DPD deficiency was taken into account. 
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Table 1. Baseline characteristics of patients who underwent three or four DPD phenotyping assays 
and from the main study cohort
Characteristic Phenotyping assays 
(N=92)




     Male 







     Median [IQR] 60 [53-67] 64 [56-71] 0.011
Ethnic origin
     Caucasian
     African descent
     Asian














     GC












Type of treatment regimen
     CAP mono 
     CAP + RT
     CAPOX
     CAP other
     5-FU mono 
     5-FU + RT
     FOLFOX



















     Median [IQR] 2.0 [1.79-2.10] (N=91) 1.92 [1.77-2.10] (N=1075)
0.207
WHO performance status
     0
     1
     2










Number of treatment cycles






















a All p-values represent a comparison of 92 patients who underwent three or four DPD phenotyping 














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The oral uracil loading dose assay was performed in 92 patients. Results of 82 wild-type 
patients were compared between study centres. The mean U/DHU ratio was significantly 
lower in one centre (0.622) compared to the reference centre (1.03, p=0.046). It appeared 
that baseline BSA was significantly associated with the outcome of the U/DHU ratio 
(p=0.008), a higher baseline BSA was related to a lower U/DHU ratio. Baseline BSA was not 
differently distributed between the centres (p=0.637). The different mean U/DHU ratio of 
one centre was far from the cut-off U/DHU ratio (2.4)21  of DPD deficient patients, therefore 
no patients were excluded from further analyses.
2-13C-uracil breath test
The 2-13C-uracil breath test was determined in 82 patients.23 On average, 488 mg 2-13C-uracil 
was administered, ranging from 312 to 840 mg (6 mg/kg dose). Results of 74 wild-type 
patients were compared between study centres. The mean delta-over-baseline ratio at t=50 
minutes (DOB50) was significantly lower in one centre (137.7 ‰) compared to the other 
two centres (173.5 ‰ and 168.4 ‰, p<0.009). It appeared that gender was significantly 
associated with the outcome of the DOB50 (p=0.003), with higher DOB50 values in females. 
Males and females were not significant differently distributed between the centres (p=0.263). 
The significantly different mean DOB50 was not as low as the DOB50 cut-off value (128.9 ‰)
25 
for DPD deficient patients, therefore no patients were excluded. A significant correlation 
between the DOB50 determined in breath samples and the 
13C-dihydrouracil plasma levels 
(r2=0.178, p<0.001) could be demonstrated, not for the 13C-DHU/U ratio (r2=0.014, p=0.29). 
Results are shown in Supplementary Figure 2.
Association with onset of severe toxicity
Clinical validity parameters, i.e. sensitivity, specificity, NPV, PPV and F1-score of the 
endogenous DHU/U ratio and the endogenous uracil levels for their association with the 
onset of severe fluoropyrimidine-induced toxicity were calculated and shown in Table 3. 
The endogenous uracil levels have the highest F1-score of 24%. No significant difference 
was identified between the median endogenous DHU/U ratio or endogenous uracil level 
between patients who experienced severe toxicity or not (Figure 2). For the oral uracil 
loading dose and 2-13C-uracil breath test too few patients were enrolled, therefore the 
association with the onset of severe toxicity was investigated in an explorative way only 
for these two phenotyping assays (Supplementary Table 2, Supplementary Figure 3). Yet, 
the data show similar results in clinical validity parameters and also no difference between 
medians of patients who experienced severe toxicity or not.
Association with DPD deficiency
DPD deficiency, defined as low DPD activity levels in PBMCs (≤5.9 nmol/[mg*h]),6 was 
identified in 7 out of 73 patients (9.6%) or 6 out of 64 patients (9.4%). Clinical validity 
parameters for association with DPD deficiency are shown in Table 4. High specificity and NPV 
values were identified, but low sensitivity and PPV values. The oral uracil loading dose has the 
highest F1-score of 40%. The endogenous uracil levels have the highest sensitivity of 43%. 






















































































Figure 2. Results of phenotyping assays separated by the occurrence of severe fluoropyrimidine-
induced toxicity 
Dots represent individual results. Black lines represent the median and 25th and 75th percentile of 
the data. All DPYD variant allele carriers were excluded from the analysis as they received initial dose 
reductions based on their genotype result. For the endogenous uracil levels, 161 wild-type patients 
were excluded due to divergent phenotyping assay results of the centre in which these patients were 
recruited. 
Abbreviations: U: uracil; DHU: dihydrouracil; NS: not significant p-value. 
Table 3. Comparison of phenotyping assays in performance for prediction of severe fluoropyrimidine-
induced toxicity 
Clinical validity parameters for the prediction of severe (grade ≥3) fluoropyrimidine-induced toxicity 
are shown for the endogenous DHU/U ratio and endogenous uracil levels. DPYD variant allele carriers 
were excluded, since DPYD variant allele carriers received an initial dose reduction based on their 
genotype, and therefore bias could exist in the onset of severe fluoropyrimidine-induced toxicity. For 
the endogenous uracil levels, 161 wild-type patients were excluded due to divergent phenotyping 
assay results of the centre in which these patients were recruited. 


























≥13.9 ng/ml20 21 82 77 27 24
a The F1-score represents the harmonic mean of sensitivity and PPV;
b This cut-off value is determined by calculating the 6% lower limit of the data, as was described by 
Meulendijks et al. 20
Abbreviations:  IQR: interquartile range; DPD: dihydropyrimidine dehydrogenase; NPV: negative 




Despite recent advances by applying prospective DPYD genotyping, ~20% of patients treated 
with fluoropyrimidines still suffer from severe toxicity.7 These patients are wild-type for the 
four genotyped DPYD variants, yet could still be DPD deficient due to currently untested 
variants. Therefore, it is of great importance to explore the clinical value of DPD phenotyping 
assays in order to potentially further reduce the risk of severe fluoropyrimidine-induced 
toxicity. In this study, we conducted two DPD phenotyping assays in 1,037 patients and 82 
patients underwent all four DPD phenotyping assays, in order to rule out inter-individual 
variation. To the best of our knowledge, this is the first study with this unique design, taking 
into account that our patient cohort was not selected based on –or enriched for– (severe) 
toxicity, but represents a patient cohort more representative of routine clinical care. However, 
in the analyses with severe toxicity we excluded DPYD variant allele carriers, thus relatively 
more wild-type patients were included. Still, some wild-type patients are DPD deficient, 
indicating that we were able to calculate assay performance measures, such as sensitivity 
and specificity, for the onset of severe toxicity. In the comparison of DPD deficiency, DPYD 
variant allele carriers were not excluded.
 
Table 4. Comparison of phenotyping assays in performance for prediction of DPD deficiency 
Per phenotyping assay clinical validity parameters are shown for the prediction of DPD deficiency. DPD 
deficiency is defined as a DPD enzyme activity in PBMCs ≤5.9 nmol/(mg*h), and was identified in 7 
out of 73 patients (9.6%) and 6 out of 64 patients (9.4%). The results of the DPD enzyme activity were 
substantially divergent in one centre. Therefore, these results were considered unreliable and could 
not be compared to results of the phenotyping assays in predicting DPD deficiency. 19 patients were 
excluded.


























≥13.9 ng/ml20 43 73 92 14 21
2-13C-uracil 
breath test





33 86 93 20 25








120 min ≥2.421 
29 98 93 67 40
a The F1-score represents the harmonic mean of sensitivity and PPV;
b This cut-off value is determined by calculating the 6% lower limit of the data, as was described by 
Meulendijks et al.20;
c The 2-13C-uracil breath test was executed in 64 out of 73 patients.
Abbreviations:  IQR: interquartile range; DPD: dihydropyrimidine dehydrogenase; NPV: negative 
predictive value; PPV: positive predictive value; DHU: dihydrouracil; U: uracil; NA: not applicable; 
DOB50: delta-over-baseline ratio at 50 minutes.
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The goal of this study was to explore the clinical value of DPD phenotyping assays to identify 
DPD deficient patients with an increased risk for severe fluoropyrimidine-induced toxicity. 
 Previously, high endogenous uracil levels have been associated to the onset of severe 
toxicity.20 In our study, there was no difference between the mean endogenous DHU/U ratio 
or mean endogenous uracil levels between wild-type patients for four DPYD variants, who 
experienced severe toxicity or not. Possibly, when including DPYD variant allele carriers 
a difference would have been visible. Yet, we aimed to identify DPD deficient patients in 
addition to DPYD variant allele carriers who are DPD deficient. In terms of clinical validity 
parameters, our results for the endogenous uracil levels (sensitivity 21%, specificity 82%, 
NPV 77%, PPV 27%) were only slightly different from previously published parameters to 
predict severe fluoropyrimidine-induced toxicity (sensitivity 18%, specificity 95%, NPV 
90%, PPV 35%).20 Taking the limited number of patients for two out of four phenotyping 
assays into account, none of the phenotyping assays investigated in this study showed a 
combination of both high PPV and NPV parameters, which could predict the clinical value of 
a test. Of note, sensitivity and PPV of an assay will remain limited even though there is a high 
odds ratio, if e.g. adverse events are frequent and deficient patients are rare.32 This is also 
the case for DPD deficiency and severe fluoropyrimidine-induced toxicity, and we identified 
low clinical validity parameters.  
 Our study is the first study in which several phenotyping assays were compared head-
to-head in the same patients. For two out of four assays (endogenous DHU/U ratio and 
endogenous uracil levels), we recruited over 1,000 patients representative of routine clinical 
care patients. However, our study has some limitations. The 92 patients who underwent 
three or four phenotyping assays were a little younger compared to patients from the main 
study cohort, possibly due to the higher patient burden to participate in multiple DPD 
phenotyping assays. However, we feel this difference is not clinically relevant and it did not 
influence the occurrence of severe fluoropyrimidine-induced toxicity in these patients. 
 Secondly, we identified variation in the results of the phenotyping assays, either possibly 
caused by differences between centres or baseline characteristics (i.e. age, gender or BSA). 
Per assay, we have examined divergent results and we have corrected for these variations by 
excluding patients. While we now attributed the identified variation to differences between 
study centres, these divergent results might also be caused by already existing fluctuation in 
phenotyping results due to the character of the assay and measurement method. In addition, 
variation in the clock time of sampling may have affected uracil levels as the metabolizing 
enzyme DPD shows significant circadian variation.11 Variation in phenotyping results might 
also be caused by a different distribution of DPD deficient patients between centres. 
 Furthermore, predefined cut-off values per phenotyping assay derived from literature 
were used to be able to divide patients in DPD deficient and non-DPD deficient patients 
and calculate clinical validity parameters. Cut-off values are also necessary for clinical use, 
as it would be difficult to determine which patients would require an initial dose reduction 
without the use of cut-off values. However, the use of cut-off values limits the interpretation 
of the data of each phenotyping assay. In addition, DPD deficiency itself does not follow a 
cut-off at a certain point as its severity varies in gradation between completely DPD deficient, 
partially DPD deficient or non-DPD deficient. Therefore, it would be better not to use cut-off 
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values in DPD phenotyping assays, but to analyse the results without categorizing patients. 
 We discussed differences in DPD phenotyping assays, yet the endpoint toxicity can 
also influence the results. Variation in the outcome of severe toxicity might be caused by 
different types of treatment regimens between patients, which we did not correct for. As 
explained for DPD deficiency, analysing the data by categorizing patients also applies to the 
categorization of toxicity into severe (grade 3-5) and non-severe (grade 0-2) toxicity, where 
grade 2 toxicity is a grey area in the assessment of toxicity. 
 Despite our unique data set, we were unable to show that any of the phenotyping assays 
was associated with DPD deficiency or the onset of severe fluoropyrimidine-induced toxicity 
very well. The latter is possibly due to the fact that only ~30-50% of severe fluoropyrimidine-
induced toxicity can initially be explained by DPD deficiency.33 Previously it was described 
that clinical validity and utility were not yet determined for all phenotyping assays,29 yet 
with this study we were unable to fully complement this lack of evidence. 
Conclusion
We compared four DPD phenotyping assays (the endogenous dihydrouracil/uracil (DHU/U) 
ratio, endogenous uracil levels, the oral uracil loading dose, and the 2-13C-uracil breath 
test) in a first-time head-to-head comparison study. None of the phenotyping assays were 
associated with DPD deficiency or the onset of severe fluoropyrimidine-induced toxicity 
very well. In order to determine the clinical value of DPD phenotyping assays additional 
research is required. 
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Calculation of sample size
Within DPYD wild-type patients a variability in DPD enzyme activity exists. We assumed that 
95% of the DPYD wild-type patients would be classified as having normal enzyme activity 
and 5% of the DPYD wild-type patients would be classified with a low DPD enzyme activity 
(DPD deficient), with an increased risk of toxicity. This results in an unequal sample size, 
therefore a total sample size of 240 evaluable patients was required to achieve at least 80% 
power at significance level α=0.05 to detect an increase in the probability of toxicity from an 
estimated 20% in non-DPD deficient patients to 60% in DPD deficient patients. 
Methods assays
DPD enzyme activity1,2 
The DPD enzyme activity in PBMCs was determined using a validated radio-assay, which 
is based on conversion of the radiolabelled probe 4-14C thymine to 4-14C dihydrothymine.1 
As this method is considered the gold standard in DPD measurements in the Netherlands, 
four phenotyping assays were correlated to this assay. Between 8 and 9 am, after overnight 
fasting, 20 ml blood (EDTA tube) was drawn, combined with a blood draw for determining 
the endogenous DHU/U ratio. Depending on the hospital of inclusion (N=4), whole blood 
was either shipped overnight to the Academic Medical Center in Amsterdam for further 
processing, or was processed at the hospital of blood draw (N=3) as described before, to 
isolate PBMCs.1 After processing, isolated PMBCs were kept at -80°C before measurement 
of DPD activity at the Academic Medical Center in Amsterdam. 
Endogenous DHU/U ratio and endogenous uracil levels3,4 
The uracil and DHU levels were determined in plasma using a validated ultra-performance 
liquid chromatography tandem mass-spectrometry (UPLC-MS/MS) method.4 All samples 
were measured at the Netherlands Cancer Institute in Amsterdam. In patients who 
participated in three or four DPD phenotyping assays, a 4 ml blood (heparin tube) was 
drawn between 8 and 9 am, after overnight fasting, and centrifuged at 4°C at 1500g for 10 
minutes. Plasma was kept at -80°C until measurement. In patients from the clinical trial, 
blood to determine uracil and DHU levels could be drawn throughout the day and in non-
fasting state, but information was collected on how long before the blood draw the patient 
had eaten a meal, as food status could influence the uracil levels in patients.5
Oral uracil loading dose6,7 
Previously, a loading dose of 500 mg/m2 uracil was used in this assay. To increase feasibility, 
a standardized dose of 1,000 mg uracil was administered. Patients had to fast overnight for a 
minimum of eight hours. Food and drinks had to be abstained for the duration of the assay. 
Uracil was dissolved in warm water and administered between 8 and 9 am, to minimize 
effects of circadian rhythm. Four ml blood (EDTA tube) was taken at 60 and 120 minutes 
after oral intake of uracil. Sample processing consisted of adding 0.15 ml of the DPD inhibitor 
gimeracil to a 4 ml sample and centrifuging at 4°C at 1,500g for ten minutes. Plasma was 




plasma using a high-performance liquid chromatography ultra-violet (HPLC-UV) method in 
the laboratory of the Department of Pharmacy at the Scheper Hospital in Emmen.  
2-13C-uracil breath test8-10
A personalized dose of 6 mg/kg 2-13C uracil was administered to patients after overnight 
fasting (minimum eight hours) and alcohol abstaining (minimum 24 hours). Food and drinks 
had to be abstained for the duration of the assay as well. The 2-13C uracil was dissolved in 
hot water and administered between 8 and 9 am, to minimize effects of circadian rhythm. 
Just prior to the administration of the 2-13C uracil solution the patients had to ingest two 
tablets of Alka-Seltzer Gold® (containing anhydrous citric acid, potassium bicarbonate and 
sodium bicarbonate) with water, to stimulate uniform and fast absorption of the 2-13C uracil 
solution. Breath samples (300 ml in a Otsuka Pharmaceuticals breath bag, Japan®) and blood 
samples (4 ml in a heparin tube) were taken pre-dose and 50 minutes after administration 
of uracil. Blood samples were centrifuged immediately at 4°C at 1,500g for ten minutes. 
Plasma was kept at -80°C until analysis. Quantification of 13C-uracil and 13C-dihydrouracil 
levels was done using the same UPLC-MS/MS method as for the endogenous DHU/U ratio 
at the Netherlands Cancer Institute, Amsterdam, but with uracil-13C4,
15N2 and dihydrouracil-
13C4,
15N2 as internal standards. 
13CO2 and 
12CO2 concentrations were determined in the exhaled 
breath samples by infrared spectrometry using the FDA approved POCone IR spectrometer 
(Photal Electronics, Japan®) at the laboratory of the department of Clinical Pharmacy and 
Toxicology at the Leiden University Medical Center or at the Division of Pharmacology at the 
Netherlands Cancer Institute, Amsterdam. A delta-over-baseline (DOB) ratio at 50 minutes 
was calculated that represents a change in the 13CO2/
12CO2 ratio of two breath samples.
Supplementary results
Supplementary Table 1. Toxicity data of patients who underwent three or four DPD phenotyping 
assays and the main study cohort
Type of event Phenotyping 
assays (N=92)
Main study cohort 
(N=1,103)
P-valuea
Overall grade ≥3 toxicity 19 (21%) 264 (24%) 0.477
     Grade ≥3 gastrointestinal toxicity 6 (7%) 103 (9%) 0.367
     Grade ≥3 hematological toxicity 10 (11%) 78 (7%) 0.180
     Grade 3 hand-foot syndrome 4 (4%) 37 (3%) 0.389
     Grade ≥3 cardiological toxicity 0 10 (1%) 0.447
     Grade ≥3 other treatment-related toxicity 3 (3%) 87 (8%) 0.106
Fluoropyrimidine-related hospitalization 7 (8%) 156 (14%) 0.079
Stop of fluoropyrimidines due to adverse events 20 (22%) 190 (17%) 0.133
Fluoropyrimidine-related death 0 2 (0%) ND
a All p-values represent a comparison of 92 patients who underwent three or four DPD phenotyping 
assays to patients from the main study cohort. We used χ² test or Fisher exact test.
Abbreviations: ND: not done.
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Supplementary Table 2. Comparison of phenotyping assays in performance for prediction of severe 
fluoropyrimidine-induced toxicity
Clinical validity parameters for the prediction of severe fluoropyrimidine-induced toxicity are shown 
for the 2-13C-uracil breath test and uracil loading assay. DPYD variant allele carriers were excluded, 
since DPYD variant allele carriers received an initial dose reduction based on their genotype, and 
therefore bias could develop in the onset of severe fluoropyrimidine-induced toxicity. 
Assay N of 
patients























82 U/DHU ratio at 
120 min: 0.58 
(0.31-1.09)
U/DHU-ratio 
at 120 min 
≥2.46
7 97 82 33 11
a The F1-score represents the harmonic mean of sensitivity and PPV. 
Supplementary Figure 1. Endogenous uracil levels and endogenous DHU/U ratio plotted against the 
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Supplementary Figure 2. Correlation between breath samples and plasma samples of the 2-13C-uracil 
breath test
The association between plasma samples (measured 13C-DHU/U-ratio and 13C-uracil levels at 50 
minutes) and breath samples (calculated as DOB50) of the 2-
13C-uracil breath test was evaluated by 
estimating Pearson’s correlations coefficients.












































































Supplementary Figure 3. Results of phenotyping assays separated by the occurrence of severe 
fluoropyrimidine-induced toxicity 
Dots represent individual results. Black lines represent the median and 25th and 75th percentile of 
the data. All DPYD variant allele carriers were excluded from the analysis as they received initial dose 
reductions based on their genotype result.
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DPYD genotyping prior to fluoropyrimidine treatment is increasingly implemented in clinical 
care. Without phasing information (i.e. allelic location of variants), current genotype-based 
dosing guidelines cannot be applied to patients carrying multiple DPYD variants. The primary 
aim of this study is to examine diagnostic and therapeutic strategies for fluoropyrimidine 
treatment of patients carrying multiple DPYD variants.
 A case series of patients carrying multiple DPYD variants is presented. Different genotyping 
techniques were used to determine phasing information. Phenotyping was performed by 
DPD enzyme activity measurements. Publicly available databases were queried to explore 
the frequency and phasing of variants of patients carrying multiple DPYD variants. 
 Four out of seven patients carrying multiple DPYD variants received a full dose of 
fluoropyrimidines and experienced severe toxicity. Phasing information could be retrieved 
for four patients. In three patients, variants were located on two different alleles, i.e. in 
trans. Recommended dose reductions based on the phased genotype differed from the 
phenotype-derived dose reductions in three out of four cases. Data from publicly available 
databases show that the frequency of patients carrying multiple DPYD variants is low 
(<0.2%), but higher than the frequency of the commonly tested DPYD*13 variant (0.1%). 
 Patients carrying multiple DPYD variants are at high risk of developing severe toxicity. 
Additional analyses are required to determine the correct dose of fluoropyrimidine 
treatment. In patients carrying multiple DPYD variants, we recommend that a DPD 
phenotyping assay be carried out to determine a safe starting dose.
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Fluoropyrimidines (including 5-fluorouracil (5-FU) and capecitabine) are the cornerstone of 
treatment for various types of cancer, and are used by millions of patients worldwide each 
year.1-3 However, up to one-third of treated patients experience severe toxicity (common 
terminology criteria for adverse events (CTC-AE) grade ≥3), such as diarrhea, hand-foot 
syndrome or mucositis upon treatment with fluoropyrimidines.4,5 These adverse events 
can lead to mortality in approximately 1% of patients who experience severe toxicity.4,6 
Dihydropyrimidine dehydrogenase (DPD) is the key enzyme in the metabolism of 5-FU 
and its decreased activity is strongly associated with toxicity.7,8 Variants in DPYD, the gene 
encoding DPD, can lead to decreased DPD enzyme activity.9-12 Prospective DPYD genotyping 
of four main DPYD variants followed by dose reductions in patients carrying any of these four 
DPYD variants is safe, cost-effective and feasible in clinical practice.13-15 These DPYD variants 
are DPYD*2A, rs3918290, c.1905+1G>A, IVS14+1G>A; DPYD*13, rs55886062, c.1679T>G, 
I560S; c.1236G>A/HapB3, rs56038477, E412E; and c.2846A>T, rs67376798, D949V. For 
these four variants, convincing evidence has been provided warranting implementation in 
clinical practice.4,5,12,15-17
 An increasing number of hospitals apply prospective DPYD genotyping when treating 
patients with fluoropyrimidines.18 Individual dosing guidelines for the abovementioned four 
DPYD variants are provided by the Dutch Pharmacogenetics Working Group (DPWG) and 
the Clinical Pharmacogenetics Implementation Consortium (CPIC).19,20 Dosing guidelines 
are based on the expected remaining DPD enzyme activity and can be applied to patients 
who are heterozygous carriers of a single DPYD variant. For homozygous DPYD variant allele 
carriers (two identical variants) and compound heterozygous DPYD variant allele carriers 
(two or more different variants), dosing guidelines are not yet available (or treatment with 
an alternative drug is advised), although safe treatment with low-dose fluoropyrimidines in 
these homozygous DPYD patients was demonstrated by a recent case series.21 
 Patients who carry multiple variants (compound heterozygous) can carry the variants on 
a single allele (in cis) or on different alleles (in trans). In the first case, one functionally 
active allele remains, whereas in the latter case, both alleles are affected, which may result 
in a proportionally decreased enzyme activity (Figure 1). With currently used genotyping 
techniques, the allelic location of variants (phasing) cannot be determined. This uncertainty 
hampers adequate interpretation of the pharmacogenetic test result in compound 
heterozygous patients and makes it impossible to give an appropriate dose recommendation 
based on the genotype alone. Since it is likely that in the future, even more DPYD variants 
will be tested, the probability of finding compound heterozygous DPYD variant allele carriers 
will increase. The aims of this study are to examine diagnostic and therapeutic strategies for 
fluoropyrimidine treatment of patients carrying multiple DPYD variants and the frequency 
and phasing of variants of compound heterozygous DPYD patients in publicly available 
databases. 
Methods 
In this study, we present seven compound heterozygous DPYD variant allele carriers as clinical 




Data and DNA from patient cases carrying multiple DPYD variants were collected. Patients 
were identified either after development of severe toxicity from fluoropyrimidine-containing 
therapy, by additional retrospective genotyping in a clinical trial (clinicaltrials.gov identifier 
NCT00838370),13 or prior to treatment in routine clinical care. The study was reviewed 
and approved by the institutional review board of the Leiden University Medical Center 
(LUMC, G18.15). Patient data from the electronic medical records was handled following 
the codes of proper use and proper conduct in the self-regulatory codes of conduct.22 
Toxicity to fluoropyrimidine-containing therapy was graded by the treating physicians using 
the National Cancer Institute CTC-AE version 4.03,23 and severe fluoropyrimidine-induced 
toxicity was defined as CTC-AE grade ≥3. In some cases, additional patient material to 









Figure 1. Illustration of zygosity and clinical interpretations
A wild-type patient carries no variants, resulting in normal activity alleles (green). A heterozygous 
patient carries one variant, resulting in one reduced or inactive allele (red) and one active allele 
(green). A partly reduced enzyme activity is expected, since there is still one active allele left. For 
homozygous patients, both variants result in a reduced or inactive allele (red). Depending on the 
effect of the variants on the protein, a reduced or absent enzyme activity is expected. Compound 
heterozygous patients can carry variants on different alleles (in trans) or on one allele (in cis), resulting 
in differences in enzyme function, either like that of a heterozygous patient or a homozygous patient. 
Stars represent variants; boxes represent alleles.
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Dihydropyrimidine dehydrogenase enzyme activity measurements 
For all patients, DPD enzyme activity was determined. This could be either prior to treatment 
or retrospectively after the occurrence of severe toxicity. DPD enzyme activity measurement 
in peripheral blood mononuclear cells (PBMCs)24,25 was used as a reference to assess DPD 
activity, and has been used previously to determine dosages in DPYD variant carrying 
patients.21,26 A validated method27 was used, containing radiolabeled thymine as a substrate 
and consisting of high-performance liquid chromatography (HPLC) with online radioisotope 
detection using liquid scintillation counting. Normal values for healthy volunteers are 9.9±2.8 
nmol/(mg*h), for DPD deficient patients are 4.8±1.7 nmol/(mg*h), and reference values 
range from 5.9 to 14 nmol/(mg*h).28 Dose reductions based on DPD enzyme activity were 
performed in a one-to-one ratio, as was previously described by Henricks et al.21 Thereafter, 
toxicity-guided dosing was used. 
Molecular methods for estimation of phasing
In regard to the size of the DPYD gene, the location of the variants, and the material 
available (DNA, RNA) from the patients, three molecular methods to determine the phasing 
of the variants could be used in this study. In four patients, we could execute one or more of 
these methods. These methods are explained and illustrated in the Supplementary Material 
(Figure S1). Details on these techniques have been published elsewhere.29-31 
Frequencies of compound heterozygous DPYD carriers 
To investigate the incidence of compound heterozygous DPYD variant allele carriers (of 
the four genotyped DPYD variants) large databases were queried.32,33 The incidence was 
calculated using minor allele frequencies (MAFs) of each variant identified in the databases 
separately. Since the determined variants are not in the same haplotype, it was assumed 
that the inheritance of these individual DPYD variants is independent. All genotypes from 
the databases were calculated to be in Hardy-Weinberg equilibrium, except for DPYD*2A 
and c.1236G>A for the Exome Aggregation Consortium (ExAC)32 and Genome Aggregation 
Database (gnomAD)33 due to a slight overrepresentation of homozygous cases. The 
calculated frequencies were compared to frequencies from databases in which phasing 
could be determined.
Exome Aggregation Consortium and Genome Aggregation Database 
Both the ExAC32 and gnomAD33 databases collect exome sequencing data and aggregate the 
data for public use. The ExAC dataset (v.0.3.1) contains sequenced data of 60,706 unrelated 
individuals. The gnomAD dataset (v.2.0) contains sequenced data of 123,136 exomes and 
15,496 genomes from unrelated individuals. In ExAC, 2,791 DPYD variants, and in gnomAD, 
2,190 DPYD variants were found. MAFs of DPYD variants from these databases reflect those 
of the population due to the large group size in the databases. Since both ExAC and gnomAD 
do not contain individual matched or phased data, it is not possible to search for compound 
heterozygous patients in these databases.
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Phasing in compound heterozygous DPYD carriers 
Three databases were used to identify compound heterozygous DPYD variant allele carriers 
and determine the phasing, i.e. allelic location, of variants. 
Genome of the Netherlands Datasets 
The Genome of the Netherlands (GoNL) trio datasets contain information of related fathers, 
mothers, and children, and phasing information is therefore available. Datasets were 
previously processed and phased using trio-aware variant calling.34 After the exclusion of 
children, phased variant call format (VCF) files for 496 subjects (fathers and mothers) were 
obtained from the GoNL repository. The toolset Bedtools (v2) was used to extract all variants 
found in the DPYD locus (chr1:97,543,300─98,386,615). Next, for all individuals, the carrier 
status of DPYD*2A, DPYD*13, c.1236G>A and c.2846A>T was examined. Individuals who 
carry at least one of the four actionable DPYD variants were identified and, using a custom 
Python script,35 the phasing of variants was assessed for individuals with multiple variants. 
1000 Genomes Database 
The 1000 Genomes Project is the largest publicly available catalogue of human variation and 
genotyped phased data. It originally ran from 2008 until 2015, and thereafter it was maintained 
and expanded by the IGSR (International Genome Sample Resource).36 On 27 October 2016, 
phased data of the DPYD gene (chr1: 97,543,300─98,386,615) was downloaded from the 
1000 Genomes ftp server (phase 3; GRCh37; chr1: 97,543,300─98,386,615) using Tabix 
(v1.1).37 The statistical program R (v3.2.5)38 was used to select the genotypes at four DPYD 
risk alleles in unrelated individuals of Caucasian descent. 
Exome Trios Leiden University Medical Centre Database 
This diagnostic database of the clinical genetics department of LUMC contains 433 complete 
exome trios (father, mother, and child). The exome was enriched by the Agilent sureselect 
v5 kit and sequenced using various Illumina (San Diego, CA, USA) sequencers (Hiseq 2000, 
2500, 4000, Nextseq). Carrier status of the abovementioned DPYD variants was established 
by querying the trio VCF files. We also investigated all samples with sufficient coverage of 
this region to obtain a reliable frequency estimate. In the case of trios, only parents were 
taken into account. 
Results
Patient cases and clinical implications
Details of the demographics and clinical characteristics of the seven cases are described 
in the Supplementary Material (patient cases). All patients received treatment with 
fluoropyrimidines and were identified as compound heterozygous DPYD variant allele 
carriers, either prior to the start of treatment or retrospectively. Table 1 shows an overview 
of the cases. Table 2 shows all genotype and phenotype results. With additional genetic 
testing phasing could be determined in four out of seven patients. In three patients, the 
variants were located in trans and one patient carried the variants in cis. With the phasing 
information available, it is possible to calculate a dose recommendation using publicly 
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available pharmacogenetic dosing guidelines.19,20 For example, patient 1 carried DPYD*2A 
and c.1236G>A in trans. The gene activity values range from inactive (0) to fully active (1). 
DPYD*2A and c.1236G>A/HapB3 have values of 0 and 0.5, respectively. As this patient 
carries the variants in trans, each allele contains one variant and no fully functional allele 
remains. Therefore, the cumulated gene activity score (GAS) is 0.5. The GAS can be used to 
determine dose recommendations according to the genotype, as was previously described.12 
The GAS ranges from 0 to 2, and a score of 0.5 corresponds to a dose recommendation of 
25%. The DPD enzyme activity of patient 1 was 0.9 nmol/(mg*h). This was divided by the 
mean of the reference value (9.9), which results in a theoretical DPD activity of 9%. For each 
patient for whom phasing details were known, the GAS was determined and compared to 
the theoretical DPD activity. Dose recommendations according to the GAS (genotype) and 
theoretical DPD activity (phenotype) were divergent in almost all cases, as shown in Table 2. 
Table 1. Characteristics of patient cases
Shown per patient are primary tumor, treatment, capecitabine dose, executed assays (genotype, 
dihydropyrimidine dehydrogenase (DPD) enzyme activity, and additional assays) information. 
Additional assays are droplet digital PCR, PacBio sequencing (Menlo Park, CA, USA), or an in-house 
developed technique. For the executed assays it is shown whether these were executed prior to 
treatment (P) or retrospectively (R).
Patient # Primary 
Tumor
Treatment Capecitabine dose Executed assays
1                  BC CAP 1,000 mg/m2/bid Genotyping (R), DPD activity (R), in-house 
technique (R), droplet digital PCR (R)
2                 BC CAP 800 mg bid (50%) Genotyping (P), DPD activity (R), in-house 
technique(R)
3 CRC CAP+OX 900 mg bid (50%)a Genotyping (P), DPD activity (P), PacBio (R)
4                     BC CAP 1,500 mg bid Genotyping (R), DPD activity (Rb)
5 CRC CAP+RT 800 mg bid (50%) Genotyping (P+Rc), DPD activity (Rd), PacBio (R)
6 CRC CAP+OX 1,000 mg/m2/bid Genotyping (R), DPD activity (R)
7 CRC CAP+OX+ 
BEV
1,000 mg/m2/bid Genotyping (R), DPD activity (R)
a Increased to 70% in the second cycle;
b During hospital admission;
c DPYD*2A was prospectively identified, c.2846A>T was retrospectively identified;
d During treatment.
Abbreviations: BC: breast cancer; CRC: colorectal cancer; CAP: capecitabine; RT: radiotherapy; OX: 
oxaliplatin; BEV: bevacizumab; bid: bis in die/twice a day.
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Table 2. Dose advice for compound heterozygous DPYD variant allele carriers
Shown per patient are DPYD variants, phasing of the DPYD variants, GAS, retrospective DPWG dosing 
advice based on phasing, DPD enzyme activity, and percentage of DPD enzyme activity considered 
for dose advice. According to the DPWG guidelines 19 a gene activity score can be given to compound 
heterozygous patients when phasing is known. Fully functional/reduced functionality: gene activity 
score of 1.5; fully functional/inactive: gene activity score of 1; reduced functionality/reduced 
functionality: gene activity score of 1; reduced functionality/inactive: gene activity score of 0.5; 
inactive/inactive: gene activity score of 0. 
Patient # DPYD variants Phasing GAS12 DPWG dose 
advice






1                  DPYD*2A + c.1236G>A in trans 0.5 25% 0.9 9%
2                 DPYD*2A + c.2846A>T in trans 0.5 25% 6.0 60%
3 c.1236G>A + c.2846A>T in trans 1 50% 4.5 45%
4                     DPYD*2A + c.2846A>T unknown X X 0.11 1%
5 DPYD*2A + c.2846A>T in cis 1 50% 7.2 72%
6 DPYD*2A + c.1236G>A unknown X X 3.8  38%
7 DPYD*2A + c.1236G>A unknown X X 1.6 16%
a The reference DPD activity ranges from 5.9-14 nmol/(mg*h) 28, and therefore the percentage of DPD 
activity can be calculated using the average of the reference (9.9 nmol/(mg*h)). This percentage could 
be used as a percentage of the regular dose.
Abbreviations: DPD: dihydropyrimidine dehydrogenase; GAS: gene activity score; DPWG: Dutch 
Pharmacogenetic Working Group; X: could not be determined.
Preventing toxicity
Three of the seven case patients were identified as carriers of one or more DPYD variants 
prior to the start of therapy. For one patient, the DPD enzyme activity was determined prior 
to the start of therapy. Based on their genotype or phenotype, these three patients received 
initially reduced fluoropyrimidine dosages of 50%. They experienced limited and reversible 
toxicity (CTC-AE grades 0─2). The dose of one patient was increased to 70% in the second 
treatment cycle, after which CTC-AE grade 3 toxicity occurred. 
 Four of the seven case patients received a full dose, since their genotype was unknown 
prior to the start of therapy. These patients all experienced severe toxicity (CTC-AE grades 
3─5), and three of them were admitted to the hospital for seven to 14 days. An overview of 
cases, including the toxicity, is shown in Table 3.
Frequencies of compound heterozygous DPYD carriers without phasing information
The ExAC and gnomAD databases revealed an average MAF for DPYD*2A, DPYD*13, 
c.1236G>A, and c.2846A>T of 0.55%, 0.03%, 1.43%, and 0.27%, respectively. MAFs for ExAC 
and gnomAD separately are summarized in Table 4. The probability of identifying a compound 
heterozygous DPYD patient for two variants according to these databases was ≤0.008%, 
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as was calculated using frequencies of combinations of DPYD variants. Results for each 
combination of DPYD variants are shown in Table 5. With several million fluoropyrimidine 
users each year, thousands of patients worldwide are compound heterozygous for a subset 
of these four DPYD variants.
Table 3. Toxicity profiles of compound heterozygous DPYD variant allele carriers
Shown per patient are DPYD variants, fluoropyrimidine dose as a percentage of the regular dose, and 
experienced toxicity with this dose. All patients retrospectively identified as DPYD variants carrier 
received full doses and experienced severe (CTC-AE ≥3) toxicity. All patients prospectively identified 
as DPYD variant(s) carrier received dose reductions and experienced a maximum of CTC-AE grade 2 
toxicity with the initial dose. 
Patient # DPYD variants Dose (% of regular dose) Toxicity (maximal CTC grade)
1                  DPYD*2A + c.1236G>A 100% 4
2                 DPYD*2A + c.2846A>T 50% 1─2
3 c.1236G>A + c.2846A>T 50%  70% 0 (on 50% dose)  3 (on 70% dose)
4                     DPYD*2A + c.2846A>T 100% 5
5 DPYD*2A + c.2846A>T 50% 0
6 DPYD*2A + c.1236G>A 100% 4 
7 DPYD*2A + c.1236G>A 100% 3
Abbreviations: CTC-AE: common terminology criteria for adverse events.
Frequencies of compound heterozygous DPYD carriers with phasing information
In the GoNL database, genetic data from 496 subjects (fathers and mothers only) was 
reviewed. One subject was found who carried two DPYD variants. This subject was a carrier 
of the DPYD c.1236G>A and DPYD c.2846A>T variants, both of which were located on a 
single allele (in cis). Based upon the data in GoNL, the probability of having compound 
heterozygosity of the four DPYD variants is <0.2%. 
 In the 1000 Genomes database, data of 2,513 individuals was available. After the 
selection of unique, unrelated individuals, 407 individuals remained. One subject was found 
who carried two DPYD variants. This subject was a carrier of DPYD c.1236G>A and DPYD 
c.2846A>T, both of which were located on different alleles (in trans). Based upon the data 
in 1000 Genomes, the probability of having compound heterozygosity of the four DPYD 
variants is <0.3%.
 In the LUMC clinical genetics database (exome trios LUMC), the analysis was restricted 
to the children, since this would allow phasing. None of the 433 children carried more than 
one DPYD variant, thus compound heterozygosity in this database is <0.2%. 
Despite the low frequency, compound heterozygous patients were identified in all databases 
except the LUMC clinical genetics database. However, the low frequency did not allow to 








































































































































































   
   
   
   
   
   


































































































































































































































































































































































































































































































































































































































































































































Prospective genotyping of DPYD variants followed by individual dose adjustments is 
increasingly applied as the standard of care for patients starting fluoropyrimidine therapy. 
Standard dose reductions from CPIC and DPWG guidelines cannot be applied in patients 
who carry more than one DPYD variant, as the phasing of the variants is unknown. Despite 
the low population frequency of <0.2%, the absolute number of identified compound 
heterozygous patients will increase as the number of genotyped patients increases and the 
panel of tested variants is expanded. To the best of our knowledge, this is the first study 
that describes a case series of compound heterozygous DPYD variant allele carriers and 
investigates diagnostic and therapeutic strategies for these patients. 
 Our study shows the clinical need for further information on the genotype, as four 
patients were identified as compound heterozygous carriers retrospectively and all of them 
experienced severe toxicity. These compound heterozygous DPYD variant allele carriers 
have an increased risk of developing severe fluoropyrimidine-induced toxicity if dosages are 
not adequately adjusted. Previously, compound heterozygous patients have been described 
with severe or even lethal side effects after fluoropyrimidine treatment.39,40 Three patients 
in this study were prospectively identified as compound heterozygous carriers, received 
initial dose reductions, and developed only mild toxicities. 
 Out of the four patients for whom we were able to retrieve phasing information, three 
were in trans and one was in cis orientation. Data from publicly available databases also 
showed that both in cis and in trans orientations exist. However, the recently updated CPIC 
guidelines on DPYD assumes in trans phasing for compound heterozygous patients.20 The 
DPWG guidelines do not mention phasing; however, the dosing recommendations of the 
DPWG use the GAS, a score based on the activity of individual alleles.19 This implies the need 
for phasing information. The assumption of in trans phasing could result in the underdosing 
of patients with variants phased in cis, and thus exemplifies the need for the determination 
of the phasing of variants.
 In this study, we looked at different diagnostic strategies to determine the phasing of DPYD 
variants in compound heterozygous patients. In four patients, the phasing of DPYD variants 
could be determined using one of three different molecular methods. These methods are in 
the early phases of development, not routinely available, quite expensive, and not always 
conclusive. For two of these techniques, patient RNA is used, which degrades quickly after 
the blood draw unless specifically designed blood tubes are used. Compound heterozygous 
patients are rare, yet here we describe seven patients heterozygous for multiple DPYD 
variants. A limitation of our study is that most patients were identified retrospectively and in 
different institutions. Because of this, not enough of or not the right material was available 
for analysis, thus not all genotyping techniques could be executed in each patient. For two 
samples, tests failed or produced inconclusive results (data not shown). For this reason, 
a formal comparison of their suitability to identify phasing was not possible. However, 
of the three explored molecular methods, PacBio sequencing seems most promising. 
While phasing improved the prediction of DPD enzyme activity, patients with identical 
combinations of DPYD variants and identical phasing showed considerable differences in 
DPD enzyme activity, which could potentially limit the added value of the determination of 
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the phasing of DPYD variants. However, larger numbers of compound heterozygous DPYD 
variant allele carriers would be necessary to draw a firm conclusion.
 The measurement of DPD enzyme activity in PBMCs was used as a reference to assess 
DPD activity. The method is well-established, commonly available, and shows limited intra- 
and interpatient variability.27 However, recently, differences in intrapatient variability in DPD 
enzyme activity related to circadian rhythm were shown,41 which can result in the under- or 
overestimation of DPD enzyme activity. In this study, we present one patient with extremely 
low DPD enzyme activity, which could possibly be influenced by the presence of severe 
neutropenia, as DPD activity is normally measured in mononuclear cells. Therefore, DPD 
enzyme activity can differ depending on the clinical condition of the patient, and should 
thus be measured prior to treatment.
 A major question is whether genotyping or phenotyping is the best method to determine 
DPD activity to guide fluoropyrimidine dosing in patients carrying multiple DPYD variants. 
Despite the low population frequency, we present seven patients carrying multiple DPYD 
variants, of which three received initially reduced fluoropyrimidine dosages. However, 
based on these data, it is not possible to determine if a dose recommendation based on 
phased genetic information or DPD enzyme activity measured in PBMCs is safer. In three 
out of four cases, differences were observed between the theoretically calculated DPD 
activity using genotyping or phenotyping. These differences would result in different dosing 
recommendations. For example, there is a considerable interpatient variability in DPD 
enzyme activity in carriers of the DPYD variant c.1236G>A/HapB3.12 Due to this variability, 
genetic dose recommendations are categorized (e.g. 25 or 50%) on the average of the 
phenotypes. This categorization could explain the observed dosing differences derived from 
genotyping and phenotyping. Other variants of DPYD currently not routinely tested for or 
variants in other genes, e.g. MIR27A,42 might also be involved in reducing DPD activity or 
explaining fluoropyrimidine-induced toxicity. DPD enzyme activity measurements are well-
established, and additional molecular methods to resolve phasing are still in early phases 
of development. Therefore, in our opinion, the current therapeutic strategy for compound 
heterozygous DPYD variant allele carriers should be to determine initial dose reductions 
based on a DPD phenotyping test, for example by measuring enzyme activity in PBMCs. 
Dosing could be adjusted by the treating physician in subsequent cycles based on observed 
severe toxicity (or lack thereof). 
Conclusions
In conclusion, patients carrying multiple DPYD variants are at high risk of developing severe 
toxicity. Additional analyses are required to determine the correct dose of fluoropyrimidine 
treatment. In patients carrying multiple DPYD variants, we recommend that a DPD 
phenotyping assay be carried out to determine a safe starting dose. The dose could be 
titrated in subsequent cycles based on observed toxicity. 
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A 50 year old patient was diagnosed with breast cancer (cT3N3M0, triple negative), for 
which neo-adjuvant chemotherapy was started, followed by a breast saving surgery and 
axillary lymph node dissection (ypT1N1), and thereafter radiotherapy. Approximately a year 
later, lymph node metastases were found, for which capecitabine (1,000 mg/m2 bid) was 
started. The patient experienced severe toxicity in the first cycle of capecitabine and was 
hospitalized for one week (allergic reaction ─red swollen face─, complaints in the mouth, 
neutropenic fever, nausea, diarrhea, leukopenia CTC-AE grade 4). The patient was genotyped 
hereafter and turned out to be a carrier of DPYD*2A and c.1236G>A. DPD enzyme activity 
was determined and was reported to be as low as 0.9 nmol/(mg*h) (normal range 5.9─14 
nmol/(mg*h)). Internal evaluation using plasmids showed that these variants were both 
located at a different chromosome (in trans). Digital droplet PCR showed inconclusive 
results. 
Patient 2
A 44 year old patient was diagnosed with breast cancer (cT1N1M0), for which the 
patient underwent surgery followed by radiotherapy and adjuvant chemotherapy 
(cyclophosphamide/methotrexate/5-FU dosed 600 mg/m2 iv). Approximately seven years 
later, a relapse was discovered and one breast was removed followed by hormonal therapy 
(tamoxifen for three years, anastrozol for three years). Three years hereafter, palpable 
axillary lymph nodes were found, which turned out to be metastases of the tumor. TAC 
(docetaxel, doxorubicin, cyclophosphamide) cycles were started, however poorly tolerated 
and therefore cycles 2─6 were continued on 75% of the dose. Axillary radiotherapy was 
given hereafter. All was followed by letrozole. Then, metastases in the liver, bones and 
adrenal glands were found. Palliative chemotherapy with capecitabine (1,000 mg/m2 bid) 
was started, for which DPYD genotyping was performed. She turned out to carry both 
DPYD*2A and c.2846A>T. Taking this result into account and previous 5-FU combination 
therapy without any problems, capecitabine was started at 50% dose (800 mg twice daily). 
The therapy was discontinued due to side effects (hand-foot syndrome CTC-AE grade 1, 
diarrhea CTC-AE grade 1─2 and abdominal cramps CTC-AE grade 1─2). Internal evaluation 
using plasmids showed that the SNPs were both located at a different chromosome (in 
trans). For the purpose of this study, additional material was collected for DPD enzyme 
activity, which was low, but within normal range 6.0 nmol/(mg*h) (normal range 5.9─14 
nmol/(mg*h). 
Patient 3
A 61 year old patient was diagnosed with metastatic colorectal cancer (pT4N2M1). After 
a laparoscopic hemicolectomy was performed, chemotherapy with capecitabine and 
oxaliplatin was scheduled. The DPYD genotype was determined and two variants (c.2846A>T 
and c.1236G>A) were found. In addition to this, the DPD enzyme activity was measured, 
which was 4.5 nmol/(mg*h). The capecitabine dose was adjusted to ~50% (1,800 mg per 




cycle. Upon this increased dose, the patient developed thrombocytopenia CTC-AE grade 3 
and complaints of anorexia, nausea and fatigue CTC-AE grade 1─2. In the third cycle, 57% 
dose was applied, resulting in a new thrombocytopenia CTC-AE grade 2. After these three 
cycles disease progression was noted and treatment was discontinued. For the purpose of 
this study, additional material was collected for the PacBio analysis and this patient carried 
both DPYD variants on different alleles (in trans). (Also described by Henricks et al.).1
Patient 4
A 38 year old patient was diagnosed with breast cancer. After surgery (pT2N0) and hormonal 
therapy (tamoxifen for three years) disease progression was established, and other hormonal 
therapies (anastrozole for two years, exemestane for two years andfulvestrant) followed. 
Due to liver metastases treatment was continued with capecitabine (1,500 mg twice daily). 
Severe side effects (CTC-AE grade 3 oral mucositis) occurred after seven days of treatment 
for which chemotherapy was discontinued immediately and the patient was admitted to the 
hospital. During two weeks of hospital admission severe thrombocytopenia (CTC-AE grade 
3), neutropenia and leukopenia (both CTC-AE grade 4) occurred. The patient deteriorated 
(respiratory problems, multiple organ failure), treatment against side effects was stopped 
and the patient died. During hospital admission, DPD enzyme activity was measured, which 
was extremely low (0.11 nmol/(mg*h)). Also, the DPYD genotype was determined and two 
variants (DPYD*2A and c.2846A>T) were found. No additional analyses for this study were 
performed for this patient.
Patient 5
A 57 year old patient was diagnosed with colorectal adenocarcinoma (T4N0) for which a 
right hemicolectomy and trans anal endoscopic microsurgery of the rectum were performed. 
Approximately one year later, recurrence of rectal carcinoma was discovered (T4N2). The 
patient was also diagnosed with prostate cancer around the same time. Chemo radiotherapy 
was planned, consisting of radiotherapy on the rectum (25x2Gy) and prostate (total of 78Gy) 
combined with capecitabine. The patient participated in a clinical trial (NCT00838370) for 
which prospective genotyping (DPYD*2A) was performed.2 The patient tested positive and 
treatment was adjusted on the second day to 50% of capecitabine dose (800 mg twice daily). 
No severe side effects occurred. During treatment, DPD enzyme activity was measured, and 
was within normal range (7.2 nmol/(mg*h)). After treatment the patient was genotyped 
retrospectively for additional DPYD variants and was also a carrier of the c.2846A>T variant. 
For the purpose of this study, extra material was collected for the PacBio analysis and this 
patient carried both DPYD variants on a single allele (in cis).
Patient 6
A 67 year old patient was diagnosed with metastasized colorectal adenocarcinoma and 
treated with capecitabine (1,000 mg/m2 twice daily) and oxaliplatin. The patient experienced 
CTC-AE grade 4 neutropenia, thrombocytopenia and leukopenia, CTC-AE grade 3 nausea, 
vomiting, diarrhea, stomatitis and anorexia. Toxicity resolved after continuing with an 
unknown dose reduction. The DPD enzyme activity and DPYD genotype were determined 
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after toxicity was resolved. A reduced enzyme activity of 3.8 nmol/(mg*h) and two variants 
(DPYD*2A and c.1236G>A/c.1129-5923C>G) were found. Approximately a year later, the 
patient was again treated with the unknown reduced capecitabine dose and oxaliplatin, 
which was stopped after six cycles due to toxicity. No additional analyses for this study were 
performed for this patient.
Patient 7
A 61 year old patient was diagnosed with disseminated colorectal cancer (pT4N1M1) who 
underwent surgical hemicolectomy. Palliative chemotherapy consisting of capecitabine 
(1,000 mg/m2 twice daily, day 1─14), oxaliplatin (130 mg/m2, day 1) and bevacizumab (7.5 
mg/kg, day 1) was started. After eleven days of chemotherapy, the patient was admitted 
to the hospital with CTC-AE grade 3 diarrhea and nausea with vomiting, and CTC-AE grade 
2 fever. Capecitabine was stopped immediately. Loperamide therapy was started but the 
diarrhea persisted. The patient was discharged from the hospital after 13 days. The measured 
DPD enzyme activity was low (1.6 nmol/(mg*h)), and DPYD genotype was DPYD*2A and 
c.1236G>A/c.1129-5923C>G, both measured after therapy. No additional analyses for this 
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Supplementary Figure 1. Illustration of molecular methods
 ddPCR: Droplet Digital PCR (ddPCR)3 is a method based on water-oil emulsion droplet technology. 
DNA isolation is performed using MagNA Pure Compact Nucleic Acid Isolation Kit I (Hoffmann-La 
Roche, Basel Switzerland). A DNA sample is fragmented into tens of thousands of droplets (A) and PCR 
amplification of DNA is present in each droplet (B). PCR is based on standard TaqMan probe-based 
assays. In this study, we used FAM and HEX fluorescent labels, shown in red and blue (primers and 
probes used are; F-primer: CTGATCTTCATCTTCATTCC, R-primer: AGGTGGGAGAATTGTTGCTAT, probe: 
HEX-CCAGTTTCATCTTGTTCTGTCCGAACAA-BHQ, F-primer: TCACTGAACTAAAGGCTGA, R-primer: 
CAACTTATGCCAATTCTCTTG, probe: FAM-CTTTCCAGACAACATAAGTGTGATTTAAC-BHQ). In patients 
with two variants on a single allele (in cis) most droplets will emit both fluorescent labels, resulting 
in a combined color purple, where in patients with two variants on different alleles (in trans) most 
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droplets only emit one fluorescent label, red or blue, when the DNA strands are being amplified. All 
droplets are read out one by one (C) and in cis or in trans phasing can be determined (D). ddPCR can 
be used for DNA samples and detect phasing of variants in up to 200 kb. For DPYD, combinations of 
DPYD*2A+DPYD*13 (66 kb distance) and DPYD*2A+c.1236G>A (124 kb distance) can be determined 
using ddPCR. 
 PacBio: Pacific Biosciences RSII (PacBio)4 starts with RNA isolation from PAXgene tubes using 
RNeasy® Mini Kit (Qiagen, Hilden Germany) according to manufacturer’s protocol. Then, cDNA is 
synthesized using SuperScript® III First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad 
CA USA) using oligo-dT or DPYD gene specific reverse primers (F2: GTTTGCCAGAACCCAATAAAGA, 
F3: CGTCATTGTACTTGGAGCTGG, Rev: CCACAAAACCTGTATTACTGAATAA, Rev-comp: 
TTATTCAGTAATCAGGTTTTGTGG). cDNA is amplified using KAPA HiFi HotStart ReadyMixPCR Kit 
(Kapabiosystems, Wilmington MS USA). Amplicon preparation is executed according to PacBio® 
Procedure and Checklist - Amplicon Template Preparation and Sequencing. PacBio is based on single 
molecule real-time (SMRT) sequencing. On each of the four nucleotides different fluorophore labels 
are attached (A), which will emit when the nucleotide is build-in, which is shown as a fluorescence 
pulse or color peak (B). When a patient carries multiple variants, multiple fluorescent labels will be 
emitted at the same time, resulting in two color peaks simultaneously (C). Variants can either be 
located on the same strand (in cis) or on different strands (in trans), determined by reading the strands 
(D). The advantage of SMRT-sequencing is that longer read lengths of DNA or RNA are possible, 
therefore phasing of variants in the large DPYD gene can be determined.
 Plasmid: cloning as described previously.5 First, patient RNA was isolated using RNeasy® Mini Kit 
(Qiagen, Hilden Germany). With 500 ng RNA, cDNA was synthesized using 10 mol/µl oligodT primer in 
a 10.25 µl volume which was incubated for 10 minutes at 70 degrees Celsius. After cooling, 2 µl 0.1M 
DTT, 2 µl dNTPs (5 mM), 4 µl first strand buffer, 0.5 µl reverse transcriptase (RT), and 0.25 µl RNasin® 
(Invitrogen, Bleiswijk the Netherlands) was added and incubated for 1 hour at 37 degrees Celsius. 
Thereafter, a PCR was performed using Qiagens universal mastermix and primers approximately 
500 nucleotides up or downstream of the variants (DPYD*2A: ACCACCTCTGGCCCCATG, c1236G>A: 
GGTGGGAGAATTGTTGCTATG and c.2846A>T: GTAGCCAGAATCATTACAGG). Plasmids were created by 
ligation of the specific PCR products into pGEM-T Easy vector (A) (Promega, Leiden Netherlands) as 
follows: 0.5 µl pGEM-T Easy, 0.5 µl Ligase, 3 µl PCR product and 4 µl buffer was incubated for 2 hours 
at room temperature. Ligation mixture was transformed to competent E coli cells (JM109) (B) and 
plated on IPTG/Xgal (Promega, Leiden Netherlands) containing LB-ampicillin agar plates (Acumedia 
Neogen, Ayrshire UK). Plates were incubated overnight at 37 degrees Celsius. Next day, cells with 
successful insertions (resulting in white colonies) are grafted in 2 ml LB-ampicillin and shaken overnight 
at 37 degrees Celsius. Plasmid DNA was isolated using Miniprep Kit (Qiagen, Hilden Germany) and 
restriction enzyme EcoR1 as used to check for insertion of PCR product (approximately 1000 bp 
insert). Thereafter, sequencing was performed by Macrogen (Amsterdam, the Netherlands) using 
primers T7 (GTAATACGACTCACTATAGGGC) and SP6 (ATTTAGGTGACACTATAGAA) located on both sides 
of A-T ligation side (C). Plasmids contain only one allele of the PCR product, thus combined sequence 
result of T7 and SP6 primers determines the haplotype. Thus, when only one variant was found, the 
unidentified variant is located on the other allele, and therefore phasing results are in trans. When 
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Fluoropyrimidines are widely used anticancer drugs, but may lead to severe toxicity in up 
to 30% of patients. Prospective DPYD genotyping is increasingly used in clinical practice 
to predict and prevent severe toxicity, by means of initial dose reductions in DPYD variant 
allele carriers. While this strategy successfully reduces the incidence of severe toxicity, 
substantial toxicity remains that is not attributable to genetic variation in DPYD. A genome-
wide association study (GWAS) was initiated to discover novel genetic variants associated 
with the onset of severe fluoropyrimidine-induced toxicity. 
 We conducted a GWAS in 1,146 patients treated with fluoropyrimidines who participated 
in the Alpe DPD study. Patients were genotyped using the Illumina Global Screening 
Array and data was imputed using the 1000 Genomes reference panel. The primary 
outcome was severe (grade ≥3) fluoropyrimidine-induced toxicity, compared to grade 0 
or 1 fluoropyrimidine-induced toxicity. Variants were tested for association with severe 
fluoropyrimidine-induced toxicity using logistic, Cox, and ordinal regressions. A Polygenic 
Risk Score (PRS) was constructed by extracting all variants with p<0.01 in the association 
test.
 1,101 patients passed the quality control (QC) analyses and 599 patients were included 
in the primary analysis. After imputation, 4,650,899 variants were included in the analysis. 
None of the genetic variants showed genome-wide significance (p<5x10-8). Six variants were 
suggestive (p<5x10-6) for the onset of severe fluoropyrimidine-induced toxicity. A PRS was 
constructed including 5,055 variants and predicted 62% of severe toxicity by non-genetic 
covariates alone and 96% by the combined analysis including covariates. 
 While no genome-wide significant variants could be identified, six variants were 
suggestive for the onset of severe toxicity in merely Caucasian patients. These variants are 
located outside of known fluoropyrimidine-pathway genes. Using a PRS consisting of 5,055 
variants combined with clinical variables explained 96% of toxicity in this discovery cohort. 
This GWAS is one of the first attempts to identify variants predictive for fluoropyrimidine-
induced toxicity and identified variants and the PRS require replication in an independent 
cohort.
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Fluoropyrimidines, including 5-fluorouracil (5-FU) and capecitabine, represent the backbone 
of chemotherapeutic regimens used to treat solid tumours, such as colorectal and breast 
cancer. Severe (grade ≥3) fluoropyrimidine-induced toxicity can occur in up to 30% of the 
patients, depending on the treatment regimen and may even be lethal in up to 1% of the 
patients experiencing toxicity.1,2 Common fluoropyrimidine-induced adverse events are 
diarrhoea, mucositis, hand-foot syndrome and myelosuppression.1,3 Dihydropyrimidine 
dehydrogenase (DPD) plays a key role in the degradation of 5-FU into inactive metabolites4 
and is encoded by the gene DPYD. Both DPD and genetic variants in DPYD have been widely 
investigated to explain severe fluoropyrimidine-induced toxicity. Recently, we have shown 
that prospective genotyping and dose reduction based on four variants in DPYD (DPYD*2A, 
c.2846A>T, c.1679T>G and c.1236G>A) reduces severe fluoropyrimidine-induced toxicity in 
these DPYD variant allele carriers.5 These four variants were selected based on previous 
studies and meta-analyses in which the association with fluoropyrimidine-induced toxicity 
was reported.6-13 Nonetheless, severe toxicity did still occur in 23% of patients wild-type for 
these four variants, showing that other genetic variants or non-genetic factors may play a 
role in the onset of severe toxicity.5 
 Variants in genes other than DPYD could also play a role in the onset of severe 
fluoropyrimidine-induced toxicity. Previously, research to identify genetic variants 
has been conducted based on the pharmacological background of fluoropyrimidines, 
for example in pathway analyses or candidate gene studies. Several variants in CDA 
(cytidine deaminase), CES1 (carboxylesterase 1), TYMS (thymidylate synthase), MTHFR 
(methylenetetrahydrofolate reductase), ENOSF1 (enolase superfamily, member 1), SLC22A7 
(solute carrier family 22, member 7), UMPS (uridine monophosphate synthase) and TYMP 
(thymidine phosphorylase) genes were previously identified and associated with severe 
fluoropyrimidine-induced toxicity.1,14-21 However, genome-wide association studies (GWAS) 
have the potential to identify novel variants without making assumptions based on a 
pharmacological background. Previously, O’Donnell et al. executed a GWAS on 503 cell 
lines to identify novel single nucleotide polymorphisms (SNPs) associated with capecitabine 
sensitivity.22 Five variants showed genome-wide significance in this cell-line based GWAS, 
but replication in 268 patients only showed an association with sensitivity for capecitabine 
for ADCY2 rs4702484.23 Fernandez-Rodzilla et al. analysed data of 221 colorectal cancer 
patients treated with 5-FU or FOLFOX (folinic acid, 5-FU and oxaliplatin).24 Seven SNPs were 
associated with adverse drug reactions, yet none reached the genome-wide significance 
level. Low et al. executed a GWAS on 13,220 patients in total, of which 1,460 patients 
received 5-FU, focussing on neutropenic and leukopenic toxicities.25 For 5-fluorouracil, 
they identified four SNPs associated to neutropenia and leukopenia, yet none reached the 
genome-wide significance level. We conducted a GWAS to discover novel genetic variants 





Patients were recruited for the Alpe DPD study (clinicaltrial.gov identifier NCT02324452)5 
between April 30, 2015 and December 21, 2017, and were newly treated with fluoropyrimidines 
and genotyped prospectively for four DPYD variants (DPYD*2A, rs3918290, c.1905+1G>A, 
IVS14+1G>A; c.1679T>G, DPYD*13, rs55886062, I560S; c.1236G>A/HapB3, rs56038477, 
E412E; and c.2846A>T, rs67376798, D949V). Upon identification of one of these variants, 
heterozygous variant allele carriers received an initial dose reduction (25 or 50%) based on 
pharmacogenetic guidelines to prevent severe fluoropyrimidine-induced toxicity. Wild-type 
patients for these four DPYD variants received standard fluoropyrimidine dosages. After the 
second cycle the dose could be titrated upwards or downwards according to the occurrence 
of toxicity. The study was reviewed and approved by the medical ethical committee of the 
Netherlands Cancer Institute, Amsterdam, the Netherlands, and approval of the board of 
directors of each individual hospital was obtained for all participating centres. All patients 
signed informed consent prior to inclusion in the study, which included approval for the 
use of clinical data and remaining DNA to perform the current GWAS. All patients of whom 
sufficient DNA was available were genotyped. DPYD variant allele carriers (N=85) received 
dose reductions based on the four variants mentioned and were therefore excluded in the 
GWAS analyses. 
Clinical data
Baseline characteristics, treatment type and toxicity data were collected for each patient. 
Ethnicity of the patients was self-reported, merely Caucasian patients participated in the 
Alpe DPD study. Toxicity was graded according to the National Cancer Institute common 
terminology criteria for adverse events (CTC-AE; version 4.03) and severe toxicity was 
defined as CTC-AE grade ≥3.26 Relation to the study drugs 5-FU and capecitabine was 
recorded for each adverse event and only adverse events classified as possible, probable, or 
definite were taken into account. 
Genotyping and quality control
Patient DNA remaining from the Alpe DPD study was collected. For each patient 200 ng 
of DNA was required and genotyping was executed at the Human Genotyping Facility 
of the Erasmus Medical Center, using the Illumina Global Screening Array (GSA).27 The 
array contains 692,842 SNPs and includes rare variants with allele frequencies <1%. 1000 
Genomes reference phase 3 GRCh37.p13 was used to impute the data. Quality control 
(QC) checks were performed using software R version 3.5.028 and PLINK software, version 
1.07.29,30 Patients were excluded from analyses based on an individual genotype call rate 
<97%, gender mismatch between reported and estimated sex based on genotypes of the 
X-chromosome (using PLINK), or excess of heterozygous genotypes as measured by the 
inbreeding coefficient. An inbreeding statistic of F>0.1 was judged to be outlying and patients 
were removed from the analysis. Genetic markers were excluded based on a SNP call rate 
<97% and a p-value ≤10-7 for the Hardy-Weinberg equilibrium (HWE) goodness-of-fit test. 




for integrative QC assessment. In order to evaluate the possibility of population stratification 
or outliers, multidimensional scaling (MDS) analysis was performed in PLINK. In addition, 
pairwise identity by state (IBS)/identity by descent (IBD) statistics was calculated to assess 
duplicates. MDS, IBS and IBD were computed using PLINK. Patients who were identified as 
outliers based on IBS clustering were excluded from the analysis. MDS coordinates were 
extracted and used as covariates in the association analysis. SNP imputation was performed 
using the programs shapeit and impute2 with default parameters in which the reference 
panel 1000Genomes build version 3 was used with total, ‘cosmopolitan’, set of individuals.31 
An MDS plot was created to compare self-reported ethnicity of patients.
Statistical analyses
Genetic variants were tested for an association with the onset of severe fluoropyrimidine-
induced toxicity. The primary outcome was severe (grade ≥3) fluoropyrimidine-induced 
toxicity, compared to grade 0 or 1 fluoropyrimidine-induced toxicity. Grade 2 toxicity 
was excluded from this analysis to maximize the contrast between toxicities. Gender, 
age, baseline BSA and treatment type (grouped as previously published)5 were used as 
pre-specified covariates. Statistical analyses were performed in R statistics version 2.3.2. 
Base packages stats,  survival and MASS were used to evaluate logistic, Cox, and ordinal 
regressions, respectively. Associations with a p-value ≤5x10-8 were considered statistically 
genome-wide significant. Associations with a p-value between 5x10-8 and ≤5x10-6 were 
considered suggestive. Post association QC was performed by visual inspection of Quantile-
Quantile (QQ) plots of p -values of association tests and computation of the inflation factor 
given as: λ=(median(T1,…,Tn)/0.675)
2, where T1,…,Tn are square roots of χ
2 quantiles. 
 A Polygenic Risk Score (PRS) was constructed by extracting all SNPs with a p-value <0.01 
in the association test. To avoid problems due to collinearity, in the list sorted according to 
p-values, SNPs in a window of 100 kb were excluded after inclusion of a SNP. A penalized 
regression model was fitted using R-package glmnet. Included clinical parameters were 
gender, age, baseline BSA and treatment schedule.
Results
Patients
Sufficient DNA was available for 1,146 out of 1,181 recruited patients (97%). These 
patients entered the QC procedure prior to association analyses. The flowchart on 
patient inclusion is shown in Figure 1. The observed individual genotype call rates varied 
between 97% and 100% and therefore meet the quality criteria. Based on subsequent 
QC steps, 45 patients (3.9%) were excluded from the analyses. Of these 45 patients, 30 
patients (2.6%) were excluded due to missing genotypes, four (0.3%) patients were 
excluded due to a gender mismatch with the clinical data, six patients (0.5%) were 
excluded based on outlier removal of IBS plots. The inbreeding coefficient was 0.01 
(-0.03─0.004), therefore, five (0.4%) patients were excluded. Of the 1,101 remaining 
patients, screen failures (N=55), patients with missing BSA at baseline (N=24) and DPYD 
variant allele carriers who received initially reduced dosages (N=80) were excluded (Figure 
1). In addition, we chose to exclude patients who experienced grade 2 toxicity (N=343) 
from the primary analysis to maximize contrast between severe and non-severe toxicity. 
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Excluded by QC analyses (N=45):
- Missing genotypes (N=30)
- Incorrect gender (N=4)
- IBS rule (N=6)
- Inbreeding coefficient (N=5)
Toxicity grade 2
N=343





- Screen failure (N=55)
- DPYD variant carrier (N=80)
- Baseline BSA missing (N=24)
Evaluable patients
N=1101
Figure 1. Flowchart of patients in the study
Patients who experienced toxicity grade 2 were excluded from the primary analyses to maximize 
contrast between severe and non-severe toxicity.
Abbreviations: QC: quality control; IBS rule: identity by state rule; DPYD: gene encoding 
dihydropyrimidine dehydrogenase; BSA: body surface area.
Association analysis
In the primary analysis, severe (grade ≥3) toxicity was compared to grade 0 and 1 toxicity 
in 599 patients. Patient characteristics of patients included in the primary analysis of this 
study and patients from the Alpe DPD study are shown in Table 1. There were no statistical 
differences between the cohorts, except for the number of treatment cycles. 
 The number of patients varied per SNP due to genotype missingness, which was limited 
to up to 3% as per QC. For the primary analysis, a MAF of 2% was used on imputed data to 
ensure stable numeric evaluation of all logistic regression models. This resulted in a total of 
4,650,899 markers for which an association test was performed.
 The primary analysis association test for severe fluoropyrimidine-induced toxicity (grades 




Manhattan plot is shown in Figure 2. The corresponding QQ-plot of p-values is shown 
in Figure 3. The inflation factor is 1.04. Table 2 shows the list of the top 30 identified 
markers. No variants were identified to be statistically significant associated with severe 
fluoropyrimidine-induced toxicity at the genome-wide level. However, six SNPs were found 
to be suggestive. None of these SNPs have previously been reported in publications or in 
the ClinVar database of the National Center for Biotechnology Information (NCBI).32 The 
variants are reported in the SNP database of the NCBI.33 Three variants are stated on the 
website as having ‘no gene consequence’, two were listed as an intron variant in RNA gene 
LOC101927414 (rs114105116) and protein coding gene COL6A3 (rs12622722), and one was 
listed as an 2KB upstream variant in LOC107984256 (rs10786179). 
Genotyping and quality control
A set of 692,367 markers was genotyped. After several QC steps, 186,920 markers were 
excluded. Of these, 18,114 markers (2.6%) were excluded based on a deviation from Hardy-
Weinberg equilibrium (HWE). Filtering for allele frequencies (threshold 0.5%) resulted in 
the exclusion of 147,607 markers (21.3%). The missingness cut-off was set at 10%, 23,835 
markers (3.4%) were excluded based on the missing data analysis. Of the abovementioned 
excluded markers, 2,636 had multiple QC failures. In total, 505,447 markers met the QC 
for statistical analyses. These markers were imputed using the 1000 Genomes dataset as 
a reference panel. In total, 4,650,899 variants were available for statistical analyses. In the 
integrative QC, individuals and markers from the marginal QC steps were excluded. An MDS 
was executed in order to detect population stratification. No individuals were excluded. IBD/
IBS clustering was executed to assess duplicates. No individuals were excluded. 
Polygenic risk score
To calculate the PRS all SNPs with a p-value <0.01 for their association with severe 
fluoropyrimidine-induced toxicity were selected. To reduce linkage disequilibrium, SNPs 
were pruned for a minimum distance of 105 bps. This resulted in a set of 5,055 SNPs. Finally, 
an elastic net regression (R package glmnet, α=0.5) was performed and evaluated by cross-
validation. The receiver operating characteristic (ROC) curve is shown in Figure 4, where it 
is compared to the model containing only clinical covariates. The two corresponding areas 
under the curve (AUCs) were 96% and 62%, respectively. 
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Table 1. Patient characteristics
Patient characteristics of patients included in the primary analysis of this GWAS (N=599) and patients 
included in the Alpe DPD study (N=1,103). Data are N(%) or median(IQR). P-values comparing 
patients from the primary analysis to the Alpe DPD study patients. We used a nonparametric test for 
independent samples to compare medians of age, BSA, and number of treatment cycles; and a χ² test 
for gender, ethnic origin, tumour type, treatment regimen and WHO performance status.
Characteristic GWAS cohort 
(N=599)




   Male










   Asian














   Gastric cancer







































BSA [IQR] 1.9 [1.8─2.1] 1.9 [1.8─2.1] 0.503
WHO performance status
   0
   1



























a Other ethnic origins included Hispanic descent, mixed racial parentage, and unknown ethnic origin;
b Other tumour types included anal cancer, oesophageal cancer, head and neck cancer, pancreatic 
cancer, bladder cancer, unknown primary tumour, vulva carcinoma, and several rare tumour types;
c WHO performance status was not specified for these patients, but was either 0, 1, or 2, as required 
by the study inclusion criteria.
Abbreviations: IQR: interquartile range; BSA: body surface area; DPD: dihydropyrimidine dehydrogenase; 
DPYD: gene encoding dihydropyrimidine dehydrogenase; WHO: world health organisation; NA: not 
applicable. 
Figure 2. Manhattan plot
Manhattan plot for association with severe fluoropyrimidine-induced toxicity (grades 3─5), including 
de covariates gender, age, baseline BSA and treatment type. Genome-wide significance of the 
association with the onset of severe fluoropyrimidine-induced toxicity is indicated by the upper dark 
red line (≤p-value of 5x10-8). Suggestive association is indicated by the lower red line (p-value of ≤5x10-
6). No SNPs were found to be associated with severe fluoropyrimidine-induced toxicity. Six SNPs were 
found to be suggestive for association with severe fluoropyrimidine-induced toxicity, shown in Table 2. 
Abbreviations: BSA: body surface area; SNPs: single nucleotide polymorphisms. 
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Figure 3. QQ-plot of p-values
The Quantile-Quantile (QQ)-plot shows the extent to which the observed distribution of the test 
statistic follows the theoretical null distribution. The inflation factor was λ=1.04. 
Table 2. Thirty SNPs with lowest p-values 
Variants are selected on allele frequency >0.01, β within -5 to 5, and are separated from another 
variant with more than 10 bps. Variants suggestive for the onset of severe toxicity are marked with 
an *. 
Nr. Marker Chr Position A0 A1 AF β P-value
1 rs17114875 * 14 29999987 G A 0,409 1,554562193 9,73E-07
2 rs114105116 * 4 138539880 T A 0,02 1,213779485 1,1E-06
3 rs12622722 * 2 238269120 G A 0,484 0,657789872 1,77E-06
4 rs10786179 * 10 96759531 T G 0,889 -0,345506543 2,03E-06
5 rs367239 * 3 21421935 T C 0,546 1,719787858 3,16E-06
6 rs11630087 * 15 75261673 G T 0,456 0,757448146 4,71E-06
7 rs77579689 8 137130325 G A 0,021 1,286849892 5,18E-06
8 rs11187969 10 96231169 G A 0,129 1,381495967 5,59E-06
9 rs11187974 10 96239326 G A 0,181 1,527446065 6,25E-06
10 rs12414693 10 97228795 C T 0,259 0,713658584 6,87E-06
11 rs482061 1 182485749 T C 0,847 -0,737925221 6,96E-06
12 chr4:164083322:D 4 164083322 TG T 0,051 1,218271821 7,11E-06
13 chr16:78157332:I 16 78157332 G GTT 0,065 1,023072586 7,63E-06
14 rs1838947 11 119691200 T C 0,297 0,928423057 7,7E-06





Nr. Marker Chr Position A0 A1 AF β P-value
16 rs56338926 15 75259335 C A 0,448 0,772401797 7,94E-06
17 rs449973 3 21425977 C G 0,548 1,69493935 7,97E-06
18 rs1722291 7 56238936 G A 0,198 1,553925389 8,02E-06
19 rs2344989 17 70924851 T C 0,04 1,54932572 8,33E-06
20 rs2512155 11 117889448 C T 0,179 1,449722565 8,45E-06
21 rs8076418 17 70921917 T C 0,042 1,608309687 8,5E-06
22 rs2738545 16 78629320 G A 0,673 0,420462271 9,13E-06
23 rs10851447 15 47411086 T A 0,059 1,464774341 9,21E-06
24 rs722910 5 52781597 A T 0,496 0,35577388 9,36E-06
25 rs8070810 17 70921851 G A 0,042 1,61395951 9,42E-06
26 rs8067883 17 70921731 C T 0,042 1,612564569 9,43E-06
27 rs6501582 17 70921801 T C 0,042 1,613613576 9,44E-06
28 rs113309475 1 11430624 A T 0,023 1,200617555 9,49E-06
29 rs9911437 17 70922305 T C 0,042 1,614540275 9,49E-06
30 chr17:70923098:D 17 70923098 AC A 0,042 1,614669511 9,65E-06
Abbreviations: Nr: number; Chr: chromosome; A0: nucleotide on allele 0; A1: nucleotide on allele 1; 
AF: allele frequency.
Figure 4. PRS-plot 
The PRS-plot shows the predictive power of a covariate model (Clinical, blue line) and a covariate 
model plus 5,055 SNPs (PRS, red line). Included clinical parameters were gender, age, baseline BSA 
and treatment schedule. The AUC for the covariate model is 0.620 (95%CI: 0.577-0.663, p=1.34-09), 
compared to the AUC for the combined model (prs) 0.956 (95%CI: 0.939-0.973, p=3.98-140). 




It is well recognized that DPYD genotyping is useful in preventing severe fluoropyrimidine-
induced toxicity by applying initial dose reductions in patients who carry a specific DPYD 
variant.5 However, not all toxicity can be predicted and prevented by the current four DPYD 
variants. Indeed, still ~20% of the patients experience toxicity, thus the search for genetic 
variants predictive for severe fluoropyrimidine-induced toxicity continues. We executed a 
GWAS in order to identify novel genetic variants possibly associated with the onset of severe 
fluoropyrimidine-induced toxicity.
 To perform this GWAS on toxicity of fluoropyrimidines, over 1,100 patients were genotyped. 
Severe toxicity includes the National Cancer Institute CTC-AE grades 3─5. Scoring clinical 
toxicities can be difficult sometimes, as it can be open to interpretation. As severe toxicity 
has the most clinical impact, we chose to maximize contrast to the toxicity endpoint, and we 
excluded patients with grade 2 toxicity in the primary analysis. We were unable to identify 
genome-wide significant SNPs, yet we identified six SNPs suggestive (p-value of 5x10-6) of 
association with severe fluoropyrimidine-induced toxicity. Possibly the number of patients 
in our study is too small to reach genome-wide significance. However, we repeated the 
analysis including the patients with grade 2 toxicity, increasing the number of patients while 
reducing the contrast between toxicities. Yet, this did not result in a different outcome. The 
suggestive variants need to be re-tested in an independent cohort of patients who were 
treated with a fluoropyrimidine drug.
 This GWAS was executed using DNA from patients participating in the Alpe DPD study. 
A formal comparison of GWAS analysed patients with the entire Alpe DPD cohort shows 
the cohorts were comparable. The range of number of treatment cycles was statistically 
different, with fewer cycles in the GWAS cohort. Possibly this is due to the exclusion of 
patients with grade 2 toxicity in the GWAS cohort, as grade 2 toxicity, if not developing into 
severe toxicity, may possibly arise from longer periods of fluoropyrimidine-treatment. We 
have no reason to believe that selection bias was introduced by leaving out patients with 
grade 2 toxicity. We believe the GWAS cohort is representative for patients in daily clinical 
care, as in the Alpe DPD study there were only limited restrictions on the inclusion criteria 
and the burden for patients to participate was very low.
 With a large amount of genotyping data, we were able to compare ethnicity strings in the 
MDS plots to self-reported ethnicity from the Alpe DPD study. When adding two principal 
components, including ethnicity, to the statistical analysis, no differences were visible. 
Therefore, ethnicity was not of influence on the outcome of this GWAS and no patients 
were excluded based on self-reported ethnic origin. 
 Data on the functionality of the six SNPs suggestive of association with severe 
fluoropyrimidine-induced toxicity is limited. To the best of our knowledge, these six SNPs 
were not previously identified by other GWAS or other studies, or previously described 
in relation to the fluoropyrimidine pathway. Genome-wide significant SNPs (rs4702484, 
rs8101143, rs576523, rs361433) and suggestive SNPs (rs16857540, rs2465403, rs10876844, 
rs10784749, rs17626122, rs7325568, rs4243761, rs10488226, rs6740660, rs1567482 and 
rs6706693) identified in previously executed GWAS,22,24,25 were not identified in this GWAS, 




GWAS of Low et al. focused only on neutropenia and leukopenia as toxicity endpoint.25 In 
the current GWAS we chose to include all types of fluoropyrimidine-induced toxicity, as we 
aim to improve fluoropyrimidine treatment by reducing all types of toxicity. Compared to 
the GWAS of O’Donnell et al. 22, we offer a cohort with clinical patient data representative of 
daily clinical care, in order to identify variants which could be clinically relevant. Compared 
to the GWAS of Fernandez-Rodzilla et al. our cohort is much larger.24 
 When applying prospective DPYD genotyping, still 23% of patients treated with 
fluoropyrimidines experience severe toxicity.5 In order to further reduce this number, other 
genetic variants predictive for severe toxicity need to be identified. Options are to screen 
for rare variants in DPYD, investigate epigenetics, or look outside of the DPYD gene as 
was performed in this GWAS. The onset of severe toxicity might not only be linked to the 
start of fluoropyrimidines, but can be multifactorial and linked to patient characteristics or 
co-medication. In line of that thought, the onset of toxicity might be better predicted by 
multiple genetic variants. For this reason, we executed the PRS analysis. In addition, the 
future of genotyping is quickly evolving, with less single SNP-based assays and more assays 
with a panel of SNPs in genes or assays sequencing entire regions of genes, leading to future 
possibilities to apply a PRS in patients in clinical care. Our PRS analysis showed that a panel 
of 5,055 SNPs combined with clinical covariates outperforms clinical parameters alone, and 
can predict 96% of severe fluoropyrimidine-induced toxicity. Our PRS analysis possibly shows 
too optimistic results due to the pre-selection of significant SNPs into the score. Although 
we used cross-validation to verify the score, this step did not include the SNP selection as 
this would have been computationally prohibitive. We see this as an exploratory analysis 
that needs validation, but still suggests that low penetrance variants exist which are difficult 
to prove in a single-variant association test. The PRS analysis shows the possibility of future 
research with a multifactorial research approach. The panel of SNPs needs replication in a 
validation cohort and additional research is needed to be able to link the result to a dose 
adjustment advice in order to prevent toxicity.
 In conclusion, while no genome-wide significant SNPs could be identified in our unique 
dataset of patients, six variants were suggestive for the onset of severe toxicity. These 
variants are located outside of known fluoropyrimidine-pathway genes. Using a PRS 
consisting of 5,055 SNPs combined with clinical variables explained 96% of toxicity in an 
optimistic analysis, suggesting highly polygenic nature of toxicity predisposition. This GWAS 
is one of the first attempts to identify variants predictive for fluoropyrimidine-induced 
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Severe (grade ≥3) toxicity remains a significant problem in treatment with fluoropyrimidines 
such as 5-fluorouracil (5-FU) and capecitabine. Personalised medicine, specifically DPYD 
genotyping, is a promising strategy to predict and prevent severe fluoropyrimidine-
induced toxicity. This thesis focusses on reducing the risk of severe fluoropyrimidine-
induced toxicity by optimizing DPYD genotyping and improving implementation of DPYD 
genotyping in daily clinical care. In addition, we investigate DPD phenotyping and innovative 
genotyping techniques beyond current DPYD pharmacogenetics (PGx) to prevent severe 
fluoropyrimidine-induced toxicity.
Personalised medicine: why choose pharmacogenetics (PGx)?
Up to 30% of patients treated with fluoropyrimidines experience severe treatment-related 
toxicity. Besides the direct consequences of severe fluoropyrimidine-induced toxicity, it 
additionally can affect patients’ quality of life and efficacy of the therapy can be reduced when 
treatment cannot be resumed due to toxicity. A major contributor to the onset of severe 
fluoropyrimidine-induced toxicity is a reduced activity of the enzyme dihydropyrimidine 
dehydrogenase (DPD), as has been described since the eighties in several case reports.1-3 
Patients with a complete deficiency for DPD are rare (~0.1%) and have shown neurological 
disorders, such as convulsion, seizures and epileptic attacks.4-7 Yet, there is great variation 
between patients. Also, patients who are partially DPD deficient generally do not show 
any phenotypic features. In order to predict and prevent severe fluoropyrimidine-induced 
toxicity, DPD deficient patients must be identified prospectively and treated individually 
(personalised medicine). 
 One way to identify DPD deficient patients, is to measure the DPD enzyme activity in 
peripheral blood mononuclear cells (PBMCs).2,8,9 However, the method is not widely used 
since feasibility in clinical practice is difficult due to substantial costs, complex sample 
logistics and specific equipment required for the radio assay. In addition, there is substantial 
intra patient variability (up to 25%) in DPD enzyme activity, possibly caused by circadian 
rhythm.10,11 An estimated 3─8% of the patients is DPD deficient. Therefore it is important to 
have inexpensive diagnostics for DPD deficiency, as all patients receiving fluoropyrimidines 
need to be tested while the majority of the tested patients does not require an adjusted 
dose or therapy. When a treatment plan has been decided, it is important to start the 
chemotherapy as soon as possible, thus short turn-around times of a test are essential as 
well. 
 Multiple genetic variants in DPYD, the gene encoding for DPD, lead to altered DPD enzyme 
activity.12 Identifying such DPYD variants can indirectly identify DPD deficient patients. 
There are relatively quick, easy and inexpensive methods available to perform genotyping, 
therefore upfront DPYD genotyping can be used successfully to apply personalised medicine 
of fluoropyrimidines (pharmacogenetics, PGx).13 This was shown in a prospective clinical trial 
by Deenen et al.14 Prospective genotyping of the variant DPYD*2A, followed by initial dose 
reductions in heterozygous carriers, reduced the risk of severe fluoropyrimidine-induced 
toxicity in these patients significantly. Also, this study showed that the genotyping approach 
did not increase costs, despite the fact that only 1.1% of tested patients was a carrier of the 
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DPYD*2A variant. In chapter 5 and chapter 6, we have shown similar results, i.e. increasing 
patient safety without increasing treatment costs, for prospective genotyping of four 
DPYD variants (DPYD*2A, rs3918290, c.1905+1G>A, IVS14+1G>A; c.1679T>G, DPYD*13, 
rs55886062, I560S; c.1236G>A/HapB3, rs56038477, E412E; and c.2846A>T, rs67376798, 
D949V).15,16
 Feasibility of DPYD genotyping in daily clinical care was shown in chapter 8 of this thesis.17 
DPYD genotyping at the Leiden University Medical Center (LUMC) was investigated, starting 
with the introduction as routine care in April 2013 until the end of the observation period 
in December 2014. This study showed that the implementation of DPYD genotyping was 
first characterised by a learning or acceptance curve, but was feasible thereafter in a real 
world clinical setting with 90-100% of the patients treated with fluoropyrimidines being 
genotyped. The dose adherence in this study was 90% instead of 100%, due to concerns of 
oncologists to reduce the dose in a DPYD variant allele carrier about to start chemoradiation 
therapy. The doubt was caused by the fact that fluoropyrimidine dosages in chemoradiation 
therapy are already lower compared to fluoropyrimidine dosages in other treatment 
regimens, and further reduction of the fluoropyrimidine dose could result in underdosing. To 
remove the uncertainty on fluoropyrimidine dose reductions in DPYD variant allele carriers 
who will receive chemoradiation therapy, we investigated this specific group in chapter 7.18 
DPYD variant allele carriers treated with regular fluoropyrimidine doses in chemoradiation 
therapy experienced more severe toxicity compared to DPYD variant allele carriers treated 
with reduced fluoropyrimidine doses in chemoradiation therapy, showing dose reductions 
are required as well in this treatment regimen.
 The abovementioned studies show that DPYD genotyping to reduce severe 
fluoropyrimidine-induced toxicity is a useful strategy for all patients starting treatment 
with fluoropyrimidines. Both implementation of DPYD genotyping and adherence to a dose 
advice is feasible in a real world clinical setting.
Resistance and acceptance in implementation of DPYD genotyping
Despite substantial evidence on the association between DPYD variants and the onset of 
severe fluoropyrimidine-induced toxicity,19-26 implementation of DPYD genotyping in clinical 
practice remained limited.27,28 To improve uptake of genotyping an opinion review (chapter 
2) was written, in which arguments for and against genotyping were discussed.29 One of 
these arguments against genotyping was that a randomized clinical trial (RCT) is necessary 
to obtain the required evidence on DPYD genotyping prior to implementation. As described 
in chapter 2, there was one attempt to perform such an RCT. Dose adjustments were applied 
based on the prospectively determined DPYD genotype and DPD phenotype of patients 
in arm A, compared to patients in arm B who were retrospectively analysed and treated 
with full dose. This trial was stopped prematurely due to ethical reasons, and was later 
published in 2017.30 Patients were in fact not randomized, as inclusion in either study arm 
was dependent on current practice of each participating institution and some patients were 
thus predestined to receive treatment in the control arm. However, this large trial of the 
group of Boisdron-Celle et al. was closest to the set-up of an RCT thus far performed and 




deficient patients between study arms at baseline were detected, with more DPD deficient 
patients in the retrospectively screened study arm. This results in bias and could lead to 
the expectation of lower toxicity in the prospectively screened study arm, regardless of 
applying their multi-parametric approach.31 Due to the available evidence on the increased 
risk of toxicity in DPD deficient patients or DPYD variant allele carriers, most researchers 
consider it unethical to perform an RCT and no further attempts are to be expected. 
Therefore, evidence from an RCT will never be gathered. In addition to this, it was debated 
that adequate (pharmacogenetic) evidence can also be provided by small-scale, innovative, 
prospective interventional studies,32 and indeed, some other predictive biomarkers were 
previously implemented in clinical care without evidence from an RCT.29 In the study of 
Deenen et al, a historic cohort of patients who appeared to be carrier of DPYD*2A after 
treatment with fluoropyrimidines, was used to compare severe toxicity between groups.14 
The use of a historic cohort was applied as well in the clinical trial presented in this thesis 
(chapter 5).15 Considering ethics, this study set-up is the best possible method to collect 
evidence in a prospective way, since an RCT is not possible. 
 Besides the lack of evidence from an RCT, there are other arguments against DPYD 
genotyping. The fear of underdosing patients is an often used argument not to implement 
DPYD genotyping. However, both the study of Deenen et al. and our study (chapter 5) show 
that DPYD variant allele carriers who received initial dose reductions have comparable 5-FU 
levels or 5-FU metabolite levels to DPYD wild-type patients treated with a standard dose,14,15 
therefore differences in efficacy are less likely. Secondly, treating physicians could increase 
fluoropyrimidine dosages in DPYD variant allele carriers during treatment based on the onset 
of severe toxicity (dose titration). In 55% of the DPYD variant allele carriers in whom the 
dose was increased during treatment, treatment had to be stopped or the dose had to be 
reduced again due to toxicity. Lastly, a recently published matched pair analysis by Henricks 
et al. showed no differences in efficacy, measured as overall survival and progression-free 
survival, between carriers of DPYD*2A treated with a reduced dose and DPYD*2A wild-type 
patients.33 These results indicate that the fear of underdosing is unjustified. 
 Many of the arguments against DPYD genotyping can be refuted with the current evidence 
in favour of DPYD genotyping. Unfortunately, negative opinions on DPYD genotyping will 
always exist and maybe not everyone can be convinced. In 2010, Ciccolini et al. already 
pointed out that it was time to mandate the integration of systematic prospective testing 
for DPYD as part of routine clinical practice in oncology.27 Yet, in order to align patient care, 
guidelines of health care authorities should be available.
Recommendations and guidelines 
The Food and Drug Administration (FDA) state warnings or contraindications for the use of 
5-FU or capecitabine in DPD deficient patients, however does not recommend to test for DPD 
deficiency.34 No formal recommendations on DPD deficiency testing prior to treatment are 
given by health authorities, regulatory agencies or guideline committees from the National 
Comprehensive Cancer Network (NCCN) or American Society of Clinical Oncology (ASCO). In 
March 2018, the European Medicine Agency (EMA) has asked the involved pharmaceutical 
companies to update the Summary of Product Characteristics (SPC) of capecitabine by 
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including information on DPYD genotyping and the associated risk of severe fluoropyrimidine-
induced toxicity.35 An updated SPC, including a paragraph on DPYD genotyping, is attached 
to the European Public Assessment Report (EPAR) for capecitabine on the EMA website.36 
They state that genotyping of four variants is recommended, and variant carriers should 
be treated with extreme caution. Yet, it cannot be excluded that patients with a negative 
result can experience severe toxicity. The European Society for Medical Oncology (ESMO) 
explicitly states that they do not recommend upfront routine testing for DPD deficiency,37 
which was publicly questioned.38,39 In October 2018, the results of chapter 5 were presented 
at the ESMO conference and the presenter suggested to ESMO to update their guidelines. 
In the Netherlands, updated guidelines (September 2017) for colorectal carcinoma from 
the Dutch Society of Medical Oncology clearly state that DPYD genotyping is recommended 
prior to treatment with fluoropyrimidines.40 These updated guidelines were of assistance 
in the uptake of prospective DPYD genotyping in the Netherlands, which implies that the 
lack of official recommendations on pre-therapeutic genotyping is limiting the process of 
implementation of DPYD genotyping in other countries.
Dosing recommendations for DPYD genotyping
There are several pharmacogenetic dosing guidelines available for the use of fluoropyrimidines 
in DPYD variant allele carriers published by the Clinical Pharmacogenetics Implementation 
Consortium (CPIC), the Dutch Pharmacogenetics Working Group (DPWG) established by the 
Royal Dutch Pharmacists Association (KNMP), the French Network of Pharmacogenetics 
(RNPGx) and the Italian Association of Medical Oncology (AIOM-SIF, unpublished guidelines, 
edited by the AIOM-SIF Working Group).41-43 In addition to dosing guidelines, the DPWG also 
describes an implication score in which DPYD genotyping is considered ‘essential’, directing 
DPYD genotyping prior to treatment with fluoropyrimidines (chapter 4). Both CPIC and 
DPWG guidelines recommend to treat carriers of the DPYD*2A and DPYD*13 variants with a 
50% dose reduction. CPIC recommended to treat carriers of the c.2846A>T and c.1236G>A 
variants with a 25─50% dose reduction due to limited evidence for these variants, compared 
to the DPWG who recommended a 25% dose reduction. These dose reductions are based 
on the functional effect of a variant on the DPD enzyme activity and represent an expected 
remaining DPD enzyme activity, as described in chapter 3.44 However, after publication of 
chapter 5, both groups discussed the results of this study and the possibility to adjust the 
recommendation from a 25% dose reduction to a 50% dose reduction for variants c.2846A>T 
and c.1236G>A/HapB3. This has resulted in an update from CPIC published online November 
2018, in which dose reductions of 50% are recommended for all four DPYD variants.45 An 
update from the DPWG is expected soon and will be implemented in the guideline. 
 In chapter 5 we indeed describe that a 25% dose reduction seems inadequate to reduce 
the risk of severe toxicity in carriers of c.2846A>T and c.1236G>A to the risk of severe toxicity 
for DPYD wild-type patients. We could not provide evidence that a 50% dose reduction is the 
best option for these patients. In fact, for carriers of c.2846A>T a 35% dose reduction seems 
more logical, which is based on the median DPD enzyme activity (67% of DPYD wild-type 
patients) and the additional dose reductions made by physicians in carriers of c.2846A>T 




data). On the other hand, a 35% dose reduction for carriers of c.2846A>T is not proven to 
be more adequate compared to a 50% dose reduction. In addition, a 50% dose reduction 
would be more feasible in clinical practice. The c.1236G>A variant has a large variation in 
DPD enzyme activity with a median of 74% activity of DPYD wild-type patients in our study. 
However, our study showed that a 25% dose reduction in carriers of c.1236G>A did not 
result in a reduction of the relative risk for these patients, as some patients require a larger 
dose reduction.15 As was commented by Amstutz and Largiader, our study would support a 
50% dose reduction in carriers of both c.2846A>T and c.1236G>A, provided that this should 
be used as a starting dose.46 Further dose adaptations guided by the onset of toxicity (dose 
titration) are possible and should be applied slowly, as fluoropyrimidine-induced toxicity can 
occur with a certain delay. 
 Currently, there are no specific recommendations available on how to apply these 
additional dose adaptations. Recently, Kleinjan et al. retrospectively investigated dose 
escalations in DPYD variant allele carriers according to a local pre-specified protocol.47 
Eleven DPYD variant allele carriers were identified, of which six patients (55%) received a 
dose escalation of 15%. In two patients, the dose had to be reduced again due to toxicity, 
resulting in a median dose escalation of 9%. In two DPYD variant allele carriers (18%) the 
initially lower dose was further reduced. In the clinical trial (chapter 5) no pre-specified 
protocol was available for dose adjustments. We identified 85 DPYD variant allele carriers. 
In eleven patients (13%) the dose was increased by 21% on average, yet in five patients 
the dose had to be reduced again and one patient had to stop treatment, resulting in a 
mean dose escalation of 13%. In ten patients (12%) initially lower dosages were further 
reduced by 20% on average. Without a pre-defined protocol, the dose was increased in 
fewer patients, yet the dose adjustment steps were larger. The dose reductions applied after 
a dose escalation point out the importance of slowly applying dose escalations in relatively 
small steps. The additional dose reductions required after the low initial dose, again point 
out the variation in DPD enzyme activity in DPYD variant allele carriers, and could explain 
the higher overall severe toxicity rates in DPYD variant allele carriers of the clinical trial (39% 
versus 23% for wild-type patients).15
Dose adjustments after exposure to 5-FU or capecitabine
Therapeutic drug monitoring (TDM) is a useful method to guide dose adaptations after 
start of therapy. Unfortunately, the use of TDM for fluoropyrimidines in the Netherlands is 
limited as the wide majority of patients (approximately 90%) are prescribed capecitabine 
over 5-FU. For TDM of 5-FU defined target ranges and dosing algorithms are available.48-50 
Yet, the intracellular conversion of capecitabine into 5-FU and its metabolites result in low 
plasma concentrations of capecitabine and its metabolites, which makes it more difficult to 
develop TDM protocols for capecitabine.51 Until such protocols have been established, TDM 
of fluoropyrimidines in the Netherlands will be used sparingly. Furthermore, TDM can be 
used to monitor drug levels after start of treatment, not to determine initial dose reductions 
in order to prevent quick-onset severe fluoropyrimidine-induced toxicity. 
 A method to determine if initial dose adaptations in patients are required, is to expose 
the patient prior to treatment to a 5-FU test dose of 250 mg/m2.52,53 After the test dose, 5-FU 
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and 5-fluoro-5,6-dihydrouracil (5-FDHU) plasma levels are used to calculate pharmacokinetic 
parameters. In a study setting, three patients had marked alterations in pharmacokinetic 
parameters and possibly severe toxicity was avoided by changing the 5-FU treatment into 
irinotecan treatment.52 The 5-FU test dose did not result in side effects in any of the patients 
in this study, which questions the suitability of this test dose, as the metabolizing enzyme 
DPD has a certain overcapacity. As was stated by van Staveren et al., a test dose of uracil of 
500 mg/m2 fully saturates the DPD enzyme.54
Implementation of DPYD genotyping in the Netherlands
Three Dutch hospitals participated in the study of Deenen et al., applying DPYD*2A 
genotyping in over 2,000 recruited study patients between May 2007 and October 2011. 
Thereafter, more studies on DPYD variants and their association with the onset of severe 
fluoropyrimidine-induced toxicity became available. Within this period, some hospitals in the 
Netherlands implemented routine DPYD genotyping of all patients starting fluoropyrimidines, 
e.g. the LUMC in April 2013 and the Maastricht University Medical Center in 2013 as well.9,17 
In April 2015 we started recruiting patients in our prospective study (chapter 5).15 Seventeen 
hospitals in the Netherlands participated in this study and implemented or outsourced 
DPYD genotyping either for study patients only or for all patients starting fluoropyrimidine 
treatment. In 2016, a survey was published in the Dutch Medical Oncology Journal.55 This 
survey was sent to oncologists in the Netherlands. Some remarkable results were found. 
First, 65% of the responders answered that DPD status was determined as standard for all 
patients starting treatment with fluoropyrimidines. Second, 80% of the oncologists used 
DPYD genotyping to determine DPD deficiency, compared to 15% of responders who used 
a DPD phenotyping test. Possibly these results were a little overestimated, as physicians 
who had experience with requesting these tests were more likely to reply to the survey 
compared to physicians who did not order DPD deficiency tests. Also, the results of the 
survey were not adjusted based on the number of respondents per hospital, which could 
give a misleading image on the status of DPYD genotyping in the Netherlands in 2016. Yet, 
it is clear that the use of DPYD genotyping in the Netherlands is ahead of the use in many 
other countries. Some research groups in France, the UK, Italy, Germany and the USA were 
able to implement DPYD genotyping, whether or not combined with DPD phenotyping, in 
their hospital or clinical institute and surrounding centres. 
Other aspects of implementation
Treatment costs for patients did not increase when applying prospective genotyping of 
DPYD*2A, or DPYD*2A, DPYD*13, c.2846A>T and c.1236G>A, as was shown by Deenen et 
al. and in chapter 6 of this thesis.14,16 Expanding the genotyping panel from one variant to 
four variants did not increase the costs of genotyping much, while more patients at risk 
could be identified, and thus more (costs of) severe toxicity could be prevented. Currently, 
most hospitals can offer DPYD genotyping tests for approximately €100. Genotyping assays 
are becoming less expensive despite the addition of more variants to a genotyping panel, 
therefore it is expected that DPYD genotyping will probably remain cost-neutral. However, 




genotyped with current genotyping techniques, and more expensive genotyping techniques 
need to be used, it is uncertain if DPYD genotyping remains cost-neutral. For example, at 
this moment sequencing the entire DPYD gene is too expensive to be used in a daily clinical 
care setting. Also, reimbursement for DPYD genotyping costs in the Netherlands is not (yet) 
covered by nationwide health care insurances. Therefore, hospitals in the Netherlands will 
cover costs in different ways, which leads to differences in health care between patients. 
 In chapter 9 we describe the dilemma of required confirmation practice as a quality 
control aspect of PGx testing.56 Implementation of DPYD genotyping will benefit from the 
inexpensiveness of current genotyping arrays. Yet, as PGx tests are usually only executed 
once in a lifetime, it is of utmost importance to have a correct genotyping result. When 
applying the most adequate, but comprehensive, confirmation method, i.e. executing a 
second, independent genotyping assay, erroneous results can be discovered. In this study 
we discovered that, even after extensive validation, erroneous results can still occur due to 
misclassification of a genotype, e.g. caused by allele dropout. Despite the increase in costs 
and labour, a confirmation method is useful for genetic tests with a high clinical impact, such 
as DPYD testing. We also showed substantial variability between laboratories in the use of a 
second, independent technique for PGx testing. As is the case for applying DPYD genotyping 
in the first place, clear guidelines are required to align confirmatory laboratory practices for 
PGx as well. 
 Currently, mostly assays testing single variants are used to genotype DPYD. In case of a 
compound heterozygous DPYD variant carrier, a patient who carries multiple different DPYD 
variants, the genotyping result cannot be translated into a dose recommendation when 
phasing information (the allelic location of variants) is missing. Compound heterozygous 
DPYD variant allele carriers are at increased risk of severe fluoropyrimidine-induced toxicity 
when dose reductions cannot be applied. In chapter 11, we describe seven cases and examine 
diagnostic and therapeutic strategies for fluoropyrimidine treatment of patients carrying 
multiple DPYD variants.57 The additional genotyping methods investigated in this study 
are still in early phases of development or currently too expensive to implement in clinical 
care, compared to a well-established DPD-phenotyping test. Therefore, we concluded to 
execute a phenotype test in these patients in order to determine a safe starting dose. When 
genotyping techniques which can determine the phasing of variants, such as long-read 
sequencing, will become less expensive in the future and are implemented in clinical care, 
phasing of variants of compound heterozygous DPYD variant allele carriers will be known 
directly and these patients can be treated according to dosing guidelines. 
 The probability of identifying a compound heterozygous DPYD variant carrier is low, yet 
while completing this chapter, five other patients were discovered in several genotyping 
facilities in the Netherlands, showing that this is a clinically relevant issue. Some of these 
patients were identified prospectively, after which the advice was given to determine the 
DPD enzyme activity. One patient was a carrier of three DPYD variants (DPYD*2A, c.2846A>T 
and c.1236G>A) and was treated safely with a 40% dose based on the results of an executed 
DPD enzyme activity measurement. The other patients were carriers of two DPYD variants 




Beyond current DPYD genotyping
It is known that DPYD variants are not the only risk factor for DPD deficiency, and DPD 
deficiency is not the only risk factor for severe fluoropyrimidine-induced toxicity. 
Approximately 17% of patients experiencing severe fluoropyrimidine-induced toxicity can 
be identified as carriers of one of the four currently genotyped DPYD variants. 39-61% of 
the patients who experienced severe toxicity were identified as DPD deficient patients, thus 
it was estimated that less than half of the DPD deficient patients could be identified by the 
four currently genotyped DPYD variants.58 In order to increase the predictability of severe 
fluoropyrimidine-induced toxicity, we must better predict risk factors for DPD deficiency, 
and additionally look into factors outside of DPD. Recently, a study was published in 
which eight years of combining genotyping and phenotyping tests were described.9 This 
study showed that only 25.3% of the DPD deficient patients was a carrier of one of the 
four currently genotyped DPYD variants. Patients with a DPD deficiency, but who did not 
carry the DPYD*2A variant, were genotyped for the entire coding region of DPYD. DPD 
deficiency could be explained by DPYD variants in 23% of these patients. This results in an 
expected approximately 42% of DPD deficiency related to DPYD variants. Variants in other 
regions, which have not been sequenced before, could still contribute to DPD deficiency. 
Unfortunately, the abovementioned study had no toxicity data of the patients, thus the 
prediction of DPYD variants for DPD deficiency could be made, but not the prediction for 
severe toxicity. 
 It is clear that not only DPYD variants are involved in the onset of severe fluoropyrimidine-
induced toxicity. Therefore the DNA of the patients participating in chapter 5 was analysed 
by genome-wide association study (GWAS), in order to discover novel variants related to 
the onset of severe fluoropyrimidine-induced toxicity. This study was described in chapter 
12. Approximately 700,000 single nucleotide polymorphisms (SNPs) in different genes were 
genotyped, and imputed to over four million SNPs. While no genome-wide significant SNPs 
could be identified, six variants were suggestive for the onset of severe toxicity. These variants 
warrant replication in an independent cohort. After validation, variants can be added to the 
prospective genotyping panel. In addition to the variants in chapter 12, validation is required 
for all newly identified variants. For example, some newly identified variants were recently 
presented in a series of patients who experienced severe toxicity,59 yet it is unclear if these 
variants could also be identified in patients who did not experience severe toxicity, and thus 
the clinical value of these variants needs to be determined. As described by Ciccolini et al. in 
2010, both genetic and epigenetic factors, such as promotor hyper methylation or variations 
in transcriptional factor expression, play a role in DPYD dysregulations,60 and should be a 
focus of future research in DPYD genotyping.
Phenotyping assays
DPD phenotyping could also be used to predict severe fluoropyrimidine-induced toxicity. 
As described before, the DPD enzyme activity measurement in PBMCs is a well-established 
method to determine DPD activity.2,8,9 Additionally, DPD phenotyping assays were developed, 
such as the 2-13C uracil breath test,61-63 the uracil loading dose,54,64 endogenous dihydrouracil/




phenotyping assay was summarized in two reviews.58,67 Advantages and disadvantages per 
assay were discussed, such as the limited feasibility of an assay in clinical practice, lack of 
calculated test parameters (i.e. sensitivity, specificity), or lack of clear threshold values for 
patients who are prone to develop severe fluoropyrimidine-induced toxicity. In chapter 10, 
we executed a first-time head-to-head comparison of four DPD phenotyping assays in a 
patient cohort which was not selected based on –or enriched for– (severe) toxicity, but 
represents a daily clinical care patient cohort. We could not show associations with DPD 
deficiency or the onset of severe fluoropyrimidine-induced toxicity. The latter is possibly 
due to the fact that only ~30─50% of severe fluoropyrimidine-induced toxicity can initially 
be explained by DPD deficiency.68 Previously it was described that clinical validity and utility 
were not yet determined for all phenotyping assays,58 yet with this study we were unable 
to fully complement this lack of evidence. In order to determine the clinical value of DPD 
phenotyping assays additional research is required. DPD phenotyping assays, whether or 
not combined with DPYD genotyping, are already used in clinical care in some centres to 
predict and prevent toxicity. Yet, it is clear that additional research should be performed in 
order to determine and compare the clinical value of DPD phenotyping assays.
FUTURE PERSPECTIVES
Dosing algorithms
It is clear that toxicity is not caused by a single factor, but is due to a combination of multiple 
risk factors. In order to be able to predict and prevent severe fluoropyrimidine-induced 
toxicity in a larger number of patients, multiple risk factors should be taken into account. 
An algorithm in which multiple factors are included, can be used to calculate the total risk 
of severe toxicity and potentially required dose adjustments. This algorithm should include 
the abovementioned four DPYD variants, as they are proven to be associated to the onset 
of severe toxicity. However, the algorithm should be expanded by including other factors.
 In an ongoing study, we investigate rare variants in DPYD by means of sequencing, as 
they might be predictive for the onset of severe fluoropyrimidine-induced toxicity. Besides 
the current four DPYD variants, identified rare DPYD variants, variants outside of the DPYD 
gene, or variants in modifier gene regions, could be added to the algorithm in the future 
when their association with toxicity has been validated. Possibly, a large panel of genetic 
variants could be used to calculate the ‘genetic’ risk, so-called polygenic risk score, which 
is increasingly being applied in research. Depending on which variants from the panel are 
identified in the patient, the patient has a different risk to develop severe toxicity. 
 The algorithm could also be supplemented by non-genetic factors, as they can play a role 
in the onset of (severe) toxicity. For example, results of phenotyping assays for DPD or other 
enzymes involved in the metabolism of 5-FU related to severe toxicity,69 could be included 
in the algorithm. In addition, baseline characteristics of patients, such as age, gender, 
performance status or renal dysfunction, were described as risk factors for toxicity.70-74 Also 
therapy-related factors, such as dosing schedule or co-medication, could influence the risk 
of toxicity.75 Not all of the abovementioned risk factors have a similar effect on (severe) 
toxicity, therefore each risk factor included in the algorithm should have a corresponding 
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weighing factor, depending on the severity of the risk. 
 In addition to analysing DPYD genetics, baseline characteristics of patients and therapy-
related factors to develop dosing algorithms, ethnicity should also be taken into account. 
The current four DPYD variants associated to the onset of severe fluoropyrimidine-induced 
toxicity are mainly identified in Caucasian patients. DPYD*2A and c.2846A>T have been 
identified in ~0.1% in African-Americans, compared to a frequency of ~1% in Caucasians.76-78 
Novel deleterious DPYD variants can be identified in different ethnic populations, as was 
recently shown for an East African population.79 Dosing algorithms might not predict DPD 
activity correctly in patients who are not Caucasian, depending on the variants included in 
the algorithm. 
 Current genotyping techniques are mostly single SNP-based assays or chip-based assays. 
In the near future extensive sequencing techniques will become less expensive and more 
available for daily practice in the laboratories of hospitals, or hospitals can outsource 
genotyping to special genotyping facilities. An increasing amount of genotyping data of 
patients will be known in a shorter period of time, and should be linked to clinical patient 
data in order to first translate the genotype into a prediction for toxicity, and second, the 
data can be used to complement and perfect the algorithm. The question that remains 
is, can we build an algorithm which can predict the majority of severe fluoropyrimidine-
induced toxicity? When all previously reported risk factors for toxicity are validated and 
included, and when the complete genotype of patients is taken into account, what risk 
factors will remain to be discovered? 
The future of fluoropyrimidines
5-FU has been used to treat cancer for decades and the first studies on DPD deficiency 
were published in the eighties.1-3 Now, capecitabine is the preferred drug of use over 5-FU 
in various tumour types in several countries, including the Netherlands. To improve efficacy 
of cancer therapy, fluoropyrimidines are combined with several other anticancer drugs, yet 
they remain the backbone of therapy for a substantial number of tumour types. 
 To conclude with the following quote by Hamzic et al.: “While additional genetic factors 
or phenotyping approaches may complement pharmacogenetic testing in the future, 
DPYD genotyping provides an important tool that is available today to identify patients at 
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Fluoropyrimidines, such as 5-fluorouracil (5-FU) and its oral pro-drug capecitabine, are widely 
used anti-cancer drugs in the treatment of several tumour types. Despite ample experience 
with these drugs, severe adverse drug reactions occur in up to 30% of patients treated 
with fluoropyrimidines. Over 80% of 5-FU is inactivated by the enzyme dihydropyrimidine 
dehydrogenase (DPD), which is encoded by the gene DPYD. Because of this, DPD plays an 
important role in the development of adverse drug reactions, mentioned here as toxicity. 
To prevent severe fluoropyrimidine-induced toxicity, it is important to identify patients who 
have an increased risk of toxicity and treat them in a personalised way. In other words, it 
is important to identify patients with a deficient DPD enzyme and treat them with reduced 
fluoropyrimidine dosages. Research has been executed on DPD deficiency, or variants in the 
DPYD gene, and the association with severe fluoropyrimidine-induced toxicity. This thesis 
focusses on reducing the risk of severe fluoropyrimidine-induced toxicity by optimising 
DPYD genotyping and improving implementation of DPYD genotyping in daily clinical care. In 
addition, we investigated DPD phenotyping and innovative genotyping techniques beyond 
current DPYD pharmacogenetics (PGx) to prevent severe fluoropyrimidine-induced toxicity.
DPYD genotyping: proof of principle and implementation in clinical practice
Despite substantial evidence on the association between DPYD variants and the onset of 
severe fluoropyrimidine-induced toxicity, implementation of prospective DPYD genotyping 
in clinical practice remained limited. Therefore, an opinion review was written (chapter 
2). In this review we summarize the available evidence on the association with severe 
fluoropyrimidine-induced toxicity for four variants in the DPYD gene. We discuss several 
advantages and disadvantages of DPYD genotyping. We substantiate why arguments 
against genotyping are unfounded and advocate implementation of prospective DPYD 
genotyping. In chapter 3 literature was extensively checked to discuss the functional effect 
of four DPYD variants on the DPD enzyme activity. This is converted into a gene activity 
score for each DPYD variant, which represents an expected remaining DPD enzyme activity, 
and which will be used in PGx guidelines to translate the DPYD genotype into a DPD 
phenotype. PGx guidelines by the Dutch Pharmacogenetics Working Group (DPWG) of the 
Royal Dutch Pharmacists Association (KNMP) were already present in the Netherlands for 
DPYD and fluoropyrimidines. This guideline is made available outside of the KNMP network 
in the Netherlands in chapter 4, and provides a dose reduction advice for heterozygous 
DPYD variant allele carriers of the following four DPYD variants: DPYD*2A, rs3918290, 
c.1905+1G>A, IVS14+1G>A; DPYD*13, c.1679T>G, rs55886062, I560S; c.1236G>A/HapB3, 
rs56038477, E412E; and c.2846A>T, rs67376798, D949V. In addition to dosing guidelines, 
the DPWG also described an implication score in which DPYD genotyping is considered 
‘essential’, directing DPYD genotyping prior to treatment with fluoropyrimidines.
 DPYD genotyping was applied prospectively in a nationwide clinical trial in chapter 
5. Patients with an intention to treatment with fluoropyrimidines were genotyped for 
DPYD*2A, DPYD*13, c.2846A>T and c.1236G>A. Heterozygous carriers of a DPYD variant 
were treated with an initially reduced dose of fluoropyrimidine according to the DPWG PGx 
guidelines at the start of the study. This study showed that prospective DPYD genotyping 
followed by individualised dose adjustments improved patient safety by reducing the risk 
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of severe fluoropyrimidine-induced toxicity. No treatment-related deaths occurred in DPYD 
variant allele carriers who were treated with a reduced dose. Despite the low frequency of 
DPYD variant allele carriers, executing prospective DPYD genotyping did not increase costs, 
but reduced average costs slightly with €50 per patient, as was shown in the cost analysis of 
the trial (chapter 6). 
 Current PGx guidelines do not distinguish fluoropyrimidine dosing recommendations 
between treatment regimens. Fluoropyrimidine dosages in chemoradiation therapy are 
substantially lower compared to fluoropyrimidine dosages in other treatment regimens. 
Therefore, it was unclear if further fluoropyrimidine dose reductions could result in 
underdosing in DPYD variant allele carriers treated with chemoradiation therapy. In chapter 
7 we compared severe toxicity between wild-type patients and DPYD variant allele carriers 
who received chemoradiation therapy, the latter group either treated with standard 
or reduced fluoropyrimidine dosages. DPYD variant allele carriers treated with regular 
fluoropyrimidine doses in chemoradiation therapy experienced severe toxicity more often 
compared to DPYD variant allele carriers treated with reduced fluoropyrimidine doses in 
chemoradiation therapy, showing dose reductions are required as well in this treatment 
regimen.
 The feasibility of implementing prospective DPYD genotyping in daily clinical care was 
shown in chapter 8 of this thesis. The first 21 months of DPYD genotyping at the Leiden 
University Medical Center (LUMC) were investigated, starting with the introduction as 
routine care in April 2013 until the end of the observation period in December 2014. This 
study showed that the implementation of DPYD genotyping was first characterised by a 
learning or acceptance curve, but was feasible in a real world clinical setting with 90─100% 
of the patients treated with fluoropyrimidines being genotyped. This study also showed 
90% dose adherence. 
 Another aspect of (DPYD) genotyping is the certainty of a test result, and the consequences 
of an erroneous result. In chapter 9 we describe the dilemma of confirmation practice as 
a quality control aspect of PGx testing. We discuss if it should be required to have two 
independent genotyping assays to correctly determine a genotype. In this study we 
discovered that, even after extensive validation, erroneous results can still occur due to 
misclassification of a genotype, e.g. caused by allele dropout. Despite the increase in costs 
and labour, a confirmation method is useful for genetic tests with high clinical impact, such 
as DPYD testing. Clear guidelines will help to align confirmatory laboratory practices for 
pharmacogenetics, which may need to be specified per gene and test.
Beyond current DPYD pharmacogenetics
In the first part of this thesis we describe how to reduce severe fluoropyrimidine-induced 
toxicity by DPYD genotyping of DPYD*2A, DPYD*13, c.2846A>T and c.1236G>A. Yet, it is 
known not all severe fluoropyrimidine-induced toxicity can be predicted by these four 
variants alone. Therefore, we investigated other options, beyond genotyping of the current 
four DPYD variants, to reduce severe fluoropyrimidine-induced toxicity. This is shown in the 
second part of this thesis, entitled “beyond current DPYD pharmacogenetics”. 




phenotyping assays in a patient cohort which was not selected based on –or enriched for– 
(severe) toxicity. The goal was to determine the clinical value of each DPD phenotyping assay, 
by assessing clinical validity parameters (e.g. sensitivity and specificity) for DPD deficiency 
and the onset of severe fluoropyrimidine-induced toxicity. We could not show associations 
with DPD deficiency or the onset of severe fluoropyrimidine-induced toxicity. To determine 
the clinical value of DPD phenotyping assays additional research is required.
 In chapter 11 we investigated a special subgroup of DPYD variant allele carriers, i.e. the 
compound heterozygous patients. These patients carry multiple DPYD variants and the 
effect of the DPYD variants on the DPD enzyme activity cannot be predicted using the gene 
activity score. Without dose reductions, these patients have an increased risk to develop 
severe toxicity. We describe seven cases and examine diagnostic and therapeutic strategies 
for fluoropyrimidine treatment of patients carrying multiple DPYD variants. The additional 
genotyping methods investigated in this study are still in early phases of development or 
currently too expensive to implement in clinical care, compared to a well-established DPD-
phenotyping test. Therefore, we concluded to execute a phenotype test in these patients to 
determine a safe starting dose.
 It is expected that other enzymes besides DPD, and thus other genes besides DPYD, are 
involved in the onset of severe fluoropyrimidine-induced toxicity. With the genome-wide 
approach in chapter 12 we aimed to discover other variants, mainly outside the DPYD gene, 
which are associated to the onset of severe fluoropyrimidine-induced toxicity. Approximately 
700,000 single nucleotide polymorphisms (SNPs) in different genes were genotyped and 
imputed to over four million SNPs. We identified six variants suggestive of association to 
the onset of severe fluoropyrimidine-induced toxicity. In addition, we present an optimistic 
polygenic risk score analysis, suggesting highly polygenic nature of toxicity predisposition.
 With the execution of the clinical trial described in chapter 5, an increasing number 
of hospitals in the Netherlands applied DPYD genotyping prior to start of therapy. An 
increased uptake in implementation of DPYD genotyping was thus visible, especially in the 
Netherlands. Outside of the Netherlands, great differences exist in the uptake of DPYD 
genotyping, whether or not including DPD phenotyping. In some countries initiatives to 
implement prospective testing for DPD deficiency are effective, where in other countries 
great differences in execution of tests exist between centres within that country. Uptake of 
DPYD genotyping will benefit from clear guidelines, i.e. recommendations whom and when 
to genotype, and dosing recommendations for DPYD variant allele carriers. 
 Currently four DPYD variants are included in the genotyping panel, yet it is known these 
four variants cannot predict all patients who will develop severe toxicity. It is likely other 
variants are associated to the onset of severe fluoropyrimidine-induced toxicity. To further 
improve the predictive power of the genotyping panel DPD phenotyping tests can be used, 
or novel variants can be added to the genotyping panel. Novel variants can be e.g. rare 
variants in the DPYD gene or variants in other genes. 
The future of fluoropyrimidines
5-FU has been used to treat cancer for decades. Now, capecitabine is the preferred drug 
of use over 5-FU in various tumour types in several countries, including the Netherlands. 
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To improve efficacy of cancer therapy, fluoropyrimidines are combined with several other 
anticancer drugs, yet they remain the backbone of therapy for a substantial number of tumour 
types. Ample research on fluoropyrimidines and DPD (deficiency) has been executed. Right 
now, prospective DPYD genotyping should be executed for all patients starting treatment 
with fluoropyrimidines. Additional research will be executed to continue the search for 







Fluoropyrimidines, zoals 5-fluorouracil (5-FU) en haar orale prodrug capecitabine, zijn veel 
gebruikte kankergeneesmiddelen voor de behandeling van verschillende tumortypen. 
Ondanks vele ervaring met deze geneesmiddelen, treden ernstige bijwerkingen op bij 30% 
van de patiënten die met fluoropyrimidines worden behandeld. Meer dan 80% van 5-FU 
wordt geïnactiveerd door het enzym dihydropyrimidine dehydrogenase (DPD), dat wordt 
gecodeerd door het gen DPYD. Hierdoor speelt DPD een belangrijke rol bij de ontwikkeling 
van bijwerkingen, hier toxiciteit genoemd. Om ernstige fluoropyrimidine-geïnduceerde 
toxiciteit te voorkomen, is het belangrijk om patiënten met een verhoogd risico op toxiciteit 
te identificeren en hen op een gepersonaliseerde manier te behandelen (therapie op maat). 
Met andere woorden, het is belangrijk om patiënten met een deficiënt DPD-enzym te 
identificeren en ze te behandelen met gereduceerde fluoropyrimidine-doseringen. DPD-
deficiëntie, of varianten in het DPYD-gen, en de associatie met ernstige fluoropyrimidine-
geïnduceerde toxiciteit zijn reeds onderzocht. Dit proefschrift richt zich op het verminderen 
van het risico op ernstige fluoropyrimidine-geïnduceerde toxiciteit door DPYD-genotypering 
te optimaliseren en de implementatie van DPYD-genotypering in de dagelijkse klinische zorg 
te verbeteren. Om ernstige fluoropyrimidine-geïnduceerde toxiciteit te voorkomen hebben 
we daarnaast ook DPD-fenotypering onderzocht en meer innovatieve technieken voor 
genotypering vergeleken met de huidige farmacogenetica van DPYD.
DPYD-genotypering: bewijs van het principe en implementatie in de klinische praktijk
Ondanks substantieel bewijs over de associatie tussen DPYD-varianten en het ontstaan van 
ernstige fluoropyrimidine-geïnduceerde toxiciteit, bleef de implementatie van prospectieve 
DPYD-genotypering in de klinische praktijk redelijk beperkt. Daarom werd een opiniërend 
review geschreven (hoofdstuk 2). In deze review vatten we het beschikbare bewijs over 
de associatie met ernstige fluoropyrimidine-geïnduceerde toxiciteit voor vier varianten 
in het DPYD-gen samen. We bespreken verschillende voordelen en nadelen van DPYD-
genotypering. We onderbouwen waarom argumenten tegen genotypering ongegrond zijn 
en pleiten voor implementatie van prospectieve DPYD-genotypering. In hoofdstuk 3 wordt 
uitgebreide literatuur samengevat om het functionele effect van vier DPYD-varianten op 
de DPD-enzymactiviteit te bespreken. Dit wordt omgezet in een gen-activiteitscore voor 
elke DPYD-variant, die een verwachte resterende DPD-enzymactiviteit vertegenwoordigt. 
Deze zal worden gebruikt in farmacogenetica-richtlijnen om het DPYD-genotype in een DPD-
fenotype te vertalen. Farmacogenetica-richtlijnen van de Nederlandse Farmacogenetica 
Werkgroep (DPWG) van de Koninklijke Nederlandse Maatschappij ter bevordering der 
Pharmacie (KNMP) waren reeds aanwezig in Nederland voor DPYD en fluoropyrimidines. 
Deze richtlijn wordt buiten het KNMP-netwerk in Nederland beschikbaar gesteld in hoofdstuk 
4 en geeft een advies voor dosisreductie voor heterozygote dragers van DPYD-varianten 
van de volgende vier DPYD-varianten: DPYD*2A, rs3918290, c.1905+1G>A, IVS14+1G>A; 
DPYD*13, c.1679T>G, rs55886062, I560S; c.1236G>A/HapB3, rs56038477, E412E; en 
c.2846A>T, rs67376798, D949V. Naast doseringsrichtlijnen beschreef de DPWG ook een 
implicatiescore waarin DPYD-genotypering als ‘essentieel’ wordt beschouwd, waarbij DPYD-
genotypering wordt geadviseerd voorafgaand aan de behandeling met fluoropyrimidines.
 DPYD-genotypering werd prospectief toegepast in een landelijke klinische studie in 
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hoofdstuk 5. Patiënten met een intentie om te starten met fluoropyrimidines werden 
gegenotypeerd voor DPYD*2A, DPYD*13, c.2846A>T en c.1236G>A. Heterozygote dragers 
van een DPYD variant werden bij de start van de therapie behandeld met een initieel 
gereduceerde dosis fluoropyrimidines volgens de farmacogenetica-richtlijnen van de 
DPWG. Deze studie heeft aangetoond dat het prospectief genotyperen van DPYD gevolgd 
door geïndividualiseerde dosisaanpassingen de veiligheid van de patiënt verbeterde door 
het risico op ernstige fluoropyrimidine-geïnduceerde toxiciteit te verminderen. Er zijn geen 
DPYD-variant dragers overleden naar aanleiding van een behandeling met een gereduceerde 
dosis. Ondanks de lage frequentie van DPYD-variant dragers, heeft het uitvoeren van 
prospectieve DPYD-genotypering de kosten niet verhoogd, maar de gemiddelde kosten licht 
zelfs verlaagd met €50,- per patiënt, zoals werd aangetoond in de kostenanalyse van het 
onderzoek (hoofdstuk 6).
 De huidige farmacogenetica-richtlijnen maken geen onderscheid in fluoropyrimidine-
doseringsaanbevelingen tussen de verschillende type behandelingen. Fluoropyrimidine-
doseringen in chemoradiotherapie zijn aanzienlijk lager in vergelijking met fluoropyrimidine-
doseringen in andere type behandelingen. Daarom was het onduidelijk of verdere verlaging 
van de fluoropyrimidine-dosis zou kunnen leiden tot onderdosering bij DPYD-variant dragers 
die werden behandeld met chemoradiotherapie. In hoofdstuk 7 hebben we de ernstige 
toxiciteit tussen wildtype-patiënten en DPYD-variant dragers die chemoradiotherapie kregen 
vergeleken. De DPYD-variant dragers werden behandeld met standaard of gereduceerde 
fluoropyrimidine-doseringen. DPYD-variant dragers die met reguliere fluoropyrimidine-
doseringen in chemoradiotherapie werden behandeld, hadden vaker ernstige toxiciteit 
vergeleken met DPYD-variant dragers die met verder gereduceerde fluoropyrimidine-
doseringen in chemoradiotherapie werden behandeld. Dit toont aan dat dosisreducties ook 
in dit type behandeling nodig zijn.
 De haalbaarheid van het implementeren van prospectieve DPYD-genotypering in de 
dagelijkse klinische zorg werd aangetoond in hoofdstuk 8 van dit proefschrift. De eerste 21 
maanden DPYD-genotypering in het Leids Universitair Medisch Centrum (LUMC) werden 
onderzocht, te beginnen met de introductie als standaardzorg in april 2013 tot het einde van 
de observatieperiode in december 2014. Deze studie toonde aan dat de implementatie van 
DPYD-genotypering eerst gekenmerkt was door een leer- of acceptatiecurve, maar daarna 
haalbaar bleek te zijn in de dagelijkse klinische zorg, waarbij 90─100% van de patiënten die 
werden behandeld met fluoropyrimidines waren gegenotypeerd. Deze studie toonde ook 
aan dat 90% van de aanbevelingen voor een dosisreductie werden opgevolgd.
 Een ander aspect van (DPYD)-genotypering is de betrouwbaarheid van een testresultaat 
en de gevolgen van een incorrect resultaat. In hoofdstuk 9 beschrijven we het dilemma om de 
resultaten van farmacogenetica testen te bevestigen als een aspect van de kwaliteitscontrole. 
We bespreken of het nodig zou moeten zijn om twee onafhankelijke genotyperingstesten 
te gebruiken om een  genotype correct te bepalen. In deze studie ontdekten we dat, zelfs 
na uitgebreide validatie van de testen, incorrecte resultaten kunnen optreden als gevolg 
van misclassificatie van een genotype, bijvoorbeeld veroorzaakt door dropout van allelen. 
Ondanks de toename in kosten en werkzaamheden, kan het bevestigen van het resultaat 




DPYD-genotypering. Duidelijke richtlijnen zullen helpen om de praktijk in laboratoria gelijk 
te trekken wat betreft het bevestigen van resultaten van farmacogenetica testen. Deze 
richtlijnen zullen mogelijk per gen en test moeten worden gespecificeerd.
Buiten de huidige DPYD-farmacogenetica
In het eerste deel van dit proefschrift beschrijven we hoe ernstige fluoropyrimidine-
geïnduceerde toxiciteit kan worden verminderd door middel van het uitvoeren van DPYD-
genotypering voor DPYD*2A, DPYD*13, c.2846A>T en c.1236G>A. Het is bekend dat niet alle 
ernstige fluoropyrimidine-geïnduceerde toxiciteit wordt voorspeld door deze vier varianten 
alleen. Daarom onderzochten we andere opties, naast de genotypering van de huidige vier 
DPYD-varianten, om ernstige fluoropyrimidine-geïnduceerde toxiciteit te verminderen. Dit 
wordt toegelicht in het tweede deel van dit proefschrift, getiteld “buiten de huidige DPYD-
farmacogenetica”.
 In hoofdstuk 10 onderzochten we vier DPD-fenotyperingtesten voor het eerst in een 
vergelijking binnen dezelfde patiënten. Het cohort was niet geselecteerd, of verrijkt, 
met patiënten die (ernstige) toxiciteit hebben ervaren. Het doel van deze studie was 
om de klinische waarde van elke DPD-fenotyperingtest te bepalen door klinische 
validiteitsparameters (bijvoorbeeld sensitiviteit en specificiteit) te beoordelen voor DPD-
deficiëntie en het ontstaan van ernstige fluoropyrimidine-geïnduceerde toxiciteit. We 
konden geen relatie aantonen tussen de DPD-fenotyperingtesten en DPD-deficiëntie of het 
ontstaan van ernstige fluoropyrimidine-geïnduceerde toxiciteit. Om de klinische waarde van 
DPD-fenotyperingtesten te bepalen is aanvullend onderzoek nodig.
 In hoofdstuk 11 onderzochten we een speciale subgroep van DPYD-variant dragers, 
namelijk de samengestelde heterozygote patiënten. Deze patiënten dragen meerdere 
DPYD-varianten en het effect van de DPYD-varianten op de DPD-enzymactiviteit kan niet 
worden voorspeld met behulp van de gen-activiteitscore. Zonder een dosisreductie hebben 
deze patiënten een verhoogd risico om ernstige toxiciteit te ontwikkelen. We beschrijven 
zeven patiënten en onderzoeken diagnostische en therapeutische strategieën voor 
behandeling met fluoropyrimidines bij patiënten die meerdere DPYD-varianten dragen. De 
aanvullende onderzochte genotyperingmethoden uit deze studie bevinden zich nog in de 
ontwikkelingsfase of zijn momenteel te duur om in de klinische zorg te implementeren, in 
vergelijking met een reeds gevestigde DPD-fenotyperingtest. Daarom adviseren we om bij 
deze patiënten een fenotypetest uit te voeren om een  veilige startdosis te bepalen.
 Verwacht wordt dat andere enzymen naast DPD, en dus andere genen naast DPYD, 
betrokken zijn bij het ontstaan van ernstige fluoropyrimidine-geïnduceerde toxiciteit. Met 
de genoomwijde associatie studie in hoofdstuk 12 hebben we geprobeerd andere varianten 
te ontdekken, voornamelijk buiten het DPYD-gen, die geassocieerd zijn met het ontstaan 
van ernstige fluoropyrimidine-geïnduceerde toxiciteit. Ongeveer 700,000 single nucleotide 
polymorphisms (SNP’s) in verschillende genen werden gegenotypeerd en geïmputeerd tot 
meer dan vier miljoen SNP’s. We hebben zes varianten gevonden die suggestief waren voor 
de associatie met ernstige fluoropyrimidine-geïnduceerde toxiciteit. Daarnaast laten we een 
optimistische analyse zien van een polygene risicoscore, wat duidt op een hoge polygene 
aard van het ontstaan van toxiciteit.
Chapter 14
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Vanwege de uitvoering van de klinische studie beschreven in hoofdstuk 5 pasten steeds 
meer ziekenhuizen in Nederland DPYD-genotypering toe voorafgaand aan het begin van de 
behandeling. Een toegenomen implementatie van DPYD-genotypering was dus zichtbaar, 
vooral in Nederland. Buiten Nederland bestaan  er grote verschillen in de implementatie van 
DPYD-genotypering, al dan niet inclusief een DPD-fenotyperingtest. In sommige landen zijn 
initiatieven om prospectieve testen voor DPD-deficiëntie uit te voeren effectief, terwijl er 
in andere landen grote verschillen bestaan in de uitvoering van testen tussen verschillende 
centra in dat land. De implementatie van DPYD-genotypering zal profiteren van duidelijke 
richtlijnen, d.w.z. aanbevelingen wie en wanneer te genotyperen, en doseringsaanbevelingen 
voor DPYD-variant dragers.
 Momenteel zijn vier DPYD-varianten opgenomen in het panel voor genotypering, maar 
het is bekend dat deze vier varianten niet alle patiënten kunnen voorspellen die ernstige 
toxiciteit zullen ontwikkelen. Het is waarschijnlijk dat andere varianten geassocieerd 
zullen zijn met het ontstaan van ernstige fluoropyrimidine-geïnduceerde toxiciteit. Om de 
voorspelling van het genotypepanel verder te verbeteren, kunnen DPD-fenotyperingtesten 
worden gebruikt, of kunnen nieuwe varianten aan het genotypepanel worden toegevoegd. 
Nieuwe varianten kunnen bijvoorbeeld zeldzame varianten zijn in het DPYD-gen of varianten 
in andere genen.
De toekomst van fluoropyrimidines
5-FU wordt al tientallen jaren gebruikt in de behandeling van kanker. Inmiddels is capecitabine 
het voorkeursgeneesmiddel boven 5-FU in de behandeling van verschillende tumortypes 
in verschillende landen, waaronder Nederland. Om de effectiviteit van kankertherapie te 
verbeteren, worden fluoropyrimidines gecombineerd met verschillende andere middelen 
tegen kanker, maar ze zullen een standaard onderdeel van de therapie blijven voor een 
aanzienlijk aantal tumortypen. Veel onderzoek naar fluoropyrimidines en DPD(-deficiëntie) 
is reeds uitgevoerd. Op dit moment dient prospectieve DPYD-genotypering te worden 
toegepast voor alle patiënten die een behandeling met fluoropyrimidines beginnen. 
Aanvullend onderzoek zal worden uitgevoerd waarin de zoektocht naar andere factoren 
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